Automated morphometric analysis and phenotyping of mouse brains from structural µMR images by Powell, N
 
Automated morphometric analysis 
and phenotyping of mouse brains 
from structural µMR images 
 
 
Nicholas Morton Powell 
 
 
 
Submitted in partial fulfilment of the requirements for the degree of 
Doctor of Philosophy of University College London 
January 2016 
 
Supervisors 
Professor Sebastien Ourselin 
Professor Mark Lythgoe 
 
University College London 
UK
2 
3 
Declaration 
I, Nicholas Morton Powell, confirm that the work presented in this thesis is my own, 
except where stated otherwise in the text. This work is based on research conducted by 
me, during the time period November 2011 to December 2015 at University College 
London. 
 
 
 
Nicholas Morton Powell 
19th January 2016 
4 
 
5 
Abstract 
In light of the utility and increasing ubiquity of mouse models of genetic and neurological 
disease, I describe fully automated pipelines for the investigation of structural microscopic 
magnetic resonance images of mouse brains – for both high-throughput phenotyping, 
and monitoring disease. 
Mouse models offer unparalleled insight into genetic function and brain plasticity, in 
phenotyping studies; and neurodegenerative disease onset and progression, in therapeutic 
trials. I developed two cohesive, automatic software tools, for Voxel- and Tensor-Based 
Morphometry (V/TBM) and the Boundary Shift Integral (BSI), in the mouse brain. 
V/TBM are advantageous for their ability to highlight morphological differences between 
groups, without laboriously delineating regions of interest. The BSI is a powerful and 
sensitive imaging biomarker for the detection of atrophy. 
The resulting pipelines are described in detail. I show the translation and application of 
open-source software developed for clinical MRI analysis to mouse brain data: for tissue 
segmentation into high-quality, subject-specific maps, using contemporary multi-atlas 
techniques; and for symmetric, inverse-consistent registration. I describe atlases and 
parameters suitable for the preclinical paradigm, and illustrate and discuss image 
processing challenges encountered and overcome during development. 
As proof of principle and to illustrate robustness, I used both pipelines with in and ex 
vivo mouse brain datasets to identify differences between groups, representing the 
morphological influence of genes, and subtle, longitudinal changes over time, in 
particular relation to Down syndrome and Alzheimer’s disease. I also discuss the merits 
of transitioning preclinical analysis from predominately ex vivo MRI to in vivo, where 
morphometry is still viable and fewer mice are necessary. 
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This thesis conveys the cross-disciplinary translation of up-to-date image analysis 
techniques to the preclinical paradigm; the development of novel methods and 
adaptations to robustly process large cohorts of data; and the sensitive detection of 
phenotypic differences and neurodegenerative changes in the mouse brain. 
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Abbreviations 
2/3D two-/three-dimensional 
3Rs replacement, refinement and reduction of research animals (NC3Rs) 
AD Alzheimer’s disease §2.3 
AN(C)OVA analysis of (co)variance 
APP amyloid precursor protein §2.3, §4.2 
BG background (signal) 
BSI boundary shift integral §6 
BV brain volume 
CAD computer-aided design (software) 
CNR contrast-to-noise ratio E4.2 
CPP control point positions 
CPU central processing unit 
CSF cerebrospinal fluid; eCSF: external; vCSF: ventricular 
CT computed tomography; µCT: microscopic 
DBM deformation-based morphometry 
DOF degrees of freedom 
DS Down syndrome §2.4 
DTI diffusion tensor imaging 
EM expectation maximisation (segmentation) §2.2.4 
FDR false discovery rate 
FFD / F3D free-form deformation / fast FFD 
FSE fast spin echo 
FSL The Oxford Centre for Functional MRI of the Brain (FMRIB)  
 Software Library 
FTD frontotemporal dementia 
FOV field of view 
FWHM full width at half maximum 
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Gd-DTPA gadolinium-diethyltriamine pentaacetic acid (Magnevist) 
GE(3D) (3D) gradient echo 
GLM general linear model §2.2.7 
GM grey matter 
GPU graphics processing unit 
GWR group-wise registration §2.2.6 
ṳௗ௘௧ Jacobian determinant E2.1 
LNCC locally normalised cross-correlation 
MCI mild cognitive impairment 
MR(I) magnetic resonance (imaging); µMRI: microscopic 
MRF Markov random field 
NFTs Neurofibrillary tangles §2.3, §5.1 
NIfTI(-1) Neuroimaging Informatics Technology Initiative (data format version 1) 
NMI normalised mutual information 
NRR non-rigid registration 
NUC non-uniformity correction (of intensities) §3.4 
PBVC percentage brain volume change §6; E6.10 
PV partial volume 
ROI region of interest 
SD standard deviation 
SNR signal-to-noise ratio E4.1 
SPM statistical parametric map (or Statistical Parametric Mapping  
 software, www.fil.ion.ucl.ac.uk/spm/software) 
STEPS Similarity and Truth Estimation for Propagated Segmentations §2.2.3 
T1, T2, T2* Longitudinal, transverse, and transverse (gradient echo) magnetisation
 relaxation time constants; T1W: images weighted by T1 (etc.)  
TBM tensor-based morphometry §2.2.7 
TIV total intracranial volume E3.13 
TP time-point 
TPM tissue probability map §2.2.5 
VBM voxel-based morphometry §2.2.7 
WM white matter 
WT wild-type 
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Brain atlases frequently referenced 
NUS National University of Singapore – mouse brain, in vivo. See: 
 www.bioeng.nus.edu.sg/cfa/mouse_atlas.html and Bai et al. (2012). 
UFL University of Florida (USA) Magnetic Resonance Microimaging 
 Neurological Atlas (“MRM NeAt”) – mouse brain, in and ex vivo. See: 
 brainatlas.mbi.ufl.edu, Ma et al., (2005) and Ma et al., (2008). 
Acronyms for organisations 
ADNI Alzheimer’s Disease Neuroimaging Initiative, adni.loni.usc.edu 
CABI UCL Centre for Advanced Biomedical Imaging, www.ucl.ac.uk/cabi 
CMIC (TIG) UCL Centre for Medical Image Computing, (Translational Imaging 
 Group), cmictig.cs.ucl.ac.uk 
FDA United States Food and Drug Administration, www.fda.gov 
IKMC International Knockout Mouse Consortium 
IMPC International Mouse Phenotyping Consortium, 
 www.mousephenotype.org 
MRC Medical Research Council, www.mrc.ac.uk 
NC3Rs National Centre for the Replacement, Refinement & Reduction of 
 Animals in Research, www.nc3rs.org.uk 
A note on notation 
Throughout, §1.1 refers to Chapter 1, section 1; E1.1 to Chapter 1, equation 1; Fig 1.1 to figure 
1 in Chapter 1 (etc.); footnotes are numbered as1 per chapter and references are ordered 
alphabetically and all included at the end. 
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1 Introduction 
This chapter introduces the context in which this thesis rests – including the motivations 
behind genetic and disease mouse model phenotyping, and for translating clinical image 
analysis techniques to the preclinical paradigm. 
1.1 The promise of MRI 
Apart from the satisfaction of scientific curiosity, the chief motivation behind medical 
imaging technologies – pioneered by Wilhelm Röntgen’s x-rays in 1895 – is to 
noninvasively diagnose pathologies and help plan for their treatment. The desire to see 
within the body without cutting tissues – causing additional damage and perhaps 
exposing the inner organs to infection (heightened risks in a population of ageing 
patients) – has driven billions of pounds from governments and companies into imaging 
research over the past century. Endoscopy, positron emission tomography (PET), 
ultrasound and x-ray computed tomography (CT), each with unique advantages, have 
cemented themselves in hospitals worldwide. 
To the horror of radiology’s first practitioners, high doses of x-rays were linked directly 
with terminal cancer (Sansare et al., 2011). Thus, although still used routinely thanks to 
its low cost and the relative safety of low exposures, and although capable of very high 
tissue contrast and detail (for example, Wong et al., 2012), the use of ionising radiation 
for imaging and treatment remains a balance of risks with benefits. 
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Magnetic resonance imaging (MRI), developed in the 1970s, is an attractive alternative, 
despite its relatively high cost (a high field strength, 9.4T small animal scanner may cost 
several million pounds). The extraordinary resolution and contrast achievable with MR 
(§2.1), and its diagnostic utility, have led to increased use over the past 20 years (Lang et 
al., 2013). MR techniques and biomarkers are an established facet in the study and 
diagnosis of one of the most important contemporary diseases: dementia (§2.3). 
Among MR’s advantages, its use of non-ionising radiation must be one of the greatest: 
the modality is truly non-invasive and, provided a patient is not fitted with metallic 
implants – safe. Different structural MR contrasts give complementary information on 
the physical and chemical properties of tissue, and various techniques, such as diffusion 
tensor imaging (DTI, for measuring connectivity); arterial spin labelling (ASL, for blood 
flow and volume); and functional MRI (fMRI, via blood oxygenation) can provide 
quantitative assessments of in vivo physiology. The digital, three-dimensional (3D) 
images can be interpreted by clinicians directly or automatically analysed using 
computational techniques, providing objective, quantitative assessments of subtle 
pathologies, such as lesions in multiple sclerosis and atrophy in the early stages of 
Alzheimer’s disease. 
The advance of high magnet field strengths and availability of hardware, such as signal 
receiver coils, specifically designed for preclinical use, has enabled microscopic magnetic 
resonance imaging (µMRI) with fine resolutions (10—100µm per voxel) and high 
contrasts to probe smaller structures, such as those in the brains of small animal models, 
and to detect subtle pathological and developmental effects (Benveniste & Blackband, 
2002; Nieman et al., 2005; 2011). 
1.2 Phenotyping mice 
The mouse – quick to mature; cheap to house; with a genome we can engineer to model 
human disorders, and orthologs of 99% of human genes among its own 20—25,000 
(Gunter & Dhand, 2002; Rosenthal & Brown, 2007) – is a crucial human surrogate in the 
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study of gene function, the observation of disease progression, and the search for effective 
drugs (McConville et al., 2005; Collins et al., 2007; Henkelman, 2010). 
Physical and behavioural traits – determined both by genetics and environment – define 
an organism’s phenotype. Mouse genetic, disease and behavioural models are phenotyped 
to confirm accurate recapitulation of human pathology, to determine behavioural 
correlates, such as neuroplasticity in learning, and to observe the effects of abnormalities 
at different developmental stages (e.g. Cryan & Holmes, 2005; Cleary et al., 2009; Sawiak 
et al., 2009b; Lerch et al., 2011; Norris et al., 2013). The validity of models is vital for 
testing therapeutics and evaluating the risks of inheriting certain genes. 
Owing to its importance as a model organism, after Homo sapiens (IHGSC et al., 2004), 
only the second mammalian genome to be fully sequenced was that of the mouse (Mus 
musculus strain C57Bl/6J – Church et al., 2009). Knowledge of this sequence, however, 
does not elucidate individual genes’ interactions, or their function. This challenge is the 
target of the International Mouse Phenotyping Consortium (IMPC), a large-scale 
ongoing study involving 18 centres worldwide, with aims to comprehensively phenotype 
mouse strains in which genes are individually disabled (knocked out), thereby 
determining that gene’s effects under controlled conditions. A phenotype may encompass 
a broad spectrum of characteristics: two thirds of strains have pleiotropic phenotypes 
(with multiple effects). A phenotype may express differently at different ages. Easily-
assessed features (such as weight, litter size, fur or eye colour, gait, behaviour, etc.) are 
captured by ‘first-line’ phenotyping, but subtler structural biomarkers may warrant 
‘second-line’ approaches, such as histology or µMRI, potentially increasing the rate of 
phenotype discovery (Fuchs et al., 2010; Brown & Moore, 2012). 
This study is primarily concerned with structural features of the mouse brain, although 
embryos are also briefly considered. In the brain, structure is thought to be inherently 
tied to function, with structural changes such as atrophy in neurodegeneration severely 
affecting cognitive ability (Fox et al., 1999), and plasticity evident with learning (Maguire 
et al., 2000; Draganski et al., 2004; Lerch et al., 2011). 
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The vast number of genetic knock-outs, knock-ins, disease models, large cohorts, and the 
increasing usefulness of µMRI as a phenotyping tool, motivate a ‘high-throughput’ 
approach to phenotyping (Norris et al., 2013), such as simultaneously scanning multiple 
brains. Automated analysis is essential for the large, high-resolution datasets produced, 
and image processing tools must be designed to cope. There is currently an unmet need 
for such tools. 
1.3 Morphometry in preclinical studies 
Morphological variability can arise from mouse age, sex, genetic background, and 
environment. In-bred mice (of more than 20 generations) are isogenic, maintaining 
consistent characteristics. This reduced and manipulable gene pool eases comparisons 
between studies (Beck et al., 2000); in-bred mice exhibit less variability than humans. 
Mice are heterogeneous between strains – exhibited in behavioural phenotypes (Rogers et 
al., 1999) and brain structure, with much smaller differences within-strain (Chen et al., 
2005). Within C57Bl/6J (“black six”) mice, one of the most commonly-used strains, 
Kovačević et al. (2005) found over 90% of brain structures exhibited under 180µm 
positional variability (even after physical extraction from the skull, a potentially damaging 
procedure, Badea et al., 2007a). 
Physical changes in the brain and developing embryo are detectable with traditional 
techniques. Histology offers unparalleled detail, sensitivity and specificity: often, 
individual cells may be stained, visualised, and counted (Cleary et al., 2011b). However, 
the technique is prohibitively time-consuming when considering the whole brain, so is 
limited to small pre-defined regions of interest within a small number of animals. It is 
also reliant upon intact, delicately-preserved tissues, but is necessarily destructive, and 
therefore non-repeatable. Phenotypes can be partially penetrant and not appear in every 
animal. Rather than comparing individuals with a known “wild-type” strain, therefore, 
statistical techniques can be wielded to compare the average phenotype, across many 
animals. 
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In concert with µMRI, powerful statistical morphological analysis techniques such as 
Voxel- and Tensor-Based Morphometry (V/TBM, described in more detail in §2.2.7) 
enable non-invasive, hypothesis-free structural investigations covering an entire organ or 
organism. VBM employs maps of grey and white matter (GM/WM) to reveal tissue 
density changes in the brain. TBM is used to detect volumetric differences in physical 
structures (Ashburner & Friston, 2000). Both offer exploratory, whole-brain assessment, 
without operator bias – particularly pertinent to phenotyping, genetic, or disease studies. 
They reduce the requirement for histology or the laborious expert delineation of regions 
of interest (ROIs), which are vulnerable to intra- and inter-rater variability and may miss 
unexpected changes in unexplored regions (White et al., 2003; Carducci et al., 2013). 
These computational techniques have much to offer the field of preclinical phenotyping. 
Despite their potential, and although V/TBM enjoy widespread use in human studies 
with popular software packages such as SPM1, FSL2 and Freesurfer3, morphometry is not 
routinely employed preclinically (Sawiak et al., 2013; Table 2.1 includes a selection). The 
image processing burden for large datasets remains high. Standard protocols for 
phenotyping mice with MRI have yet to be developed (McConville et al. 2005; Scheenstra, 
2011), and several pre-processing steps, unique to high-throughput preclinical studies, 
must currently be performed manually, with disparate software. Few atlases – datasets 
containing structural MR mouse brain images and corresponding anatomical labels 
which may be used as prior knowledge – are publicly available (§2.2.1; Ma et al., 2014). 
These limitations form a bottleneck to automated analysis techniques including V/TBM, 
segmentation propagation, or the examination of individual substructures. 
 
                                                        
1: http://www.fil.ion.ucl.ac.uk/spm 
2: http://fsl.fmrib.ox.ac.uk/fsl/fslwiki 
3: http://freesurfer.net 
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1.4 From ex vivo to in vivo 
Despite its many advantages for phenotyping mouse brains, MRI, as discussed in the first 
half of this thesis and in the majority of preclinical morphometry studies, cannot be 
considered non-invasive; the animal is sacrificed to achieve greater spatial resolution, or 
contrast, or to preclude motion artefacts. While histology at the end of a study – perhaps 
preceded by ex vivo MR – might remain essential for many years, MR still has much to 
offer in vivo, where tissues and physiological processes remain intact (Benveniste & 
Blackband, 2002). Indeed, there are numerous advantages of longitudinal, multi-time-
point studies over cross-sectional, single time-point investigations (§5). It is feasible to 
follow mouse development and ageing throughout the animal’s entire lifespan – difficult 
in humans both because of the time required and the number of uncontrollable lifestyle 
factors (Fjell et al., 2014) – and monitor the trajectory of disease and treatment effects 
without confounding inter-individual variability. The Boundary Shift Integral (BSI, §6, 
Freeborough & Fox, 1997) is one technique for doing so, by measuring voxel intensity 
differences between scans. 
Ethical justifications for sometimes controversial animal research rest upon the lack of 
viable alternatives for both phenotyping and drug studies. Mice are intimately involved 
in the drug development pipeline: both for identifying and validating drug targets, and 
eventual testing of new therapeutic compounds (Hall & Roberson, 2012). To ensure their 
safety, animal studies are mandatory for all drugs to be approved by the Food and Drug 
Administration (FDA) in the United States4. Over four million animals were used for 
scientific research in both 2012 and 2013 in the UK5. The National Centre for the 
Replacement, Refinement and Reduction of Animals in Research (NC3Rs) aims to 
reduce this number, by improving the quality and reproducibility of such studies. One 
method for doing so in neurological studies which investigate disease progression, or a 
gene’s effects, over time, is to observe the same animals longitudinally, with multiple 
 
                                                        
4: “The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective”, 
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm 
5: http://www.understandinganimalresearch.org.uk/animals/numbers-animals 
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time-points – rather than culling different animals at different ages (as, for example, 
Badea et al., 2010; Chuang et al., 2011). Being non-invasive, MRI is well-suited to such 
investigations. 
There remain some advantages to ex vivo MR (§5.7): extended scan times enable higher 
resolutions and signal-to-noise ratios (SNR). Maintaining animals on anaesthesia, in vivo, 
is difficult (Balaban & Hampshire, 2001). Contrast agents – which may otherwise be 
neurotoxic (Lerch et al., 2012) – enable improved tissue contrast and image quality. 
Multiple brains may be easily scanned in parallel (§3.2.1), and motion artefacts are 
eliminated. In §5, the phenotyping pipeline developed for ex vivo MRI is applied to in 
vivo, longitudinal data, with appropriate parameter adjustments. Morphometric results 
from ex vivo and in vivo scans of the same animals are compared. If the latter are able to 
show the same phenotypic effects of disease, despite the image contrast and resolution 
trade-offs, a compelling case may be made for the exclusive use of in vivo MRI for 
investigations of brain structure in preclinical studies. 
1.5 Aims and contributions of this research and 
thesis 
The aim of this thesis is to present the development, translation and application of two 
software pipelines, for Voxel- and Tensor-Based Morphometry, and the Boundary Shift 
Integral – both established clinical MR image processing techniques – to the preclinical 
paradigm. As proof of principle, I show and discuss results from each in mouse models 
of Down syndrome and tauopathy in Alzheimer’s disease. The main contributions of this 
work are: 
1. The development of a cohesive, automated software pipeline for analysing multiple 
mouse brain and embryo images, using advanced, up-to-date MR image analysis 
techniques employed in the clinical paradigm to reduce bias and measurement error, 
such as multi-atlas parcellation and segmentation, and symmetric registration. I describe 
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novel techniques for multiple subject extraction, global orientation correction, and 
improved tissue segmentations, prior to voxel-wise statistical morphometry (§3). I 
demonstrate the application of this pipeline to preclinical genetic phenotyping studies 
and disease models, as proof both of principle and of high-throughput robustness, 
anticipating large cohorts. 
2. Using this pipeline with TBM and VBM, I show and discuss novel structural findings in 
the brains of several mouse models, including the Tc1 model of Down syndrome (DS, 
§4); the Tc1xJ20 model (a DS model cross-bred with an Alzheimer’s disease model), and 
the rTg4510 model of tauopathy (§5). Appropriate software parameters for investigative 
phenotyping with both ex vivo and in vivo data are described, and the statistical power 
of preclinical morphometry is investigated. The rTg4510 study involved a large, cross-
sectional and longitudinal analysis, comparing untreated animals with wild-types (WTs) 
and those treated with two drugs, and afforded the opportunity to compare both drug 
effectiveness and in vivo and ex vivo morphometry in the same animals, and to assess at 
which ages the technique could differentiate groups. 
3. Continuing the analysis of longitudinal data, I adapted the Boundary Shift Integral (BSI) 
algorithm for measuring whole-brain atrophy in T2-weighted mouse brain images, and 
show and discuss the results of its application to a large in vivo mouse brain dataset. This 
is the BSI’s first application to a non-human animal. In evaluating the technique, I show 
that the method is a sensitive and promising measure for the early detection and 
quantification of atrophy in the mouse brain, and for future use in preclinical therapeutic 
trials (§6). 
Ethics statement 
All studies in this thesis were conducted following approval from an internal UCL ethical 
review, and were authorised by the UK Home Office, Animals (Scientific Procedures) 
Act 1986 under the relevant Project Licence authority. I strove for high standards in the 
design and conduct of animal-related work, and took full consideration of the 3Rs (as 
introduced above). 
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1.6 Overview of chapters 
The structure of the following six chapters comprising this thesis is laid out below. There 
are two introductory chapters, four methodological and experimental chapters, and a 
concluding discussion. Each chapter has its own introduction and discussion. A 
bibliography of all references follows the final conclusions. 
Chapter 2: Background theory and state-of-the-art practices 
This chapter summarises established voxel-wise methods for the analysis of clinical data, 
Voxel- and Tensor-Based Morphometry, and the Boundary Shift Integral. Both 
techniques harness the wealth of information present in high-resolution, microscopic MR 
images, by considering data from all voxels. Image processing theory, atlases, and state-
of-the-art methods for registration and segmentation are also described, upon which these 
methods are dependent, and some preclinical studies employing morphometric 
techniques are discussed. Finally, to provide motivating context for the mouse models 
employed in this thesis, I introduce the aetiology and current MRI-based study of 
Alzheimer’s disease and Down syndrome. 
Chapter 3: Development of a high-throughput software 
pipeline for phenotyping preclinical subjects 
This chapter describes the translation and application of the techniques introduced in §2 
to the preclinical paradigm, for the development of a high-throughput, fully automatic 
morphometric image processing pipeline designed to phenotype large cohorts of mouse 
brains and meet the needs described in §1. The considerations necessary for high-
throughput embryo data are briefly included. I also discuss suitable atlases, parameters, 
and some of the existing literature concerning each pipeline step. 
I incorporate an accessible approach for simultaneously scanning multiple ex vivo brains, 
requiring only a 3D-printed brain holder. The software toolbox I developed includes 
novel pre-processing methods for the separation of multiple subjects from a single MRI 
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scan, their orientation to a standard space, skull-stripping based upon publicly-available 
atlases and tissue segmentation using accurate subject-specific tissue prior maps. These 
steps are followed by group-wise registration and the generation of statistical parametric 
maps based upon the resulting deformation fields. 
Chapter 4: Application of the pipeline to ex vivo mouse brains 
Here, I present the application of the morphometric analysis pipeline developed in §3 to 
ex vivo mouse brain datasets, describe some of the considerations necessary in each case, 
and show and discusses results. 
I report novel brain morphological phenotypes in the Tc1 mouse model of Down 
syndrome, as compared with wild-type littermates. I also analyse the Tc1xJ20 Down 
syndrome and APP (Alzheimer’s disease) cross-bred mouse model, to investigate how the 
two phenotypes interact in the brain. 
Chapter 5: In vivo morphometry 
This chapter describes the application and refinement of the pipeline for in vivo data, 
specifically the rTg4510 mouse model of tauopathy in Fronto-Temporal Dementia and 
Alzheimer’s disease, in collaboration with Eli Lilly. Whereas the previous chapter 
necessarily dealt with cross-sectional, single time-point analyses, and while ex vivo scans 
may provide higher image resolution and contrast, in vivo scans introduce the possibility 
of longitudinal study. The structural integrity of brains is also preserved. This has the 
potential to reduce the number of animals used in preclinical research, and hence lower 
costs. Over 250 scans were analysed, including a cross-sectional study and 87 animals 
with up to three time-points. I examined whether in vivo morphometry could sufficiently 
capture the findings of ex vivo, by comparing TBM in the same brains. 
35 
Chapter 6: Longitudinal atrophy measurement using the 
Boundary Shift Integral in the mouse brain 
Finally, continuing the large longitudinal study of §5, I describe a translation of the 
Boundary Shift Integral, a sensitive and objective clinical measure of atrophy, to the brain 
of the rTg4510 mouse model. This is the first application of the BSI to a non-human 
animal, and its first application to T2-weighted MR data, and required adaptations to the 
code and clinical pipeline. I evaluated the power of the technique, using sample size 
estimates, to detect changes in atrophy rate. The results indicate the BSI’s ability to 
measure subtle longitudinal brain volume changes and differentiate groups, which may 
be of significant use in preclinical therapeutic drug trials. 
Chapter 7: General discussion, conclusions and future work 
A summary and conclusion drawn from all the findings and work completed for this 
thesis. Possible future work, limitations, and recommendations for moving forward with 
preclinical image analysis are also discussed, including the continuation of phenotyping 
investigations, the development of atlases, and the further use of image analysis tools to 
investigate preclinical models. 
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2 Background theory and state-of-
the-art practices 
This chapter describes the theoretical principles and existing state-of-the-art concepts and 
methods upon which the research in this thesis is built. I show examples of mouse brain 
images analysed, whose acquisitions have previously been optimised, and discuss the MR 
contrast and image quality as it pertains to the processing techniques I employed. Existing 
methods to analyse MR images are next discussed, including registration, segmentation 
and statistical morphometry methods. I include a summary of existing pipelines for 
morphometry in preclinical studies, covering the steps detailed in §3. My work concerned 
the investigation of mouse models of Alzheimer’s disease and Down syndrome, hence, 
finally, both conditions are briefly introduced, along with biomarkers and treatments – 
investigated further in §6. The mouse models I investigated are introduced in their 
respective chapters: Tc1 in §4.1; Tc1xJ20 in §4.2; rTg4510 in §5.1. 
2.1 MR images of the mouse brain 
Researchers at CABI, including Jon Cleary, Ben Sinclair, Francesca Norris, Holly 
Holmes, James O’Callaghan and Yichao Yu all worked to develop and optimise the high-
resolution, high-contrast mouse brain and embryo fixation and scan protocols used to 
acquire each image processed as part of this thesis. Fig 2.1 shows example ex vivo and in 
vivo scans acquired from the same brain. 
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Figure 2.1 Example ex vivo and in vivo images of the same mouse brain. 
Equivalent coronal (left column), sagittal (top right) and transverse (lower right) slices from 
a wild-type brain (from §5, age 7.5 months), scanned at CABI ex vivo (a: 40µm isotropic 
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voxels with contrast agent, 11hr 4min spoiled GE3D sequence; TE 4.54ms; TR 17ms; flip 
angle 51°; 6 averages; further parameters in §4.1.2) and in vivo (b: 150µm isotropic voxels, 
no contrast agent; 1hr 30min 3D fast spin echo (FSE) sequence; TEeff 43ms; TR 2500ms; 
further parameters in §5.2.3). High resolution and excellent contrast from 9.4T T2W 
scans, optimised for high GM (light)/WM (dark) contrast. Slice locations indicated in top 
right. Note the ventricles (containing bright CSF) have mostly collapsed, ex vivo, and the 
brain has shrunk slightly (see §5.7). Most flesh at the top of the skull was removed prior 
to the ex vivo scan, but in vivo, increased partial volume reduces the brain’s apparent 
separation from external material. Cerebellar and cortical layers are visible ex vivo, but not 
in vivo. Fig 5.19 includes labels for the meninges. Note also the relative homogeneity in 
vivo, compared with ex vivo, of the striatum and midbrain. See also Fig 2.2. 
Thanks to the high field strength magnet (9.4T), the liberty to perform long (overnight, 
11-12 hour) scans, and optimised protocols (Cleary et al., 2011b), an extraordinary level 
of detail is obtainable ex vivo, including cortical and cerebellar layers, the Purkinje cell 
layer, and the thin external capsule. Magnevist1 was used to improve contrast and shorten 
scan times. External tissues have a similar intensity as the brain, here, owing to their 
uptake of the contrast agent. 
The commonly-used in vivo contrast agent, manganese, also shortens scan times – thus 
increasing the likelihood for anaesthetised mice to survive several longitudinal scans, and 
enabling increased in vivo throughput (Benveniste & Blackband, 2002). However, 
manganese is believed to have neurotoxic effects, which could interfere with observations 
of pathology (§5; Lerch et al., 2012). A contrast agent was therefore not employed for in 
vivo scans; however, acquisition sequences were optimised for high grey matter (GM) and 
white-matter (WM) contrast. Detail and contrast are lower in vivo, but structures such 
as the hippocampus, corpus callosum, and cerebellar folds are clearly distinguishable. 
Contrast-to-noise and signal-to-noise ratios (CNR, SNR) are reported in §4.1.5 (ex vivo) 
and §5.5 (in vivo). 
 
                                                        
1: Gd-DTPA, containing paramagnetic gadolinium. 
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To increase throughput, this ex vivo scan involved three subjects simultaneously (§3.2), 
necessitating a large field of view (FOV). To reduce the FOV and so shorten acquisition 
times, some studies (e.g. Keifer et al., 2015) omit the olfactory bulbs or cerebellum. Such 
cropping is acceptable when the region of interest is known, but this may compromise 
inter-subject registration (if the FOV is variable) and registration to atlases (which include 
the whole brain, §2.2.2). Additionally, a substantial benefit of investigative morphometry 
is its ability to identify unexpected differences (Sawiak et al., 2009b). 
Ideally, images should have high resolution, to give better detail of fine structures. 
Contemporary µMRI of mouse brains is limited to resolutions of about 15µm3 or greater 
(Janke & Ullmann, 2015; Lerch, 2010). As this does not reach the cellular scale, each 
voxel constitutes a shared signal from various sources. GM consists of neuronal cell 
bodies, axons, and supporting glial cells. WM is predominately composed of myelinated 
axonal tracts connecting GM neurons. Cerebrospinal fluid (CSF), thought to be 
protective and to facilitate waste clearance, fills the ventricles, aqueducts and cisternae. 
(The mouse skull fits very tightly around the brain; there is little external CSF visible in 
vivo.) Each voxel therefore necessarily exhibits a degree of partial volume (PV). Larger 
voxels have more, and therefore lower structural contrast, but smaller voxels compromise 
SNR (which is proportional to voxel volume). Kale et al. (2008) showed that an SNR of 
around 20 was ideal for morphometry. 
In-plane resolution can be significantly increased at the expense of slice thickness, while 
decreasing scan times, but this has several disadvantages. A chief advantage of 
morphometry is the ability to construct 3D atlases and view features from any angle. 
Registration algorithms (§2.2.6) typically rely upon information from all dimensions. 
Inevitable out-of-plane transformations and warps will result in the corruption of in-
plane voxels with severe PV effects (Lerch, 2010). Isotropic voxels are therefore preferable. 
The human brain measures approximately 140 × 167 × 93ⅎⅎ. Total intracranial 
volume (TIV) is approximately 1700ml: 1400ml brain tissue; 150ml blood; 150ml CSF 
(Rengachary & Ellenbogen, 2005). Clinical structural whole-brain MR resolution from 
the most common 1.5—3T scanners is typically 1 − 1.5ⅎⅎᾨ, giving around 1.7 million 
voxels per image. With 4 bytes per voxel, images thus occupy under 10MB. 
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A healthy adult mouse brain occupies approximately 0.5ml. Structures of interest, such 
as the hippocampus, are relatively large (compared with the overall brain volume, and the 
same ratio in humans). The ex vivo and in vivo brains shown above, respectively, occupy 
around 31MB and 0.6MB. (Given the FOV and presence of external tissues, however, 
more typical image file sizes are 150MB and 4MB.) 
2.2 Morphometry 
The mouse brain images described above each represent a rich source of data. 
Hippocampal volume may be useful for the assessment of Alzheimer’s disease (§2.3), for 
example, but individual voxels’ intensities and neighbourhoods are also valuable. The aim 
of morphometry is to quantify this morphological information, allowing the derivation 
of meaningful conclusions relating to phenotype or disease. 
To compare the volume or shape of specific sub-regions, which may have functional, 
disease, or phenotypic significance, brains can be parcellated using manual or automated, 
atlas-based techniques. Redwine et al. (2003) and Delatour et al. (2006), for example, both 
used manual delineation of structures to measure atrophy in AD mouse models. Manual 
volumetry is thought to be the most accurate in both human and preclinical studies, but 
is very time-consuming (taking hours per scan, even for experienced raters2, and ideally 
requiring more than one rater), becoming prohibitive for all except very small cohorts 
(Teipel et al., 2013). Manual measurements require strict protocols, yet are still prone to 
inter- and intra-rater variability (Riegler et al., 2010). Automated methods are repeatable, 
and now approach manual accuracy, so are preferred. 
 
                                                        
2: Leung et al. (2010a) noted that it took trained raters 45 minutes to manually delineate the hippocampus 
with good reproducibility (<5% volume difference within and between raters). 
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Figure 2.2 3D surface rendering of a mouse brain. 
Two oblique views of a WT brain mask following automated extraction from the skull 
(§3.5), with prominent features labelled. A: anterior; P: posterior; S: superior; I: inferior. 
I refer to “parcellation” here to mean the classification of distinct anatomical brain regions 
into probabilistic or binary spatial maps (hippocampus; cerebellum; corpus callosum). I 
use “segmentation” to refer to probabilistic or binary tissue classification (into GM, WM, 
CSF, etc.), which is generally intensity-based and not confined to individual anatomical 
regions – for example, both GM and WM exist in the cerebellum (Fig 2.1). 
The majority of this thesis is concerned with measurements taken at every voxel. These 
are either compared, individually, between animals (V/TBM, §4, §5) – or combined into 
summary measurements for a single subject (BSI, §6). In each case, large groups may be 
required to detect statistically significant differences between populations, and both 
require image registration, to ensure anatomically equivalent regions are compared 
between animals: for morphometry, to deform scans from individuals to achieve voxel-
level correspondence across the group; and for the BSI, to align the same animal’s serial 
scans between time-points. 
Automated methods are essential, requiring suitable prior information (atlases with 
accurate labels) and unbiased registration. State-of-the-art techniques for clinical data 
should be adopted. In this section, I discuss recent developments for atlas-based 
parcellation (§2.2.1); tissue segmentation (§2.2.4); and alignment with registration 
(§2.2.6). These key steps are fundamental to morphometry and segmentation 
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propagation. However, several other pre-processing steps are required to initialise image 
data and ensure accuracy and low bias – including multiple subject extraction (from 
multi-subject scans); orientation (from arbitrary initial alignments in those scans); non-
uniformity correction and intensity standardisation. These are often omitted from 
descriptions of preclinical morphometry (§2.2.8; Table 2.1). I discuss them, along with 
current methods, in more detail in §3. 
2.2.1 Atlases 
Neuroimaging atlases provide a common reference space, including a standardised 
orientation and set of coordinates, against which researchers may compare findings. One 
of the earliest atlases of the human brain was the Talairach atlas (published 1967), which 
consisted of histological slices from a single female brain, to assist surgery. MRI atlases 
emerged in the 1990s. The Colin27 atlas, an early example, consists of 27 T1W images 
from separate scans of the same subject, aligned and averaged to improve SNR and 
contrast (Holmes et al., 1998). 
Advanced registration algorithms allow near-exact alignment between atlas images and 
new patient images. The transformations calculated to map one image to the other allow 
the propagation of atlas information, such as anatomical labels. Atlas databases 
comprising more than one image help to account for natural inter-subject morphological 
variation (Aljabar et al., 2009), e.g. between sexes; right and left-handedness; across age-
groups, and so on. There is a greater chance a new image will match at least some of the 
atlas images, hence improving alignment and the ability to propagate information. For 
example, Leung et al. used such a “template library” for automated hippocampal (2010a) 
and whole-brain (2011) delineation. 
Contemporary human brain atlases thus include many subject images and multi-
dimensional data, such as corresponding parcellations, probabilistic tissue class maps, and 
image weightings, to provide as much information as possible. For example, the 
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MNI3152 atlas contains 152 brains and individual tissue maps aligned to a stereotaxic 
“MNI space”. Fig 2.3 shows average structural images created from this database, with 
parcellations and tissue maps. These are included with software analysis packages such as 
SPM and FSL. Using smoothed or blurred structures, average or probabilistic atlases 
attempt to balance natural variability with enough spatial specificity to be anatomically 
useful when registered to new data (Hammers et al., 2003). Average images also have 
higher SNR and improved contrast over individuals (Fig 2.9 inset). Furthermore, 
domain-specific atlases exist for developing, ageing or diseased brains (Evans et al., 2012). 
 
Figure 2.3 Example human brain average atlas images. 
Equivalent transverse (top row), sagittal and coronal slices through aligned atlas images, 
with multiple weightings and segmentations, from the “ICBM 2009a” nonlinearly 
registered, symmetric template (1mm3 isotropic resolution). By registering data to a 
relevant atlas image, parcellations and tissue class maps can be applied. Columns from left: 
T1W structural average; T2W; proton density weighted; T2 relaxometry map; probabilistic 
GM, WM and CSF maps; and binary anatomical parcellations. Image from 
www.bic.mni.mcgill.ca/ServicesAtlases/ICBM152NLin2009. 
2.2.2 Mouse brain atlases 
For years, early editions of Paxinos & Franklin (2012), containing histology slice images 
and derived diagrams, served as the primary mouse brain atlas. As mouse studies have 
 
                                                        
3: Montreal Neurological Institute; sometimes also “ICBM”, the North American International Consortium 
for Brain Mapping. 
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proliferated, digital mouse MRI atlases have been released to ease the localisation of 
functional and anatomical findings. Several mouse brain atlases exist and are in 
development, but there are fewer preclinical atlases than human. Given the extraordinary 
number of mouse strains (Beck et al., 2000), it is important to select a relevant atlas for a 
given study. Ventricle sizes and shapes are variable, and, just as in humans, the brain 
changes shape in the first few months after birth. 
Single-subject atlases (for example, MacKenzie-Graham et al., 2004) may exhibit 
deviations from normal shape or suffer from image artefacts at particular locations. 
Kovačević et al. (2005) created an atlas via group registration of 9 in-bred, ex vivo brains. 
The average image was manually parcellated and its variability measured using 
deformation fields. Dorr et al. (2008) used the same technique to label 62 structures in a 
40-mouse average image with isotropic, 32µm3 voxels. This atlas has been subsequently 
employed many times for annotating morphometry results (e.g. Ellegood et al., 2010; 
Lerch et al., 2011; Badhwar et al., 2013). 
A promising equivalent of MNI space for mouse brain atlasing is Waxholm space (Johnson 
et al., 2010), a standardised orientation atlas, with average and probabilistic parcellations, 
aligned to a histology correlate. The Australian Mouse Brain Mapping Consortium4 has 
generated high resolution, detailed atlases of the C57Bl/6J cortex, cerebellum, 
hippocampus and other sub-regions (30µm isotropic voxels), from averaged ex vivo 
images (e.g. Ullman et al., 2012; 2013). The group continues to release further 
parcellations and recommendations for atlas-building (Janke & Ullmann, 2015; Ullmann 
et al., 2015). Efforts are also underway to construct embryo (Cleary et al., 2011a; Wong 
et al., 2012; Norris et al., 2013) and developmental (Aggarwal et al., 2009; Chuang et al., 
2011) atlases. 
Ex vivo images, especially when skull-stripped (such as in Kovačević et al., 2005 and Ma 
et al., 2005), may exhibit damage to the cortical surface, and so deviate from natural 
mouse anatomy (Chen et al., 2005; Dorr et al., 2008). In vivo atlases are usually lower 
resolution and have lower contrast. The mouse brain exhibits a high degree of partial 
 
                                                        
4: www.imaging.org.au/AMBMC 
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volume (PV) – a mixture of tissue classes within individual voxels. Contrast between 
structures is often low, especially in the midbrain: both manual and automatic 
parcellation methods may struggle to accurately, reproducibly delineate boundaries. Bae 
et al. (2009) and Wu et al. (2012) used a support vector machine with multi-spectral MR 
data (T2W, proton density-weighted and DTI) to parcellate brains, together with a 
Markov random field (MRF), and atlas-based priors for spatial consistency. 
Probabilistic atlases incorporate some natural anatomical variability (e.g. Ali et al., 2005); 
however, the weight of each voxel is determined by its probability of appearing in the 
original dataset used to create the atlas; thus, both local variability and resolution may be 
reduced when there are a large number of subjects (Leung et al., 2010a). When 
segmenting, each image is initialised using the same probabilities; there is no ability to 
weight similar images more highly in particular regions. 
Multi-subject atlas databases are preferred in the human paradigm, but have only recently 
been implemented preclinically. Only three multi-atlas mouse brain databases are 
presently available, from the National University of Singapore (NUS, Bai et al., 2012, 
Fig 2.4); and the University of Florida (UFL, Ma et al., 2005, 2008); only one of which 
is ex vivo (UFL, Ma et al., 2005). 
 
Figure 2.4 Example slices from a single brain of the NUS atlas, with parcellations. 
Transverse, coronal and two sagittal views, with labels overlaid. This in vivo atlas has large 
ventricles, relatively low GM/WM tissue contrast, and is skull-stripped, but it has more 
detailed labels than the UFL atlas – for example, the cerebellar WM is delineated. Images 
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in this atlas were rigidly aligned to that of MacKenzie-Graham et al. (2004), and hence the 
Paxinos & Franklin atlas. 
2.2.3 Multi-atlas label fusion for parcellation 
To automatically parcellate a new image, after atlas registration, labels are propagated to 
the image space using, for example, nearest neighbour or trilinear interpolation. 
Registration accuracy thus plays an important role in the quality of automatic 
parcellation. Large atlas databases can aide the process by providing images with variable 
morphology (encompassing natural variation between individuals and across age groups, 
or in disease). Registration is more likely to succeed in at least some cases, even to new 
images with outlier morphology, such as hydrocephalus (grossly enlarged ventricles); 
severe atrophy, or cranial damage. Each atlas image is registered to the new image, the 
labels propagated, and an appropriate label chosen for a given region. Multi-atlas 
techniques thereby reduce bias and increase accuracy over single-atlas and probabilistic 
approaches (Barnes et al., 2008; Leung et al., 2010a). 
One method for deciding upon a consensus label is voxel-wise majority voting. Label 
decision fusion techniques attempt to be less naïve. A subset of templates from the atlas 
database can be chosen based upon metadata (such as age or sex), or the registered atlas 
images can be ranked by global or local similarity with the data, a subset of top-ranked 
atlases chosen, and their corresponding labels’ contribution to the voting weighted by 
this similarity (Wu et al., 2007; Aljabar et al., 2009; Iglesias et al., 2013). 
To segment hippocampi and whole brains, Leung et al. (2010a), (2011) used a method 
developed by Warfield et al. (2004), STAPLE5, which provides a probabilistic estimate of 
the true underlying parcellation given a set of registered templates and labels, finding 
good performance (using the Jaccard index) compared with manual labelling and the 
sensitive distinguishing of diseased and healthy brains. Cardoso et al. (2013b) proposed 
an extension, Similarity and Truth Estimation for Propagated Segmentations (STEPS), 
 
                                                        
5: Simultaneous Truth and Performance Level Estimation. 
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which ranks classifiers (combinations of the registration and atlas label) by local similarity 
to the data, using locally normalised cross-correlation. This improves robustness to local 
deficiencies either in atlas quality, or registration accuracy, and the authors showed 
improved performance, using a Dice score, while requiring a smaller atlas database. In a 
recent technique, Wang et al. (2013) showed improved parcellations could be achieved 
when atlases’ contributions were negatively weighted based upon their local similarity to 
one another – such that atlases with similar errors contributed less. 
Chakravarty et al., 2013 showed the automatic creation of atlas databases for both human 
and mouse brains, from a single starting atlas (for mice, that of Dorr et al., 2008), enabling 
multi-atlas label fusion techniques and improvement over single atlases. However, this is 
likely to have similar drawbacks as single-atlas label propagation, as any errors in the 
original atlas, and arising from multiple registrations, will bias the final result. 
Perhaps due to the scarcity of multi-subject mouse brain atlas databases, and the 
availability of higher-resolution single-subject and probabilistic atlases, very few studies 
have employed multi-atlas label fusion techniques to segment data. Bai et al. (2012) 
found that multi-atlas techniques, including STAPLE, outperformed single-atlases in 
terms of a volume overlap percentage, compared with manual labels. Both Ma et al. 
(2014) and Badea et al. (2012) also reported improved accuracy using multi-atlas 
techniques. Nie et al. (2013) used region of interest (ROI, or parcellation) boundaries in 
the atlas (UFL, Ma et al., 2005, 2008) to inform the registration step (reasoning that 
these are the most important regions to correctly register, for parcellations). The resulting 
surfaces were then updated using a support vector machine. 
Many mouse studies use manual parcellation (Table 2.1) or single-atlas label propagation 
to delineate structures (Chen et al., 2005; Scheenstra et al., 2009; Badhwar et al., 2013). 
Badea et al. (2007a) used parcellations’ surface deformations to measure shape differences 
in C57Bl/6J mice. Whole-brain parcellation (skull-stripping, §3.5) is an important 
preprocessing step for excluding extraneous material prior to tissue segmentation or 
morphometry. Parcellation of the cortex and adjacent structures enables measurement of 
cortical thickness and, with sufficient contrast, sublayer thickness (e.g. Lerch et al., 2008; 
Sawiak et al., 2012; Hébert et al., 2013), which is applicable to neurological conditions 
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including AD. More recently, this has been extended to the cerebellar cortex, a 
significantly more complex structure with tighter laminar folds (Ma et al., 2015). 
The mouse brain has large regions of homogeneous and gradually-varying intensity (such 
as the brainstem, midbrain, colliculus, thalamus and striatum). Even at high resolutions 
below 50µm, there is a large degree of PV. In these low-contrast areas, parcellation 
techniques may struggle to accurately delineate anatomical sub-regions, resulting in 
imprecise or low-confidence parcellations (Fischl et al., 2002; Fig 2.5). 
2.2.4 Tissue segmentation 
Brain tissue segmentation aims to classify image voxels by their predominant, underlying 
type (GM; WM; CSF), rather than anatomical location, enabling analysis based upon 
physical – hence, functional – properties, and with less dependence upon parcellation, or 
registration, accuracy. Tissue volumes can be highly sensitive to diseases such as dementia 
(Teipel et al., 2004; Serra et al., 2010). Segmentation into binary or probabilistic labels 
proceeds via contrasting signals: physically similar tissues exhibit comparable intensities 
in MRI. Manual tracing of regions has the same drawbacks as anatomical parcellation, 
and is especially subjective for PV voxels. Automated segmentation can rest simply upon 
thresholding (Wright et al., 1995), but this requires assumptions about the arbitrary MR 
intensity scale. Artefacts, such as noise; inhomogeneity; magnetic susceptibility; low 
contrast; or unexpected pathological features can corrupt these assumptions. Intensity 
distributions of each tissue type can vary between scans, patients and scanners. To add 
robustness, the majority of segmentation techniques require some prior information, such 
as the number of tissue classes, and probabilistic maps of their location, provided in atlases 
(Fig 2.3) and software packages such as SPM, FSL, and Freesurfer (Klauschen et al., 2009). 
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Figure 2.5 Example T1W MRI human brain intensity histogram. 
Structures labelled to illustrate their overlapping intensities, and the broad range of 
intensities in some structures. Adapted from Fischl et al. (2002). 
In this work, an expectation maximisation (EM) algorithm, implemented in the open-
source NiftySeg software6 is used to fit a probabilistic model to the image data intensity 
histogram. It is assumed that the log-transformed histogram may be represented as a 
mixture of Gaussian distributions with different means and standard deviations; a 
Gaussian Mixture Model (GMM). Each Gaussian is parameterised by its mean, standard 
deviation, and the number of voxels. The number of classes is given a priori, as are initial 
estimates of the mean intensity and variance of each tissue. For segmentation of brain 
tissues, these are obtained from a tissue probability map (TPM) aligned with structural 
images, which can be registered to new data (Fig 2.3). 
Image voxels are classified probabilistically based upon these initial parameter estimates 
(expectation step), and new parameters estimated based on this classification 
(maximisation). This proceeds iteratively, and advantageously, the parameter estimation 
continuously improves (Do & Batzoglou, 2008). The EM method has been adapted into 
several segmentation frameworks for human brains. 
 
                                                        
6: Available from http://sourceforge.net/projects/niftyseg 
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Figure 2.6 Example ex vivo mouse brain T2W image intensity histogram. 
Approximate grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) peaks 
noted, assuming a Gaussian mixture (blue lines). Most CSF is expelled during fixation. 
The MR intensity scale (x-axis) is arbitrary. The GM and WM peaks are not well-
separated: there is a high degree of partial volume (PV), particularly in the midbrain. 
Van Leemput et al. (1999a) included iterative correction for smoothly-varying image 
intensity non-uniformity. The bias field is assumed to be multiplicative in MRI, but after 
log-transformation of the intensities it is additive, and can be modelled using a 
polynomial function, whose parameters are estimated after the maximisation step based 
upon tissues with a narrow intensity distribution. Van Leemput et al. (1999b) and Zhang 
et al. (2001) added a Markov random field (MRF) weighting to increase spatial 
consistency. Voxels’ classifications are assumed to depend statistically upon the content 
of their immediate neighbours, avoiding the misclassification of noise and voxels 
surrounded by other tissue types. In SPM, segmentation, non-uniformity correction and 
registration with TPMs are unified in a single iterative framework, allowing for PV effects 
by assuming each tissue can be represented by more than one Gaussian, and constraining 
classifications based upon the spatial priors (Ashburner & Friston, 2005). TPMs 
supplement the image intensity information and provide a spatial context for the expected 
classification of each voxel. 
TPMs are used to initialise segmentations. They are smoothed or blurred to account for 
population variance, and spatially correspond to template images from an atlas. Within 
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TPMs, voxels are probabilistically assigned one of a number of classes: GM, WM, CSF 
and ‘non-brain’, or ‘background’ (BG). Human studies utilise extensive public TPM 
databases such as MNI305 and ICBM152 (Evans et al., 2012; Fig 2.3), which represent 
a range of naturally-occurring morphologies, balancing specificity for the group under 
study with natural variability. 
TPMs are typically based upon healthy brains. Natural variability (for example, of human 
cortical folds) and pathology (such as severely enlarged ventricles or tissue damage), or 
even healthy ageing, may complicate the use of priors, even when warped to the data 
using non-rigid registration: segmentation results may be biased towards healthy, young 
morphology. If the priors are smoothed to incorporate more variability, they become less 
useful. Cardoso et al. (2011) therefore introduced a prior probability relaxation factor. 
After EM has converged to voxels’ initial classification, the TPMs are multiplied by this 
factor dependent on whether the classified voxels neighbour a different class, thereby 
generating a new ad hoc, image-specific prior for subsequent iterations of EM. This was 
shown to improve segmentation accuracy in an Alzheimer’s disease dataset. 
2.2.5 Mouse brain segmentation and tissue probability maps 
Different approaches have been adopted for segmenting mouse brain data. To avoid an 
atlas, Wang et al. (2010) used a threshold-based method to separate the skull and brain, 
followed by k- and fuzzy c-means clustering of brain tissues based upon intensity. This 
required manual initialisation and would be sensitive to signal inhomogeneity and 
artefacts. Noting the sensitivity of EM to converge to incorrect maxima with 
inappropriate atlases, Tohka et al. (2007) combined EM with a genetic algorithm to 
segment human and mouse brain data without priors. In mice, the technique showed 
improved results over naïve, prior-free EM; however, it required setting a lower bound 
on the amount of GM in different structures (60%, overall). The mixture model had 
classes: {cerebellar GM; cortical GM; WM; CSF} and three PV classes. Noting the 
considerable degree of intensity overlap in mouse brains, the authors stated, 
“segmentation between [GM] structures does not appear possible without applying 
spatial information”. 
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Owing to the variable and reduced MR contrast of the still-myelinating newborn human 
brain, Prastawa et al. (2005) employed atlas-based priors to initialise segmentations, 
noting that histogram-based techniques could not reliably differentiate tissues. Because 
of the increased PV content, a similar issue faces mouse brain segmentation. Atlas-based 
techniques will likely be advantageous. 
Several groups have performed VBM in rodents, although the technique is more complex 
than TBM as it requires prior knowledge of each voxel’s fractional tissue content. A 
substantial source of rodent brain TPMs – a database equivalent to the MNI152 human 
atlas – does not yet exist. Though TPMs based on non-representative atlases may 
misclassify voxels (Cardoso et al., 2011), it is unrealistic to create atlases for each of the 
vast number of mouse strains available. Additional difficulties of tissue classification lent 
by the smaller structures and greater partial volume (PV) proportion in mouse brains, 
especially at resolutions above 150µm (Natt et al., 2002) has meant a slow uptake of 
preclinical VBM. 
Li et al. (2009) classified tissues based solely upon intensity, using FSL FAST. Biedermann 
et al. (2012) initialised SPM segmentations by assigning equal probabilities to every brain 
voxel, and improved classifications via iteration. In both approaches, the observed data is 
fitted without anatomical prior information, which can result in unreliable segmentations 
due to morphological variability, PV, intensity inhomogeneity, image artefacts and 
natural intensity variation within tissues (Cardoso et al., 2011). Other mouse TPM 
creation strategies have included manually thresholding DTI mean diffusivity images to 
create probabilistic priors (Oguz et al., 2011), and segmenting and smoothing the GWR 
average of 87 brains using SPM (Sawiak et al., 2009c). To my knowledge, these comprise 
the only publicly available mouse TPMs. They are included with SPMMouse, a plugin 
for SPM version 5 (Sawiak et al., 2009a; Fig 2.7). However, there is no anatomical 
reference to which external data may be registered; alignment – necessary for priors to 
initialise segmentations – relies entirely upon the TPMs. This may involve some manual 
adjustment, which for large datasets would be prohibitive to high-throughput analysis. 
Nevertheless, Sawiak et al. (2012) manually aligned 399 mouse brain images to these 
TPMs. Kielar et al. (2012) did the same for 30 brains. 
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Figure 2.7 SPMMouse tissue prior maps 
Sample transverse, sagittal and coronal slices (positions indicated by blue lines) through 
GM (row a), CSF (b) and WM (c) maps provided in the SPMMouse package (Sawiak et 
al., 2009a). These are the only publicly-available mouse brain TPMs of which I am aware. 
The scale represents average tissue class proportion. The WM map exhibits a ‘rim’ of WM 
around the cortex (green arrows) and caudally at the cerebellum (pink). Although only 
initialisations for EM in SPM, these misclassifications may cause errors in subsequent 
segmentations, and mismeasurement of tissue volumes (see Fig 2.8). 
TPMs published so far appear to possess several defects, which could propagate to any 
dataset which uses them for a priori information. Those of Sawiak et al. (2009a), Li et al. 
(2009), and Biedermann et al. (2012) exhibit an artificial WM ‘rim’ around the brain, 
where GM/BG PV voxels with lower signal intensity are apparently misclassified. Signal 
drop-off at the cerebellum causes a similar artefact (Fig 2.8). This could cause 
overestimation of BV in probabilistic segmentations (by classifying PV voxels as WM 
with more confidence than deserved); could misattribute volume changes at the brain 
surface to the wrong tissue type; or could cause over- or under-estimation of tissue loss 
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to atrophy. Good et al. (2001) noted similar artefacts in GM segmentations of human 
brains. This was the motivation for their introduction of an “optimised” VBM protocol. 
In Sawiak et al. (2012), the SPMMouse priors were used to initialise the creation of a set 
of study-specific TPMs. The segmentation was repeated using the averaged results of this 
initial segmentation as new priors. The results appear to inherit this problematic rim. 
 
Figure 2.8 Examples of published mouse brain tissue classification results. 
The green arrows, in each case, indicate erroneously classified WM at the cortical surface 
or cerebellum. (a-c): GM and WM slices; only WM is shown for the last example. Results 
from an individual brain are shown in (b); (c) is the combined result after group 
registration, averaging, and smoothing. Adapted from, (a): Li et al. (2009); (b,c): 
Biedermann et al. (2012); (d): Sawiak et al. (2012). 
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2.2.6 Image registration 
Registration algorithms seek to align images with corresponding features, such as 
anatomy, by performing global transformations and local warps. Registration can be used 
to fuse images from different modalities: for example, PET and MRI (Rowland et al., 
2005), which provide complementary functional and structural information. To monitor 
changes in a single patient, it can be useful to align baseline and follow-up MR images 
minutes (such as for MR mammography, Rueckert et al., 1999) or years apart (detecting 
subtle atrophy rates in the brain, Freeborough & Fox, 1997), so that anatomy can be easily 
compared. Surgery may require “real-time” registration, for motion correction. 
Registration provides aligned images (interpolated into the same space) and the 
deformations necessary to repeat the alignment. This is vital for segmentation 
propagation, the transfer of labels from one image (such as an atlas) to another. 
Furthermore, by aligning groups of images, statistical tests can be performed between 
anatomically equivalent regions, either comparing those deformations, or the images 
themselves (§2.2.7). 
Medical image registration algorithms face several difficulties. First, there may not be a 
true, biologically meaningful match between two different images either of the same, or 
different, subjects: in pathology, structures may have atrophied, or be damaged or absent. 
Second, there can be more than one possible “good” solution (a global maximum 
similarity). Third, noise, image non-uniformity and other artefacts may corrupt the 
available information. 
Registration requires: a model describing the transformations between images; a measure 
of similarity or error; a way to interpolate images; and a method for adjusting the 
transformation to maximise similarity or minimise error (an optimiser, Crum et al., 
2003). These are introduced briefly below. 
Algorithms may rely upon the alignment of landmarks or surfaces, principal axes, or the 
centre of mass, assuming that their alignment imputes the alignment of other structures 
(Modersitzki, 2004). However, manual landmark identification is time-consuming for 
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large datasets and subject to human error (Crum et al., 2003), and automatic feature 
extraction requires an additional step. Instead, voxel intensities can be used to measure 
similarity. Within-modality, a direct relationship between images’ intensities may be 
found. A more robust technique, normalised mutual information (NMI, Studholme et al., 
1999), assumes a statistical relationship between intensities, and allows inter-modality 
registration. NMI involves the minimisation of information (joint entropy) in a joint 
histogram, on which two well-aligned images should produce little dispersion. 
A transform is computed between source images ẋ௜ and a target, ẍ, which specifies a 
mapping of voxels in ẍ to those of ẋ௜. The transformation model might be rigid or affine 
(for global adjustments), or non-rigid: elastic, fluid or basis spline (B-spline, for local 
warps). Transformations are usually updated iteratively, with small changes applied, the 
similarity tested, and the optimiser deciding whether an ideal match has been found (halt 
iterations, if a threshold is reached, or the measure has converged on a maximum) or to 
continue improving the accuracy. 
3D rigid-body registration involves 6 parameters, or degrees of freedom (DOF): 
independent translations along, and rotations about, the (ݔ,ݕ, ݖ) axes. Affine 
transformations include these, as well as scaling and shears along the (ݔ,ݕ, ݖ) axes – thus, 
12 DOF. 
Non-rigid registration (NRR) is performed after global alignment, and involves many 
more degrees of freedom to compute a deformation field mapping voxels in ẍ to those in 
ẋ௜: either every voxel in the image can move independently (non-parametric), or a subset 
of voxels is used. A successful, popular implementation is free-form deformation (FFD, 
Rueckert et al., 1999), which parameterises deformations using a mesh of regularly-spaced 
control points (CP), several voxels apart. This mesh is deformed, moving the CPs (to 
improve the similarity metric) and calculating intervening voxels’ displacements, using a 
cubic B-spline. As one CP moves, the four nearest CPs’ positions (in each dimension) are 
updated. In 3D, this involves 4ߜ௫ × 4ߜ௬ × 4ߜ௭ voxels, where ߜ is the CP spacing. 
Reducing ߜ can improve alignment, but drastically increase the required number of 
computations. 
58 
Regularisation constraints can be placed upon the warps to ensure plausible deformations 
and preserve topology. For example, “folding” of the mesh will result in a deletion of 
parts of the image, so should be prevented. This can be achieved using a penalty term on 
the Jacobian determinant, ṳௗ௘௧  (calculated from partial first derivatives of the 
deformation field – see below – and corresponding to expansion or contraction, which 
should never be zero or negative). Also, in some applications of intra-subject registration 
(for example, to correct for inhalation and exhalation), between time-point images TP1, 
TP2, TP3, composing the transformations ẍṿῺ → ẍṿῼ and ẍṿῼ → ẍṿᾨ should equal 
ẍṿῺ → ẍṿᾨ, assuming no tissue loss (such as atrophy). 
A regulariser in FFD is bending energy, the second derivative of the deformation field 
(the rate expansion/contraction varies, spatially). Constraining bending energy results in 
smoothed, more evenly-distributed expansion or contraction, which allows whole 
structures to deform evenly, rather than homogeneous regions exhibiting no change, but 
high-contrast boundary regions exhibiting extreme deformations. 
For this study, I used the open-source NiftyReg7 software, which implements rigid, affine 
and non-rigid registration. Many other tools are available, implementing different 
methods, including ANIMAL8, ANTs9, FLIRT/FNIRT10, and SPM’s DARTEL11. 
The global transformations are computed using a block-matching technique (Ourselin et 
al., 2001), in which sub-regions of ẍ are independently, affinely transformed to match 
equivalent regions, given a search space, in ẋ௜. A subset of these blocks, with the best 
similarity performance, is used to compute the overall transformation – the method is 
thus robust to outliers. 
As preclinical MR images may contain millions of voxels, high-throughput and large-
cohort studies may involve millions of control points. FFD is thus computationally 
expensive. In NiftyReg, NRR can be computed using an efficient version of FFD, fast 
 
                                                        
7: Available from http://sourceforge.net/projects/niftyreg. 
8: Automated Nonlinear Image Matching and Anatomical Labelling 
9: Advanced Normalization Tools, http://stnava.github.io/ANTs 
10: FMRIB (FSL)’s Linear/Nonlinear Image Registration Tool 
11: Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra, (Ashburner, 2007). 
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free-form deformation (F3D, Modat et al., 2010), which was optimised for multi-core 
graphics processing units (GPUs). Several mouse papers have employed FFD (e.g. 
Maheswaran et al., 2009a; Badea et al., 2010; Cleary et al., 2011a; Lebenberg et al., 2011). 
Lee et al. (2009) compared FFD with a fluid registration-based technique for mouse brain 
parcellation. The methods produced comparable performance and were both suitable for 
mouse brains, although the latter required prior intensity standardisation between 
images. Bai et al. (2012) also compared registration methods for parcellation accuracy. 
Non-rigid registrations performed best and produced comparable results. FFD was 
outperformed by a technique known as LDDMM12, although an asymmetric 
implementation of FFD was used. 
In both the block-matching and FFD approaches, a coarse-to-fine scale “pyramidal” 
scheme is used, to increase speed and reduce the chance of local minima. For block-
matching, the registration is first performed using downsampled images. The resulting 
transformation is used to initialise a second registration, with a lower degree of 
downsampling – and so on, until the native image resolution is reached. For FFD, initial 
CP spacing can be doubled a number of times, providing coarse initial alignment. At 
successive levels, ߜ is then halved, until the desired spacing is reached. 
Following registration, each ẋ௜ is resampled into the space of ẍ, which may have a 
different number of – or slightly offset – voxels. The interpolation scheme provides a 
method for treating discrete image data (voxels) as continuous, by computing new 
intensities in the target space. The simplest method is nearest neighbour (used, for 
example, for binary masks and labels); other methods include (tri-)linear and splines, 
which result in sub-voxel smoothing and hence a loss of information. Interpolation thus 
introduces a directional bias, by lowering the quality of the resampled ẋ௜, but not the 
(static) ẍ. 
As discussed throughout this thesis, clinical studies require sensitivity to both disease 
progression and treatment effect: this lowers costs, and increases the efficiency and quality 
 
                                                        
12: large deformation diffeomorphic metric mapping. 
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of therapeutic research. Through its employment in morphometry and other techniques, 
registration plays an important role in such studies. 
Yushkevich et al. (2010), for example, found that directional bias (the asymmetric 
interpolation of only one image in a registered pair) from both global and local 
registrations induced overestimations of hippocampal atrophy in a morphometric study 
of Alzheimer’s disease. Thompson & Holland (2011) showed that such biases in TBM 
could severely influence power calculations and sample size estimates for clinical trials. 
Leung et al. (2012) showed that symmetric registration provided improved estimates of 
atrophy over asymmetric, using the Boundary Shift Integral (§6). Recent developments 
in registration algorithms have therefore focussed on reducing biases. 
Both the global block-matching and local NRR methods in NiftyReg have been updated 
to provide symmetry and inverse consistency (Modat et al., 2014; 2012), such that the 
transformation from registering image ṡ → ṣ equals the inverse of that from ṣ → ṡ. 
Although there are several other implementations of symmetric NRR (e.g. Avants et al., 
2008 – part of ANTs; Tao et al., 2009), there are very few inverse-consistent global 
registration techniques (Modat et al., 2014 identified only one other). These robust 
methods are likely even more important for in vivo mouse brain MRI, as the larger voxels, 
greater PV and lower contrast mean there is less image information available to drive 
accurate registration. 
Group-wise registration 
Group-wise registration (GWR) aims to align all images within a common coordinate 
space, resulting in an average “atlas” image representing the mean group morphology, 
and deformation fields mapping each voxel to points in the original image space. 
Parcellations of the average can thus be easily propagated to each original image, and 
group statistical comparisons performed at each voxel within the common space. The 
multi-level, iterative scheme (Fig 2.9) was described by Rohlfing et al. (2004) for bee 
brains, and then Kovačević et al. (2005) for mice – and adopted by many subsequent 
papers. 
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Figure 2.9 Iterative group-wise registration illustrated using sagittal images from in-
skull mouse brain MRI. 
All images from each group are initially rigidly registered to a randomly-chosen target (*). 
In the target space, the intensity average is found. For the second global iteration, 12 DOF 
affine registration is used to match each image to that average (thin green arrows), and a 
second average is computed. This continues for several iterations (pink arrows), after which 
NRR iterations begin, initially using the final affine average image as a target. The average 
images consist of the mean sample shape from all groups. See Figs 3.18, 3.20 for more. The 
lower inset images show detail zooms of the same cerebellar region in ṡே (indicated) and 
the NRR iteration (it.) 15 average. The average image has been smoothed from 
interpolation, but has lower noise than the individual. Fine detail, such as the Purkinje cell 
layer (dark, indicated Pkj), a single cell thick, is still clearly visible. 
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Registration is performed between a target, ẍ, and the source images, ẋ. ẍ is initially 
randomly selected from the images under study, eliminating possible bias toward external 
features. During iteration ⱶ, each image ẋ௜ is registered to ẍ, and the intensity average 
ṡ௡ of all transformed, resampled ẋ௜ in the space of ẍ found. In the subsequent iteration 
ⱶ + 1, ṡ௡ replaces ẍ. For the first iteration, rigid registration is used (6 DOF only), and 
ṡῺ is thus quite blurred and unbiased by features of ẍ besides global position and 
rotation. For ⱶ = 2 onward, affine (12 DOF) registration is used. As ⱶ increases, the 
alignment improves, and ṡ௡ sharpens. After several iterations of affine registration, non-
rigid registration is employed (initialised by the final affine transformation), and ṡ௡ 
sharpens further and approaches the true average global morphology (Figs 2.9, 3.18). 
The stopping point can be decided subjectively via observation of ṡ௡, or using a measure 
(such as intensity standard deviation at each voxel, Fig 3.20, or label overlap, as Lau et 
al., 2008) which plateaus or converges after a certain number of iterations. Only one 
interpolation is performed at each level, as the global and local transformations are 
composed together before final calculation of voxel positions (Yushkevich et al., 2010).  
For mice, Nieman et al. (2006) adopted a different technique, registering mutant mouse 
brains to the GWR average of the control group, which is unlikely to provide the optimal 
deformations or an unbiased average morphology. Biedermann et al. (2012) used SPM to 
register brains, scaling images × 10 for human parameters. SPMMouse includes adjusted 
parameters and a mouse TPM for use as the initial target to which the group is registered. 
However, targets should have a similar background to the subjects studied; any features 
not reflected in the cohort may introduce bias toward external morphology. The large 
number of mouse strains thus constitutes a significant impediment to the construction 
of a universally applicable target. 
2.2.7 Voxel- and Tensor-Based Morphometry 
Following GWR into the space of an average image, the deformation fields are used in 
TBM to measure local volume differences between groups. In VBM, segmentations are 
derived from the intensity information embedded in voxels, and used to determine 
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changes in local tissue volume or concentration between groups or over time. Segmented 
tissues are aligned into the GWR average space, and compared at every voxel. 
These techniques are non-invasive and hypothesis-free, covering the entire brain and 
thereby reducing the need for the laborious delineation of regions of interest. In an early 
VBM paper, Wright et al. (1995) registered GM and WM maps from 15 patients with 
schizophrenia. The authors found that GM density (in the temporal lobe) and WM 
density (in the corpus callosum) were correlated with patients’ scores in tests of 
schizophrenia syndromes. In a well-cited work, Maguire et al. (2000) sensitively showed 
specific hippocampal volume increases in London taxi drivers, compared with controls, 
suggesting a structural correlate with spatial navigation skills. These studies highlighted 
the sensitivity of morphometry to group differences due to both disease and plastic 
learning and memory-related brain changes, and presaged the techniques’ widespread 
utilisation in the clinical literature. 
In animal studies, they ease the burden of exploratory histology, which is both destructive 
and time-consuming. Statistical tests of other values are possible in the GWR average 
space. For example, Teipel et al. (2011) measured brain T2 relaxation times on a voxel-
wise basis in an AD mouse model, compared with controls. Lebenberg et al. (2011) used 
a GWR approach to register autoradiographic data of glucose uptake and metabolism in 
mouse brain tissue slices reconstructed into a 3D volume. 
Tensor-Based Morphometry 
In TBM, for each source image, the 3D displacement transformation ɤ(⃗ݔ) = ቌẍ௫ẍ௬
ẍ௭
ቍ 
maps a voxel at position ⃗ݔ = (ݔ,ݕ, ݖ) in the final GWR average (reference) space to its 
corresponding position in the original image. For 3D deformation fields, the Jacobian 
matrix ṳ at each voxel is a 3 × 3 tensor of displacement gradients (Chung et al., 2001), 
given by the first-order partial differentials of each component of the transformation. Its 
determinant is: 
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Where ɤ௫(⃗ݔ) is the first component of the deformation field which transforms voxel 
position ⃗ݔ in the reference image to the equivalent position in the floating image. ṳ 
contains information about the elongation and contraction, in each direction (Ashburner 
& Friston, 2003). The determinant ṳௗ௘௧  is a scalar value which represents the relative 
expansion (when >1) or contraction (when <1) of that unit voxel to encompass an 
equivalent region in the original image (Fig 2.10). If ṳௗ௘௧ = 1, there is no volume change, 
and if ṳௗ௘௧ < 0, as previously stated, there is “folding” of the voxel grid (Ashburner & 
Friston, 2000). 
 
Figure 2.10 Local expansion and contraction in a deformation field. 
A regular grid overlaid on an average mouse brain image (after several iterations of GWR) 
and warped following a deformation field which maps the average to an individual image. 
The inset illustrates some regions expanding (blue; ṳௗ௘௧ > 1), while others contract (red; 
ṳௗ௘௧ < 1) from their average volume to encompass the same anatomy in the original. 
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The NiftyReg implementation of GWR includes the final affine (global) and NRR (local) 
iterations’ transformations in ṳ. If the affine were omitted, the ṳௗ௘௧  value can simply be 
multiplied by the determinant of the affine matrix, to give the overall scaling factor. 
In deformation-based morphometry (DBM), the vector lengths themselves (or 
sometimes the directional components of ṳ, giving shape change) are compared, between 
groups. In TBM, ṳௗ௘௧  values from each group are compared, at every voxel, often using 
a t-test. An assumption of t-tests is that values are normally distributed, but because ṳௗ௘௧  
is always positive, the distribution is skewed, and assumed lognormal. ṳௗ௘௧  values are 
therefore usually log-transformed, prior to statistical tests, to render them more normally 
distributed (Chung, 2012). This renders, via symmetry about zero, expansions and 
contractions of equal magnitude to be equally likely (Leow et al., 2007). 
Smoothing (with a Gaussian kernel with given full width at half maximum, FWHM) 
also aides this assumption of normality13, compensates for imprecise registration, and 
reduces the influence of noise. The FWHM is chosen to correspond to, and hence 
enhance, the expected spatial scale of structural differences between groups: smaller 
structures’ volume changes are likely to be smoothed out14 (Ashburner & Friston, 2001). 
In the human brain, this is generally of the order 8—12mm (e.g. Good et al., 2001; 
Carducci et al., 2013). 
The result of performing these mass-univariate, voxel-wise t-tests is a statistical parametric 
map (SPM), conferring (after multiple testing correction) significance or non-significance 
of the mean local volume difference between groups. These maps are useful for 
exploratory or naïve morphometry, without prior assumptions about the location of 
volume differences. Thus, for example, regional growth or atrophy can be estimated 
between time-points (Brambati et al., 2007; Maheswaran et al., 2009a), or local volumes 
compared between transgenic and wild-type groups (Ellegood et al., 2010). Alternatively, 
the ṳௗ௘௧  values themselves can be integrated over parcellated regions of interest in the 
 
                                                        
13: Via the Central Limit Theorem: that is, with enough observations with a well-defined (unique) variance 
and expected value, the mean of observations tends towards a normal distribution. 
14: The Matched Filter Theorem. 
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final average image, giving structural volumes for each subject (Jacobian integration, Boyes 
et al., 2006). 
Voxel-Based Morphometry 
In VBM, images are registered and aligned to GWR space, as above. They are either 
segmented beforehand (in which case, the segmented tissues are warped and interpolated 
into the final average space, using their images’ respective transformations), or after 
alignment (it is assumed that interpolation and consequent PV does not corrupt the 
subsequent segmentation, Ashburner & Friston, 2000). 
The aligned segmentation values, for each tissue class of interest, are then compared at 
each voxel. It is assumed that these accurately represent the underlying tissue, and that 
there are no systematic differences between image acquisitions, which might bias 
segmentations via, for example, different noise levels between scanners. VBM was 
developed prior to the advent and common availability of highly accurate, computer 
resource-intensive NRR algorithms, and thus transformations were not expected to 
achieve precise alignment between images (Ashburner & Friston, 2001). A smoothing step 
(as above) is applied to compensate for possible misalignments. Smoothing also 
introduces a PV continuum, and, by incorporating neighbouring voxels, constitutes a 
spatial averaging of segmented values – equivalent to assessing GM “density” or 
“concentration” within an ROI, or the proportion of GM relative to other tissue types, 
since at every voxel following segmentation, the proportions of all tissues sum to 1 
(Ashburner & Friston, 2000). 
Because smoothing introduces a spatial aspect to the segmentation, Ashburner & Friston 
(2000; 2001), and Good et al. (2001) suggested applying a “modulation” step. This 
compensates for the change in total volume of the tissue within structures commensurate 
with the deformations from registration (Fig 2.11). Voxels’ concentration values are 
multiplied by their ṳௗ௘௧  from TBM, thereby preserving tissue volume, and the statistical 
test is between regional absolute tissue volumes. Modulation allows this comparison 
having accounted for larger volume differences via registration. Without modulation, the 
comparison is not between local volume differences (GM or otherwise); it is directly 
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between tissue concentrations (from the original images’ space – i.e., GM probability, or 
proportion). Hence Ashburner & Friston (2001) placed modulated VBM on a 
“continuum” with TBM: both examine local volume. 
 
Figure 2.11 Explanation of modulation in VBM. 
If initial segmentations seg1 and seg2 of structural images i1 and i2 represent the relative 
volume of a particular tissue at each voxel, then modulation is a volume-preserving step. 
Here, greyscale represents intensity, hence, the voxel values after image segmentation. 
Following segmentation of i1 and i2, i1 is registered to i2. The resulting transformation T 
is used to warp seg1 into the space of i2. Here, region A shrinks and region B retains its 
volume. To preserve tissue volume at each voxel, transformed seg1 is modulated (M) by 
dividing voxel values by the relative local volumes of (transformed i1)/i1 (equivalent to 
multiplying by ṳௗ௘௧). Intuitively, in this illustration, the density increases (modulated A is 
darker), thereby preserving volume. Region B does not change size, so intensities remain 
constant. Voxel-wise tests will show differences in B, but none in region A. If modulation 
was not performed, here they would show differences at all voxels. 
Contemporary fine-scale NRR methods, with high degrees of freedom, likely account for 
the majority of group volume differences within the deformations (as predicted by 
Ashburner & Friston, 2000). Modulated VBM may therefore closely approximate TBM. 
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Unmodulated VBM may still be used to test for voxel-wise differences in the underlying 
tissue concentration. Each method is valuable and likely to reveal group effects in 
different regions due to distinct aspects of neuroanatomy (Keller et al., 2004; Mechelli et 
al., 2005). 
Criticisms of VBM 
VBM originally incorporated allowances for some uncertainty in the alignment achieved 
between brains. Registration would model “macroscopic” volume and shape, while 
segmented values could reveal smaller-scale, regional volume differences. Several 
criticisms arose of the formalised VBM methodology proposed by Ashburner & Friston 
(2000). Bookstein (2001), adopting the “continuum” analogy, noted the difficulty of 
quantifying volume differences (from registration) using the same scale as intensities 
(from segmentation). However, this is accounted for by modulation (as above). The same 
paper indicated, and Ashburner & Friston (2001) agreed, that significant apparent group 
differences may arise between tissues at boundaries where there is a misregistration. This 
is particularly concerning when the registration is known to be imprecise, such as when 
low-dimensional warps are used to align images (as in the original VBM 
implementations), and when there is no true one-to-one correspondence between brains, 
as in the highly variable human cortex (Crum et al., 2003). Systematic misregistrations 
may also be caused by biological differences between groups (Teipel et al., 2013). 
Contemporary NRR algorithms, with many degrees of freedom, allow improved 
alignments, especially between the relatively simple structures of mouse brains, and these 
can be checked visually. Using VBM to examine residual volume differences may 
therefore be redundant (Crum et al., 2003). 
Keller et al. (2004) noted that unmodulated VBM appeared less sensitive for detecting 
hippocampal GM atrophy than modulated VBM, when using ‘optimised’ VBM (Good 
et al., 2001), which improves alignment using customised GM templates. Both 
techniques revealed bilateral patterns of hippocampal volume loss, but this suggests that 
the majority of group differences were volumetric rather than in tissue concentration. 
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While the physical meaning of TBM results (volume differences) is unambiguous, the 
effects underlying statistical maps from VBM require interpretation; rejection of a null 
hypothesis does not confer the underlying cause. At the beginning of the century, the 
technique’s clinical usefulness was unclear. VBM is a test of either local segmented tissue 
concentration or (after modulation) absolute volume. The past decade has provided 
accumulating evidence that VBM measures are reproducible (Ewers et al., 2006) and 
correlate well with pathology, such as atrophy in Alzheimer’s disease (Karas et al., 2003; 
Chételat et al. 2005; Whitwell et al., 2008; Teipel et al., 2013). Several hypotheses exist 
regarding the tissue changes underlying VBM, including atrophy, altered neurogenesis or 
cell-specific changes such as size and density (Keifer et al., 2015). These will affect tissue 
T1 and T2 relaxation times, and hence the MRI signal and its segmentation (Zatorre et 
al., 2012). 
Additional criticisms arise from the fact that segmentation methods which produce 
variable or unpredictable estimates in the presence of PV may produce unreliable VBM 
results in these regions (Thacker, 2003). This might be an important concern in the 
mouse brain, wherein the degree of PV is high, and may vary regionally between strains. 
Statistical tests 
In the final GWR average space, at each brain voxel (and thus, at anatomically equivalent 
locations across all images), groups’ tissue segmentations or log-transformed ṳௗ௘௧  values 
may be statistically compared to derive the most significant regions of difference, and 
hence of most scientific interest, visualised using a statistical parametric map. A common 
method for doing so is with t-tests to compare group means, using the general linear 
model (GLM) embedded in SPM, FSL, or other analysis software. The null hypothesis 
H0 is that means are equal. It is assumed that every voxel in image ⱪ can be tested 
independently, and that after fitting the model, the residuals are normally distributed 
(Ashburner & Friston, 2000). Each voxel represents a response variable ݕ௜ which is linearly 
dependent upon a summed combination of ⱴ independent variables ݔ௜, and their 
respective weights ẙ, which represent the contribution of the variable to ݕ௜: 
70 
E2.2 ݕ௜ = ẙΏ + ẙῺݔ௜Ὼ + ⋯+ ẙ௞ݔ௜௞ + ߝ௜ 
Here, ẙΏ is an intercept term and ߝ௜ is the residual error. In general form, E2.2 can be 
expressed as: 
E2.3 ࢅ = ɨɒ + ʢ 
Here, ࢅ is a matrix whose rows correspond to each image and columns to aligned voxels; 
ɨ is a design matrix coding group memberships (such as WT or transgenic) and covariates 
describing the independent variables (such as TIV; age; sex); ɒ is a vector of parameters 
to be estimated; ɨɒ is their dot product; and ʢ is a vector of assumed normally-
distributed errors, such as noise. ɒ is estimated (ɒ෡ ) to give the smallest sum of squares of 
the residuals, ∑ ߝ௜
ῼ
௜ . In SPM this is done using the pseudoinverse of ɨ, ɨᾯ (Kiebel & 
Holmes, 2006): 
E2.4 ɒ෡ = ɨᾯࢅ 
The model predictions (fitted values ࢅ෡) and residual sum of squared errors ẉ are then: 
E2.5 
ࢅ෡ = ɨɒ෡  
ẉ = Ѷ൫ࢅ− ࢅ෡ ῼ
௜
 
To isolate the contribution of certain parameters ẙ to ݕ, for example if genotype is of 
interest, and a confounding covariate such as age is not, ɒ෡  may be multiplied using a 
vector of appropriate contrasts, ɬ. The following equations show the calculation of the t-
statistic using the mean residual sum of squares ṹẉẋẋ, and the standard error, ẋṩ: 
ṹẉẋẋ = ẉ
ṧṽṫ
 
ẋṩ = │ṹẉẋẋ × ɬ((ɨ்ɨ)ᾯɬ்)మ  
ݐ = ɬɒ෡
ẋṩ
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The DOF is the number of images minus the number of independent regressors 
(columns) in ɨ. Thus, mass-univariate tests are performed over the entire brain, fitting 
parameters to each voxel. 
Non-parametric permutation tests (as implemented in FSL’s Randomise) may be more 
robust to non-normally distributed data (Ashburner & Friston, 2000), but require a long 
time to test each possible permutation of every voxel (or a large enough number of 
permutations to achieve an estimate of the distribution, Groppe et al., 2011). Under the 
assumption that there is no effect of, for example, genotype (H0), for each voxel genotype 
labels are exchanged amongst images and a test statistic calculated comparing groups. A 
distribution is constructed by repeating the test after permuting label combinations. A 
voxel’s p-value is the probability, over the image, of observing a more extreme test statistic 
(Nichols & Holmes, 2001). 
The multiple testing problem and false discovery rate 
In a 0.5ml mouse brain with 40µm3 voxels, using conventional mass-univariate t-tests, 
there shall be 7.8 × 10ᾮ tests of H0. A Type I error rate ߙ = 0.05 therefore implies 
390,625 false positives (the familywise error rate, FWER, over the whole image): this is 
the multiple testing problem (Nichols & Hayasaka, 2003). There are various methods for 
compensating. 
Decreasing ߙ at every voxel increases specificity (1 − ߙ), lowering the probability of a 
single false positive. This simultaneously increases the false negative (Type II error) rate, 
ߚ (thereby lowering sensitivity, or power, 1 − ߚ), and is the reason the highly 
conservative Bonferroni correction (ߙᾥ௢௡௙ = ߙ/ṻ, where ṻ is the number of tests) is 
avoided in morphometry with thousands of voxels. 
Given an SPM with some voxels declared significant, cluster-based approaches use the 
size and “mass” of regions of significance to distinguish less significant “noise” such as 
single, isolated significant voxels (Smith & Nichols, 2009). Clusters’ locations can be 
compared with a Gaussian random field to estimate which might arise randomly. This is 
helpful because smoothing introduces spatial correlation between neighbouring voxels, 
reducing the number of independent observations (Brett et al., 2003). There are 
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difficulties applying this to structural data, however, as there is greater variance at 
boundaries, where smaller clusters might be expected than in large, homogeneous regions 
(Thompson et al., 2003). 
The false discovery rate (FDR) is a popular and simple alternative control of false positives 
in functional and structural experiments. If there are ẉ total rejected null hypotheses, ẉῲ 
of which are false, controlling FDR limits the expected mean of ẉῲ/ẉ over many tests 
(Groppe et al., 2011). If the chosen FDR rate ݍ = 0.05, on average at most 5% of the H0 
rejections will be false. The procedure assumes tests are independent and is as follows 
(Benjamini & Hochberg, 1995; Genovese et al., 2002): 
1. Sort p-values in ascending order, such that for ⅎ tests, ݌௜ is the ⱪth smallest. 
2. Let ⱴ be the greatest ⱪ for which ݌௜ ≤ ቀ
௜
௠
ቁݍ. If ⱴ does not exist, stop. 
3. All null hypotheses 1…ⱴ are rejected; the remainder are not. 
Because structures’ variance between subjects is higher in some regions (such as the 
ventricles), controlling the overall ߙ at an arbitrary level can lower sensitivity. Controlling 
the proportion of H0 rejections which are false is more powerful. 
2.2.8 Preclinical use of V/TBM 
In humans, inter-subject variability in the cortical gyri and sulci make true anatomical 
correspondence impossible, even in healthy individuals (Crum et al., 2003). Hence, 
techniques such as the Boundary Shift Integral (§2.3; §6) rely upon affine registration 
alone. However, the mouse cortex is far simpler. The low variability within in-bred strains 
even allows one-to-one correspondence within cerebellar folds (Fig 2.9 inset). 
Morphometric techniques are therefore especially valid: registration exploits this reduced 
variability to precisely align large groups, allowing statistical techniques to search for 
subtle structural changes at small spatial scales. 
Though not comprehensive, Table 2.1 provides an overview of preclinical mouse 
V/TBM, as used in the literature. DBM (deformation based morphometry) refers to the 
direct comparison of deformations’ magnitude or direction, used for example to compare 
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in vivo to ex vivo (Ma et al., 2008) or within-group local variation (Kovačević et al., 2005). 
TBM refers to the voxel-wise analysis of Jacobian determinants (expansion or 
contraction). 
Both TBM and DBM have been used to identify neuroanatomical phenotypes in diseases 
such as Huntingdon’s (Sawiak et al., 2009b; Zhang et al., 2010), multiple sclerosis 
(MacKenzie-Graham et al., 2006); and Alzheimer’s (Lau et al., 2008; Maheswaran et al., 
2009a). Once these physical traits have been identified, localised histology may be used 
to confirm them (Sawiak et al., 2009b; Keifer et al., 2015; Wells et al., 2015). In light of 
the above-mentioned taxi driver study, several groups have focussed on plastic changes in 
the brain resulting from learning or abnormal behaviour. For example, Nieman et al. 
(2007) summarised findings from various MRI protocols, finding 13/15 mouse 
behavioural mutants had imaging-identified physical brain alterations. Lerch et al. (2011) 
found that just 5 days of maze training was enough to induce volume changes specific to 
the hippocampus or striatum. Carey et al. (2013) used VBM to confirm local GM 
reductions in the brains of mice with an inducible HIV15-linked gene, hypothesised from 
behavioural differences. Chen et al. (2005) noted that structural differences were not 
always predictive of functional changes, but also used morphometry to show intra-strain 
differences were smaller than those between strains. Morphometry techniques are robust 
to any structural imaging modality with sufficient resolution and contrast: Nieman et al. 
(2006) used µCT to analyse skull shape, and Wong et al. (2014) found µCT images 
possessed sufficient contrast to study mouse embryos. 
All 44 studies listed describe a registration protocol to align the group of brain images 
under investigation. 16 include multiple-subject scans. The majority of these were 
performed with a custom array of receiver coils, so subjects did not require separation 
(see §3.2). Only 7 use VBM. 14 use in vivo brains, but only 5 take advantage of 
longitudinal measurements. By culling mice at different ages and scanning at high 
resolution, cross-sectional studies may measure longitudinal development (Zhang et al., 
2005; Sussman et al., 2013). However, this requires more mice and is subject to inter-
 
                                                        
15: Human immunodeficiency virus. 
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individual variability: serial measurements in the same animals would improve statistical 
power. It is clearly important to establish whether advanced image analysis techniques 
may provide sufficient detail and power in vivo. 
The relative infrequency of mouse VBM studies may be due to several factors. TBM 
measures an intuitive, easily-identified metric from deformation fields (local physical 
expansion or contraction). VBM requires more pre-processing steps (tissue segmentation; 
transformation of those segmentations; and sometimes modulation) and is less easily 
interpreted (see criticisms, above). Although histological tissue volume has been correlated 
with TBM results (e.g. Kielar et al., 2012), it is not clinically established what underlying 
tissue changes are reflected in VBM – perhaps because of the difficulty of performing 
neuronal counts or obtaining human tissue post-mortem (Teipel et al., 2013). A recent 
paper, however, suggested that dendritic spine density may cause VBM changes (Keifer 
et al., 2015). 
Far more papers are published exploiting morphometric techniques in human brain 
MRI16. In part, this is likely thanks to the availability, and ease of use, of widely-available, 
integrated software packages, customised for human data with parameters, atlases and 
tissue prior maps. These include 3D Slicer17; AtlasWerks18; BrainVoyager19; SPM; 
Freesurfer; and FSL. 
As discussed in §3.1, these packages omit, or are not suitable for, some of the 
preprocessing steps necessary for morphometry in preclinical images. For example, there 
is no provision for multiple subject scans, and no way to orient brains automatically to 
standard space if they are not already in a predefined orientation. Tissue priors and 
registration parameters must be customised for the scale and shape of mouse brains; and 
non-uniformity correction may be necessary at several stages, to account for surface coils 
and the higher field strengths of preclinical scanners. 
 
                                                        
16: In a review, Piras et al. (2015) found 156 VBM papers addressing obsessive-compulsive disorder, alone. 
17: www.slicer.org, Fedorov et al. (2012). 
18: www.sci.utah.edu/software/atlaswerks.html 
19: www.brainvoyager.com 
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Very few of the studies listed in Table 2.1 describe the processing steps in detail. Although 
not distributed as integrated software packages, some pipelines do exist for processing 
preclinical images. Kovačević et al. (2005) included a method for intensity standardisation 
– a necessary prior step to remove bias (§3.7) – based upon the GM histogram peak. 
Lee et al. (2009) used the UFL atlas (Ma et al., 2005) as a basis for skull-stripping, tissue 
segmentation, and parcellation. Gerig et al. (2011) developed a pipeline for human and 
in vivo rodent images, incorporating a standard atlas space; EM-based tissue 
segmentations and parcellations similar to Lee et al. (2009), with DTI and cortical 
thickness analysis. They generated tissue priors for rat data using the NUS mouse atlas. 
Badea et al. (2012) described a pipeline for skull-stripping, GWR and atlas-based 
parcellation for multi-spectral (T1W; T2W; DTI) MR data, using the standard Waxholm 
space and an average atlas. Budin et al. (2013) described a web-based interface to simplify 
these steps. In each of these, procedures to accommodate multi-subject scans were 
omitted. Uptake of such standardised methods has been slower in the preclinical 
paradigm. Their use is especially important because the small scale of mouse brains will 
magnify the importance of errors. 
The aim of §3 is to show extensions to these pipelines, integrated with up-to-date clinical 
registration, segmentation and multi-atlas parcellation techniques, to perform all the 
necessary image processing steps fully automatically, to meet the need for image 
processing in high-throughput preclinical studies. 
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Ali et al. (2005) C57Bl/6J ex.  90 -  
Chen et al. (2005) WT ex.  60 DBM & TBM  
Kovačević et al. (2005) in-bred ex.  60 DBM 2 
Ma et al. (2005) C57Bl/6J ex.  47 DBM  
Verma et al. (2005) age ex.  93 & 120 - (FA)  
MacKenzie-Graham et al. (2006) MS ex.  60 -  
Nieman et al. (2006) GJA1 in. & ex.  110 & 80 DBM & TBM • 
Badea et al. (2007b) Reln ex.  21.5 shape  
Clapcote et al. (2007) schizophrenia ex.  - TBM  
Nieman et al. (2007) behaviour in. & ex.  32-115 DBM & TBM • 
Spring et al. (2007) sex ex.  32 DBM & TBM 3 
Lau et al. (2008) AD in. L 156 TBMD  
Lerch et al. (2008) HD ex.  32 DBM & TBM 3 
Ma et al. (2008) C57Bl/6J in.  100 DBM  
Aggarwal et al. (2009) C57Bl/6J in. & ex.  50-125 DBM  
Lee et al. (2009) FXS ex.  100 -  
Li et al. (2009) schizophrenia in.  98-250 VBM  
Maheswaran et al. (2009a) AD in. L 78-156 TBMD  
Mercer et al. (2009) Magel2 ex.  32 TBM 3 
Sawiak et al. (2009c) HD ex.  70 VBM  
Sawiak et al. (2009b) HD ex.  70 -  
Badea et al. (2010) AD ex.  21.5, 43 TBMD  
Ellegood et al. (2010) FXS ex.  32 TBM 3 
Spring et al. (2010) C57Bl/6J ex.  32 TBM 3 
Xie et al. (2010) AD (rTg4510) in.  125-300 TBM  
Zamyadi et al. (2010) embryo in-bred ex.  ~49 DBM & TBM 32 
Zhang et al. (2010) HD in. & ex. L 80-250 TBMD  
Cheng et al. (2011) HD in. L 100-250 TBMD  
Chuang et al. (2011) age ex.  - DBM  
Ellegood et al. (2011) autism ex.  32 TBM 3 
Lerch et al. (2011) learning ex.  32 TBMD 3 
Teipel et al. (2011) AD in.  31.25-600 VBM  
Yu et al. (2011) Fgf17 in.  100 TBMD  
Biedermann et al. (2012) exercise in.  78-156 VBM  
Carey et al. (2013) learning/memory ex.  39-500 VBM  
Kielar et al. (2012) ataxia ex.  70 TBM  
Badhwar et al. (2013) AD ex.  32 TBMD 3 
Ellegood et al. (2013) autism ex.  16 TBM 56 
Sawiak et al. (2013) HD in. & ex.  70 VBM & TBM  
Sussman et al. (2013) diet ex.  130 TBM  
van Eede et al. (2013) C57Bl/6J ex.  56 TBMD 16 
Wong et al. (2014)  embryo age ex.  13.4 (µCT) TBMD  
Allemang-Grand et al. (2015) AD in & ex. L 125, 78 & 56 TBM 7 
Keifer et al. (2015) learning ex.  81-162 VBM 9 
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Table 2.1 Selection of morphometry papers and pipeline features (previous page). 
Publications (sorted by year) including voxel-wise brain (41) or embryo (2) morphometry 
measures found during a literature search encompassing mouse MRI (one µCT) 
morphometry or phenotyping. ‘•’ indicates the processing step (detailed in §3) is at least 
mentioned. Age: ageing, development, or maturation; C57BL/6(J): in-bred WT mice; 
Fgf17: Fibroblast growth factor 17 (brain organisation in early development); FXS: fragile 
X syndrome; GJA1: oculodentodigital dysplasia; HD: Huntington's disease; Magel2: 
Prader-Willi syndrome; MS: multiple sclerosis; Reln: Reeler mouse neurodevelopmental 
model; sex: sexual dimorphism; rTg4510: tauopathy in AD (see §5); WT: comparison of 
WT in-/out-bred variability. TBMD: referred to by authors as DBM; shape: comparison of 
brain and substructure surface mesh shapes between groups; FA: comparison of registered 
FA maps. Resolution: smallest-largest voxel dimensions; isotropic otherwise. 
2.3 Alzheimer’s disease 
Among the many genetic and sporadic ailments which we may wish to model in animals, 
neurodegenerative diseases, with their devastating, debilitating effects, are perhaps the 
most sinister. Thanks to several revolutions in healthcare knowledge and practice of the 
past 200 years – including in anaesthesia, blood transfusion, germ and antiseptic theories, 
vaccines, artificial organs and imaging – humans, in increasing populations, can expect 
to live longer. With our advancing years, natural brain tissue loss is inevitable (termed 
“healthy ageing”). However, in some individuals, age confers a startlingly increased risk 
of dementia. It is not fully understood why. 
The emotional and economic burden of dementia – loss of cognitive function caused by 
accelerated neurodegeneration – is extremely high, affecting individuals, families, society, 
and countries’ finances, as individual or institutional care must be provided (Ferri et al., 
2005). The annual cost to the UK is estimated as £26.3Bn20; the majority is paid by 
individuals and families, rather than by the state. One of the strongest risk factors is age: 
in the UK, 1 in 700 people under 65 have dementia; but over 65, 1 in 14; and over 80, 
 
                                                        
20: This is 1.3% of UK gross domestic product (World Bank, 2014). 
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1 in 6. Worldwide, by 2050, the population of those over 60 years of age will increase by 
1.25Bn, and 115 million people will have dementia if disease-modifying treatments are 
not found (Brookmeyer et al., 2007; Prince et al., 2013; 2014). 
Alzheimer’s disease (AD) is the most common cause of dementia, representing 62% of 
cases in the UK. Vascular dementia (17%), dementia with Lewy bodies (4%) and 
frontotemporal dementia (FTD, 2%) follow (Prince et al., 2014). Patients may present 
for diagnosis after family members notice a slow onset of memory loss, arising over several 
months, or behavioural changes. Diagnosis relies upon a large number of factors, 
including history, performance on cognitive tests such as the Mini-Mental State 
Examination (MMSE)21, and clinical judgment. Mild cognitive impairment (MCI) may 
be suggested if the patient retains social or occupational independence; dementia, if they 
do not (Gauthier, 2007; Albert et al., 2011). Brain imaging, such as MRI, can provide 
valuable, complementary, differentiating information to distinguish early dementia or 
MCI (Frisoni et al., 2003). The patterns of atrophy revealed by high-resolution structural 
MRI can also aide the diagnostic separation of AD, FTD, dementia with Lewy bodies 
and vascular dementia (Frisoni et al., 2010). 
Cognitive decline in AD is strongly correlated with neurodegenerative atrophy, the 
cumulative damage, synapse loss and neuronal death detectable by MRI as cortical 
thinning, hippocampal shrinkage, and ventricular enlargement (Terry et al., 1991; 
Vemuri et al., 2009; Vemuri & Jack, 2010). These effects are downstream of underlying, 
driving pathophysiological brain changes. 
Diagnosis of AD is “possible” or “probable” until “definite” confirmation with histology 
via biopsy or autopsy (Gauthier, 2007). The hallmarks in tissue are extracellular plaques 
of amyloid-beta (ṡߚᾬΏ and ṡߚᾬῼ: respectively, soluble and hydrophobic amino acid 
chains) and intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated tau. 
These have characterised the disease since their first description, in 1911 (Goedert & 
 
                                                        
21: A score below 24/30 implies early dementia, but “normal” scores also vary between individuals. 
80 
Spillantini, 2006), and are found in both early- and late-onset cases (respectively, pre- 
and post-age 65). 
The majority of cases (>95%) are late-onset. The remainder usually progress faster and 
are often from families with a history of AD (Gauthier, 2007; Reitz & Mayeux, 2014). 
Both inherited genes and environmental factors are thought to play a role in AD 
pathogenesis. A subset of early-onset, familial cases (<1% overall) are autosomal 
dominant22 (ADAD), in which rare mutations in three genes are inherited. Their 
penetrance (the chance of the phenotype arising, given the mutation) is >85% (Bertram 
& Tanzi, 2008; Bateman et al., 2011; Reitz & Mayeux, 2014). As these account for only 
a small proportion of familial AD cases, there are likely further, undiscovered genetic risk 
factors. Only a few genes, most identified in genome-wide association studies, have so far 
been implicated in late-onset AD. Of these, the strongest effect is from an allele of 
ApoE23, ߝ4. Carrying one copy of this variant increases the risk of developing AD at some 
point by 2—3 times; two copies increase it by 5 or more (Reitz & Mayeux, 2014). 
ṡߚ is formed by cleavage of the amyloid precursor protein APP, by the proteases ߚ- or 
ߛ-secretase (Giacobini & Gold, 2013). All three ADAD mutations (in APP, presenilin 1 
and presenilin 2 genes) are related to this process, by increasing ṡߚ production or the 
ṡߚᾬῼ ṡߚᾬΏ⁄  ratio (Bertram & Tanzi, 2008). ApoE mediates ṡߚ clearance from the brain, 
and of its three alleles, ε4 is the least efficient (Tarasoff-Conway et al., 2015). These 
observations reinforced the “amyloid cascade hypothesis”, which posits that an imbalance 
between ṡߚ build-up and clearance precipitates synaptic damage via toxicity; the 
formation of NFTs; and subsequent neurodegeneration (Hardy & Selkoe, 2002; 
Giacobini & Gold, 2013). 
Tau is a highly soluble intracellular protein which binds microtubules and contributes to 
axonal integrity. Insoluble, hyperphosphorylated tau ends its stabilising function and 
aggregates as NFTs, which impair normal axonal transport and are implicated in both 
 
                                                        
22: Only one copy of the gene is required for an effect. The chance of inheriting the mutated gene from a 
carrying parent is 50%. 
23: Apolipoprotein E. 
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the onset and progression of neurodegeneration in tauopathies, including AD, FTD, and 
Parkinson’s disease. Neither FTD nor Parkinson’s patients exhibit amyloid plaques, 
hence, NFTs are sufficient to cause neurodegeneration by themselves. Around 5% of 
FTD cases are caused by mutations in the tau-encoding gene MAPT24 (Lee et al., 2001; 
Ballatore et al., 2007; Barten et al., 2012; Spillantini & Goedert, 2013). Elevated NFT 
levels correlate with cognitive scores better than amyloid plaques (Giannakopoulos et al., 
2003), and, unlike plaques, whose distribution throughout the brain varies between 
individuals, they spread in a recognised, characteristic pattern which correlates with grey 
matter loss (Fig 2.12; Braak & Braak, 1995; Whitwell et al., 2008). “Braak stages” are: 
I-II transentorhinal: entorhinal cortex and hippocampus; 
III-IV limbic: amygdala, basolateral temporal lobe; 
V-VI isocortical: association areas of neocortex. 
Stages III-IV coincide with initial memory loss and MCI; V-VI with dementia (Vemuri 
& Jack, 2010). 
 
Figure 2.12 The pathological spread of tau in human Alzheimer’s disease. 
NFTs spread from dark (earlier, where the disease is, eventually, most severe) to light 
(later). Tau deposits are thought to originate in the locus coeruleus. The allocortex includes 
the hippocampus. Adapted from Brettschneider et al. (2015), with permission. 
 
                                                        
24: Microtubule-associated protein tau. 
82 
ṡߚ and tau are misfolded proteins, which may act as “corruptive templates” for future 
misfolding and hence aggregation. Their spread may be governed by the strength of 
neuronal connections between regions (Brettschneider et al., 2015). Although tauopathic 
neurodegeneration occurs in FTD without ṡߚ, and in early-onset AD, ṡߚ pathology is 
a sufficient trigger, the two separate mechanisms are inexorably linked in late-onset AD 
– the vast majority of cases – which appears to result from a failure to clear these misfolded 
proteins or their toxic, soluble forms (Jack et al., 2013). A shared upstream defect has 
been suggested, for example the ApoE ߝ4 genotype (Small & Duff, 2008). 
2.3.1 Biomarkers 
Neurodegenerative diseases can coexist and their clinically-presented phenotypes (patient 
history; symptoms; MMSE score) may overlap (Clark et al., 2008). Biomarkers should 
ideally be specific (to aide differential diagnosis); cheap; non-invasive; reproducible, 
unbiased and objective (to lend confidence); and predictive of future progression (to help 
patients and families plan). Brookmeyer et al. (2007) estimated that a short (one-year) 
delay to symptom onset would reduce worldwide cases in 2050 by 11.8 million. 
Therefore, they should also be sensitive to early disease onset and the effects of potential 
treatment (Hampel et al., 2008; 2010), which also reduces the costs of clinical trials, by 
improving power and requiring fewer subjects. The Alzheimer’s Disease Neuroimaging 
Initiative (ADNI), an international, longitudinal study, was formed in 2004 to assess and 
develop such biomarkers (Weiner et al., 2013). Promising candidates include 
cerebrospinal fluid (CSF) sampling, positron emission tomography (PET), and structural 
MRI. 
Jack et al. (2013) proposed a sigmoidal model (Fig 2.13), now widely reproduced, in 
which biomarkers progress simultaneously, but are most dynamic, and reach maximum 
abnormality, in an ordered sequence. 
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Figure 2.13 Theoretical progression of AD biomarker abnormality with time. 
Each biomarker surfaces above the detection threshold, and reaches a peak rate of change, 
at different times prior to dementia, but all are dynamic simultaneously. Some “cognitive 
reserve” differentiates low- and high-risk patients with the same biomarker abnormality 
(Vemuri et al., 2011), and there is a long “preclinical phase” prior to diagnosis. Atrophy, 
detected with MRI, coincides with the onset of cognitive problems (*). Two sampling 
time-points, ݐῺ and ݐῼ illustrate that MRI may be more useful than CSF ṡߚᾬῼ at the MCI 
stage. Adapted from Jack et al. (2013). 
CSF biomarkers include reduced ṡߚᾬῼ levels, reduced ṡߚᾬῼ ṡߚᾬΏ⁄  ratio, and elevated 
phosphorylated tau. These follow directly from neurochemical brain changes. 
Additionally, elevated total tau concentration reflects neurodegeneration (Hampel et al., 
2008; 2010). CSF markers are sensitive, track the severity of disease, and in combination 
are specific to AD. However, they omit spatial information, and sampling requires an 
invasive, often painful lumbar puncture (Vemuri et al., 2009). 
For PET to map ṡߚ deposits or monitor brain metabolism, radiotracers are injected 
minutes before a scan. 11C-labelled Pittsburgh Compound-B (PiB) binds selectively to 
ṡߚ. PiB uptake very closely correlates with CSF ṡߚᾬῼ decrease (Vemuri et al., 2009) and 
has detected high plaque burdens in MCI patients, but also in cognitively normal elderly 
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people: it is only loosely predictive of decline (Hampel et al., 2010; Jack et al., 2013). 18F 
fluorodeoxyglucose (FDG) may be injected to measure resting state glucose metabolism: 
its uptake, like neuronal activity, is locally reduced in neurodegeneration-afflicted 
regions. FDG-PET is highly predictive of conversion from MCI to AD (Hampel et al., 
2008; 2010). The short half-lives25 of the isotopes 11C and 18F; their radioactivity; and 
PET’s high cost and limited spatial resolution may, however, limit its usefulness, 
especially in small animal studies (Clark et al., 2008; Götz & Ittner, 2008). 
In Fig 2.13, prodromal amyloid markers (CSF ṡߚᾬῼ; PiB-PET) are the first to surface 
above the current “detection threshold”. Buchhave et al. (2012) found that CSF ṡߚᾬῼ 
levels reached maximum abnormality in MCI patients up to 10 years prior to conversion 
to AD. It is increasingly recognised that underlying pathophysiological processes, as 
measured by these techniques, begin a decade or more before cognitive decline and 
subsequent diagnosis. This asymptomatic “preclinical phase”, during which subjects can 
be cognitively normal (Ewers et al., 2011; Sperling et al., 2011), motivated the extension 
of ADNI to even earlier biomarkers for detecting and distinguishing newly-defined early 
MCI and subjective (worries of) memory impairment (SMI) stages, which carry an 
elevated risk of eventually developing AD (Jessen et al., 2014; Beckett et al., 2015). 
There is histological evidence from autopsy of young brains (under 30 years) that 
pathologic, phosphorylated tau appears before amyloid deposits (Spillantini & Goedert, 
2013). CSF total tau levels are directly related to age and tangles also form in healthy 
ageing. They may cause the slow atrophy which accompanies all healthy ageing, and 
underlie associated mild memory impairment (Fjell et al., 2014). Hence, in Fig 2.13, tau 
abnormality is postulated to precede amyloid deposits, but is only detectable at autopsy. 
MRI biomarkers 
Non-invasively, and relatively cheaply, structural brain MRI provides high tissue contrast 
and resolution, enabling the sensitive and localised detection of atrophy, which can both 
differentiate dementias and objectively stage AD in vivo (Frisoni et al., 2010; Vemuri et 
 
                                                        
25: 11C has a half-life of approx. 20 minutes, requiring a cyclotron on-site; 18F: 110 mins. 
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al., 2010). Atrophy follows NFT pathology in the signature Braak stages, and its rate 
correlates with cognitive decline (Fox et al., 1999). Vemuri et al. (2009) found that MRI 
performed better than CSF biomarkers at separating MCI and AD groups, and at 
predicting MMSE score. These advantages have propelled MRI to the early stages of 
clinical diagnosis. Other MR techniques, including diffusion tensor imaging (DTI, to 
measure white matter integrity) and functional MRI (fMRI, to assess the decline in 
connectivity), have been used as biomarkers of AD (Reitz & Mayeux, 2014), and may be 
acquired in the same patient visit, but these are currently not clinically established (Frisoni 
et al., 2010), and this thesis is exclusively concerned with structural images. 
 
Figure 2.14 Human T1W MRI showing structural changes with MCI and AD. 
Equivalent coronal T1W slices from cognitively normal (CN), amnestic MCI (aMCI) and 
AD brains, with ventricular enlargement (V), hippocampal volume loss (H), and atrophy 
of the entorhinal cortex (E) and neocortex (NC). Adapted from Vemuri et al. (2010). 
The first MR atrophy measures involved visual assessment, or manual volumetry via 
delineation of vulnerable regions, such as the hippocampus (Fig 2.14). The advance of 
clinical scanner field strengths from 1.5T to 3 and 7T has improved resolution and 
contrast, and hence the feasibility of these techniques. However, visual inspection is 
subjective and manual measurements are extremely time-consuming, and variable. 
To better-elucidate and quantify structural brain changes, advanced image processing 
techniques – including VBM and TBM – have emerged over the past two decades, 
exploiting increases in computer processing power, which have enabled high-dimensional 
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image registration and accurate automated anatomical parcellation. These techniques are 
widely available for human studies, thanks to free software packages (§2.2.7) and atlas 
databases (§2.2.1). 
For example, in a longitudinal study, Chételat et al. (2005) showed VBM could 
distinguish MCI patients who converted to AD from those who did not. Whitwell et al. 
(2008) used VBM in a cross-sectional study of 82 human subjects with probable AD and 
different Braak stages, and showed regional GM loss proportional to the degree of NFT 
pathology (Fig 2.15). Hua et al. (2013) used an unbiased implementation of TBM and 
detected constant atrophy rates in AD over 6—24 months, with most changes localised 
to the cortical and hippocampal GM, as well as temporal lobe WM. 
 
Figure 2.15 VBM-derived GM loss at different Braak stages. 
In a cross-sectional study, human brain MRI scans from patients with late Braak stages 
were compared with controls from earlier stages (Braak 0—II). VBM detected the 
characteristic pattern of progressive atrophy. 3D surface map (top) and four coronal slices 
for each set of stages. N=20 controls; N=23 III-IV; N=32 V; N=27 VI. FDR-corrected, 
ݍ = 0.005. From Whitwell et al. (2008), with permission. 
The onset of NFT-related neurodegeneration likely precedes MCI by several years (Teipel 
et al., 2013). Fig 2.13 illustrates that MRI-measured atrophy is highly dynamic during 
MCI and conversion to AD (between ݐῺ − ݐῼ, the MRI biomarker’s gradient is one of 
the largest). Meanwhile, CSF ṡߚᾬῼ approaches its maximum abnormality, and the degree 
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of change between time-points is smaller. A multi-time-point study of atrophy rates, to 
stage disease, distinguish high risk from low risk patients, or to monitor drug 
effectiveness, may thus use more closely-spaced samples and require lower sensitivity or 
fewer subjects than CSF ṡߚᾬῼ (Frisoni et al., 2010). While CSF ṡߚᾬῼ may be abnormal 
and sensitive earlier, without symptoms or a policy of population screening, it is unlikely 
to be measured so early in a patient’s life. Screening is expensive, may induce needless 
worry, and currently there are few treatment options, even with a positive diagnosis 
(§2.3.3). The side-effects of existing treatments also mean that confidence in diagnosis is 
vital. 
Recent efforts have therefore focused on using imaging to detect subtle changes prior to 
the onset of symptoms (lowering Fig 2.13’s “detection threshold”), by improving 
robustness (such as by using symmetric registration, with brain masks, for TBM: Hua et 
al., 2013), and focusing on volumes of the entorhinal cortex, hippocampus, ventricles 
and whole brain (Frisoni et al., 2010; Vemuri et al., 2010; Teipel et al., 2013). Using 
VBM, Tondelli et al. (2012) detected structural differences between the brains of healthy 
controls and people who would go on to develop AD symptoms up to 10 years before 
they did so. 
2.3.2 Outcome measures 
Measurable outcomes, relevant to both the disease and treatment, are required evidence 
for drug trials (Frisoni et al., 2013). Direct outcome measures include patient feeling, 
function, and survival. Imaging biomarkers, such as slowing of atrophy, can substitute 
for clinically meaningful trial endpoints. Whole-brain summary metrics can provide such 
surrogate markers of disease progression. The STAND26 score summarises individual 
patients’ GM densities by comparing with a database of clinically well-characterised 
images. This performs well in comparison to CSF sampling (Vemuri et al., 2008; 2009). 
 
                                                        
26: Structural Abnormality Index. 
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Figure 2.16 Illustration of the Boundary Shift Integral in the human brain. 
Left, two transverse slices of the same brain, from serial MR scans several months (or years) 
apart. Middle, probabilistic masks of each; right: probabilistic boundary region and, below, 
result map (blue indicating atrophy; red indicating growth). The BSI provides a summary 
whole-brain measure of longitudinal volume change. Adapted from Prados et al. (2014). 
Early in AD, total tissue volume loss may fall within a broad range explicable by natural 
variation and healthy ageing (Fjell et al., 2014). The rate of change within an individual 
patient is thought to provide a better biomarker. This is the motivation behind the 
Boundary Shift Integral (§6; Fig 2.16). The BSI uses voxel intensity differences between 
aligned images from two or more time-points (e.g., ݐῺ and ݐῼ) to assess atrophy over the 
whole brain, or within delineated substructures. The method has developed from using 
absolute to, more recently, automated, unbiased and image-specific adaptive parameters 
and probabilistic segmentations (Fox et al., 1996; Prados et al., 2014), and has been 
customised for the ventricles and hippocampus (Schott et al., 2010). Local measurements 
from each voxel are combined into a summary metric, which is easily compared between 
patients. The order of 1.9% of brain volume is lost per year to atrophy (§6.5.1). 
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SIENA27 (Smith et al., 2002) also provides a summary metric from measurements of tissue 
boundary displacement, computed from intensity gradient profiles projected from the 
brain surface, over time. Such longitudinal measures can be used to assess therapeutic 
effectiveness. There is a need to improve the robustness of preclinical trials, but 
heretofore, none of these methods has been employed preclinically. 
2.3.3 Treatment 
There are presently no disease-modifying treatments for AD; contemporary drugs (5 are 
FDA-approved, Mangialasche et al., 2010) only mitigate behavioural and cognitive 
symptoms, and can delay the need for full-time care, but not progression or onset. 
Neuroinflammation, thought to be a response to amyloid plaques, is a (non-specific) 
feature of AD; some studies have suggested anti-inflammatory drugs may reduce the risk 
of, and delay, dementia (Gauthier, 2007). 
Until recently, the amyloid cascade hypothesis focussed efforts on reducing ṡߚ levels, by 
suppressing secretases or increasing clearance (Giacobini & Gold, 2013). As MCI 
symptoms begin, amyloid therapy is possible, but by this point ṡߚ abnormality has 
already plateaued, whereas atrophy is still dynamic (Jack et al., 2013). 
The interactions of ṡߚ and tau are still not fully understood. In human ADAD, APP-
related mutations are sufficient to lead to all AD features, but not in mice (Gauthier, 
2007; Ashe & Zahs, 2010). ṡߚ may “drive” or aggravate NFT pathology; tau may mediate 
the toxicity of ṡߚ, or each may amplify the effects of the other (Ittner & Götz, 2011; 
Giacobini & Gold, 2013). A recent call to reject the amyloid cascade hypothesis (Herrup, 
2015) emphasised that ṡߚ can occur in healthy humans, and that its presence in mice 
does not cause severe neurodegeneration or permanent damage: ṡߚ clearance in mouse 
models has successfully restored earlier function, but human phase II and III clinical 
immunotherapy trials28 have failed to replicate this effect (Giacobini & Gold, 2013). 
 
                                                        
27: Structural Image Evaluation, using Normalization, of Atrophy. 
28: Phase II: several hundred patients and controls, to test for a disease-modifying effect and safety; phase 
III: several thousand patients and controls, when some effect is confirmed. 
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Several trials have been abandoned due to significant side-effects, such as exacerbated 
inflammation and atrophy (Giacobini & Gold, 2013). A recent paper showed (using the 
BSI) that Bapineuzumab, an ṡߚ antibody, increased the rate of ventricular enlargement 
in some patients (Novak et al., 2016). Some AD treatments have elicited severe side-
effects in FTD patients (Götz & Ittner, 2008). That these can be serious further highlights 
the need for specific differential diagnosis, to enable correct, disease-specific, targeted 
prescriptions. 
The slowing of atrophy may therefore be a better outcome measure (or surrogate end-
point, Hampel et al., 2010). Tau levels may begin their change earlier in AD, prior to 
MCI symptoms, and so tau represents a promising therapeutic target – for example, by 
inhibiting phosphorylation (Jack et al., 2013). 
Many more drugs are currently in development. As tau and amyloid pathologies likely 
interact, effective AD treatments will have to target both (Mangialasche et al., 2010; Ittner 
& Götz, 2011; Giacobini & Gold, 2013). Mice are vital models both of the underlying 
genetic causes of AD, and for testing dosage and side effects in therapeutic trials. 
2.3.4 Mouse models of Alzheimer’s disease 
Mouse models of AD are broadly defined by their replication of either ṡߚ or tau 
pathology. Models may recapitulate only some aspects of the human disease, to enable 
targeted therapy with fewer confounding factors; no single mouse currently mimics the 
entire spectrum of AD features. AD progresses over many years in humans, so the short 
mouse lifespan may be an impediment (McGowan et al., 2006). The majority are genetic 
models, expressing mutant APP, presenilin 1 (PS1) or presenilin 2, and are thus models 
of early-onset, familial AD: a minority of clinical cases. 
Transgenic human APP (hAPP) models have been shown to exhibit cognitive and 
memory deficits preceding or alongside amyloid plaques; however, few show signs of 
atrophy. For example, the PDAPP mouse overexpresses mutant hAPP and develops age-
dependent hallmarks of AD including ṡߚ plaques and cognitive decline (Schenk et al., 
1999). Redwine et al. (2003) found volume reductions in the hippocampus in this model 
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prior to plaque formation. The J20 mouse, which has two APP mutations, exhibits 
plaques from an early age, and synaptic dysfunction, but only minor neurodegeneration 
(Mucke et al., 2000; Hall & Roberson, 2012; §4.2). 
Cross-breeding mice can give offspring with combined, interacting mutations and hence 
a more complete model. Mice expressing mutant PS1 exhibit elevated ṡߚ levels. Plaque 
aggregation is significantly increased, however, when these mice are cross-bred with a 
mutant human APP model (e.g. M146L and Tg2576, Duff & Suleman, 2004). The 
resulting PSAPP model exhibits cognitive deficits before plaques appear. The 5XFAD 
mouse combines five APP and PS1 mutations, exhibits severe AD pathology and also 
neurodegeneration. Despite their lack of aggregated NFTs, recent work has shown that 
tau is still tied to cognitive decline in hAPP models (Hall & Roberson, 2012). 
Transgenic models of mutant human tau are currently less common, but advantageous 
as they show more severe atrophy than APP models. These models do not develop plaques 
independently, so are not full models of AD; rather, they better-model FTD, with select 
AD-like pathologies, including NFTs and neurodegeneration (Hall & Roberson, 2012). 
Such mice often utilise the most common FTD-linked human tau mutation, P301L. The 
prominent role of tau in AD, and the failure of APP models to replicate the severe atrophy 
which is the main correlate of cognitive decline, and monitorable with µMRI, motivated 
the study of the rTg4510 mouse (§5, §6), which exhibits severe atrophy due to tauopathy. 
The theorised interaction of ṡߚ and tau has led to the development of cross-bred mice, 
which exhibit plaques and tangles. The 3xtg-AD mouse, for example, was bred from mice 
with PS1, APP and P301L mutations, and closely recapitulates AD pathology (Duff & 
Suleman, 2004; Götz & Ittner, 2008). 
Few studies have quantified AD mouse models using advanced neuroimaging techniques 
(Table 2.1). Both Lau et al. (2008) and Maheswaran et al. (2009a) showed unexpectedly 
increasing brain volume, with age, in APP/PS1 cross-bred mice. Badea et al. (2010) found 
volume loss prior to amyloid formation in some regions of an APP model. Using 
SPMMouse for VBM, Teipel et al. (2011) found no GM decline in APP/PS1 mice. Using 
92 
TBM, Badhwar et al. (2013) found both volume increases and localised volume decreases 
in J20 mice (discussed further in §4.2.4). 
As noted above, following the failure of treatments in humans which successfully halted 
ṡߚ accumulation and restored function in mice, there is concern about the validity of 
extrapolating treatments from mice – often models of familial and ADAD – to the 
majority of human cases, sporadic AD. Cognitive decline has been shown in APP mice 
prior to plaque formation; the reverse is found in humans. However, mice may still be 
good models of presymptomatic AD (Hall & Roberson, 2012). In preclinical drug trials, 
just as in humans, relevant outcome measures are vital. ṡߚ clearance does not appear to 
correlate with cognitive impairment (Giacobini & Gold, 2013). Thus, mice exhibiting 
atrophy, such as rTg4510 – or cross-bred mice with both amyloid plaques, NFTs, and 
subsequent neurodegeneration – may be better foci. Histology can be used to validate 
both plaque and tangle formation, via staining, and atrophy, via volume measurement. 
By measuring the slowing of atrophy, the Boundary Shift Integral (§6) can potentially 
provide such an outcome measure in these models in vivo, allowing longitudinal 
assessment. 
2.4 Down syndrome 
Down Syndrome (DS) is the most common genetic cause of human intellectual 
disability, affecting 0.11—0.13% of live births in the UK and USA, and characterised by 
physical and cognitive developmental deficits (Morris et al., 2009; Parker et al., 2010). 
DS is caused by trisomy (three copies) of human chromosome 21 (Hsa21), leading to the 
over-expression of genes encoded on this chromosome. As with AD, the majority of cases 
are sporadic, but risk factors include maternal age (over 37, which is rising on average), a 
previously affected pregnancy, and translocation of Hsa21 (a partial additional copy), 
which can be inherited. Incidence at conception has increased since the 1980s, but live 
births have remained relatively stable, thanks to improved access to prenatal screening 
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and termination: all mothers are now offered screening for chromosomal abnormalities29 
in the UK and USA. 92% of mothers in England and Wales with an antenatal DS 
diagnosis opt to terminate (Roizen & Patterson, 2003; Morris et al., 2009) – however, 
thanks to improved healthcare, life expectancy for DS individuals is also rising – to 
around 60 years today – increasing the DS population overall (Zigman & Lott, 2007; 
Wiseman et al., 2015). 
Although the entire human genome has been sequenced, the (sometimes overlapping) 
function of many of these genes, and their interactions, is still unclear (Roizen & Patterson, 
2003). The elevated gene dosage conferred by trisomy of Hsa21, and the consequent 
imbalance compared to those on other chromosomes, gives rise to various phenotypes, 
with differing prevalence and severity. All DS individuals exhibit craniofacial 
abnormalities and some learning disability. Around 40% have a congenital ventricular 
septal defect (a hole in the heart), and 38—78% have some hearing loss (Roizen & 
Patterson, 2003). Brain, cerebellar and hippocampal volumes are reduced (Pinter et al., 
2001a; Beacher et al., 2009). 
Of particular interest to AD researchers, among the 329 (or so) genes extant on Hsa21 is 
the gene encoding APP (Roizen & Patterson, 2003), which is consequently overexpressed 
in a dose-dependent manner (Lott & Head, 2001). After age 40, all people with DS 
develop amyloid plaques and NFTs. By age 60, 60—70% develop dementia in the form 
of early onset AD. DS may therefore represent a model of predementia AD (Teipel et al., 
2004). Some never develop dementia, which hints at a possible protective effect from the 
remainder of Hsa21 (Beacher et al., 2009; Wiseman et al., 2009; 2015). The large number 
of genes is thought to contribute to the correspondingly numerous phenotypes of DS. 
2.4.1 Mouse models of Down syndrome 
By attempting to replicate trisomy of Hsa21 genes, and hence the features of the human 
condition, mouse models assist investigation of the syndrome’s underlying genetic causes. 
This is essential for the development of targeted therapeutics (Wiseman et al., 2009). An 
 
                                                        
29: The “combined test” offered between 10-14 weeks. 
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initial target was the “critical region” of Hsa21, isolated by comparing overlapping 
chromosomal regions of some patients with several DS phenotypes, but only partial 
Hsa21 trisomy. However, Olson et al. (2004) showed that this sub-region was not 
sufficient to cause craniofacial dysmorphology in mice. 
The mouse has 20 chromosomes (humans have 23), and orthologous genes of Hsa21 are 
spread across mouse chromosomes Mmu10, 16 and 17. Orthologous genes may also have 
different functions between species (Reeves, 2006). Different models take different 
approaches to replicating human aneuploidy (Fig 2.17). 
 
Figure 2.17 Some common trisomic mouse models and their syntenic regions with 
Hsa21. 
The Tc1 model is trisomic for more of Hsa21 genes than other popular models, Ts65Dn 
and Ts1Cj2. It has two deletions, shown as gaps in the orange bar. Adapted from Wiseman 
et al. (2009). The scale is in million base pairs (length). 
The most popular model, Ts65Dn, carries orthologs of around 50% of Hsa21 genes by 
replicating part of Mmu16. The Ts1Cje model carries around 67% of these. Hernandez 
et al. (1999) described the creation of a new model, Tc1, via mouse embryonic stem cells 
and irradiation microcell-mediated chromosome transfer. Transchromosomal cells were 
injected into mouse blastocysts, creating chimeric mice with Has21 expressed in a subset 
of cells. The Tc1 mouse is thus transchromosomic, carrying a copy of 92% of Hsa21 
(Olson et al., 2004; Reeves, 2006). It is therefore thought to be an improved model of DS: 
initial studies have confirmed that it replicates a broad range of phenotypes (O’Doherty et 
al., 2005; Reeves, 2006). It is discussed and analysed more fully in §4.1. 
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The Tc1 mouse is not, however, functionally trisomic for APP. Sheppard et al. (2012) 
showed that older Tc1s nevertheless exhibited elevated levels of phosphorylated tau, 
without NFTs. Cross-breeding the Tc1 mouse with the J20 mouse allowed investigation 
of the DS phenotype in the presence of mutant APP. It is suspected that other Hsa21 
genes also have a modulating effect (Wiseman et al., 2015). The brain morphometry of 
this Tc1xJ20 mouse is investigated in (§4.2).  
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3 Development of a high-
throughput software pipeline for 
phenotyping preclinical subjects 
This chapter describes, in detail, the complete set of image processing steps I developed, 
which are necessary for automated morphometric analysis, following MR data from 
scanner to statistical parametric map. Every dataset described in this thesis was processed 
with a version of this pipeline. 
Throughout this chapter, datasets which are introduced in more detail later provide 
examples to illustrate the pipeline steps themselves, as well as the challenges encountered 
for making each step robust. The multi-atlas masking step is based upon work by Da Ma 
at CMIC, and published in Ma et al. (2014). Animal preparation and MR data 
acquisition was performed by others, using parameters laid out in §4.1.2. 
The datasets included in figures are of a mouse model of Down syndrome, Tc1 (§4.1); a 
model of DS cross-bred with an Alzheimer’s disease APP model, Tc1xJ20 (§4.2); a mouse 
embryo model of spina bifida, GLDC, (scanned by Francesca Norris at CABI and 
originating from Professor Nicholas Greene of the UCL Institute of Child Health); and 
a mouse model of sciatic nerve injury, created and scanned by Yichao Yu. 
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3.1 Objectives and motivation 
I describe the creation of a fully automatic software pipeline, named MouseMorph, for 
phenotyping large cohorts of mouse brains and embryos with Voxel- and Tensor-Based 
Morphometry (V/TBM). These powerful, non-destructive, automated investigative 
techniques can complement other analyses, allowing whole-organ (or organism), 
“hypothesis-free” investigations which highlight regions worthy of more time-consuming 
investigation, such as histology. The motivations for such a pipeline include: 
1. High field-strength MR scanners, such as the 9.4T Agilent/Varian instrument at the 
UCL Centre for Advanced Biomedical Imaging (CABI), allow high resolution (40µm) 
ex vivo structural investigations, attractive to investigators with newly-developed 
transgenic mice and models of disease, behaviour or learning, who wish to interrogate 
tissue morphology. Taking advantage of this equipment, optimised µMRI protocols for 
exceptionally high contrast and isotropic resolution in mouse brains (both in and ex vivo) 
and embryos have recently been developed by Jon Cleary, Francesca Norris, Holly 
Holmes and Yichao Yu (§2.1). A large number of MRI datasets of transgenic and disease 
model mice had already been acquired at CABI, and more studies were planned. 
2. V/TBM studies require significant image processing expertise, manual intervention, and 
parameter changes to existing, clinically-focused tools. No public software exists to 
seamlessly generate morphometric results from reconstructed preclinical MRI scans 
automatically; a large number of separate, time-consuming processing steps are required, 
some hitherto performed manually. These steps can also benefit – or are necessary to 
initialise – other automated analysis techniques, including segmentation propagation, 
atlas parcellation, cortical thickness estimation, and longitudinal atrophy measurement 
with the Boundary Shift Integral, which forms the final experimental §6. Such an 
automated pipeline would be useful to CABI and the wider phenotyping community, 
and would significantly contribute to the high-throughput phenotyping efforts laid out 
in §1.2. Many of the tools required are actively developed, for clinical datasets, at the 
Centre for Medical Image Computing (CMIC). 
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3. Human-centric toolboxes exist for morphometry (e.g. SPM, FSL) but are inappropriate 
for use with preclinical images: many parameters must be adjusted; assumptions 
accounted for, and several steps require manual intervention to correct non-human data. 
Several tasks unique to the high-throughput preclinical paradigm are not addressed by 
such software (e.g. multiple subject extraction; arbitrary orientation correction). Some 
existing customisations to clinically-focused tools, such as Rodent BET (Wood et al., 
2013) and SPMMouse (Sawiak et al., 2009a), address only parts of the overall pipeline. 
4. The remit was to develop a set of automated methods which completely mitigate manual 
intervention between a cohort of reconstructed structural MR images of mouse brains (in 
or ex vivo) or embryos, and a statistical parametric map (SPM) summarising the local 
morphological differences between groups, which would inform follow-up histology and 
strengthen high-throughput and large-cohort phenotyping and disease model studies. 
I describe below a new open-source, customised image processing pipeline for high-
throughput, large-cohort mouse brain (or embryo) phenotyping studies, designed to 
completely automate the steps between scanner and statistical parametric map (Fig 3.1). 
These include extraction from multiple-subject images; alignment from arbitrary 
orientations to a common, standard space; skull-stripping; tissue classification with 
accurate, subject-specific a priori tissue probability maps (TPMs); and intensity 
standardisation. I show how reference atlases may be used to automate several stages, and 
focus on the steps prior to statistical tests, which may be performed with existing packages 
such as SPM. 
This chapter is predominately methodological: V/TBM results and analysis from both 
the Tc1 and Tc1xJ20 brains are included in §4, where the MR acquisition parameters 
and the datasets themselves are also introduced (§4.1, 4.2). Some customisations 
necessary to process ex vivo embryos are included here. §5 includes the customisations 
necessary for in vivo mouse brains. Images from the GLDC and nerve injury datasets are 
used to illustrate different stages of the pipeline, as well as some of the problems 
encountered in each paradigm, and how they were overcome. 
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Figure 3.1 Overview of the modular pipeline steps. 
After GWR, tissue segmentations are resampled into the space of the final average image, 
such that equivalent regions overlap. The segmentation and back-propagation of 
parcellation labels is an optional step for quantifying substructure volumes. 
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3.2 Automated extraction of individual subjects 
from multiple-subject images 
3.2.1 Multiple subject scanning 
To achieve high throughput, Bock et al. (2005) described scanning up to 16 mice 
simultaneously in or ex vivo using a 7T clinical bore and a custom-built array of separate 
birdcage receiver coils, producing discrete, high-SNR images. However, the high field-
strength clinical scanners required to produce high-resolution images are uncommon, 
and the large number of intricately-arranged coils may be prohibitive (McConville et al., 
2005). The majority of morphometric studies implementing multiple subject scans 
include three brains per scan (Table 2.1). 
Prior to 2012, ex vivo mouse brain images were acquired individually at CABI. To 
improve throughput, one dataset was acquired by suspending three brains, in-skull, in 
Fomblin inside a syringe and scanning overnight. The advent of a 3D printed 3-brain 
holder, designed by Yichao Yu, improved this overnight scanning protocol, as related 
below. Francesca Norris and Simon Richardson also designed and 3D printed a mouse 
embryo holder (Fig 3.2a) capable of holding up to 40 embryos. These plastic holders 
enabled “high-throughput” acquisitions, using a preclinical scanner and a single coil 
(parameters in §4.1.2) – a more prevalent setup necessitating subject separation into 
individual images before processing. This is a problem unique to preclinical imaging: 
humans and large animals are scanned individually. 
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Figure 3.2 Mouse embryo holders. 
(a) Original design by Francesca Norris and Simon Richardson: 3D printed in plastic (10 
layers; 4 chambers per layer); (b) 3D CAD image of proposed holder design for future 
embryo studies: 3 layers only, to avoid signal drop-off and distortion away from the bore 
isocentre. 3 subjects per layer to duplicate the throughput of existing embryo phenotyping 
scans (Fig 3.3c). The numerous holes allow the suspension medium (e.g. Fomblin, or 
agarose) to move freely between compartments, and air bubbles to escape. The long neck 
allows precise positioning within the bore. 
 
Figure 3.3 High-throughput embryo images. 
(a) Photo of multiple mouse embryos embedded in agarose, inside a falcon tube. (b) High 
throughput µMRI of up to 40 mouse embryos. The bright background signal is from the 
agarose. Note also the signal drop-off at the top of the image. (c) Moderate throughput (9 
embryos). Photo and scans by Francesca Norris. Neither embryo holder was used to acquire 
these images. 
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3.2.2 Challenges for automated identification and extraction 
The chief complications facing automated extraction are (1) touching subjects, (2) poor 
signal from parts of a subject leading to their exclusion, and (3) inclusion of unwanted 
signal or material, such as image artefacts, noise, bubbles, debris, tube features and 
identifying markers. If the first occurs, intricate image-specific erosion/dilation, or 
complex region-growing operations are required, involving a user-determined threshold, 
number of operations, seed locations, or manual masking. Baghdadi et al. (2011) adapted 
a deformable model algorithm to segment touching embryos, balancing region-growing 
and collision forces to prevent overlap. This was sensitive to seed locations, required 
training data, and sometimes excluded small features. 
Isolation via thresholding alone, for example with an Otsu threshold (Otsu, 1979) is 
insufficient to identify subjects (Baghdadi et al., 2011): frequently, unwanted material or 
signals from image artefacts survive. Strong thresholding, conversely, may discard low-
signal tissues, or create concavities where vessels or fissures extend into the subject. 
Image non-uniformity – arising from tissue susceptibility or signal drop-off away from 
the isocentre – may induce low signal at some locations. Significant displacement from 
the isocentre may also cause distortion (O’Callaghan et al., 2014). It is therefore prudent 
to perform some non-uniformity correction (NUC) prior to extraction in large-cohort 
scans, wherein subjects may be spread further from the isocentre. The large 40-embryo 
holder (Fig 3.2a) was not used for later phenotyping scans, as these artefacts were deemed 
too great. One brain and several embryo datasets were thus acquired at CABI without 
separators (Fig 3.4). I investigated solutions to the problems described above. 
Without a holder, up to nine embryos were embedded in high-signal, viscous agarose, 
which set around them, precluding scanner-induced vibration or other movement. 
Unfortunately, without the subject separator, embryos were prone to sink or otherwise 
move slightly within the agarose before it set fully, so were not completely prevented from 
touching. Additional difficulties were lent by the process of embedding itself. First, a layer 
of agarose was poured into the syringe, which was allowed to set. A layer of 3 embryos 
was arranged on the surface, and more agarose poured in to surround them. This was 
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allowed to set before the next layer was added, and so on until 3 layers of embryos were 
set in the syringe. This process of intermittent agarose setting created distinct layer 
artefacts: thin, low-signal sheets in the reconstructed scans (Fig 3.4e, f). These sheets 
frequently touched – and hence joined – multiple subjects (also lower signal than the 
agarose). It was not possible, for example, to robustly use binary erosion/dilation 
operations in sequence to remove these artefacts or alleviate touching subjects, as narrow 
embryo features would not survive, and the number of operations to perform would 
depend upon image resolution. 
With differing fixative and background intensities, an additional step to extract the high-
signal agarose cylinder was necessary. I developed a convex hull operation, using 
QuickHull (Barber et al., 1996), to assist this and avoid omitting low-signal embryos in 
contact with the cylinder walls (and hence adjoining the low-signal background) – this 
was only a problem where the suspension medium had a different MR signal to the 
background (Fig 3.4c). 
In several cases, I eventually settled upon manual masking as the most reliable (if non-
repeatable and time-consuming) method for extracting these brains and embryos from 
their images. To mitigate the abovementioned issues, Simon Richardson and I adjusted 
the embryo holder design to include only three layers (Fig 3.2b), preventing significant 
signal drop-off or distortion, but allowing the use of low-signal, non-viscous Fomblin 
instead of agarose, as per the ex vivo brain protocol. 
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Figure 3.4 Touching subjects in multi-subject scans without separators. 
(a–b) mouse brains, in-skull, scanned in Fomblin without a brain holder; (c—f) slices of 
reconstructed syringe images from the GLDC embryo study, scanned in agarose. Arrows 
indicate (c) a subject in contact with the low-signal syringe rim; (d) touching subjects in a 
single layer; (e) an embryo in contact with dark agarose layer artefact and touching subjects 
between layers; (f) two otherwise-separated subjects joined by agarose layer artefact, as well 
as a surrounding layer of adipose tissue, containing high-signal fat (top arrow), which may 
additionally be confused with the agarose medium when using intensity-based 
segmentation methods. 
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3.2.3 Solutions for automated identification and extraction 
The simplest solution to touching subjects is an adjustment to the scan protocol itself, to 
include a subject separator. The design, for brain scans, by Yichao Yu and Simon 
Richardson, secures three skulls inside a 50ml syringe. Its 1mm walls completely preclude 
touching or partial volume (PV) between neighbouring subjects (Fig 3.5). This enables 
unsupervised overnight scans (additional time accounting for the increased FOV), 
significantly reducing overall preparation time and necessary human intervention, and 
equals the most common multi-subject throughput of other studies (Table 2.1). Aligning 
brains in one layer, and embryos in three layers (along the z-direction) minimises signal 
drop-off and geometric distortion away from the bore isocentre. An adaptation (Fig 3.7) 
allows for six brains simultaneously, without significant distortion. I recommend that 
plastic separators are used in all future ex vivo multi-subject scans, both brain and embryo, 
together with a low-signal medium. 
 
Figure 3.5 3D-printed brain separator and resulting MR image. 
(a) 3-brain holder and syringe (design and photo by Yichao Yu); (b) three ex vivo mouse 
brains (2 Tc1, 1 WT in lower right) as they typically appear, suspended in low-proton 
Fomblin, in the axial view of a reconstructed µMR image. The plastic holder (25.4mm 
diameter, 44mm length) produces minimal signal. It may rotate within the syringe, so any 
orientation is possible. The hyperintense dots are agarose markers of different lengths, for 
identifying brains. 
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To identify and extract subjects automatically (Fig 3.6), I first standardised the intensities 
of all the volumes acquired to the approximate range 0—1 (see §3.7), smoothed with a 
Gaussian kernel (FWHM 0.2mm), and used NiftySeg to fit histograms with a two-
component Gaussian Mixture Model (GMM, Cardoso et al., 2011), for subjects and 
background, omitting prior spatial information (Fig 3.6b). I discarded the background 
and thresholded the resulting probabilistic image at 0.8, producing binary masks of all 
image objects, which were then distinguished using a connected component algorithm 
with a 3D, 6-connected neighbourhood. These may include some extraneous objects and, 
despite standardisation and NUC, may not cover each subject completely (Fig 3.6c). 
To ensure complete coverage, I therefore calculated a convex hull around each distinct 
binary object (Barber et al., 1996; Fig 3.6d), and measured their resulting volumes. 
Together with smoothing, this ensured the inclusion of small external features – a 
particular problem with paws and the tail in embryo images, as encountered by Baghdadi 
et al. (2011) – as well as any parts of a subject omitted within concavities in the binary 
volume – accounting for hollow ventricles and the low-signal fissures sometimes present 
in fixed, ex vivo brains. Skull-stripping occurs later; the precision of this mask and the 
inclusion of superfluous features (such as parts of other embryos or brains) are 
inconsequential, provided the entire subject is covered. 
Given the total number of study subjects ṻ (across all images, known a priori), it is 
possible to robustly distinguish subjects from small fragments and large extraneous 
objects by choosing the ṻ objects with the closest volumes to a set of training masks. 
These were produced, for brain images, by thresholding single-subject images (including 
skull), and creating a binary convex hull around the largest 6-connected component. The 
resulting mean mask volume from several such images provided an initialisation for the 
expected subject volumes. I labelled these ṻ binary objects and used them to crop the 
original image. 
Although this similarity-based method has performed well in my experience, if the study 
includes a wide range of volumes it may not be robust: the selection method could easily 
be adapted to include other properties of the masked regions, such as texture, intensity 
range, ‘mass’ (voxel volume multiplied by intensity), shape, and so on. Atlas input could 
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also be used to initialise feature-based guesses as to which objects are subjects and which 
are of no interest. This step was not necessary for single-subject in vivo studies (§5, §6), 
nor some of the earlier ex vivo data acquired at CABI (e.g. cohort 1 in §4.1). 
 
Figure 3.6 Extraction steps in coronal and sagittal views of a downsampled Tc1 brain 
image. 
(a) Smoothed; (b) probabilistic image after GMM fit; (c) binarised mask of all objects in 
image, including high-signal agarose marker, overlaid on the structural image. Examples 
of low-signal regions which might intrude into the mask and cause incomplete brain 
coverage are indicated; (d) convex hull mask. 
 
Figure 3.7 Exploded CAD view of updated, 6-brain holder 
Designed with Simon Richardson and 3D printed for use in future scans. The holes in the 
middle insert enable the free flow of the scanning medium, and aid bubbles’ escape. The 
pointed end (right) fits inside a 50ml syringe tip; the left end is concave to snugly 
accommodate a plunger. The gold leaves (shown detached and also present in the design 
in Fig 3.5a) are hinged so brains can be easily inserted. The leaves themselves hold the 
brains in place via contact with the syringe wall. 
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3.3 Orientation correction 
Atlases are registered to the data to propagate brain masks, tissue priors, and parcellations 
(§2.2.1). To initialise this, as well as group-wise registration, subject brains must be 
approximately aligned to a standard orientation – a stereotactic space matching that of 
the atlas. Clinical software, such as SPM, assumes the human brain is already correctly 
oriented: typically, subjects lie supine within the bore during image acquisition. The rigid 
rotations necessary to align brains from the small range of possible rotations this posture 
affords are easily performed by the registration algorithms of SPM, FSL and NiftyReg, 
after a known rigid rotation orients the brain to standard space. 
In this high-throughput scenario, this assumption is no longer safe: brains may be 
arranged arbitrarily to fit more into the scanner bore (Fig 3.4a, b; 3.5b), or move after 
placement. The registration algorithms of clinical software such as SPM and NiftyReg are 
unable to resolve the resulting large (>45°) rotations necessary for alignment. Registration 
between two subjects severely out of alignment is likely to converge on an incorrect local 
maximum similarity and fail. This was also the case when I performed tests with FSL 
FLIRT1 (Jenkinson & Smith, 2001), which was designed to resolve large misalignments 
between human brain images. This problem is unique to the preclinical paradigm, with 
the exception perhaps of human foetal MRI, in which the head may be in any orientation 
within the womb (Kainz et al., 2014). 
3.3.1 Initialisation: principal axes 
To perform orientation correction automatically, I exploited the inherent 3D symmetric 
properties of mouse brains, about which some assumptions may be made, and referred to 
a set of structural images already in the desired orientation. I first assumed that the 
orthogonal principal axes of mouse brain structural images correspond approximately to 
the subjects’ anatomical axes (Alpert et al., 1990; Fig 3.8): the antero-posterior (AP), 
 
                                                        
1: FMRIB's Linear Image Registration Tool 
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right-left (RL), and inferior-superior (IS) axes, and that AP > {RL, IS} (a safe first 
approximation both in- and ex-skull, though the relative lengths of {RL, IS} may be 
interchangeable). Extraneous material – such as skull tissue and external markers (Figs 
3.5b; 3.6d) – may confound this assumption. Assuming this ellipsoidal shape, the image 
principal axes are the eigenvectors of its inertia matrix (E3.4; Arata et al., 1995; Marion 
& Thornton, 2004). 
 
Figure 3.8 Illustration of a mouse brain in RAS orientation 
From left: coronal, sagittal, transverse views. Subject +Right Anterior Superior (RAS) 
parallel to image +x y z axes respectively; a “right-handed” orientation common to most 
human atlases (e.g. ICBM152: Ashburner & Friston, 2007; Evans et al., 2012) and to 
Waxholm space (Johnson et al., 2010). Approximate principal axes (RL, AP, SI) are shown, 
dotted green and dashed orange. The latter denotes the mid-sagittal plane, which coincides 
with the YZ plane of symmetry. 
The intensity-weighted centroid of the image is located at ṥ௫,௬,௭, where: 
E3.1 ṥ௫ = ∑(ݔ௜ × ẋ௜)∑ẋ௜ ;ṥ௬ = ∑(ݕ௜ × ẋ௜)∑ẋ௜ ;ṥ௭ = ∑(ݖ௜ × ẋ௜)∑ẋ௜  
where voxel ⱪ is at position (ݔ௜ ,ݕ௜, ݖ௜) and has intensity ẋ௜, and ∑ is over all ⱪ. The 
intensity-weighted moments of inertia (Arata et al., 1995) are then: 
E3.2 
ṱ௫௫ = Ѷቀẋ௜ × ቄ൫ݕ௜ − ṥ௬ ῼ + (ݖ௜ − ṥ௭)ῼቅቁ 
ṱ௬௬ = Ѷ(ẋ௜ × {(ݖ௜ − ṥ௭)ῼ + (ݔ௜ − ṥ௫)ῼ}) 
ṱ௭௭ = Ѷቀẋ௜ × ቄ(ݔ௜ − ṥ௫)ῼ + ൫ݕ௜ − ṥ௬ ῼቅቁ 
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Similarly, the products of inertia are: 
E3.3 
ṱ௫௬ = Ѷ൛ẋ௜ × (ݔ௜ − ṥ௫) × ൫ݕ௜ − ṥ௬ ൟ 
ṱ௫௭ = Ѷ{ẋ௜ × (ݔ௜ − ṥ௫) × (ݖ௜ − ṥ௭)} 
ṱ௬௭ = Ѷ൛ẋ௜ × ൫ݕ௜ − ṥ௬ × (ݖ௜ − ṥ௭)ൟ 
and the inertia matrix (Arata et al., 1995, Marion & Thornton, 2004) is thus: 
E3.4 ṱ = ቌ ṱ௫௫ −ṱ௫௬ −ṱ௫௭−ṱ௫௬ ṱ௬௬ −ṱ௬௭
−ṱ௫௭ −ṱ௬௭ ṱ௭௭
ቍ 
The eigenvalues and eigenvectors of ṱ may then be calculated. The eigenvector ẑ with 
the smallest corresponding eigenvalue represents the greatest principal axis, AP (although 
large FOVs which included more external material, usually in vivo, sometimes 
confounded this assumption). In RAS space, we wish AP to align with the image ݕ axis. 
I assumed that the two remaining eigenvectors correspond to the RL and IS axes, which 
we wish to align with the x and ݖ axes respectively. If these eigenvectors are then arranged 
into a homogeneous rotation matrix: 
E3.5 ṯ =  ẑோ௅భ ẑᾡ௉భ ẑூௌభ 0ẑோ௅మ ẑᾡ௉మ ẑூௌమ 0
ẑோ௅య ẑᾡ௉య ẑூௌయ 00 0 0 1  
such that the first column corresponds to RL, the second to AP and the third to IS, the 
resulting affine matrix ṯ, when applied to a NIfTI image header, will rotate it such that 
the AP axis aligns with the image ݕ axis, the RL with the x axis, and the IS with the ݖ 
axis. To rotate about an arbitrary point, such as the image centroid, we must translate to 
the origin, rotate and then apply the inverse translation: 
E3.6 ṹ = ẍିῺ(ṯẍ) 
where the translation matrix ẍ translates the centroid coordinates to the origin. I thereby 
used NiftyReg to rotate each subject to align AP with the y axis (Fig 3.10a). 
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3.3.2 Using symmetry to test rotation 
As mammals, and members of bilateria, the brains of both humans and mice exhibit 
approximate mid-sagittal plane symmetry (the YZ plane in RAS orientation). I used this 
feature to correct possible misalignment (as, e.g., Liu et al., 1998; Ruppert et al., 2011 
did, with human brains). To measure symmetry, I reflected images in the YZ plane (along 
the x-axis, E3.8) and calculated the sample Pearson’s product-moment correlation 
coefficient ݎ between original and reflection, E3.9-11 (Kim & Fessler, 2004). By 
composing with additional rotation matrices ṹ௥௢௧ , I generated multiple rolls about the y 
axis within a 180° range, reflected each, and searched for the optimal rotation which 
maximised ݎ and thus best aligned LR and IS with the x and z axes respectively (Ruppert 
et al., 2011) (Fig 3.9; Fig 3.10c). 
To test symmetry, one can insert an additional rotation matrix ẉ into E3.6, where ẉ is 
found by adapting from Arata et al. (1995) for 3D homogeneous coordinates: 
E3.7 
ṹ௥௢௧௔௧௘ = ẍିῺṯẉẍ 
ẉ = ẉ௭ẉ௬ẉ௫  
ẉ௫ =  1 0 0 00 cos θ sinθ 00 −sinθ cos θ 00 0 0 1  
ẉ௬ =  cos߰ 0 −sin߰ 00 1 0 0sin߰ 0 cos߰ 00 0 0 1  
ẉ௭ =   cos߮ sin߮ 0 0−sin߮ cos߮ 0 00 0 1 00 0 0 1  
The matrix Rᾒ rotates the image ߰ radians about the ݕ axis. To rotate about the ݕ axis 
alone, θ = φ = 0, ψ = ẛ × ߨ ṧ⁄ , and I varied ẛ in integer steps from 0 to (ṧ − 1). 
The number of rolls to test, ṧ, was determined to balance computational time and 
registration accuracy. As NiftyReg may reliably recover rotations up to 28° (Ourselin et al., 
2001), I tested in steps of 24°/2 = 12° (so that ṧ = 180°/12° = 15: ṧ must be an 
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integer). In the best case (Fig 3.10di), the reflection will therefore be at most 12° × 2 =24° from the original rotated image. 
The affine transformation matrix for reflection, ṫ௒௓ (along the x axis), is composed with 
the rotation in the following order: 
E3.8 
ṹ௥௢௧௔௧௘ ௔௡ௗ ௥௘௙௟௘௖௧ = ẍିῺṯẉṫ௒௓ẍ 
ṫ௒௓ =  −1 0 0 00 1 0 00 0 1 00 0 0 1  
I found Pearson’s ݎ between each of the ṧ image pairs (Kim et al., 2004; Rodgers & 
Nicewander, 1988) using E3.9, where ṱை  is the original image and ṱோ the reflected; and 
the sample covariance ṥⱷݒ is given by E3.10: 
E3.9 ݎ௦௔௠௣௟௘ = ṥⱷݒ(ṱோ , ṱை)
┐ߪூӐ
ῼ ߪூӉ
ῼ
 
E3.10 ṥⱷݒ(ṱோ , ṱை) = 1ṻ − 1Ѷ൫ṱோ௜ − ṱோԍ ൫ṱை௜ − ṱைԍ  ே
௜ୀῺ
 
ṱோԍ  denotes the mean intensity value of all ṻ voxels ⱪ in the reflected image, and the sample 
variances are given by: 
E3.11 
ߪூӐ
ῼ = 1
ṻ − 1Ѷ൫ṱோ௜ − ṱோԍ ῼே
௜ୀῺ
 
ߪூӉ
ῼ = 1
ṻ − 1Ѷ൫ṱை௜ − ṱைԍ ῼே
௜ୀῺ
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Figure 3.9 Determining optimal orientation via reflection. 
I resampled 14 in-skull WT brain images into RAS space, so that the correct orientation 
was known. Rolls were applied about the Y axis (Fig 3.10b), in 5° increments from -90° to 
+85°. Each was reflected in the YZ plane and the reflection compared with the rotated 
original using Pearson’s ݎ (values in grey; mean in red). First/second column: comparison 
without/with prior 6-DOF rigid registration. First row: full-size images; second row: 
images downsampled by a factor of 4; (e): downsampled by a factor of 2. 
The peaks at 0° illustrate the ability of this technique (Fig 3.10b—d) to correctly orient 
mouse brains using their symmetry, with robustness to extraneous material. Registration 
resulted in a plateau (b,d,e), which broadened with the degree of downsampling. 
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Fig 3.9 shows the results ݎ in tests with 14 ex vivo WT brains rotated at 5° increments 
from a ground truth correct orientation, demonstrating that this rotation, reflection and 
symmetry test technique was robust for many different brains. The plateaus demonstrate 
the ability of NiftyReg to correctly register reflected brains within a certain rotation range. 
However, this figure also demonstrates that it was better not to apply rigid registration 
after reflection, before calculating ݎ, as this resulted in a broad plateau about ‘0’ degrees 
from the ground truth, and hence made the best alignment more ambiguous. 
I corrected any remaining misalignments (due to performing a limited number of 
rotations and tests) by rigidly registering the image pair with the maximum ݎ, giving an 
initial affine transformation matrix, ṡ. Applying the (log Euclidean) half of ṡ, ṡ௛௔௟௙, to 
the original, rotated image thus correctly aligned the anatomical axes to RAS (Fig 3.8, 
3.10d). 
E3.12 ṡ௛௔௟௙ = ⱡݔ݌ⅎቆↄⱷⱦⅎ(ṡ)2 ቇ 
Where ↄⱷⱦⅎ and ⱡݔ݌ⅎ denote, respectively, the matrix logarithm and the matrix 
exponential. 
3.3.3 Final choice of orientations 
As the principal axis calculation omits anatomical direction, AP is equivalent to PA, LR 
to RL and IS to SI. After correctly aligning principal axes, therefore, the subject could 
still be in one of four possible orientations, one of which conforms to RAS. I generated 
the three remaining candidates by composing with additional rotations: a 180° roll about 
y, inverting IS and RL; a 180° yaw about z, inverting AP and RL; and a 180° pitch about 
x, inverting IS and AP (Fig 3.10e). The ṹ௥௢௧  and ṡ௛௔௟௙ which align one of these four 
will also align the others. 
I rigidly registered each candidate to 3 correctly aligned images from the UFL ex vivo 
mouse brain atlas (Ma et al., 2005), and selected the candidate with the highest ݎ in the 
most cases as the correct orientation (Fig 3.10f). A subset of correctly oriented candidates 
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could be manually chosen instead of external data. In practice, it was almost always 
possible to forgo this voting step and only test against one correctly oriented atlas image. 
 
Figure 3.10 Overview of orientation correction steps, with coronal views. 
See Fig 3.9 for validation of the symmetry measure technique (c). In the configurations 
illustrated (e), 4 orientations are possible: in the coronal views, the mouse is either facing 
the viewer or away (L and R interchangeable); in the transverse views, the view is from 
below or above. 
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3.3.4 Orientation of embryos 
After extraction from the mother’s gravid uterus, mouse embryos are typically found in 
the foetal position. Little extraneous material is included. Their gross morphology is thus, 
overall, largely symmetric and ellipsoidal (Fig 3.11) – with the exception of some internal 
organs, such as the heart, and the variable positions of their limbs and tail. Exactly the 
same orientation technique is therefore applicable, employing appropriate ‘atlas’ or target 
embryos already in the correct orientation for the final stage. 
 
Figure 3.11 Illustration of a mouse embryo in RAS orientation 
From left: coronal, sagittal, transverse views, as Fig 3.8. Approximate principal axes (RL, 
AP, SI) are shown, dotted green and dashed orange. The latter denotes the mid-sagittal 
plane, which, again, coincides with the YZ plane of approximate symmetry. In this case, 
AP corresponds with skull to tail. 
3.4 Intensity non-uniformity correction 
A smoothly-varying, hardware-induced, low-frequency intensity gradient often corrupts 
MR images (Sled & Pike, 1998). This is caused by inhomogeneity of the scanner’s B0 
field, variable sensitivity of the receiver coils, or inhomogeneity of the radiofrequency 
pulse, which can be induced via non-uniformity of the transmission coil or via 
electromagnetic interactions and distortions by the subjects themselves (Lewis & Fox, 
2004). As this effect becomes especially pronounced at high field strengths (Boyes et al., 
2008), intensity non-uniformity modelling is essential in preclinical studies. NUC 
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improves automated tissue classifications and image registration (Sled & Pike, 1998; Van 
Leemput et al., 1999; Lewis & Fox, 2004). Locally adaptive NUC algorithms, such as N3, 
have been shown to outperform nonadaptive methods (Arnold et al., 2001). 
I initially employed N3 (Sled et al., 1998), and later the N4ITK (N4) algorithm (Tustison 
et al., 2010), found to reliably correct bias at high field strengths, using 200 iterations; 
256 histogram bins; a 0.15mm FWHM Gaussian kernel to model the bias field; 
subsampling factor 4 (for high-resolution, ex vivo images) or 2 (for lower-resolution in 
vivo images). NUC is further refined during the iterative expectation maximisation steps 
of tissue segmentation. In neither technique is the image resampled; thus image quality 
is maintained. 
 
Figure 3.12 NUC of multiple-subject brain and embryo images prior to extraction. 
NUC has the potential to benefit multiple-subject extraction by improving subject 
identification. a-f: Three sciatic nerve injury study brains in Fomblin; g-l: nine GLDC 
embryos in agarose. First row: uncorrected original images; second: after NUC; third: 
calculated, inverted bias field (to illustrate, I enhanced the contrast in the final row by 
25%). 
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Multiple-subject scans (with greater FOV than single-subject) may benefit from 
preliminary NUC prior to extraction, as signal drop-off away from the isocentre 
compounds non-uniformity (Fig 3.3b). In the 9-embryo and 3-brain scans analysed here, 
non-uniformity was not problematic for identifying subjects prior to extraction – 
however, if the larger embryo holder (Fig 3.2a) were to be used, to increase throughput, 
signal drop-off away from the bore isocentre would be more appreciable. 
In ex vivo data, N4 occasionally “corrected” the lower WM intensities of the brainstem, 
particularly around the pons. The degree of GM/WM PV between the thalamus and 
brainstem yields a similar effect to a smoothly-varying intensity gradient, which may be 
misinterpreted by the NUC algorithm. Thus, after NUC, it is prudent to visually inspect 
the data for quality improvements or over-correction (Fig 3.13). In such ex vivo cases, 
NUC was not applied. 
 
Figure 3.13 Non-uniformity over-correction in an ex vivo brain. 
Transverse and sagittal views showing the original data (a,b) and results of NUC using N4 
(c,d). The WM of the midbrain and brainstem (red asterisks) is artificially brightened – a 
result of the misinterpretation of naturally smoothly-varying tissue intensities in the mouse 
brain. 
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3.5 Brain masking (skull-stripping) 
To reduce damage, and hence improve the validity of morphometry results, it is better to 
scan mouse brains in-skull (Sawiak et al., 2012). Automatically distinguishing brain tissue 
from skull in humans, and localising the brain surface, is a prerequisite for many analysis 
techniques, and one of the most fundamental computational tasks in neuroimaging, 
addressed in many clinical papers. 
Accurate brain masks benefit tissue classification, intensity standardisation, bias 
correction, registration and segmentation, by restricting the ROI and excluding variable 
extraneous material. This saves time and computer memory during registration, and helps 
constrain the multiple testing problem for voxel-wise statistical tests. Accurate brain 
surface localisation is important for the detection of cortical atrophy in V/TBM, as well 
as for measurement of brain volume and cortical thickness (Smith, 2002; Leung et al., 
2011). As manual masking (e.g. Cheng et al., 2011) is extremely time-consuming at high 
resolutions, susceptible to inter- and intra-rater variability, and lacks repeatability, several 
automated techniques, most tailored to human brains, have arisen – for example, FSL’s 
brain extraction tool, BET (Smith, 2002); SPM. 
FSL’s BET expands a spherical mesh ROI initialised within the human brain from half 
the estimated radius, until it reaches the surface, determined by an intensity threshold. 
In SPM, brains are skull-stripped using GM and WM tissue probabilities, requiring a 
priori maps with sufficient subject similarity. This probabilistic approach beneficially 
accounts for structural variability in the complex configuration of folding cortical gyri 
and sulci, which vary between subjects as well as with age and neurodegenerative disease 
(Cardoso et al., 2009; Chakravarty et al., 2013). 
The mouse cortex is lissencephalic – smooth, without gyri – and less variable than a 
human’s. The cerebellum, proportionally larger, varies in shape with age and background. 
The brain overall exhibits greater morphological variation than a rat’s (Paxinos & 
Franklin, 2012). The brainstem also exhibits significant variability, depending on 
positioning during fixation in ex vivo scans or the alignment of the head in the scanner 
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when in vivo (see §5.7.2 and Fig 6.4). As in humans, overall brain shape changes with 
age. Additional variability arises between mouse strains, and in disease. Oguz et al. (2014) 
followed mathematical morphology operations with an intensity gradient-based graph 
cut method to constrain the outer surface of a rodent brain mask. This required varying 
smoothness constraints across the resulting brain surface, and a manually-specified upper 
bound on the brain volume. The method was fast, but would be sensitive to external 
material with a similar intensity as the brain, without clear separation, and omitted the 
paraflocculi and brainstem in an image with severe intensity inhomogeneity. 
As mouse brains are much smaller and more ellipsoidal than humans’, Biedermann et al. 
(2012) scaled their data × 10, and then × 0.5 in the AP dimension, to fit BET’s initial 
spherical ROI, and reversed this scaling when the optimal segmentation was achieved. 
Rodent BET – released by Tobias Wood at King’s College London – provides modified 
parameters for rodent brains, including an ellipsoidal brain surface initialisation (Wood et 
al., 2013), but in extracting rat brains, generally omits the olfactory bulbs and 
paraflocculi, which do not conform to the assumed generic ellipsoid2. For investigative 
morphometry, it is better to include all parts of the brain. 
Li et al. (2009) employed a 3D active surface model (using ITK-Snap3, Yushkevich et al., 
2006), requiring manual seeding and corrections. Such edge-based region-growing 
approaches are vulnerable to regions where the brain appears to be in contact with 
external tissue with similar intensity – a problem in mice, as the skull tightly encases the 
brain – or non-uniformity and PV at the brain boundary, which obfuscate the exact 
surface location. Uberti et al. (2009) developed a level set method, requiring accurate user 
delineation of several slices to initialise an evolving 3D function, as well as constraint 
points placed at extrema to prevent expansion beyond the surface. Chou et al. (2011) 
employed Pulse-Coupled Neural Networks, expanding a 3D mask based upon the 
intensity values of neighbourhood voxels. Each voxel’s inclusion in the mask is 
determined by the number of times it is ‘activated’, above a threshold. Voxels beyond 
 
                                                        
2: See image at http://www.nitrc.org/projects/rbet (accessed 2015-11-25) 
3: http://www.itksnap.org 
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borders represented by steep intensity gradients require more iterations to activate; thus 
the mask volume plateaus. The result is reliable and includes the olfactory bulbs; however, 
the user must intervene to stop progression beyond the optimal segmentation, or provide 
parameters to search within a range for the centre of the plateau. Janke & Ullmann (2015) 
advocated a manual correction step, as “in many cases it is nearly impossible to prevent” 
the inclusion of extraneous material. 
3.5.1 Multi-Atlas masking with STEPS 
I adopted a multi-atlas technique, developed by Da Ma and Jorge Cardoso at CMIC 
(§2.2.3; Ma et al., 2014), relying upon registration accuracy and the applicability of atlas 
images, given potential morphological variability. 
I created brain masks using Similarity and Truth Estimation for Propagated 
Segmentations (STEPS, Cardoso et al., 2013b) label fusion, implemented in NiftySeg, 
with the UFL atlas database of 10 skull-stripped ex vivo T2*W structural images (47µm 
isotropic resolution; 20 corresponding labels) as a reference. Exploiting the approximate 
inherent symmetry of the atlas brains, I doubled the database size by reflecting structural 
and label images in the mid-sagittal plane (see §3.3.2, Bowden et al., 2011 and Ma et al., 
2014). I binarised and merged labels to create atlas brain masks ṡெ. 
I registered each subject image ẋ to each of the structural atlas images ṡௌ using affine 
registration with 12 degrees of freedom (DOF), using NiftyReg. The inverse of the 
calculated affine matrix was used to transform each corresponding ṡெ to the space of ẋ, 
resampling with nearest neighbour interpolation. These masks were dilated by 5 voxels 
to account for incomplete brain coverage (resulting from differing morphology of ẋ and 
ṡௌ) and used to constrain a symmetric non-rigid registration (NRR, Modat et al., 2012) 
between ẋ and each ṡௌ (parameters: control point spacing 0.3mm, 4 levels of doubled 
CP spacing, bending energy penalty 0.1, inverse consistency penalty 0.1). The inverse 
deformation field was then used to propagate each ṡெ and ṡௌ to the space of ẋ. The 
resampled ṡெ were then combined. 
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In STEPS, the subject image ẋ is compared with each propagated ṡௌ, using locally 
normalised cross correlation (LNCC) over a Gaussian kernel. Atlas images are locally 
ranked based on this similarity metric, and the masks corresponding to the voxel-wise ẕ 
highest-ranked atlas images are fused into a consensus mask (Cardoso et al., 2013b). 
Poorly locally-matched atlases are thus excluded. The user defines ẕ and the kernel 
standard deviation ߪ as algorithmic parameters (here for ex vivo data, ẕ = 9; ߪ = 8 
voxels). Optimised parameters were recently investigated using this atlas (Ma et al., 
2014). Instances of minor incomplete coverage (such as at the brainstem and paraflocculi) 
were all accounted for by dilating and filling the final consensus masks (Fig 3.14). 
 
Figure 3.14 Mouse brain masks after the STEPS procedure. 
Original masks (left of dashed lines in coronal views) overlaid on representative slices (a, 
sagittal; b—c, coronal) from a single WT brain, and dilated by 5 voxels (right of dashed 
lines). Solid white lines indicate slice locations. Green markers indicate, from left, over-
generous coverage of olfactory bulbs; minor incomplete coverage of the inferior brainstem, 
posterior cerebellum, and paraflocculi, where atlas registration was more imprecise – all of 
which are included after dilation. 
3.5.2 Problems for automated mouse brain masking 
Problematic regions for masking in-skull images include the area around the olfactory 
bulbs; the base of the brainstem; the lower cerebellum just superior to the cisterna 
cerebellomedullaris, and sometimes the posterior face of the cerebellum (Fig 3.14). In all 
these locations, the brain is in close contact with external tissues exhibiting similar signal 
intensities. The cerebellum, furthermore, is one of the regions of greatest morphological 
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variability in the studies conducted for this thesis; its shape changes with age, and the 
material surrounding it may be fully or partially excised during skull extraction. 
The masks generated are dilated to include the intensity gradient at the brain boundary, 
informing registration, in which external tissues may thus play a role. A generous mask, 
advantageously, may later be refined via tissue classification. Indeed, such a two-step brain 
extraction technique may be preferable in whole-skull mouse MRI, as (for the 
abovementioned reasons) a parcellation- or region-growing-derived mask may include 
some external material. If tissue were to be cropped by an over-zealous or conservative 
mask, it cannot be recovered later, and the intensity gradient introduced at the boundary 
may bias registration. 
3.6 Segmentation of brain tissues 
I initialised intensity-based segmentation with subject-specific TPMs propagated from 
an atlas (§2.2.5), and used non-rigid registration to resolve structural differences. 
Custom, study-specific TPMs are more likely to reflect the anatomical variability of the 
data than external TPMs, and hence reduce bias toward the healthy morphology of atlases 
(White et al., 2003). I based the TPMs upon the NUS atlas (Bai et al., 2012), preferring 
its greater number of labels – including cerebellar WM – over the UFL atlas, which – for 
example – does not delineate the GM and WM of the cerebellum. Lee et al. (2009) 
nevertheless used the UFL atlas to initialise an itkEMS-based segmentation, subsequently 
used for probabilistic skull-stripping. In summary, the process was: 
1. Classify anatomical atlas labels based upon their tissue content 
2. Register each atlas structural image to each data image 
3. Propagate the tissue labels to the data space, and calculate the average at each voxel 
4. Use these normalised probabilistic labels as TPMs to initialise segmentation 
5. Correct CSF classifications, using voxel intensities. 
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I manually classified 22 of the 39 NUS atlas parcellations as GM; 9 WM (Table 3.1), 
based upon their predominant tissue content. Following Lee et al. (2009), I initially 
classified 3 regions (caudate putamen/striatum, thalamus, superior and inferior colliculi) 
as a separate GM/WM mixture class (GWmix). I excluded ventricular CSF (vCSF), as 
the large in vivo atlas ventricles did not register well to ex vivo data, whose ventricles in 
most cases almost completely collapse upon perfusion-fixation (see §5.7). 
To account for variable locations of external CSF, I added an eCSF label to the outer rim 
by dilating the atlas masks – excluding the pituitary gland – by 1 voxel, and subtracting 
the original. I added a BG label in the same manner to account for skull tissue, dilating 
by 5 voxels and subtracting both the original mask and eCSF. These classes helped to 
avoid misclassification of the meninges and skull as brain tissue, as well as of GM PV 
voxels at the cortical surface as WM (Good et al., 2001; Teipel et al., 2004). I again 
doubled the atlas size, by reflecting in the mid-sagittal plane (§3.5). 
I registered the 10 structural NUS atlas images to each data image (12 DOF symmetric 
affine registration, then symmetric NRR to account for local morphological differences). 
I resampled the tissue labels to the data space following the resulting deformations, using 
linear interpolation. Average labels were then calculated in the data image space, 
probabilities were normalised at each voxel (to sum to unity) and the results smoothed 
(using a Gaussian kernel with a 4-voxel standard deviation), creating subject-specific 
TPMs of 5 classes {GM, WM, GWmix, eCSF, BG}. 
I used these TPMs to initialise an iterative expectation-maximisation (EM) algorithm, 
implemented in NiftySeg (Van Leemput et al., 1999; Cardoso et al., 2009), assuming 
approximately normally distributed tissue histograms. This was spatially constrained with 
a Markov Random Field (prior strength 0.25), giving robustness to noise and preventing 
the misclassification of brain surface PV voxels as WM, and proceeds until convergence. 
The priors were iteratively relaxed by a factor of 0.25 and regularised (Gaussian kernel 
standard deviation 0.5 voxels) to avoid overt bias towards the atlas and account for local 
anatomical variability (Cardoso et al., 2013a). The algorithm includes iterative NUC, 
assuming a smoothly-varying polynomial bias field. The dilated mask generated earlier 
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constrained classification to the brain and its immediate surrounds, limiting confounding 
external tissue. 
To account for vCSF, which in most images was minimal, within the ventricular regions 
propagated from the atlas, I classified voxels within one standard deviation of the mean 
of the eCSF class as vCSF (binary), and subtracted these from other classes. Resulting 
TPMs for a single Tc1 mouse are shown in Fig 3.15. 
 
Figure 3.15 Representative slices from a Tc1 brain illustrating probabilistic tissue 
segmentations. 
Column a, sagittal; b, transverse; c, coronal. First row: GM (red); second: GM/WW 
mixture (green); third: WM (blue). Solid white lines indicate slice locations. Green markers 
indicate, from top, minor misclassification of external tissue as GM; thin dark GM 
Purkinje cell layer misclassified as WM. 
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In subsequent analyses, I replaced these TPMs with maps generated used the same 
scheme, omitting the GWmix class, which lacked direct biological meaning. The regions 
previously classified as GWmix (Table 3.1) were initialised prior to propagation to the 
data space with a probability of 50% GM and 50% WM. The updated segmentations 
(Fig 3.16) include PV as regions of lower GM or WM probability. 
I calculated total intracranial volume (TIV), a measure used clinically to account for 
natural cross-sectional variability of head size (Whitwell et al., 2001; Ridgway et al., 2011) 
as: 
E3.13 ẍṱẑ = Ѷ ẑ × (ṿῷெ + ṿௐெ+ṿ௘ᾣௌῲ + ݒṥẋṫ)
௔௟௟ ௩௢௫௘௟௦  
Where ẑ is the voxel volume and ṿῷெ is the segmentation-derived probability of GM 
within the voxel. TIV may be used to normalise volumetric measurements of brain 
structures, and brain volume (BV) itself, which is calculated in the same way, excluding 
CSF. I generated a conservative brain mask by binarising the {GM, WM} probability 
images above 50%, adding vCSF, and binary-filling the resulting volume to include 
possible omitted internal regions. These refined masks excluded potentially misclassified 
external tissues. 
 
Table 3.1 Manual binary classification of NUS atlas labels used to initialise EM. 
The NUS atlas (Bai et al., 2012) includes the pituitary gland, excluded here. In the second 
implementation (Fig 3.16), GM/WM mixture tissues were initialised as 50% GM, 50% 
WM. 
CSF cerebral aqueduct, lateral ventricles, third ventricle, fourth ventricle 
GM amygdala, auditory cortex, cerebellar cortex, cortex general, dentate gyrus, entorhinal 
cortex, frontal cortex, general basal ganglia, hippocampus CA1, hippocampus CA3, 
hippocampus general, hypothalamus, lateral olfactory tract, midbrain (remainder), motor 
cortex, olfactory system, periaqueductal grey, perirhinal cortex, septum, somatosensory 
cortex, substantia nigra, visual cortex 
GWmix caudate putamen (striatum), superior & inferior colliculi, thalamus 
WM anterior commissure, cerebellar lobules, cerebral peduncle, corpus callosum, fornix system, 
internal capsule, medulla, optic nerve, pons 
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Figure 3.16 Improved tissue classifications. 
The same sagittal (top), coronal (middle row) and transverse slices from a single 
representative WT brain in-skull, overlaid with probabilistic tissue classifications, 
including only GM (a; red) and WM (b; blue). Note the boundary between GM and WM 
at the brainstem is less definitive than in Fig 3.15. 
3.7 Intensity standardisation 
The MRI intensity scale is inherently non-standardised and lacks diagnostic meaning: an 
identical tissue location in a repeat scan, using the same scanner and parameters under 
ideal conditions, may produce a different signal (Nyúl & Udupa, 1999). Subject 
movement, electronic and ambient noise, temperature and cellular tissue changes 
contribute to signal variation. These confounds are compounded between subjects and 
scanners. MR images are diagnostically valuable without standardisation, so procedures 
are surprisingly uncommon (Bagci et al., 2010; Leung et al., 2010b). 
An intensity average image is created following each iteration of group-wise registration 
(§3.8). I standardised the MR intensity scale beforehand to the approximate [0 1] range, 
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to prevent individual images’ noise, intensity extremities and features from dominating, 
and to ensure similar intensity ranges represented equivalent anatomical regions between 
images. The best standardisation results are achieved after NUC (Bagci et al., 2010). 
A ‘robust’ standardisation involves the trimming of the image histogram tails by e.g. 1%: 
voxels are sorted by intensity, the 1st and 99th percentiles ݌ẚ of their total number found, 
and all voxels with values less than those at ݌ẚῺ and greater than ݌ẚᾫᾫ are set to these 
respective extremes. All intensity values are divided by the maximum, limiting the range 
to [0 1]. This beneficially broadens the histogram, increasing contrast, while maintaining 
relative intensity relationships between voxels. The intensity values themselves are not 
analysed in V/TBM studies, so their adjustment is not problematic, provided contrasts 
between structures, which drive the registration, are maintained. The arbitrary choice of 
1% tails, however, fails to account for dominant intensities between [݌ẚῺ ݌ẚᾫᾫ]: one 
image’s GM peak may be at a higher intensity than another’s – so will dominate the 
average, despite having the same maximum intensity. Kovačević et al. (2005) linearly 
scaled intensities to standardise them based upon the GM peak alone – which may have 
similar drawbacks, for non-GM structures. 
I used the piecewise linear approach to standardisation described by Nyúl et al. (2000). 
This method involves a training step, incorporating the whole dataset (or a subset), and 
an application step. During training, within the dilated brain masks, 11 histogram 
landmarks were found for each image: the 1st and 99th percentiles, and evenly-spaced at 
each 10th percentile. The landmark configuration as per Nyúl et al. (2000) was thus: 
E3.14 ṷ = {݌ẚῺ,݌ẚᾫᾫ,݌ẚῺΏ,݌ẚῼΏ , … ,݌ẚᾫΏ}  
The landmark means across images were found, and each image’s intensities were scaled 
linearly between these (Fig 3.17). This piecewise-linear scaling was quick, so I trained 
using the entire dataset, avoiding bias to a sub-population. 
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Figure 3.17 Intensity standardisation results in the Tc1 (cohort 1, §4.1) dataset. 
(a) original Tc1 images’ histograms (within dilated masks), scaled to the [0 1] range for 
comparison with results of intensity standardisation (b). 
3.8 Group-wise registration 
As described in §2.2.6, registration acts to align corresponding voxels between images, to 
account for morphological differences arising from anatomical variation, by applying 
deformations and maximising a similarity measure. I spatially normalised all structural 
images into a common coordinate space (Kovačević et al., 2004; Kovačević et al., 2005; 
Cleary et al., 2011a) using NiftyReg, which performs global (rigid, affine) and local (non-
rigid) registrations, with the group-wise registration (GWR) technique outlined in §2.2.6 
and Fig 2.9. I employed 5-voxel dilated masks of each ẋ௜ to include a sufficient intensity 
gradient at the brain boundary for accurate alignment, while excluding irrelevant 
material. Results are shown in Fig 3.18. 
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Figure 3.18 Group-wise registration average images 
Results of the process illustrated by Fig 2.9. The same sagittal, coronal and transverse slices 
of average images from the Tc1xJ20 cohort (N=49 brains, §4.2) showing progressive 
sharpening as the iterations (number at left) increase. By the final NRR iteration, 
cerebellar, hippocampal and cortical sublayers are clearly visible, at this high resolution. 
The right-hand column shows a zoom of the region indicated in the top coronal view. 
Voxel-wise standard deviation may also be used to assess the improvement in alignment, 
as illustrated in Fig 3.20. 
The first iteration was rigid-only, 6 DOF: 3D rotation and translation. Iterations 2—5 
were affine (12 DOF, including 3D shears and scaling), employing a symmetric block-
matching algorithm at progressively smaller scales (Ourselin et al., 2001; Modat et al., 
2014). (Fig 3.20 shows 5 iterations of global registration, but I later adopted up to 10, as 
the standard deviation continued to reduce after 5 iterations.) Due to the small features 
of mouse brains and the global variability of images, I found that it was sometimes 
necessary to adjust the number of pyramidal coarse-to-fine-scale levels – for example, 
when performing affine registration between in-skull and ex-skull images. For the affine 
stages of GWR I used 4 levels. I performed 15—20 subsequent, non-rigid registration 
iterations using symmetric, inverse-consistent Free Form Deformation (Rueckert et al., 
1999; Modat et al., 2012): the image was warped using cubic B-splines deformed between 
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increasing numbers of control points placed at progressively finer scales, employing 
normalised mutual information as the similarity measure to be optimised. NiftyReg was 
parameterised with constraints on the final control point spacing: 5 voxels for ex vivo 
data; 5 levels of doubled CP spacing; and a penalty term for bending energy (0.005). 
Deformations at a particular iteration of GWR may be summarised for the whole cohort 
with a mean positional distance image (MPD, Fig 3.19), wherein the magnitude of the 
3D deformation vectors is calculated at each voxel and the mean found over all ṻ image 
displacement fields, ⱪ: 
E3.15 ṹṿṧ (ݒⱷݔⱡↄ) = 1
ṻ
Ѷ┐ݔ௜
ῼ + ݕ௜ῼ + ݖ௜ῼே
௜ୀῺ
 
where ݔ,ݕ, ݖ are the voxel’s vector components from the non-rigid registration only 
(excluding rigid and affine). 
Regions outside the brain, the brainstem and the ventricles show the greatest variability 
in Fig 3.19. To avoid external tissues’ deformations interfering with brain tissue, 
particularly at the cortical surface, I used conservative dilated masks (3—5 voxels ex vivo) 
when performing the GWR used for TBM analysis. The hippocampus, cortex and corpus 
callosum were more affected than the thalamus and midbrain in this cohort, although 
the relative intensity homogeneity within the latter structures also limits the ability of 
registration to recover morphological changes. The olfactory bulbs show more variability 
than the rest of the brain, but in these in-skull images the degree of deformations 
(<<50µm) is far less than that seen in the ex-skull images of Kovačević et al. (2005), which 
had deformations in this region >500µm, and damage or handling-related deformations 
in the cortical surface of around 250µm. Similarly, in registering ex-skull ex vivo to in-
skull in vivo images, (which I show in §5.7.2), Ma et al. (2008) showed deformations 
>500µm in the brainstem and olfactory bulbs, and changes around 250µm in the 
cerebellum – all attributable to brain extraction (see Fig 5.17). 
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Figure 3.19 Ex vivo mean positional distance image from a cohort scanned in skull. 
Sagittal, coronal and transverse slices, showing the mean magnitude of all images’ NRR 
deformations overlaid on the final Tc1xJ20 group-wise average (§4.2). The scale, in mm, 
gives a summary of the amount each region deformed to meet the final average, and hence 
a quantified overview of local morphological differences within the cohort. The greater 
distances in extraneous material result from high variability, in part caused by damage and 
variable flesh and fat-stripping following skull excision. 
3.8.1  Assessing GWR quality 
GWR is by far the most time-consuming aspect of the pipeline, taking several days to 
complete 20 NRR iterations of ex vivo data, even when run in parallel on a cluster (this 
was usually a combination of job queuing and the actual time taken per registration step). 
Each registration generally converged after less than eight hours, even at the highest 
resolutions (40µm). It was prudent to visually inspect each deformed image for 
misregistration, which may converge on local maximum similarities with false or non-
physiological deformations which do not represent the overlapping of equivalent tissues. 
The performance of GWR can be quantitatively assessed, to determine the number of 
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iterations necessary to reasonably align images and sufficiently recover morphological 
variation. 
A single registration’s accuracy may be checked by manually segmenting both the target, 
ẍ, and each source image, ẋ௜ (the whole brain or individual substructures), applying the 
transformations and deformations to the segmentation of ẋ௜, and calculating a Dice score 
between the two resulting segmentations to quantify their overlap. Dice has disadvantages 
as it is sensitive to scale (as smaller structures are more sensitive to registration error, Ma 
et al., 2014), and this assumes each manual segmentation is equally accurate. Lau et al. 
(2008) assessed the performance of their GWR at each iteration by computing a voxel 
overlap metric: parcellating each individual image and propagating these to the average 
after registration. They showed acceptable convergence to 1 (perfect overlap) after about 
6 iterations of NRR. 
Registration errors may be revealed in the “difference image” between image pairs – the 
GWR target and each resampled floating image. The standard deviation (SD) of all 
resampled images at each voxel (requiring prior intensity standardisation) may be 
visualised (Fig 3.20) to summarise regions of high variability, where registration has more 
difficulty. Both highlight large intensity differences and are thus biased towards structures 
bounding CSF regions over subtler GM/WM boundaries. 
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Figure 3.20 Plot of the overall mean standard deviation (SD) of voxel intensities, within 
the original target brain mask, of the resampled structural Tc1 and WT images at each 
stage of GWR. 
Inset images (top right) show the same coronal slice of the SD images at indicated 
iterations. Bottom row shows the same transverse slice. The maximum intensity of 
individual images, and hence the average, was approx. 1.2, after intensity standardisation; 
these images are thresholded so their maximum (white) is 0.05. The registration 
progressively improves alignment, reducing SD – dramatically so, after the first iteration 
(it.1) of NRR (C). Although improvement after NRR it.6 is not obvious and there is some 
minor fluctuation, in this case the minimum occurs at it.13. Note the variability of the 
striatum, even at it.20 (red asterisk). See also Fig 5.5. This plot may still display low values 
despite misregistration; it was important to also visually inspect the final results. 
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3.9 Segmentation propagation for Jacobian 
integration 
I segmented the final GWR average image using STEPS and the UFL atlas, as per Ma et 
al. (2014) and §2.2.3. The resulting parcellations (e.g. Fig 3.21) were used to localise 
statistical results, and, using the NRR deformations, may be back-propagated to 
individual subjects to measure volumes (Cleary et al., 2011a). This has the disadvantage 
of including an additional interpolation step, which may reduce accuracy. Instead, I 
measured the volume of each region in each mouse brain via integration of the 
determinants of the NRR deformations’ Jacobian matrices (§2.2.7; Boyes et al., 2006). 
 
Figure 3.21 Final Tc1 NRR average image with UFL atlas parcellations overlaid. 
(a) Sagittal; (b) coronal; (c) transverse views. Right half semi-transparent in b, c. Arrows 
indicate, from top left, incomplete coverage of the brainstem owing to improper atlas 
registration; successful exclusion of eCSF; slightly over-generous coverage of the corpus 
callosum. 
3.10 Transformation of Jacobian determinant maps 
For TBM, I took the loge of the Jacobian determinant ṳௗ௘௧  at each voxel in the 
deformation fields generated from GWR (§2.2.7), having multiplied with the 
determinant of the affine matrices from the final affine iteration, to include global scaling 
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(discussed in more detail in §5.6). The log transformation gives a more intuitive (and 
symmetric) scale: values < 0 represent contraction; values > 0 represent expansion; 
values of 0 represent no change. I smoothed the result with a 3D Gaussian kernel 
(FWHM 0.16mm, both ex vivo, §4 and in vivo, §5.3), chosen to maintain sufficient 
resolution to identify small features, which helps to account for remaining registration 
imprecision and renders the values more normally distributed, an assumption of 
subsequent statistical tests (Ashburner & Friston, 2000). 
3.11  Modulation of tissue class maps 
For VBM, each image’s tissue class maps were resampled to the final group-wise structural 
average space, thereby dilating or contracting (originally probabilistic) individual voxels, 
whose values remain constant. The deformed maps may then be modulated by 
multiplying with the ṳௗ௘௧  values, which represent the relative volume change of individual 
voxels, to preserve intra-subject tissue volumes, and smoothed (as above). The result is a 
comparison of voxel-wise volume of each tissue class between animals. The local 
concentration (proportional density) of the tissue class is compared if modulation is 
omitted, as it was for the Tc1 study (§4.1.9; Ashburner & Friston, 2000; Good et al., 2001; 
Mechelli et al., 2005). 
3.12  Statistical tests 
The final step is the generation of 3D statistical parametric maps (SPMs) consisting of 
False Discovery Rate (FDR)-corrected two-tailed t-statistics at every voxel of the final 
average image from the GWR. In most cases I used a conventional FDR threshold of 
q=0.05 (Benjamini & Hochberg, 1995; Genovese et al., 2002). I performed mass-univariate 
two-tailed t-tests using the General Linear Model (GLM) on the transformed 
deformation fields (TBM) and, for the Tc1 dataset (§4.1), unmodulated tissue class 
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images (VBM), with ANCOVA covariates for TIV (measured by the segmented tissue 
volumes). 
The models used were (ex vivo) E4.3, E4.4; (in vivo) E5.1. Some groups opted to 
threshold the resulting maps at a minimum cluster volume, to exclude very small regions 
of significance, which may be spurious or result from random noise (e.g. Li et al., 2009 
thresholded at 150 voxels; Biedermann et al., 2012 at 200 voxels). I did not perform this 
additional thresholding step. 
3.13  Discussion 
µMRI statistical morphometry offers several advantages for phenotyping transgenic and 
disease model mice – by enabling computational approaches and, by covering large 
regions in an unbiased manner, reducing the need for time-consuming, destructive 
exploratory histology. Clinical image processing tools have been used to process 
preclinical data; however, this often requires adjustment to fit human-centric parameters. 
Manual image processing and preparation remains prohibitively time-consuming. 
Heretofore no approach has unified all the pre-processing steps necessary for fully 
automatic, large-cohort, high-throughput preclinical phenotyping with MRI. 
This pipeline is applicable to ex- or in vivo mouse brain and ex vivo embryo studies 
employing µMRI analysis techniques including V/TBM and segmentation. Other 
preclinical models, such as rats, may also be analysed. The only steps requiring an 
applicable atlas are tissue segmentation and parcellation. The pipeline is designed to 
eliminate laborious steps, including multiple-subject extraction, orientation correction 
and skull-stripping, given appropriate data, with minimal intervention. I prioritised 
automation and robustness over speed; in these earlier steps, the process may be initialised 
with downsampled images to save time. Although the majority run in a few hours on a 
single modern processor, registration is better suited to parallel environments: I used a 
cluster running the Sun Grid Engine to queue jobs and run many registrations, and other 
tasks, in parallel. 
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A high resolution (40µm) imaging protocol was used for ex vivo structural phenotyping 
at 9.4T, giving greater SNR and spatial precision than is available at lower field strengths, 
and increasing contrast between anatomical structures and tissues, which mitigates PV 
effects (Natt et al., 2002). For a full investigation of the SNR and CNR achieved, see 
§4.1.5 (ex vivo) and §5.5 (in vivo). A subject separator eliminated complications arising 
from touching subjects in multi-brain scans. In these images, subjects were identified 
using brain or embryo volumes from training data; additional features such as intensity, 
texture or shape could also be included for this step. 
The order of the steps is deliberate. Orientation correction is perhaps the most important, 
as it enables subsequent atlas-based approaches. However, some flexibility is beneficial; 
both multiple subject extraction and orientation correction may benefit from prior non-
uniformity correction. 
Orientation correction – to a standard space – enabled the multi-atlas techniques 
described to produce high quality brain masks, subject-specific tissue segmentations, and 
anatomical parcellations. The UFL atlas contains more brains and is thus suited to ex vivo 
and in vivo masking; the NUS atlas has more detailed parcellations, including cerebellar 
GM and WM, which were useful for initialising tissue segmentation. The earlier brain 
masks provide a good initial estimate of brain volume, which I employed in §5; the 
segmentation step may be skipped if VBM is not required. 
Using registered priors from the NUS atlas resulted in significant qualitative 
improvements over prior-free segmentations based upon intensity alone. External non-
brain voxels may be misclassified, for example, as GM, or cortical surface PV voxels as 
WM; separate background and eCSF classes mitigated this and improved GM 
classification at the brain surface (see Fig 4.10). As Van Leemput et al. (1999a) noted, 
external tissues may still be mis-segmented after affine registration with external priors; 
hence, to account for local variability, I used NRR. Extraneous tissues in the Tc1 and 
rTg4510 cohorts occasionally registered to the surface of the skull-stripped UFL atlas 
brains, particularly at the cerebellum and olfactory bulbs, where tissue separation is 
minimal. This required refinement of registration parameters, or substitution of a more 
appropriate atlas, for masking (§5.3.2). 
140 
The impetus for including GWmix as a separate class in segmentation (Fig 3.14) was that 
mouse brains exhibit a substantive proportion of PV, compared with human brains: GM 
and WM are not clearly delineated in some large subcortical regions, such as the 
thalamus, midbrain and pons. Lee et al. (2009) had a similar motivation. However, it was 
not clear what the implications of the GWmix class were, for VBM. Because the 
proportions of GM and WM in this region varied significantly between animals, 
statistical tests of GM or WM proportion did not appear to be meaningful. The class 
could be excluded from statistics, but this reduces the usefulness of morphometric tests, 
which ideally cover the entire brain. My subsequent segmentations, omitting GWmix, 
(Fig 3.15) appeared to be superior. 
While not without faults (for example, misclassification of the dark Purkinje cell layer of 
the cerebellum as WM), these tissue segmentations (Fig 3.15, 3.16) represent significant 
improvements over those previously published in the literature (§2.2.5). 
Atlas-based approaches should be used with caution given the extraordinary number of 
available mouse strains. A significant issue is the relevance of atlas-based TPMs to 
pathological data: TPMs based upon healthy subjects may be poor fits for those 
exhibiting gross brain changes. This concern should be reduced when expected 
morphological changes are likely to be subtle, accounted for by registration; and where 
V/TBM techniques are more relevant. 
Most structural differences between the in vivo, skull-stripped NUS atlas the ex vivo, in-
skull data discussed here were resolved with NRR. However, as the ex vivo brains’ 
ventricles had mostly collapsed, segmentation improved after discarding ventricular CSF 
labels and classifying remaining internal CSF using eCSF intensities post-hoc (see §5.7, 
§6.2.3). Furthermore, the intra-class variance of GM and WM intensities was high, 
particularly between cortical and cerebellar GM, as well as between corpus callosum and 
deep cerebellar WM. Currently-available atlases are limited by relatively low contrast and 
resolution compared with those achievable at high field strengths. Both masking and 
segmentation could be improved with an in-skull atlas more suited to the datasets 
described in this thesis; many opportunities exist for extending the size and quality of 
currently available MRI mouse atlases. 
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Brain masks were refined for statistics using tissue segmentations, and group-wise 
registration resolved remaining spatial differences. The pipeline’s modularity enables 
flexibility, as well as the substitution of other analysis packages – such as SPMMouse – 
for later stages, if preferred. Permutation testing, e.g. using FSL’s Randomise, may be 
used to validate parametric statistics if desired (Sawiak et al., 2013; Winkler et al., 2014). 
Despite the difficulties posed to registration and segmentation techniques by the close 
proximity of brain and external tissue, in-skull imaging is vastly preferable to ex-skull, 
owing to near-inevitable damage incurred by the brain during extraction or manual 
handling (Fig 3.19; Kovačević et al., 2005; Ma et al., 2008; Scheenstra et al., 2009; Sawiak 
et al., 2012). 
3.14  Conclusions 
I have described an automated software package for the high-throughput phenotyping of 
large cohorts of mouse brains, from MRI to statistical parametric map, using novel 
approaches for separation from multiple-subject scans and orientation correction – 
previously performed manually – followed by skull-stripping and tissue class 
segmentation based upon external atlases. I applied freely available software, developed 
for use with clinical data, to this preclinical paradigm, using appropriate parameters and 
custom atlases, without requiring the data be adjusted to conform to human tools. In the 
following two chapters, I show the pipeline’s application to ex vivo and in vivo mouse 
brain datasets, including the Tc1 transgenic model of Down syndrome, and the rTg4510 
model of tauopathy in neurodegenerative disease. In the latter I describe some adaptations 
for in vivo images. 
As the pipeline is modular, the steps may be performed individually, enabling integration 
with other analysis techniques such as segmentation propagation or cortical thickness 
estimation based upon the deformation fields from GWR; or segmentation with label 
fusion techniques based upon prior parcellated atlases; as well as with other packages, 
such as SPM. 
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The pipeline may be of use to the phenotyping community. With the homogenisation of 
scan parameters, standardisation of analysis pipelines, and improved availability and 
accuracy of TPMs and atlases, multi-site and large cohort studies are possible, increasing 
the feasibility of µMRI and morphometry as important, powerful preclinical phenotyping 
tools. Many more mouse model MR images are available, and this software should greatly 
simplify their morphometric analysis. 
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4 Application of the pipeline to ex 
vivo mouse brains 
The previous chapter described the development and testing of a software pipeline for 
automatically and robustly processing large cohorts of mouse brains and embryos for 
morphometric phenotyping. This chapter includes results, and discussion arising from 
two ex vivo mouse brain datasets processed with this pipeline: 
§4.1 The Tc1 model of Down syndrome 
§4.2 The Tc1xJ20 cross-bred mouse model of Down syndrome and AD 
Each dataset is briefly introduced with background about the mouse model and the 
motivations behind the study. Study details are given, along with any necessary 
adjustments to the pipeline, followed by morphometry results output and discussion. 
Each dataset provided a unique opportunity for discussing various aspects of 
morphometry, including the statistical analysis. The Tc1 study was the most detailed 
investigation and comprises the bulk of this chapter. Some issues with the data, including 
a perfusion artefact, are discussed. 
Research in this chapter was conducted with various collaborators and colleagues. Jon 
Cleary and Ben Sinclair acquired the first cohort of Tc1 data. Holly Holmes acquired the 
Tc1xJ20 dataset. Both of these originated with Professor Elizabeth Fisher and Dr. Frances 
Wiseman at the UCL Institute of Neurology. Da Ma provided the brain masking code 
for STEPS parcellations, and performed the thickness calculation on the hyperintense 
rim. 
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4.1 Morphometric analysis of the Tc1 model of 
Down syndrome 
4.1.1 The Tc1 model 
Down syndrome (DS) and mouse models were briefly introduced in §2.4.1. The Tc1 
mouse model carries a freely segregating copy of human chromosome 21 (Hsa21) and is 
trisomic for 92% of Hsa21 genes (O’Doherty et al. 2005; Gribble et al., 2013). This mouse 
model of DS recapitulates many features including cardiac defects, short-term memory 
impairment, motor deficits and mandible malformation seen in humans and other DS 
mouse models, such as Ts65Dn and Ts1Cje (Reeves 2006; Moore & Roper, 2007). The 
brain, however, has yet to be fully characterised. 
Using the pipeline described in §3, I performed a fully automated morphometric analysis 
of brains from the Tc1 mouse model of DS, using microscopic magnetic resonance 
imaging (µMRI) and Voxel- and Tensor-Based Morphometry. I compared 29 Tc1 brains 
with 28 wild-type (WT) littermate controls, imaged ex vivo at 9.4T. This first TBM 
analysis of a DS mouse model revealed global and local volumetric differences – both 
novel and previously described via histology. I show an unexpected increase in Tc1 TIV 
and, controlling for this, local volume and grey matter density reductions in the Tc1 
brain compared to the WTs, most prominently in the cerebellum, in agreement with 
human DS and previous histological findings. 
I here discuss the pipeline, results, custom considerations for this dataset, and further 
validate the Tc1 mouse as a preclinical model of human DS. 
4.1.2 Mice and multiple brain imaging 
Two cohorts C1, C2 of ex vivo adult Tc1 and WT brains were scanned at CABI. For 
reasons of statistical power (see discussion in §4.2.4), I analysed them together. C1 brains 
were scanned individually. For C2 brains, a multi-subject protocol was employed. 
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Ethics statement 
This study was conducted following approval by the local Ethical Review Process of the 
MRC National Institute for Medical Research and authorisation by the UK Home 
Office, Animals (Scientific Procedures) Act 1986 under relevant Project Licence 
authority. The ERP approved and reported that all work reflects contemporary best 
practice. High standards in the design and conduct of work were applied and full 
implementation and consideration of the 3Rs (where appropriate) was made. 
Mice, genotyping and fixation 
C1: 28 male mice aged 4-5 months (14 Tc1, 14 WT littermate matched controls) were 
taken from a colony maintained by mating Tc1 females to F1(129S8×C57Bl/6JNimr) 
males and genotyped as per Sheppard et al., 2012. C2: 29 male mice aged 15 months (15 
Tc1, 14 WT littermates) were taken from a colony maintained by mating Tc1 females 
(from the same colony as those used to breed C1) to B6.Cg-Tg(PDGFB-
APPSwInd)20Lms/2J males (see Cohort 2 genotypes, below). Brains were perfuse-fixed 
using an optimised protocol for structural µMRI mouse brain phenotyping (Cleary et al., 
2011b). The animals were terminally anaesthetised by administration of Euthanal 
(0.1mL) via intraperitoneal injection. Perfusion was performed through the left heart 
ventricle with 15-20mL 0.9% saline. Brains were then post-fixed (with 10% formal-
buffered saline, doped with 8mM Gd-DTPA “Magnevist” contrast agent, flow rate 3mL 
per minute) and stored for 9 weeks at 4°C, then scanned in-skull to prevent damage. 
Cohort 2 genotypes 
J20 (B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2J male mice (Jax stock code 006293) were 
used to breed C2, with Tc1 females (see §4.2). All mice included in this study were 
genotyped as being negative for the J20 transgene. These J20 male progenitors were 
maintained by mating J20 APP transgenic mice to C57Bl/6J for more than 12 
generations (Mucke et al., 2000). Mice were genotyped using polymerase chain reaction 
for the human APP transgene (as per Jax 006293). 
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Image acquisition 
Brains were secured with surgical gauze inside a 20ml syringe (C1) or within a subject 
separator (C2). Syringes were filled with proton signal-free, non-viscous Fomblin 
perfluoropolyether (PFS-1, Solvay Solexis SpA., Bollate, Italy) to avoid air interface 
susceptibility artefacts, and scanned with an Agilent/Varian 9.4T VNMRS using a 60mm 
(inner diameter) gradient set. Single brain protocol (C1): 26mm quadrature volume coil 
(RAPID Biomedical GmbH, Würzburg, Germany), 3hr spoiled GE3D sequence, 
parameters: TE 4.03ms; TR 17ms; flip angle 52°; 6 averages; FOV 
20.48x13.04x13.04mm (matrix 512x326x326, 40µm isotropic resolution). 3-brain 
protocol (C2): 33mm quadrature birdcage coil; 11hr 4min spoiled GE3D; TE 4.54ms; 
TR 17ms; flip angle 51°; 6 averages; FOV 32x25x25mm (matrix 800x625x625). 
3-brain subject separator 
For C2, a custom-designed, 3D-printed plastic mouse brain holder (25.4mm diameter, 
44mm length) (Fig 3.5a) secured three skulls inside a 50ml syringe. Its 1mm walls 
precluded touching or partial volume (PV) between neighbouring subjects. This 
significantly reduced overall preparation time, enabling unsupervised overnight scans (the 
additional time accounting for increased FOV). I measured SNR1 (E4.1) and CNR 
(E4.2) in both cohorts using the tissue maps created as per §3.6 (binarised at 50% 
probability). 
E4.1 ẋṻẉ = ⅎⱡẘⱶ ݏⱪⱦⱶẘↄ
ݏݐẘⱶẛẘݎẛ ẛⱡݒⱪẘݐⱪⱷⱶ ⱶⱷⱪݏⱡ 
E4.2 ṥṻẉ = ݏⱪⱦⱶẘↄ(ṭṹ)  −  ݏⱪⱦⱶẘↄ(ẓṹ)
ݏݐẘⱶẛẘݎẛ ẛⱡݒⱪẘݐⱪⱷⱶ ⱶⱷⱪݏⱡ  
Brains were aligned in one z-direction layer to minimise signal drop-off and geometric 
distortion away from the bore isocentre. To ensure gradient accuracy, the system was 
 
                                                        
1: McRobbie et al. (2007) suggest multiplying the result of E4.1 by 0.66, as the BG has an approximately 
Rician distribution, which has (because although noise can be negative, it is made positive when the 
magnitude image is calculated) a narrower standard deviation than Gaussian. The formula reported here is 
used for consistency with Cleary et al. (2011b), and is given by www.mr-tip.com, which recommends taking 
the signal over a small homogeneous brain region and the BG over a larger external region. 
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calibrated prior to imaging (O’Callaghan et al., 2014). Gradient linearity was within 
manufacturer’s limits, as measured within a centred sphere (20mm radius) encompassing 
the 3-brain FOV. Scaling measurements were performed throughout data acquisition to 
measure temporal stability (see §4.1.5). To remove possible group bias caused by 
remaining distortion or gradient instability, genotypes were interleaved within scans, and 
positioning within the 3-brain holder was randomised. See Fig 3.5b for an example raw 
MR image containing 3 brains from this study. One WT brain from C2 was excluded 
from GWR and analysis, owing to a collapsed skull unilaterally compressing the brain. 
4.1.3 Voxel-wise statistical tests 
After processing with the complete pipeline (§3.2—3.12), I performed voxel-wise two-
tailed t-tests using a GLM. The model was: 
E4.3 ẖ = ẙῺṿ(ẍẚ1) + ẙῼṿ(ẓẍ) + ẙᾨṡⱦⱡ + ẙᾬṣẘẚⱴⱦݎⱷݑⱶẛ + ẙᾪẍṱẑ + ߳௜ 
where the vector ẖ represents, at a particular voxel, the response values from each animal: log(ṳௗ௘௧) for TBM, or the proportional density of a particular tissue class for VBM. ẙ 
are the regression coefficients; ṿ(ⱦⱡⱶⱷݐݕ݌ⱡ) is the binary encoding (0 or 1) of each 
animal being Tc1 or WT; ṣẘẚⱴⱦݎⱷݑⱶẛ is a binary encoding for C1 and C2; and ߳ is the 
residual error vector. I controlled for TIV in TBM, to reveal differences in the Tc1 group 
independent of overall volume. The TIV covariate was excluded for VBM, as the 
intensity values were not thought to have a relationship with volume. Levels of the effect 
of interest (genotype) were compared using contrasts. Tests were constrained to the brain 
mask to limit the multiple testing problem (Nichols & Hayasaka 2003), and to exclude 
skull and external tissues, which exhibit high inter-individual variability. I also performed 
two-tailed t-tests on the probabilistic GM class and parcellation volumes, after 
normalising to TIV. 
4.1.4 Group-wise registration assessment 
Morphometry is dependent upon intra-group structural registration accuracy. As 
registration is gradient-driven, contrast is crucial to success, and a driver of increasing 
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field strengths. Accuracy within homogeneous structures, such as the hypothalamus and 
brainstem, may be impeded: a local change in the centre of such a structure may be missed 
by TBM; a uniform change may be compounded and elicited only at its boundary. This 
may explain why the TIV covariate did not account for some local expansions. A similar 
issue faces parcellation-based studies when structural delineations are ambiguous, 
particularly as mice exhibit a high degree of PV. 
The 3-brain protocol (ṥῼ) realised lower SNR and CNR than single-brain (ṥῺ) scans; 
however, contrast was sufficient to drive registration. Van Eede et al. (2013) found, using 
artificially simulated deformations, that while false positive rates were below 1%, FDR 
(at q=0.1) recovered only 38% of 20% changes in volume, and that TBM (via integration 
of ṳௗ௘௧  values across deformation fields) generally underestimated true volume 
reductions. They attributed this underestimate to topological constraints put upon 
registration (such as bending energy, here). This could also arise from misregistration or 
high structural variance between groups; hence, it is important to check registration 
accuracy. The same group noted natural local volume variability within a wild-type 
cohort of up to 2.5%. If this was universal, it would be difficult to distinguish smaller 
inter-group differences with low animal numbers. 
I quantified the progressive improvement in image alignment at each iteration of group-
wise registration (GWR), and justified the number of iterations, by measuring the 
intensity standard deviation ߪூ between resampled images at every voxel within the brain 
(as §3.8.1). Inter-image intensities in equivalent aligned regions should have low standard 
deviation, thanks to standardisation prior to GWR. Fig 4.1 shows the mean ߪூ over all 
voxels, at each iteration, within the brain mask. After a dramatic decrease with the first 
iteration of NRR, ߪூ reaches a plateau after 5-10 iterations. 
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Figure 4.1 Group-wise registration assessment for the Tc1 and WT groups. 
Mean standard deviation of all brain voxels in resampled images, within the brain mask. 
Although from a different group of images, this exhibits the same characteristic pattern as 
Fig 3.20. 
4.1.5 Global volume results 
My analysis revealed several novel features of the Tc1 model, discussed below. Mean (SD) 
SNR in ṥῺ was 29.3 (2.50); ṥῼ: 13.6 (0.41). CNR in ṥῺ was 12.4 (1.40); ṥῼ: 7.06 (0.40). 
The sporadic hyperintense rim present in ṥῺ was not found to have a deleterious effect 
upon results (§4.1.14). 
The Tc1 mice exhibit greater brain and total intracranial volumes than WT littermates 
(Fig 4.2; Table 4.1a), with little overlap. BV was on average 93.8% of both WT and Tc1 
TIV (no significant difference, p=0.99), indicating CSF did not play an appreciable role 
in separating groups. 
150 
Mean absolute volumes of the 20 anatomical parcellations are shown in Table 1b and Fig 
4.3. Most segmented tissues and parcellated regions had greater standard deviation and 
volume in the Tc1 mice. The brainstem, hippocampus, neocortex, thalamus and 
ventricles were all significantly larger in the Tc1s, both before and after normalisation. 
The cerebellum, internal capsule and olfactory bulb were all significantly smaller in the 
Tc1s after normalisation – but none were significantly different before. 
The order of ṥῺ scans was randomised, with genotypes interleaved, to avoid the possibility 
of scanner miscalibration affecting group volume differences. In ṥῼ, genotypes were 
mixed randomly within 3-brain scans. ṥῺ,ῼ volumes were linearly scaled to account for 
phantom-based gradient calibration performed between acquisitions (O’Callaghan et al., 
2014). Scaling factors were ṥῺ: 1.0321; ṥῼ: 0.9983 (5 s.f.). Although the scaling did act 
to separate cohort volumes, t-tests on intra-group mean TIVs did not discern a significant 
difference between cohorts before (݌ௐ் > 0.45; ݌்௖Ὼ > 0.82), or after (݌ௐ் > 0.05; 
݌்௖Ὼ > 0.14) scaling. 
 
Figure 4.2 Total intracranial and brain volumes (TIV, BV) of WT (blue) and Tc1 
(green). 
Means (white dots) for absolute volumes (a) were significantly different (*), but after 
normalisation to TIV (b), BV means were almost identical. Outliers shown are >1.5 inter-
quartile range (IQR). 
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Table 4.1 Parcellated volume results for Tc1 and WT groups. 
Mean absolute volumes (mm3) of (a) probabilistic tissues: BV=GM+WM; TIV=BV+CSF 
and (b) parcellated regions via integration of Jacobian determinants, and their standard 
deviations (SD). (Bonferroni-adjusted two-tailed p-values shown, omitted where >>0.05). 
 WT (N=27) Tc1 (N=29) p 
region mean SD mean SD absolute TIV-normalised 
a       
GM 316.51 9.63 363.33 21.03 1.82x10-13  
WM 123.89 9.52 139.57 11.29 8.86x10-6  
BV 440.40 15.48 502.91 28.67 1.10x10-12  
vCSF 2.39 0.98 3.43 1.25 0.01  
eCSF 26.70 15.60 29.84 19.18   
TIV 469.49 15.34 536.19 28.33 7.30x10-14  
b       
amygdala 12.51 1.19 14.55 1.23 1.60x10-6  
anterior commissure 1.46 0.13 1.58 0.14   
basal forebrain and septum 13.42 0.49 15.78 0.59 1.15x10-20  
brainstem 56.52 1.83 60.08 2.63 9.81x10-6 3.39x10-6 
central GM region 15.32 0.54 17.39 0.65 2.09x10-16  
cerebellum 64.21 4.59 61.71 5.60  1.40x10-11 
corpus callosum & external 
capsule 17.70 1.19 18.88 1.91   
fimbria 3.55 0.44 4.05 0.49 5.12x10-3  
globus pallidus 4.23 0.34 4.57 0.30 5.93x10-3  
hippocampus 29.09 1.01 31.44 1.35 4.63x10-8 1.06x10-4 
hypothalamus 12.26 0.49 14.30 0.61 1.24x10-17  
inferior colliculus 7.50 0.57 8.12 0.41 4.31x10-4  
internal capsule 5.48 0.60 5.40 0.60  1.21x10-3 
midbrain (remainder) 4.97 0.40 5.72 0.38 4.08x10-8  
neocortex 136.02 8.17 145.78 9.68 4.36x10-3 2.53x10-3 
olfactory bulb 26.37 1.85 25.19 1.46  1.26x10-13 
striatum (caudate putamen) 26.84 1.20 30.72 1.52 4.17x10-13  
superior colliculus 9.36 0.62 10.97 0.80 9.52x10-10  
thalamus 26.44 0.87 27.61 1.45 0.02 7.85x10-8 
ventricles 1.65 0.22 2.22 0.45 8.21x10-6 4.56x10-2 
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Figure 4.3 Parcellated WT and Tc1 region volumes from Jacobian integration. 
Illustrating the results from Table 4.1b. Error bars show ±1 SD. The scale is mm3. 
4.1.6 Voxel-wise analysis 
Fig 4.4 shows, at each voxel, the mean proportional volume difference of the Tc1 group 
compared to the mean original WT volume, controlling crudely for TIV. To create this 
figure, I found the mean ṳௗ௘௧  values at each voxel (after smoothing), for both the WT 
and Tc1 groups, subtracted the mean WT values from the mean Tc1 values, and 
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calculated this difference as a proportion of the mean WT ṳௗ௘௧ . To remove the effects of 
global scaling, I divided this figure at each voxel by the relative proportion of Tc1 to WT 
mean TIV (E4.4). Each voxel ݒ is given by: 
E4.4 ݒ = ⅎⱡẘⱶ(ṳௗ௘௧)்௖Ὼ −ⅎⱡẘⱶ(ṳௗ௘௧)ௐ்
ⅎⱡẘⱶ(ṳௗ௘௧)ௐ் ⅎⱡẘⱶ(ẍṱẑ)்௖Ὼⅎⱡẘⱶ(ẍṱẑ)ௐ்൘  
The illustration is comparable to TBM results, except without statistical tests or 
significance thresholding. It provides an overview of the volume differences between 
groups, using the WTs as a baseline control, and shows where statistically significant 
results may be expected, given sufficient power. Note the obvious bilateral expansion of 
the ventricles (blue) in the Tc1s, and the shrinkage of the olfactory bulbs, cerebellum, 
and hippocampus. The subsequent statistical tests of TBM help to determine the 
significance of these volume differences. 
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Figure 4.4 Mean Tc1 voxel-wise volume difference from mean WT volume. 
A semi-transparent per-voxel map after smoothing and correction for the mean relative 
difference in TIVs. Red: Tc1s originally smaller than WTs; blue: larger. Sagittal (first row); 
coronal (rows 2-4) and transverse (rows 5 and 6) slices overlaid on the final group-wise 
structural average. 0 represents no difference; 0.1 where Tc1s are, on average, 10% larger 
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than WTs. Comparable to Fig 2 of Hua et al. (2008), who for human AD showed 
“percentage reduction in volume relative to controls” prior to voxel-wise statistical 
significance testing. 
4.1.7 Tensor-Based Morphometry 
I used TBM to highlight local volume differences between groups, by including TIV as 
a confounding factor in the GLM. Fig 4.5 shows representative slices through the final 
average image after GWR, with significant voxels overlaid. To localise clusters, I referred 
to the parcellated labels and Paxinos & Franklin (2012). 
TBM revealed distinct local volume differences in the Tc1 brains compared with WTs. 
There were bilateral regions of localised expansion in the amygdala, lateral ventricles and 
hypothalamus. The reticular nucleus, superior colliculus, and periaqueductal grey regions 
of the midbrain also showed expansion, possibly secondary to that of the ventricular 
aqueduct and fourth ventricle. Unexpectedly, the hippocampus showed a degree of 
bilateral, localised enlargement in the Tc1 group, in CA1. 
I observed significant bilateral reductions in local volume in the olfactory bulbs; the CA3 
region of the hippocampus, rostrally; two distinct regions of the thalamus (the rhomboid 
nucleus and the dorsal sensory-motor region); and in the brainstem, the cochlear nuclei 
of the medulla. There was a unilateral reduction in the hippocampus medially in CA1. 
The most prominent volume reductions occurred throughout the Tc1 cerebellum, 
including bilaterally in the flocculi; the central lobules (II and III) of the cerebellar vermis; 
the simple lobule and culmen (lobules IV-V); and medially in declive VI and pyramus 
(VIII). See §4.1.8 for further investigation of significant regions. 
156 
 
Figure 4.5 Tc1 TBM results 
FDR-corrected (q=0.05) t-statistics overlaid on slices (locations indicated top left) of the 
final structural GWR average. Blue: Tc1 group locally statistically significantly larger than 
WTs; red: Tc1s smaller. 
AM: amygdala; CA1, CA3: hippocampal sub-regions; CN: cochlear nucleus; FL: flocculus; 
HY: hypothalamus; LV: lateral ventricles; MB: midbrain; OB: olfactory bulb; PH: 
posterior hypothalamic nucleus; cerebellar lobules II & III; IV-V (culmen); declive VI and 
VIII (pyramus); Sim: simple lobule; TH: thalamus. 
4.1.8 Individual voxel analysis of TBM results 
ṳௗ௘௧  values at peak absolute t-statistic locations in selected regions (indicated in Fig 4.5) 
are shown in Fig 4.6. These help to quantify the degree of group separation in different 
regions. They are also useful for directing potential follow-up histological investigations, 
which are likely to be constrained, by costs or time, to focus on fewer brain regions. 
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In the midbrain and hypothalamus, where the Tc1s were locally significantly larger than 
the WTs, the mean difference was relatively small compared with other regions. Of the 
regions shown, the midbrain had the lowest effect size (E5.3; discussed further in §5.7.3), 
thanks to the relatively large standard deviation of ṳௗ௘௧  values in this region, likely due to 
the structural variability of the fourth ventricle and aqueduct. Despite exhibiting the 
smallest difference between means, the peak t-statistic voxel within the hypothalamus had 
a moderate effect size, thanks to a low WT ṳௗ௘௧  standard deviation in this region. 
 
Figure 4.6 Peak t-statistic voxel values within selected significant clusters 
Referring to significant clusters in Fig 4.5. (a) Effect sizes (Cohen’s d) with 95% confidence 
intervals; (b) ṳௗ௘௧ values for WT (blue) and Tc1 (green) groups. To show the effect 
independent of global volume, values were divided by TIV then multiplied by mean WT 
TIV. 
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4.1.9 Voxel-Based Morphometry 
VBM highlights local differences in GM tissue proportion, as measured by the 
segmentation. This may be thought of as a representation of tissue density. Owing to the 
global volume difference between groups, modulated VBM (§3.11) would have required 
a TIV covariate in the GLM when performing voxel-wise statistical tests2; I show 
unmodulated VBM results here. The GM maps had no dependence upon ṳௗ௘௧  values and 
hence no volume component. I therefore excluded the TIV covariate. 
Fig 4.7 shows representative slices through the final GWR average image, with FDR-
corrected t-statistics overlaid (q=0.05). I smoothed with a Gaussian kernel, FWHM 
0.16mm (4 voxels). To better anatomically localise some significant regions and improve 
spatial specificity, I also tested a 0.02mm smoothing kernel (0.5 voxels, Fig 4.8). 
VBM detected reduced GM in the dentate gyrus (DG) hippocampal region, and bilateral 
increases in GM proportion in the olfactory bulbs, thalamus, hypothalamus, midbrain, 
globus pallidus, motor cortex and the CA3 region of the hippocampus. The mouse 
midbrain, especially adjoining the pons and brainstem, exhibits a high degree of 
GM/WM mixture: most voxels have some PV. Additionally, this region has few high-
contrast features, which may have impeded internal registration accuracy, possibly 
contributing to the apparent increases in GM proportion seen here. There were few 
significant voxels in this region after application of the narrower smoothing kernel (see 
Fig 4.8), suggesting this regional apparent increase in GM proportion is sparse and 
nonspecific. 
GM regions adjacent to the ventricles in the final average image, such as the septal 
nucleus, show reduced GM density in the Tc1s, likely due to ventricular expansion 
encroaching into GM tissue. 
 
                                                        
2: As discussed in §2.2.7, with high-dimensional warping in NRR, modulated VBM approximates TBM: 
the volume differences between groups dominate any intensity differences. Indeed, results of modulated 
VBM (not shown) highlighted similar locations as TBM results. 
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Bilateral regions of decreased GM density were detected in the dentate gyrus region of 
the hippocampus, the entorhinal cortex, and the olfactory tubercle. The cerebellum 
showed decreases in GM proportion throughout, particularly lobules II & III, IV-V, VI 
and IX, and the simple lobule. Upon inspection with a narrower smoothing kernel (Fig 
4.8), these regions appeared predominately within the granule and Purkinje cell layers. 
 
Figure 4.7 Unmodulated VBM results 
FDR-corrected (q=0.05) t-statistics overlaid on coronal and transverse slices (locations 
indicated top left: same as Fig 4.5) of the final structural average. Blue: statistically greater 
local proportion of GM in Tc1 group; red: reduced. 
CP: caudate putamen; ENT: entorhinal cortex; GP: globus pallidus; MO: motor cortex. 
Cerebellar regions: AN: ansiform lobule. 
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Figure 4.8 VBM in the cerebellum and hippocampus, with a narrower smoothing 
kernel. 
As Fig 4.7. Sagittal, coronal and transverse views, employing a FWHM 0.02mm Gaussian 
smoothing kernel prior to statistical tests. Significant voxels are largely confined to the 
Purkinje and granule cell layers of the cerebellum and CA3 region of the hippocampus. 
Note few significant voxels in the midbrain. 
CC: corpus callosum; GCL: granule cell layer; MCL: molecular cell layer; PCL: Purkinje 
cell layer. 
4.1.10 Discussion: morphometry of Tc1 brains 
I identified several phenotypes in the Tc1 brain using the automated pipeline, the first 
such morphometric analysis of a DS brain model compared with WTs, and revealed local 
differences not distinguishable between samples by eye, histology, or segmentations 
alone. 
In human DS, BV is reduced by around 18% (Aylward et al., 1999; Pinter et al., 2001a; 
White et al., 2003). Whereas the whole mandible is reduced in size in human DS, 
O’Doherty et al. (2005) measured only partial mandible reduction in Tc1s, and no 
craniofacial malformation or reduction in skull size. Distances between landmarks in 
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µCT images of Tc1 skulls also exhibited no significant size difference compared with 
WTs. I observed significantly increased Tc1 TIV, BV, GM and WM volumes (Table 
4.1a). 
This unexpected global finding was consistent in C1 and C2 – scanned independently and 
with considerations for gradient scaling – and indicates the utility of whole-brain MR 
and tissue segmentation over histology and landmark measurements, which are 
necessarily localised and limited to a few subjects and by rater variability. 
All tissues and most parcellated regions displayed greater volume variance in the Tc1s. 
O’Doherty et al. (2005) reported that approximately 66% of Tc1 brain nuclei retain 
Hsa21. This mosaicism means Hsa21 levels are unpredictable and vary between organs, 
mice, and with background, leading to phenotypic variation (Reeves, 2006). Olson et al. 
(2004) noted: “most DS phenotypes are incompletely penetrant and variable in 
expressivity – the mechanism(s) by which increased gene dosage causes any specific DS 
feature is not established”. This could potentially be addressed using morphometry with 
more selective trisomic animal models. 
The ventricles are enlarged in human DS (White et al., 2003) and both VBM and TBM 
detected their bilateral enlargement in the Tc1s. This is likely underestimated in ex vivo 
brains, which shrink slightly during fixation as tissues relax and ventricles partially 
collapse (§5.7; Zhang et al., 2010). Although mitigated in-skull (Sawiak et al., 2013), one 
would expect the same systematic effect across groups. Brain expansion due to 
hydrocephalus has been reported in a DS model (Yu et al., 2010); however, these mice 
died by 10 weeks of age, and the Tc1s did not exhibit gross ventricular enlargement of 
the same degree. (Also, only 6.5% of those mice exhibited hydrocephalus. They had 
rounded and enlarged skulls. Although I investigated volume, I did not quantify the shape 
or roundedness of the Tc1 brains. This would be possible, however, using their principal 
axes, as calculated in §3.3.) Overall vCSF volumes did differ significantly between groups 
before and after correction for TIV. However, this measurement is likely an 
underestimate, due to unpredictable ventricular collapse. Upon visual inspection, one 
brain exhibited uncollapsed 3rd and 4th ventricles absent of CSF (and therefore appearing 
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dark), however, this came from a WT littermate. As the ventricular spaces were present 
without bright vCSF, segmenting this brain required manual attention. 
That the UFL atlas-segmented ventricles were significantly different in volume prior to 
TIV normalisation is likely a result of the atlas registering poorly in these regions, again 
owing to ventricular collapse in our data. The only tissue segmentation-derived region to 
exhibit a significant difference in volume surviving Bonferroni correction was GM/WM 
mixture (not shown). This may be due to increased PV in the Tc1 group, or imprecision 
in boundary delineation of this PV class (Fig 3.15); corresponding parcellations (broadly, 
the caudate putamen/striatum; midbrain; superior and inferior colliculi) showed 
differences. As noted in §3.6, for these reasons of imprecision, I later removed this 
measurement and replaced it with more smoothly-varying GM and WM segmentations, 
which better account for PV. 
One may safely conclude that the Tc1 mouse exhibits an enlarged brain, in contrast to 
people with DS. Tc1 mice have some rearrangements of their copy of Hsa21 (Gribble et 
al., 2013), and it is possible that this contributes to the megaly phenotype; there may also 
be some non-specific interaction of the human chromosome in the mouse cells that gives 
rise to larger brains. Finding relatively greater subcortical GM volumes in DS patients 
compared to the total GM volume, and preservation of GM volume in the parietal cortex, 
Pinter et al. (2001a) suggested that greater basal ganglia and thalamus volumes in humans 
may result from insufficient apoptosis. 
In humans and mice with deletion or truncation of the Hsa21 gene DYRK1A3, brain size 
and weight is reduced (Sebrié et al., 2008; Guedj et al., 2012). Through phosphorylation, 
this gene is thought to be tied to many DS phenotypes, and it is likely modulated by the 
presence of other genes (Wiseman et al., 2009). It is dose-dependent and hence, in 
humans and Tc1 mice, it is overexpressed. In two mouse models4 of partial trisomy, 
overexpressing the DYRK1A gene, Sebrié et al., (2008) and Guedj et al. (2012) found 
increased brain size (measured via MRI, weight and histology). The thalamus, midbrain 
 
                                                        
3: dual-specificity tyrosine-phosphorylation-regulated kinase 1A. 
4: hYACtgDyrk1a and mBACtgDyrk1a. 
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and colliculus were preferentially affected. In the thalamus, neuronal density and number 
increased, while both neuron size and extracellular space decreased. Conversely, cell 
density was negatively correlated with DYRK1A dosage in the hippocampus and 
somatosensory and entorhinal cortex (Guedj et al., 2012). This may underlie my TBM 
results, which showed expansion of the Tc1 midbrain and central thalamus. Guedj et al. 
noted that Ts65Dn mice, also with three copies of DYRK1A, do not exhibit elevated 
BVs, and that other genes may compensate. 
In subsequent voxel-wise statistical tests I controlled for TIV to reveal differences in the 
Tc1 group independent of the total volume increase. TBM detected significant bilateral, 
local volume reductions in the olfactory bulbs. Bianchi et al. (2014) recently observed, 
via histology, impaired neurogenesis in the olfactory bulbs of 13-month-old Ts65Dn 
mice, and remarked that this may parallel the loss of smell in older human DS individuals. 
The reductions seen here suggest there may be a similar functional impairment in Tc1 
mice. 
I found significant local reductions in GM volume within the cerebellum, using both 
TBM and VBM, focussed medially in Declive VI, as well as unilaterally within the simple 
lobule and lobules 4/5, in both granular and molecular cell layers. 
Cerebellar GM was reduced in a VBM study of non-demented people with DS, and 
exhibits reduced overall volume compared with TIV in humans (Raz et al., 1995; White 
et al., 2003) and the Ts65Dn, Ts1Cje and Tc1 mouse models (Ma et al., 2014; Olson et 
al., 2004). My TBM analysis reveals that rather than the cerebellum being uniformly 
reduced in volume, reductions have discrete local foci. There is evidence cerebellar lobules 
have distinct functional correlates (Stoodley & Schmahmann, 2010). It may be possible to 
map local volume reductions to functional topography and hence to behaviour in Tc1 
mice. 
The cerebellum is associated with fine motor control and cognitive processes. In children 
with DS, cerebellar hypoplasia is implicated in motor and speech difficulties (Pinter et 
al., 2001a). Galante et al. (2009) found motor learning and coordination deficits in Tc1 
mice. Histological staining revealed reduced internal granule layer density in the Tc1 
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cerebellum compared with WTs, mirroring observations of the Ts65Dn and Ts1Cje 
models (Baxter et al., 2000; O’Doherty et al., 2005; Olson et al., 2004). I repeated these 
findings with VBM, showing reduced GM density in the granule cell layer of several 
lobules (Fig 4.7, 4.8). This supports the utility of VBM for informing histology. VBM 
also showed bilateral reductions in GM density in the entorhinal cortex, recapitulating 
the progressive atrophy of this region in human DS (Teipel et al., 2004). 
VBM also detected reduced GM proportion in the dentate gyrus (DG). Long-term 
potentiation in the DG – synaptic plasticity thought to be directly related to long-term 
memory – was found to be reduced in Tc1 mice (O’Doherty et al., 2005), and behavioural 
observations demonstrated reduced spatial working memory (Morice et al., 2008). I also 
observed bilaterally elevated GM proportion in the CA3 region of the Tc1 hippocampus. 
Insausti et al. (1998) measured elevated neuronal numbers in Ts65Dn CA3, and 
suggested this may compensate for reductions in DG, although Kurt et al. (2004) found 
normal neuron density, but reduced synapse density, in both structures. Witton et al. 
(2015) also recently showed decreased synapse density in the DG, and related this to the 
poorer performance of Tc1 mice in a radial arm maze, compared with WTs. These 
cellular changes could underpin the differences in VBM GM signal observed here. 
Mouse brain tissue classification is complicated by smaller structures and greater PV 
proportion than is found in humans. Both may be mitigated using higher field strengths, 
enabling greater SNR, spatial precision, and contrast (Natt et al., 2002). Structural 
differences between the in vivo, skull-stripped NUS atlas used for tissue segmentation 
and this ex vivo, in-skull data were resolved with NRR. By employing this atlas, and 
explicitly modelling background, external tissues, PV and CSF, my tissue classifications 
included fine WM detail, including the deep WM of the cerebellum and PV regions such 
as the striatum and midbrain. I averted misclassifications which have befallen previously 
published TPMs, including the presence of a brain-enveloping ‘rim’ where GM PV is 
misinterpreted as WM (Fig 2.8). 
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4.1.11 Comparison with earlier results 
An earlier version of this pipeline, which excluded tissue segmentation and was thus 
reliant upon TIV measured from STEPS masks, produced less specific TBM results – 
similar to those of Sinclair et al., (2011). As Fig 3.14 shows, the masks exhibit good 
accuracy, but variability at the brainstem could substantially alter their volume. As TIV 
was thus imprecisely controlled in the GLM, some global voxel expansion (from rigid 
and affine stages of GWR) was included. Comparison with the results of Sinclair et al., 
(2011) indicates that these TBM maps are highly sensitive to the TIV covariate: greater 
accuracy (through measurement of TIV via probabilistic GM, WM and CSF volumes) 
improves the spatial specificity of morphometric results. For further discussion, see §5.6. 
4.1.12 Corroboration of V/TBM with cohort 2 
The ‘Tc1xJ20’ group (§4.2), from which C2 brains were taken, allowed further validation 
of the results revealed above using V/TBM. Encouragingly, although not reported here, 
when the full pipeline and TBM was performed in C1 and C2 separately, very similar 
statistical maps were observed. However, C1 results were mostly confined to the 
cerebellum and there were few significant voxels after FDR correction at q=0.05. A 
similar pattern as that reported here survived correction at q=0.1. C2 was included to 
improve statistical power. C2 results alone are shown in §4.2 (Fig 4.12). 
4.1.13 Comparison with parcellation 
Employing STEPS-based parcellations with the UFL atlas, Ma et al. (2014) reported 
significant shrinkage of the cerebellum and olfactory bulbs in Tc1 brains relative to BV, 
which was found to be significantly increased, but no other structures were significantly 
different in volume. Controlling for TIV, I repeated these findings using Jacobian 
integration, and additionally found the internal capsule to be reduced in size, possibly 
thanks to the increased contrast the group average image provides over individual scans; 
this thin structure is not easily segmented (Fig 4.9). Additional structures were also found 
to have volume differences here (Table 4.1). This increased sensitivity may be due to this 
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study’s incorporation of C2, in order to increase numbers and thereby boost statistical 
power. The earlier paper’s use of STEPS to segment each image individually, rather than 
indirectly via a group average, may have improved its sensitivity. 
Segmentation via parcellation enables volume- and shape-based analysis of substructures, 
but is limited in specificity by atlas detail. TBM here localised the contributory regions 
of difference within those structures. The noted reductions in the olfactory bulbs and 
cerebellum will have contributed to the earlier global volume findings. Furthermore, I 
observed local changes within the hippocampus, thalamus, hypothalamus, midbrain and 
ventricles undiscerned by segmentation alone. This surrogate biomarker is more useful 
for informing precise histological follow-up investigations. 
 
Figure 4.9 Comparing label propagation with tissue segmentation. 
Over-generous coverage of the corpus callosum (CC) by the propagated UFL atlas labels 
(semi-transparent, left) in the space of the final group-wise average of the Tc1 and WT 
brains (cropped transverse view). The WM segmentation (red, right, here binarised at 0.5) 
appears to cover the CC with greater accuracy. 
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Imprecise registration between the external atlas and the Tc1 data resulted in over-
generous volumes for some regions, such as the corpus callosum (Fig 4.9). Unfortunately, 
few high-quality mouse atlases are presently available. Currently-available multi-subject 
atlases (UFL, NUS) are limited by relatively low contrast and resolution compared with 
those achievable at high field strengths; many opportunities exist for extending their size 
and quality. An atlas database with more subjects, parcellations (including non-brain) 
and finer detail would aid the specificity of segmentation-based approaches, and could 
complement these V/TBM results by allowing more precise anatomical localisation of 
significant voxels – for example, nodules of the cerebellum. I expect results to improve 
further with the increased availability of such atlases. 
4.1.14 Hyperintense rim 
 
Figure 4.10 Example of hyperintense rim, and its segmentation, in the Tc1 dataset. 
Transverse, sagittal and coronal views of a single Tc1 brain (same slices, both rows) 
exhibiting a region of high signal around some parts of the brain, indicated with light blue 
arrows (a,b,c). This was thought to be a perfusion artefact. I used an EM scheme to 
automatically classify the rim (light blue in d,e,f), in order to measure its thickness. Orange: 
brain GM; green: external material and BG. 
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I noted a hyperintense ‘rim’ partially enveloping most ṥῺ brains (Fig 4.10). Cahill et al. 
(2012) suggested a similar artefact (“a blister of liquid beneath the dura mater”) 
measuring up to 500µm in thickness resulted from improperly dissolved perfusate, or a 
high perfusion rate, causing blockages and pressure build-up in the vasculature, leakage 
into CSF cavities, and resulting in ‘bubbles’ of high intensity perfusate forming between 
meninges and brain tissue. This could cause compression and hence, potentially, 
unpredictably affect registration, and render TBM unreliable. I therefore sought to 
characterise this artefact in the data. 
ṥῼ brains were perfuse-fixed in CABI using a standardised protocol: commercial formal-
buffered saline (VWR International Ltd., England), together with a low flow rate (2.5-3 
ml/min) (Cleary et al., 2011b). ṥῼ brains did not exhibit the artefact. ṥῺ brains were 
perfuse-fixed at a different site, at 3ml/min, where powder PFA was mixed with the same 
commercial solution. 
CSF is also hyperintense in T2*W images, and may become trapped during perfusion-
fixation. I took the ‘rim’ volume as the eCSF volume from tissue segmentation. As noted 
in §3.6, this involved the addition of external labels, to incorporate eCSF, BG and 
external tissues into the EM scheme. A further refinement of this method is described in 
§6.2.3. Visual inspection ensured all parts of the rim were included. eCSF occurs 
naturally, is particularly prominent in models of brain atrophy (Wells et al., 2015), and 
pools in the cisterns. After its binary segmentation, my colleague Da Ma measured its 3D 
thickness using a Laplacian field-based algorithm typically applied to the cortex (Ma et 
al., 2015). 
In contrast to Cahill et al. (2012), I found a positive correlation between eCSF volume 
and BV (r=0.449, p=0.017), suggesting the rim in ṥῺ did not compress the brain. It was 
most prominent within the interhemispheric fissure of the cortex, and never completely 
enveloped the brain. In ṥῺ, mean (SD) eCSF volume was 44.13µL (8.38µl), 9.53% of 
average BV. In ṥῼ: 12.0µL (4.08µL), 2.48% of mean BV, and no eCSF volume exceeded 
23.7µL. There was no appreciable correlation between eCSF volume and BV in ṥῼ 
(r=0.02, p=0.92). The mean thickness of the eCSF layer for all ṥῺ brains was 162µm 
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(75µm). Thickness was only measured where it was greater than 1 voxel (40µm); as the 
rim was never fully enveloping, the mean over the entire brain surface will thus actually 
be much lower. As these measurements reveal the artefact to be less severe, and do not 
show the correlations reported by Cahill et al. (2012), and additionally as I combined ṥῺ 
and ṥῼ during group registration, reducing the relative contribution of brains with the 
artefact to the structural average and to statistics, I do not believe it denigrated V/TBM 
or volumetric results, or made registration unreliable. 
4.1.15 Conclusions 
My statistical morphometric analysis identified novel phenotypes in this first 
transchromosomic animal model of DS. Overall Tc1 brain volume was unexpectedly 
elevated and, controlling for this, I found local volume reductions in the cerebellum, 
olfactory bulbs, and other brain regions. I also found GM density reductions within the 
cerebellum, consistent with previous histological findings in this model, and human DS. 
Several newly identified regions, such as the dentate gyrus, specific cerebellar lobules, and 
the olfactory bulbs, may warrant additional histological follow-up, or suggest behavioural 
investigations. 
4.2 Tc1xJ20 cross-breed study 
4.2.1 Introduction 
As introduced in §2.4, Down syndrome (DS), the leading genetic cause of intellectual 
disability, is caused by trisomy of human chromosome 21 (Hsa21). Individuals with DS 
have a greater predisposition to Alzheimer’s disease (AD) in later life, thought to be due 
to increased dosage of the amyloid precursor protein (APP) gene that maps to Hsa21 – 
an established risk factor for AD (Oliver & Holland, 1986). Analysis of mouse models of 
DS improves our understanding of the significance of trisomy of Hsa21, and its 
relationship to AD (Roizen & Patterson, 2003). 
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The Tc1 mouse (O’Doherty et al., 2005) and the J20 mouse (Mucke et al., 2000) are, 
respectively, established models of DS and ṡߚ deposition in AD. As previously discussed 
(§4.1), the Tc1 mouse carries an almost complete copy of Hsa21, but is not functionally 
trisomic for APP. It thus allows the study of the DS phenotype without the effects of 
APP trisomy. The J20 mouse expresses a mutant form of APP, as found in familial forms 
of AD (Mucke et al., 2000), and exhibits key features of human AD, including cognitive 
decline, synaptic loss and accumulation of amyloid plaques (§2.3). By cross-breeding Tc1 
mice with J20 mice, progeny with four genotypes were generated: wild-type (WT); 
trisomic (Tc1); APP transgenic (J20); and double mutants: trisomic and APP transgenic 
(Tc1xJ20): a novel model of amyloidosis in AD, in the presence of DS. Exaggerated 
behavioural changes and increased plaque load have already been observed in the Tc1xJ20 
double mutant mouse. 
I here show the results of a comprehensive morphometric analysis of these mouse brains, 
to elucidate structural differences between Tc1, J20 and WT, and between the Tc1xJ20 
and J20 littermates. This latter comparison enables the study of trisomy Hsa21 alongside 
mutant APP, in the same animal, and thus testing whether DS modulates or accentuates 
the AD phenotype. 
4.2.2 Methodology 
Animals and preparation 
Tc1 females were bred with J20 males (O’Doherty et al., 2005; Mucke et al., 2000) by 
collaborators at the UCL Institute of Neurology/MRC Prion unit (London, UK). 50 
adult male offspring mice (15 Tc1, 14 J20, 8 Tc1xJ20, 13 WT littermates) were aged to 
15 months and culled. Their brains were perfuse-fixed (20mL 0.9% saline, then 50mL 
10% buffered formal saline with 8mM Magnevist) – as §4.1.2. 
Image acquisition and quality control 
For scanning, the plastic brain holder (§3.2.3) was used to secure 3 brains at a time, in 
skull, within a 50ml syringe filled with proton signal-free, non-viscous Fomblin. To avoid 
any systematic effects from scanner distortion or gradient calibration affecting any one 
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group, genotypes were mixed randomly in each scan. Optimised protocols for high-
resolution structural ex vivo µMRI mouse brain phenotyping were employed by my 
colleague Holly Holmes at CABI (Cleary et al., 2011b) using the same parameters as for 
cohort 2 in §4.1.2. 
Upon visual inspection, one brain, a WT, was found to have a partially collapsed skull, 
unilaterally, causing compression of the cortex by about 5mm. As this would likely have 
influenced morphometry results, this brain was excluded from further analysis. Images 
were adjusted for gradient scaling errors from the manufacturer calibration using the 
protocol described by O’Callaghan et al. (2014) and in §4.1.2. 
Morphometric pipeline 
Images were all processed according to the TBM pipeline described in §3. All images in 
this study required multiple subject extraction. I performed tissue segmentation, for 
volume measurements, but not VBM. The statistical model used in the GLM was similar 
to E4.3, although I did not control for age or genetic background, as all animals were 
age-matched littermates: 
E4.4 ẖ = ẙῺṿ(ẓẍ) + ẙῼṿ(ẍẚ1) + ẙᾨṿ(ṳ20) + ẙᾬṿ(ẍẚ1ݔṳ20) + ẙᾪẍṱẑ + ߳௜  
where ẙ are the regression coefficients; ṿ(ⱦⱡⱶⱷݐݕ݌ⱡ) is the probability (0 or 1) of each 
animal being Tc1, WT, J20 or Tc1xJ20; and ߳ is the residual error vector. 
4.2.3 Results 
Segmentation 
Fig 4.11 and Table 4.2 show global intracranial volume results from the tissue 
segmentation performed across all brains in this study. (Note that the Tc1 and WT 
groups were included as part of §4.1 results and in Table 4.1, as cohort 2.) 
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Table 4.2 Tissue volumes after segmentation in WT, Tc1, Tc1xJ20 and J20 mice. 
For all groups, mean and standard deviation segmented tissue volumes (mm3) after EM 
segmentation, with BV and TIV (as Table 4.1). Two-tailed t-tests to compare BV and TIV 
means between group pairs gave Bonferroni-adjusted p-values < 0.01: † Tc1 vs. WT; ‡ 
Tc1xJ20 vs. WT; ◊ J20 vs. Tc1xJ20. (J20 vs. WT and Tc1xJ20 vs. Tc1: not significant, 
even at p<0.1.) 
 
Figure 4.11 Box plots of TIV and BV for all four groups, from tissue segmentation. 
Values in Table 4.2. Black bars represent medians; white dots means; outliers >1.5 IQR. 
Tc1s were significantly greater in TIV than WTs (p<6.4x10-6), a repeat of the unexpected 
finding from §4.1.5 in this data subset. J20s were significantly smaller than Tc1xJ20s 
(p<1.1x10-4) but not significantly different in volume, in any tissue, from WTs. Tc1xJ20s 
were also not significantly different in volume from the Tc1 group. This may be due to 
 WT (n=12) Tc1xJ20 (n=8) Tc1 (n=15) J20 (n=14) 
 mean SD mean SD mean SD mean SD 
GM 312.28 6.61 346.58 24.67 360.35 26.95 304.60 11.37 
WM 137.28 7.39 149.94 4.66 151.19 9.06 141.43 6.69 
    BV 449.56 10.16 496.52‡ 27.29 511.54† 33.47 446.03◊ 15.50 
eCSF 11.97 4.54 9.72 3.02 13.66 3.65 9.13 2.22 
vCSF 2.03 0.88 2.34 0.80 3.59 1.49 1.55 0.39 
    TIV 463.57 10.27 508.58‡ 26.66 528.79† 33.06 456.71◊ 15.84 
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the considerable spread of the Tc1 group’s volumes: apart from eCSF, which in this 
cohort was very low in volume thanks to the improved perfusion techniques discussed in 
§4.1.14, Tc1s had the greatest standard deviation in all tissue volumes. 
Tensor-based morphometry 
The TBM images show statistically significant, FDR-corrected (q=0.05) t-statistics 
revealing local structural differences between the brains of each group, controlling for 
their respective TIVs. 
 
Figure 4.12 TBM results: Tc1 vs. WT (cohort 2) 
Red: Tc1s locally smaller than WTs; blue: larger. Different slices are shown from Fig 4.5. 
Many of the same regions of expansion and contraction are highlighted as reported earlier, 
including the lateral ventricles, CA1 region of the hippocampus, bilaterally (expansion); 
and the olfactory bulbs, bilateral and central lobules of the cerebellum, including the 
flocculus, declive VIII and the simple lobule (contraction). The same slices (indicated by 
solid lines in the sagittal view key, top left) are shown in Figs 4.13, 4.14. 
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Tc1 vs. WT (Fig 4.12): The morphometric results indicate central and bilateral 
reductions in the 5/6 and simple lobules of the cerebellum of the Tc1 group, compared 
with WTs. There were also significant bilateral reductions at foci within the thalamus, 
and the hypothalamus. The cortex appeared relatively preserved. That the regions 
implicated have fewer significant voxels in this image, compared with Fig 4.5, despite the 
same degree of smoothing of the log (ṳௗ௘௧) fields, may have two causes. First, this study 
incorporated fewer Tc1 and WT images (a subset of the earlier study), so at individual 
voxels, the group means may have had poorer separation, reducing significance. Secondly, 
the GWR average image in this study incorporates Tc1xJ20 and J20 animals; thus the 
‘middle space’ defined by the deformation fields will have been slightly different. 
 
Figure 4.13 TBM results: J20 vs. WT 
Red: J20 animals locally smaller than WTs; blue: larger. TBM detected extensive bilateral 
reductions in the J20 group in the cortex, hippocampus and corpus callosum. There were 
some scattered regions of reduction in the thalamus. There were small regions of expansion, 
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bilaterally, in the cortex. The cerebellum was locally larger, around declive VIII, than the 
group average. 
J20 vs. WT (Fig 4.13): This comparison exhibits the most significant difference between 
groups: the retrosplenial region of the cortex, centrally. The dorsal apex of the corpus 
callosum, caudally, was significantly reduced in volume, bilaterally. The most extensive 
region of reduction was the cortex, bilaterally. This is distinct from the retrosplenial area 
and appears predominately in the somatosensory cortex (multiple slices of Fig 4.13), 
extending rostrally into the primary motor cortex. Some regions of the midbrain and 
cortex, in the forebrain, appear bilaterally larger in the J20 animal, along with the third 
ventricle, and some small regions of the amygdala, also bilaterally. 
 
Figure 4.14 TBM results: J20 vs. Tc1xJ20 
Red: J20s locally smaller than Tc1xJ20 group; blue: larger. The regions implicated in this 
comparison are less extensive. However, there were bilateral regions of expansion, or 
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preservation in the J20s relative to the Tc1xJ20s, in the cerebellum (including the 
paraflocculi) and olfactory bulbs. There were small, focussed, but bilateral regions of 
reduction, controlling for TIV, in the hippocampus (CA1 and CA3) and, in the forebrain, 
the lateral septal nucleus of the striatum. The ventricles in the J20 group also appear 
smaller. 
J20 vs. Tc1xJ20 (Fig 4.14): The primary regions of comparative reduction in the J20 
animals were the hippocampus (both CA1 and CA3), septal nucleus, amygdala and 
hypothalamus, all bilaterally. Regions of the cerebellum and paraflocculi appeared larger, 
reflecting the significant volume loss of the Tc1 group here (§4.1, Fig 4.12). 
In contrast with the J20 group in comparison to WTs (Fig 4.13), the corpus callosum 
here was not affected. That the paraflocculi were not affected in the J20s in that 
comparison suggests relative preservation of the J20 group here, compared with Tc1xJ20 
reduction. The olfactory bulbs show more extensive and significant reduction in the 
double mutant cohort here than in the Tc1 comparison with WTs, and there were larger, 
bilateral reductions in the geniculate region of the thalamus. 
4.2.4 Discussion 
An optimised µMRI protocol, previously described (Cleary et al., 2011b), and the fully 
automated software pipeline for TBM (§3) were here employed to investigate the global 
and local structural differences between Tc1, J20, Tc1xJ20 and WT mouse brains. The 
Tc1/WT comparison results were expected, as they formed a subset of animals in prior 
work (§4.1). This older group, with a lower total number (27), helped to corroborate 
those results, as I observed similar statistically significant regions of difference, and similar 
global volume measurements as in the younger group alone (data not shown). I concluded 
that the age difference between cohorts, controlled for in the GLM of §4.1, did not 
significantly contribute to the regions of local reduction and expansion shown. The 
discrepancy in global volumes between Tc1 animals and WTs meant inclusion of a TIV 
covariate in the GLM was important, to discern local changes in both the Tc1 and 
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Tc1xJ20 groups. In contrast, the global volumes of the J20 and WT groups were not 
significantly different, despite significant local atrophy of the cortex. 
Volume preservation in AD mouse models is not unprecedented: in APP/PS1 mouse 
models, Teipel et al. (2011) measured no reduction in GM volume, using VBM with 
SPMMouse. Lau et al. (2008) measured reduced volumes compared with WTs, but no 
longitudinal atrophy, which they suggested indicated an earlier, developmental effect. 
Delatour et al. (2006) measured increased brain volumes from 2.5—24 months, as did 
Maheswaran et al. (2009a) from 6—14 months. 
Within the J20 animals, I observed local atrophy in regions vulnerable to amyloid 
pathology in this model. These findings support the hypothesis linking amyloid plaques 
and morphometric changes in AD: Mucke et al., 2000 noted that the cortex and 
hippocampus displayed the highest levels of APP, via immunoreactive histological 
staining. It should be noted, however, that correlations between atrophy and ṡߚ 
deposition are weaker than those with NFTs (Giannakopoulos et al., 2003; Delatour et al., 
2006; Chételat et al., 2010). In the late stages of disease, after plaque aggregation, 
neurodegeneration has already begun and treatment may be less effective (Hampel et al., 
2010). 
In a study of younger J20 mice up to 9 months of age, Wright et al. (2013) observed 
localised, age-dependent neuron loss within the hippocampus (CA1 – but preservation 
of CA3), prior to the appearance of Aβ plaques. Here a small bilateral region of CA1 
appeared to be locally reduced, while the CA3 region was also preserved compared with 
the WT group. Hébert et al. (2013) showed, using an atlas-based cortical thickness 
measurement, an increased rate of cortical thinning in this model, from 3.3—15 months, 
compared with WTs. Initial thickness in transgenic mice was, however, greater – except 
in the retrosplenial, motor and somatosensory cortex regions, all of which were reduced 
here. 
These findings contrast, in part, with a previous whole-brain, atlas-based and 
morphometric analysis of the J20 model alone (Badhwar et al., 2013), which 
unexpectedly found over 50% of structures were significantly enlarged in J20s compared 
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with WTs, including the hippocampus, striatum and cortex. The corpus callosum and 
hippocampus exhibited localised regions of reduction. The greatest expansion was 
observed in the amygdala. I also observed regional expansion in the amygdala, focal 
volume increases in the cortex (forebrain), and losses bilaterally in the corpus callosum. 
However, cortical expansion was balanced by significant and larger regions of atrophy, 
both bilaterally in the somatosensory and primary motor regions, and centrally in the 
retrosplenial area, which Badhwar et al. (2013) found to significantly increase in volume, 
alongside cortical thickness increases. The authors suggested this expansion could be an 
inflammatory, or hypertrophic, response to Aβ. The animals of that study were younger 
(6 months); the discrepancy with the results here could be due to the effects of age: the 
physical losses of tissue to atrophy over time may have superseded, or be downstream 
from, the effects of inflammation, which has itself been implicated in AD pathology 
(Wright et al., 2013). 
The Tc1xJ20 vs. J20 comparison highlights regions where the presence of Hsa21 interacts 
with the J20 AD phenotype, resulting in morphological differences from the APP 
transgenic mutants alone. Here, the J20 group exhibited local hippocampal reductions 
(red in Fig 4.14) in both CA1 and CA3 (adjacent to the thalamus, bilaterally). 
The Tc1xJ20 group included regions of local cerebellar reduction (blue in Fig 4.14) seen 
in the Tc1s, and displayed more significant reductions in the olfactory bulbs. Atrophy of 
the olfactory bulbs is known to be significant in the early stages of AD in humans, and 
has been detected in MCI patients (Thomann et al., 2009). The corpus callosum and 
cortex were relatively preserved. The geniculate region of the thalamus also appeared 
affected in the Tc1 vs. WT comparison, but here, compared with J20s, the region of 
significant difference appeared larger. These regions highlight the influence of APP 
trisomy on DS-related morphometric brain changes. 
My findings highlight the usefulness of structural MRI, combined with TBM, for 
characterising novel phenotypes, localising morphological changes arising from genetic 
differences, and informing further studies. Further histological evaluation within these 
models, which may be targeted to specific regions thanks to TBM, may explore the 
biochemical mechanisms underpinning these volume changes, including within the 
179 
olfactory bulbs, and sub-regions of the thalami of the Tc1xJ20 animals. It would be 
interesting to compare these results with those at an earlier time-point, to investigate 
whether these changes are degenerative. Morphological tracking of disease progression 
over time is made possible in vivo. This is the focus of the following two chapters. 
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5 In vivo morphometry 
This chapter begins the transition from ex vivo to in vivo MRI data first mentioned in 
§1.4. Much of the rest of this thesis depends upon one mouse model. That mouse, the 
rTg4510 model of tauopathy, is first introduced, and a large study, performed at CABI 
between 2012 and 2015, is described. This is followed by a translation of the 
morphometric image processing pipeline developed and applied in the previous two 
chapters to in vivo data. Appropriate parameters are investigated. Results from both cross-
sectional (§5.5.1) and longitudinal (§5.5.2) analyses of the rTg4510 brains are then 
shown and discussed. 
To complete the transition from ex vivo to in vivo, this chapter includes an investigation 
comparing the viability of TBM both ex vivo and in vivo, in the same dataset (§5.7). This 
work was conducted with Holly Holmes, who performed the ex vivo acquisitions and 
optimised the in vivo scan protocols; and Da Ma, who performed structural parcellation 
measurements. Once again, for this dataset, the images are first introduced and 
considerations made for the processing pipeline discussed. 
All the rTg4510 work was conducted in collaboration with Eli Lilly. Scanning was 
performed at CABI by Niall Colgan, Ozama Ismail, Jack Wells, Ian Harrison, James 
O’Callaghan and Holly Holmes. The purpose was to assess the viability of various MRI 
measures – including arterial spin labelling (ASL), diffusion tensor imaging (DTI) and 
T2W structural – for the detection and quantification of brain atrophy in the rTg4510 
mouse, with the eventual aim of assessing the effectiveness of experimental drug 
treatments. (ASL and DTI were collected and analysed by CABI collaborators.) 
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Parts of the single time-point section (§5.4) were published in Wells et al. (2015). The 
cross-sectional analysis (§5.5) forms part of a publication by Holmes et al. (2016). 
5.1 The rTg4510 mouse model of tauopathy 
Alzheimer’s disease (AD) was introduced in §2.1, and I investigated the J20 APP mouse 
model in §4.2. Several potential AD therapies, targeting ṡߚ by reducing deposition or 
enhancing removal, have failed to elicit disease-slowing effects (§2.3.3). This suggests that 
hyperphosphorylated tau neurofibrillary tangles (NFTs), a second hallmark of AD and 
other neurodegenerative diseases, may be a better therapeutic target (Giacobini & Gold, 
2013). NFT load predicts cognitive status better than amyloid load (Giannakopoulos et 
al., 2003), and better-correlates with neuron loss, which is intimately tied to cognitive 
decline (Fox et al., 1999; Jack et al., 2013). The deleterious effects of NFTs, and possible 
therapies, are investigated here. 
The tetO-MAPT*P301L (rTg4510)1 mouse over-expresses a form of mutated human tau 
related to familial frontotemporal dementia with parkinsonism (FTDP-17) and AD 
(Ramsden et al., 2005). A significant advantage of the model is the rapid progression of 
gene dose-dependent AD-like features, including neuronal death, cognitive deficits, 
motor and behavioural problems. Pretangles form in the cortex by 2.5 months of age 
(SantaCruz et al., 2005). By 3-4 months, the cortex and forebrain begin to show signs of 
neurodegeneration. By 5 months, NFTs have infiltrated the hippocampus (Ramsden et 
al., 2005). The model is particularly suited to FTD, as these pathologies are limited to 
the frontal brain regions2. Their neurodegenerative effects are severe, coinciding with the 
exhibition of profound structural atrophy of the cortex, entorhinal cortex, hippocampus 
and forebrain (particularly the striatum), and ventricular enlargement, which 
progressively worsens throughout the animal’s life when left untreated – mirroring AD 
 
                                                        
1: The tetracycline-responsive promoter (tetO) controls expression of the microtubule-associated protein tau 
(MAPT) encoding gene, whose mutation causes FTDP-17. The most common missense mutation is P301L. 
The model’s tau is thus regulatable: (rTg(tauP301L)4510). 
2: Also, there are no amyloid plaques. 
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and FTD in humans (Braak & Braak, 1995; Janus, 2008; Jack et al., 2013), which 
progress over many years. Adult rTg4510s are distinguishable from wild-type (WT) 
brains by eye in MR images (Fig 5.7). 
To quantify neurodegeneration, Ramsden et al. (2005) measured brain weights in 
rTg4510s and WT littermates. Significant differences from WTs emerged after 1 month 
of age. After 4 months, brains weighed 4-7% less. This difference widened in 
measurements up to 16 months. The forebrain was visibly atrophied in histological slices 
and neuron numbers were substantially reduced at 10 months. 
Yang et al. (2011) used structural MRI with parcellations and, in another report, the same 
group used morphometry (Xie et al., 2010) to investigate the rTg4510 model. The group 
used a single iteration of GWR and a single atlas-based parcellation method. Their TBM 
detected enlarged ventricles and hippocampal reductions. Their parcellations, which 
confirmed these results, detected reduced cortical volume (Fig 5.1). 
 
Figure 5.1 Prior TBM results and parcellation in the rTg4510 mouse brain. 
Adapted from Xie et al. (2010), left, and Yang et al. (2011), right, who used TBM and 
atlas-based parcellation to measure the differences between ṻ = 7 rTg4510 mice and ṻ =7 WT littermates, aged 5 months. The scale bars show uncorrected two-tailed t-test results; 
blue here for local reductions (hippocampus and cortex); red for expansion (ventricles). 
Doxycycline 
The rTg4510 model’s tauopathy is regulatable with doxycycline – an antibiotic, and 
tetracycline derivative – in the diet. Doxycycline’s administration is known to suppress 
tau, halt atrophy and improve memory function (SantaCruz et al., 2005). Because of this 
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drug sensitivity, the rTg4510 mouse is a propitious test-bed for measuring brain 
morphometry and the sensitivity of TBM in an animal model in vivo. 
Epothilone D 
An experimental drug, Epothilone D (EpoD), was also administered, to determine its 
efficacy. EpoD is a microtubule stabilising agent, previously shown to reduce microtubule 
loss, axonal dystrophy, and hippocampal neuron loss, and improve cognitive performance 
in the PS19 mouse model3 aged 9—12 months, even with established tauopathy (Zhang 
et al., 2012). Barten et al. (2012) showed EpoD in rTg4510 mice prevented cognitive 
deficits, reduced neuron loss and restored normal microtubule dynamics. 
5.2 Study design and methodology 
5.2.1 Animals 
This study was spread over four years (2012—15), and involved 112 animals, 255 in vivo 
and 25 ex vivo structural MR scans. Mice were all female, and either rTg4510 or WT 
littermate controls. They were licensed from the Mayo Clinic (Jacksonville, FL, USA), 
bred by Taconic Biosciences (Germantown, NY, USA), and imported prior to imaging 
at CABI. 
26 animals were scanned at a single time-point (single-TP, §5.4), aged 8 months, to 
ascertain whether various imaging protocols could reliably distinguish the tau pathology 
in 9 untreated rTg4510s (UT) at a late stage, compared with 17 WTs.  
The remaining mice were scanned longitudinally at different ages, under different 
treatment regimes, to ascertain the effects of healthy ageing, tauopathy, and the ability of 
two drugs, doxycycline (DOX) and EpoD, to mitigate those detrimental effects. Those 
 
                                                        
3: MAPT*P301S 
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images form the content of both this chapter (§5.5, 5.7), and §6. Fig 5.2 illustrates the 
time course of this study. 
For the longitudinal study, 87 animals were scanned in three mixed, age- and litter-
matched cohorts {C1, C2, C3}, across up to three time-points {TP1, TP2, TP3}. Each cohort 
consisted of three groups. C1 consisted of WT, UT and rTg4510 mice treated with 
doxycycline from age 4 months onward, TRDOX-4M. C2 consisted of WT, UT and animals 
treated earlier, at 3 months of age, TRDOX-3M. C3 consisted of UT and rTg4510 mice 
treated with EpoD in low and high doses, TREpoD-LO, TREpoD-HI. A few animals did not 
survive until TP3. There were also drop-outs due to poor image quality. For the full 
numbers, ages at each TP, and inter-TP periods, see Table 5.1 and Table 6.1. C1 animals 
which survived until TP3 were also scanned ex vivo (§5.7). 
Table 5.1 Number of rTg4510 mice, and their mean ages, for the longitudinal study. 
For each TP, the N images included in this longitudinal investigation, and the mean and 
standard deviation age of the mice in days. For the time between TPs, see Table 6.1. 
Ethical statement 
This study (§5), including the following BSI investigation (§6) accorded with the United 
Kingdom Animals (Scientific Procedures) act, 1986, and was approved by UCL’s ethical 
review panel. 
 TP1 TP2 TP3 
group N mean age SD N 
mean 
age SD N 
mean 
age SD 
WT 19 115.6 19.1 19 157.4 5.5 19 214.7 11.3 
UT 30 100 27.7 30 157.2 1.7 30 226.1 18.3 
TRDOX-3M 9 96.2 2.8 10 152.9 2.7 10 203.9 2.7 
TRDOX-4M 6 136.7 4.5 7 164.1 3.6 7 236 8.1 
TREpoD-LO 10 64.5 1.4 10 155.3 1.3 9 246.9 2.5 
TREpoD-HI 10 64.2 1 10 154.9 1.7 8 247.1 0.8 
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Figure 5.2 Longitudinal rTg4510 study design, showing mouse ages at each TP. 
Each point represents a 1.5-hour structural MR acquisition (many points overlap). 
5.2.2 Treatment 
TRDOX-3M animals began doxycycline treatment at ages 98 or 105 days; TRDOX-4M at 148d. 
Doxycyline treatment consisted of an initial dose of two 10mg/kg boluses via oral gavage, 
followed by 200mg/kg in mixed feed (by chow weight), accessed ad libitum. All TREpoD 
animals began treatment at age 70d. EpoD, mixed with Captisol4, was injected twice-
weekly intraperitoneally. TREpoD-LO dosage was 0.3mg/kg. TREpoD-HI dosage was 3mg/kg5. 
The C3 UT group, as a control, was injected with Captisol vehicle without EpoD. 
5.2.3 Image acquisition 
Owing to its neurotoxicity (Lerch et al., 2012) and therefore potential to unpredictably 
interfere with, or corrupt, the effects of tauopathy, a manganese-based contrast agent was 
 
                                                        
4: Captisol, a cyclodextrin, is used as a medium for drug delivery. 
5: For comparison, Zhang et al. (2012) injected 0.3mg/kg and 1.0mg/kg, once per week, for three months. 
Barten et al. (2012) administered 0.1mg/kg and 10mg/kg doses, and found the low dose was more beneficial. 
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not used for these in vivo studies6. The imaging protocol described below was optimised 
by my colleague Holly Holmes, who aimed to enhance the contrast between the 
hippocampus and adjacent structures. 
Imaging was performed in the cohorts described above, as follows. Mice were 
anaesthetised (2% isoflurane) and secured in a custom, 3D-printed head holder with ear 
bars to ensure head stability, and maintained with 1.5% isoflurane (1L/min in 100% 
O2), as Wells et al. (2015). Structural images were generated using a T2W, 3D FSE 
sequence with parameters: FOV=19.2x16.8x12.0mm; isotropic resolution 150µm3 
(matrix 128x112x80); TR 2500ms, TEeff 43ms, echo train length: 4; number of signal 
averages: 1, imaging time approx. 1h30m per animal. 
Scans were all performed with the same Agilent/Varian 9.4T horizontal bore VNMRS, 
with a 72mm birdcage transmission RF coil and 120mm (inner diameter) gradient set. 
Signal was received with either a quadrature mouse brain surface receiver coil (single-TP, 
C1{TP1, TP3} and C2), a 2-channel array mouse brain coil (C1TP2), or a 4-channel array 
rat head coil (C3) (all RAPID Biomedical GmbH, Würzburg, Germany). To test for 
differences in SNR and CNR between cohorts, I used E4.1 and E4.2. Data was scaled 
prior to analysis to account for gradient calibration, as measured by a custom MR 
phantom (O’Callaghan et al., 2014), to exclude the possibility of gradient scaling causing 
measured volume changes. Following imaging, histology of selected brains was performed 
by collaborators at Eli Lilly, with antibody staining for NFTs7. 
Other MR measurements (not all reported here) shared the imaging session, including 
ASL (to measure CBF) and DTI (for probing structure and connectivity). 
 
                                                        
6: (Gadolinium, also toxic, was used in ex vivo scans.) 
7: The PG-5 antibody was used to stain for hyperphosphorylated tau in the cortex, hippocampus and 
thalamus, and the NFT density reported. 
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5.3 Adjustments to the pipeline for in vivo data 
Bock et al. (2005) described the acquisition of up to 16 mouse brains in vivo, 
simultaneously, in a “mouse hive”. In addition to the difficulties already discussed (§3.2), 
it is practically difficult to simultaneously, stably maintain 16 mice in vivo for the time 
required for an MRI scan. Instead, for this study, the narrow bore of the Agilent 9.4T 
scanner only permitted scanning one mouse at a time. Multiple subject extraction was 
thus unnecessary. Orientation correction was able to proceed much faster, as (just as in 
the human in vivo paradigm) all images were in the same initial orientation, so after one 
image had been oriented (§3.3), the remainder could use the same initial affine matrix. 
Although a head-holder was used during structural scans, sometimes the head would slip 
out of place, resulting either in motion artefact or FOV misplacement (some images were 
discarded), or a brain ‘rotated’ from the usual frame of reference. Fine adjustment, using 
reflected images (§3.3.2), was required. 
5.3.1 Non-uniformity correction 
NUC was necessary at several stages, and is more important in vivo than ex vivo. Because, 
to better detect tauopathy in the forebrain, the surface receiver coils were placed above 
the rostral cortex and forebrain, signal drop-off usually manifested in the brainstem and 
posterior surface of the cerebellum, Fig 5.3. In the four-coil setup, two coils were placed 
below the mouse head; however, their contributing signal was limited, owing to the 
distance between the inferior surface of the jaw and the brain. If the intensity 
inhomogeneity was severe (assessed visually) or non-symmetric, the intensity-weighted 
principal axis calculation for automated orientation could fail, and required prior NUC. 
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Figure 5.3 Single-TP WT brain, in vivo, before and after initial NUC. 
First row: typical uncorrected sagittal, coronal and transverse slices. Note the elevated GM 
intensities at the cortical surface, beneath the receiver coils (placed at the green asterisk). 
Second row: the same slices after N4, without a mask. The cerebellum and brainstem still 
exhibit signal drop-off and inhomogeneity (red asterisk), but contrast in the cerebellum is 
improved and its posterior surface is more easily distinguished. 
 
Figure 5.4 Intensity non-uniformity in an rTg4510 in vivo mouse brain image. 
Multiple iterations of NUC, with masking, confer additional benefit. The same slice of a 
WT brain at TP1, first row: (a) prior to NUC; (b) after initial application of N4ITK; (c) 
after additional NUC using a dilated brain mask. Second row: (d) semi-transparent dilated 
binary mask overlaid; subtraction images show intensity difference and hence 
improvement in brain homogeneity (e): b-a; (f): c-b. Compare with human data: Prados et 
al. (2014), figure 2. 
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NUC was usually appropriate prior to masking, in order that the low signal, poor-
contrast caudal aspect of the cerebellum (Fig 5.3) properly registered with atlas data. This 
surface would often otherwise be underestimated in the rTg4510 brains, and required 
some manual intervention (see below). An additional application of NUC was beneficial 
after masking (Fig 5.4). 
5.3.2 Brain masking with manual intervention and bootstrapping 
I used the in vivo UFL atlas (Ma et al., 2008) to perform initial multi-atlas brain masking 
of the in vivo rTg4510 data. As the atlas’ constituent images are in-skull, the region 
surrounding the brains matched the data better than the equivalent, skull-stripped ex vivo 
UFL atlas. Also, the atlas images’ ventricles registered to most rTg4510 brains reasonably 
well (assessed via visual inspection). The NUS atlas, while based upon in vivo images and 
also exhibiting large ventricles, was not chosen, as it has fewer member images (5), lower 
contrast, and the brains are skull-stripped, so their surfaces are not surrounded by 
meninges, skull, or other flesh in the images (Fig 2.4) which might match the rTg4510 
data and benefit initial registration. 
The UFL atlas has 10 images and 20 parcellations each. I doubled the database size by 
reflecting images along the right/left axis (x, in RAS orientation – i.e., in the YZ mid-
sagittal plane) – exploiting mouse brains’ inherent approximate symmetry (§3.3.2). The 
multi-atlas label fusion algorithm STEPS was used (as per §3.5.1), with parameters ẕ =9; ߪ = 3 voxels (0.45mm). The output included binary and probabilistic brain masks. 
One problem encountered with mask accuracy arose due to the significant volume of 
eCSF present in the rTg4510 images. Atlas brain surfaces were liable to erroneously 
register to the external surface of the eCSF, as the intensity gradient (in the atlas images) 
from GM to BG matched the gradient in the rTg4510 data from eCSF to BG better than 
that from GM to eCSF. This was a problem for ex vivo rTg4510 images (see §5.7.4), but 
in vivo, lower resolution and contrast compounded these difficulties. Additionally, the 
skull – separating the brain from external flesh above the cortex – often occupied less 
than a voxel’s thickness (150µm), leading to PV effects in this area. Extra tissue above the 
cortex was also often included in the mask. 
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Consequently, my colleague Da Ma manually corrected a subset of the in vivo rTg4510 
masks, removing the eCSF regions from the mask using ITK-Snap (Yushkevich et al., 
2006). These images and manually-corrected masks formed a second, rTg4510-specific 
atlas database. I replaced the UFL atlas with this subset of the rTg4510 data, and 
employed the multi-atlas label fusion procedure to automatically, and accurately, mask 
the remainder of the dataset in a ‘bootstrapping’ procedure. Parameters with this larger 
database of N=25 images were ẕ = 12; ߪ = 3 voxels. Improved accuracy was assessed 
by visually inspecting all the results. 
5.3.3 Group-wise registration 
I investigated different combinations of GWR parameters to accommodate the lower 
resolution of the in vivo data. I used the C1TP3 dataset, including WT and UT brains, to 
incorporate as much natural physical variability between brains as possible – thus testing 
registration’s performance when the images were dissimilar. For each test, I began with 
10 iterations of globally-optimised registration using the same default parameters (1 
iteration 6-DOF rigid; 9 iterations 12-DOF affine). For 15 subsequent NRR iterations, 
I varied two NiftyReg F3D parameters about their defaults, (ݏݔ, ݏݕ, ݏݖ) = 5 ݒⱷݔⱡↄݏ (the 
final grid spacing of control-point positions, all kept equal, to be isotropic) and ẙⱡ =0.005, the bending energy penalty term: 
(ݏݔ, ݏݕ, ݏݖ) = {2, 4, 6, 8} ݒⱷݔⱡↄݏ 
ẙⱡ = {0.0005, 0.0025, 0.005, 0.0075, 0.01, 0.05} 
For in vivo data, initial CP spacing was doubled 4 times (4 levels). At each GWR iteration 
of the resulting 24 combinations, within a dilated brain mask, I calculated the mean of 
the voxel-wise standard deviation between registered, resampled images. 
An example of the results is shown in Fig 5.5. I chose (ݏݔ, ݏݕ, ݏݖ) = 4 ݒⱷݔⱡↄݏ; ẙⱡ =0.005 for in vivo brains. The lowest SD values in Fig 5.5 are from (ݏݔ, ݏݕ, ݏݖ) = 2. 
However, upon visual inspection of the resampled images, there appeared to be some 
over-fitting: local structures were severely and uncharacteristically warped and distorted 
away from their natural physical appearance. The variability between iterations also 
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indicates some unreliability: unlike the other parameters, the SD results do not settle on 
a stable “inverted plateau” (or “valley floor”), even after 15 iterations. 
 
Figure 5.5 Sample group-wise registration parameter testing results. 
The mean intensity standard deviation over all voxels within a dilated brain mask, across 
all resampled images, plotted at each GWR iteration, using different (ݏݔ, ݏݕ, ݏݖ) and ẙⱡ 
values (after the same affine parameters). The former are noted adjacent to clusters of 
results on the right (in voxels). The SD images of Fig 3.20 were created in a similar manner. 
In each in vivo investigation below, I performed statistical tests on the loge-transformed 
ṳௗ௘௧  values arising from the deformation fields generated by the final iteration of this 
GWR. Unless otherwise noted, I smoothed the resulting maps with a 3D Gaussian kernel 
(FWHM 0.16mm, 1.07 voxels), as per the ex vivo analysis (§3.10). 
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5.4 Single time-point morphometric investigation 
of the rTg4510 mouse brain 
The differential structure of the 5-month-old rTg4510 mouse brain, compared with WT 
controls, was investigated previously by Xie et al. (2010) and Yang et al. (2011). To ensure 
that my image analysis and processing techniques could sensitively detect these gross 
differences, prior to the larger, longitudinal study (§5.5), I performed a single, late TP 
investigation. This analysis, and the TBM results, were published in Wells et al. (2015). 
Animal numbers are included above (§5.2.1), as are the processing pipeline steps. One 
brain, a WT, was excluded due to severe signal loss in the brainstem, which would lead 
to poor atlas and group-wise registration. 
I used binary brain masks to measure TIV. The GLM covariates were for genotype (WT, 
UT) and TIV (E5.1). The resulting SPM (Fig 5.6) was FDR-corrected (ݍ = 0.05). 
E5.1 ẖ = ẙῺṿ(ẓẍ) + ẙῼṿ(ẏẍ) + ẙᾨẍṱẑ + ߳௜ 
TBM appears to readily detect extensive reductions in volume in the UT group compared 
with WTs at this late time-point in the animals’ lives. As expected for this FTD-related 
tauopathy model, the forebrain, particularly the caudate putamen (striatum) appears 
most affected, bilaterally. Enlargement of the lateral, third and fourth ventricles is also 
clearly detected. TBM also detected enlargement of the eCSF spaces in the entorhinal 
cortex region. The cortex, hippocampus and olfactory bulbs are severely affected, beyond 
any group differences explicable by TIV alone. The results, particularly the coronal 
hippocampal slices, are in clear agreement with the single slice shown by Xie et al. (2010) 
(Fig 5.1), although it is not clear whether that group covariated with TIV; they also did 
not perform multiple testing correction. Histology of these brains revealed a clear 
negative correlation (ݎ = −0.80, ݌ = 0.01) between NFT density (assessed via cell 
staining) and rTg4510 hippocampal volume (assessed via atlas-based parcellation). 
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Figure 5.6 Single time-point TBM results from 8-month-old rTg4510 mice. 
TBM revealed (red): local volume reductions in the UT group (N=9), compared with WT 
controls (N=16); (blue): local expansion. Results (FDR-corrected t-statistics) overlaid upon 
coronal and transverse slices of the structural average image after 15 iterations NRR. Solid 
lines in the key indicate slice locations. BS: brainstem; ENT: entorhinal cortex; CP: 
caudate putamen; CX: cortex; HC: hippocampus; LV: lateral ventricles; TH: thalamus. 
The centre of the thalamus, a low tau-burden region, appears relatively unaffected, along 
with the midbrain, brainstem and cerebellum, which exhibits some regional expansion 
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relative to the controls. Yang et al. (2011) recorded, via segmentation and manual 
landmark-based measurements, hippocampal and cortical volume reductions of 26.7% 
and 20.6%, respectively, in rTg4510s, and thinning of the entorhinal region (intra-rater 
measurement variability was up to 8.2%). They did not control for TIV, but found that 
the cerebellum exhibited no global difference in volume, which may explain the apparent 
local increases, proportional to TIV, detected here by TBM. 
This first in vivo analysis of the rTg4510 brains indicated the viability of TBM for the 
detection of gross atrophy-related pathology at late time-points. The usefulness of the 
technique, however, is largely in sensitively detecting unforeseen localised changes which 
are not readily visible by eye alone; this is the purpose of including a large number of 
animals in each group. The subsequent multi-time-point study, detailed below, should 
therefore be of particular interest, as we should be able to find the developmental stage 
of pathology at which TBM becomes viable for detecting differences and separating 
groups. 
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5.5 Multiple time-point rTg4510 study 
 
Figure 5.7 Visible atrophy in the rTg4510 brain, compared with relative preservation 
of WTs. 
Whereas the WT mouse brain is preserved over three imaging time-points (a), the UT 
rTg4510 brain (b) exhibits severe neuronal cell death, manifesting as cortical thinning 
(orange arrow), ventricular expansion, and external CSF (eCSF) accumulation at the 
entorhinal cortex (green arrows). 
Progressive atrophy was clearly visible upon inspection of the scanned, reconstructed 
brains (Fig 5.7). The sequence was optimised for GM/WM contrast without a contrast 
agent, and this appeared successful: the corpus callosum and deep cerebellar WM were 
clearly visually distinguishable, as was the GM of the hippocampus. The cortex was 
visibly diminished in the later TP UT brains, alongside gross ventricular expansion. 
I found comparable SNR and CNR across all images (Table 5.2). I performed both cross-
sectional (within-TP) and longitudinal (between-TP) TBM analysis of each of these 
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cohorts, using the pipeline detailed above. These SNR measurements also compare 
favourably with those obtained from multiple-subject scans ex vivo (§4.1.5). 
cohort SNR SD CNR SD 
C1 15.13 2.62 4.43 0.71 
C2 15.7 2.69 4.64 0.73 
C3 15.83 2.63 4.55 0.82 
Table 5.2 Mean SNR and CNR for all rTg4510 scans in the longitudinal study. 
Means and standard deviations for each cohort. Although three different receiver coils were 
used, SNR and CNR remained stable throughout the study. For formulae, see E4.1, E4.2. 
5.5.1 Cross-sectional analysis 
The in vivo pipeline was used to perform TBM analyses to compare groups at each of the 
three TPs, within each cohort. Figs 5.8, 5.9, 5.10 show the GWR average images from 
C1 and C2, overlaid with statistical results (C3 omitted from figures owing to lack of 
significant voxels). Comparisons were within-cohort, and therefore between 
approximately age-matched mice. This analysis was published in Holmes et al. (2016). 
For these results, I initially tested the GLM (E5.1, including a third ṿ(ⱦⱡⱶⱷݐݕ݌ⱡ) term 
for the treated group) with a TIV covariate (as per the single-TP study, §5.4). However, 
in most cases, this removed the majority of significant voxels from the parametric maps, 
after FDR. This indicates a strong linear relationship between TIV and the local, voxel-
wise volumetric differences between groups illustrated in the figures below. It also 
suggests that, at these earlier TPs, the reduced animal numbers (compared with the single-
TP at 8 months of age) provided insufficient power to achieve statistical significance and 
detect the earlier, subtler effects of neurodegeneration. I investigated the effects of TIV 
in a group comparison separately (§5.6), and show effect size calculations at TP3 in 
§5.7.3. 
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Figure 5.8 TBM results at TP1 of the cross-sectional multi-time-point study. 
Each column in this figure, 5.9 and 5.10 represent a different comparison. FDR-corrected 
t-statistics are overlaid upon equivalent representative coronal and transverse slices of the 
final GWR average image, in each figure. Column A: cohort 1 (results for this comparison 
from cohort 2 not shown, but in all cases similar to those from cohort 1); cols B, D: cohort 
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2; cols C, E: cohort 1. In all three figures, (A,B,C), red: UT and TR groups locally smaller 
than WTs; blue: larger. (D,E), red: UT groups locally smaller than TR; blue: larger. 
At TP1 (Fig 5.8), there was a global difference in BVs between UT and WT groups. 
Although TBM could not reliably separate these groups, there were significant voxel-wise 
volume differences between the early treated group and WTs. This may be attributed to 
the greater animal number in this cohort (N=9 TRDOX-3MO; N=6 TRDOX-4M), improving 
the available statistical power: one would expect the latter group to show greater 
separation from WTs. Animals from the late treatment group were approximately one 
month older at this TP (Table 5.1). These early differences appear predominately 
bilaterally in the striatum. That no voxels survived FDR correction in the UT/WT group 
comparison may be because the global volume difference was evenly spread throughout 
the brain. No comparison of TR groups with UT animals showed significance at this TP. 
This is as expected, as the treatment start coincided with the TP1 scan. 
At TP2 (Fig 5.9), the comparison between WT and TRDOX-3M brains revealed a very 
similar pattern of atrophy: the striatum appears bilaterally affected, and there is a central 
reduction in the treated group’s hippocampus. Despite a similar difference in numbers as 
at TP1, the late-treated group exhibits a more extensive bilateral pattern of reduction 
compared with the control WTs, including apparent bilateral reductions in the thalamus. 
At this stage, the effects of doxycycline-linked tissue preservation are already apparent: 
the same regions are affected, more extensively, in UTs. 
The GWR average images have larger ventricles than at TP1. Morphometry detects a 
difference between WT and UT ventricles, as well as subtle regions of expansion around 
the lateral ventricles in the TR groups, compared with WTs. No voxels survived FDR in 
the comparison between UT and TR groups, except a very small unilateral region of 
volume reduction in the forebrain of the UT group compared with TRDOX-3M (final row), 
indicating the earliest detection of structural preservation. 
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Figure 5.9 TBM results for WT, UT and doxycycline-treated mice at TP2. 
At this TP, reductions in the UT and TR groups, compared with WTs, are clearly visible. 
The late-treated group appears preferentially reduced, over the early-treated group. 
201 
At TP2 and TP3, the thalamus also appears affected in the UT and late-treatment groups, 
despite exhibiting low NFT counts in the post-imaging histology (data not shown). This 
may be an artefact of the global volume difference between groups. 
At TP3, approximately one month prior to the single-TP investigation, very similar TBM 
results were observable in the comparison between WT and UT animals (Fig 5.6, 5.10A), 
although here without the TIV covariate. These consist of extensive bilateral reductions 
in the UT group c.f. WTs: the forebrain, striatum, hippocampus and cortex are all 
bilaterally reduced in volume. The UT cerebellum shows some increase in volume relative 
to WTs. This region was not assessed histologically for NFTs, but is not believed to be 
affected. Third and fourth ventricle expansion may have physically displaced the 
cerebellum, causing an apparent expansion (see §6 for further discussion). The lateral 
ventricles are also greatly enlarged, and TBM detects some expansion of CSF spaces in 
the entorhinal cortex region. 
Early intervention appeared more successful at limiting atrophy and ventricular 
expansion. The early-treatment group is clearly differentiated from the UTs at TP3. Parts 
of the hippocampus, bilaterally; the thalamus, the striatum and the cortex all appear 
relatively preserved. The late-treatment group is just distinguishable from UTs, here, at 
bilateral foci in the hippocampus (coinciding with the early-treatment group), but 
TRDOX-4M mice exhibit a similar pattern of atrophy as the UTs, when compared with 
WTs. In both the early and late-treatment groups, the atrophy appears more severe than 
at TP2. As the WT brains do not increase in volume over time, this suggests the dosage 
of doxycycline did not completely halt progression of neurodegenerative tauopathy. 
As well as the spread of statistically significant voxels increasing compared with earlier 
TPs, the t-statistics themselves were greater, indicating broader separation of group 
means. The differences between columns (B,C) and between (D,E) in Figs 5.8-10 may be 
explained by the tau transgene suppression, and hence preservative effects of doxycycline 
intervention. However, at no time-point did TBM, even without a TIV covariate, 
distinguish UT from TREpoD-LO or TREpoD-HI, nor did it distinguish between those groups, 
after multiple-testing correction with FDR (q=0.05). Thus, slices from those GWR 
averages images are omitted. 
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Figure 5.10 Cross-sectional TBM results at TP3. 
The t-statistics are generally much greater than in Fig 5.8 or Fig 5.9, indicating better group 
separation. In both comparisons, the early-treated group exhibits better structural 
preservation than the late-treated group. 
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5.5.2 Longitudinal analysis 
The previous, cross-sectional analysis sought to compare groups at each TP of the study, 
to determine the sensitivity of TBM to group differences in local brain structure, at 
different ages, stages of disease progression, and after different periods from the start of 
treatment. NRR may also be leveraged to compare the changes between TPs. In this 
section, registration and TBM are used to measure how each group deforms between TPs 
– the degree, extent, and location of atrophy may thus be compared. 
In a longitudinal investigation of an APP transgenic AD mouse model, Lau et al. (2008) 
registered all brains from all TPs into a single group average space, and controlled for age 
in a linear, mixed-effects model. The pair-wise registration technique I adopted was 
similar to that employed by Maheswaran et al. (2009a). After intensity standardisation 
from the in vivo pipeline described above, I individually registered each mouse brain from 
TP1 and TP3 to its corresponding image from TP2 (from the same mouse – thus, mice 
with either member of the image pair missing were excluded from the group comparison). 
For each mouse brain image ⱪ: 
ⱪẍṿῺ → ⱪẍṿῼ ← ⱪẍṿᾨ 
Where the arrows represent a pair-wise registration (affine followed by non-rigid), with 
parameters as per the in vivo GWR (§5.3.3). Dilated masks from §5.3.2 were recycled to 
constrain the ROI for these registrations. The resulting pair-wise deformation field 
ⱪṧṫ௣௔௜௥ was in the space of iTP2. One advantage of this technique is that, nominally, 
iTP2 will already approximately be in the mid-way average space from each set of {iTP1, 
iTP2, iTP3}, thus requiring the least physical deformation from other TPs. I calculated 
the voxel-wise log(ṳௗ௘௧) from each ⱪṧṫ௣௔௜௥  (again, in the space of iTP2). 
I next performed a GWR of all TP2 images, from all groups (re-using dilated masks and 
parameters from §5.3.3). I used the resulting deformations to resample each log(ṳௗ௘௧) 
image into the final TP2 average space (using trilinear interpolation). This interpolation 
doubled as a “smoothing” step, which in the ex vivo pipeline was additional. Here, the 
comparatively large voxel sizes (and hence greater PV) renders smoothing less important. 
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These steps are illustrated in Fig 5.11. The technique was thus similar to that of Kipps et 
al. (2005). 
 
Figure 5.11 Illustration of the registration steps for longitudinal TBM. 
Each image from TP1 and TP3 was registered to its respective pair from TP2, and log(ṳௗ௘௧) 
values calculated from the deformations at each voxel. TP2 images were group-wise 
registered and the log(ṳௗ௘௧) values resampled into the final average space, for voxel-wise 
statistics. 
I performed voxel-wise statistics on the resampled log(ṳௗ௘௧) images, which represent 
deformations from TP1-2 or from TP3-2, using the GLM with the following model: 
ẖ = ẙῺṿ൫ẍṿ௑ିῼ(ẓẍ) + ẙῼṿ൫ẍṿ௑ିῼ(ẏẍ)  + ẙᾨṿ൫ẍṿ௑ିῼ(ẍẉ)  + ẙᾬṧẘݕݏ + ߳௜  
Where ṿ(ẍṿ௑ିῼ(ⱦⱡⱶⱷݐݕ݌ⱡ)) is a dummy variable representing the binary group-and-
time-point classifications. TPX-2 represents deformations from TP1 or TP3 to the same 
animal’s TP2 image. The covariate ṧẘݕݏ represents, for each image, the number of days 
between the TP1 or TP3 scan and the corresponding TP2 scan. Thus I controlled for the 
variable time interval between scans (Table 6.1 shows the mean interval per group). For 
these tests, I did not include a TIV covariate, as the purpose was not to compare volume 
across groups (the inclusion of TIV would mitigate any initial global scaling factor). 
Rather, all the volume changes statistically compared here were within-group (actually 
within-animal), between TPs, thus any global scaling is likely to be due to atrophy or 
natural volume change, and is of interest. Whitwell et al. (2001) used TIV to scale serial 
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MR measurements, but this was to account for possible variations in voxel size due to 
scanner calibration, which I corrected separately (§5.2.3). 
There were no significant voxels after correction for FDR (ݍ = 0.05) when comparing: 
ẍṿῺ→ῼ൫ẏẍᾣభ  ݒݏ.ẍṿῺ→ῼ൫ẓẍᾣభ  
This might be expected, as earlier in the animals’ life and at earlier stages of the disease 
progression, changes are subtler, as indicated by the cross-sectional results above. Indeed, 
testing cohorts separately, the comparison of the later periods: 
ẍṿᾨ→ῼ൫ẏẍᾣభ  ݒݏ.ẍṿᾨ→ῼ൫ẓẍᾣభ  
ẍṿᾨ→ῼ൫ẏẍᾣమ  ݒݏ.ẍṿᾨ→ῼ൫ẓẍᾣమ  
did show some significant voxels, at the same threshold, with similar N per group. When 
data from all cohorts was combined to compare the TP1-2 deformations: 
ẍṿῺ→ῼ൫ẏẍᾣభ ,ẏẍᾣమ ,ẏẍᾣయ  ݒݏ.ẍṿῺ→ῼ൫ẓẍᾣభ ,ẓẍᾣమ  
there were still no significant results. This may be because there was significant variability 
in inter-time-point periods, because the C1 TP1-2 interval was very low (Fig 5.2), so any 
changes would be extremely subtle, or because the test was under-powered for such subtle 
changes, with this number of animals. I combined C1 and C2 to increase numbers and 
hence statistical power. Fig 5.12 shows the results of comparing: 
Column 1: ẍṿῺ→ῼ൫ẏẍᾣభ ,ẏẍᾣమ  ݒݏ.ẍṿῺ→ῼ൫ẓẍᾣభ ,ẓẍᾣమ  
Column 2: ẍṿᾨ→ῼ൫ẏẍᾣభ ,ẏẍᾣమ  ݒݏ. ẍṿᾨ→ῼ൫ẓẍᾣభ ,ẓẍᾣమ  
Column 3: ẍṿῺ→ῼ൫ẏẍᾣభ ,ẏẍᾣమ  ݒݏ.ẍṿῺ→ῼ൫ẍẉᾣభ ,ẍẉᾣమ  
Column 4: ẍṿᾨ→ῼ൫ẏẍᾣభ ,ẏẍᾣమ  ݒݏ. ẍṿᾨ→ῼ൫ẍẉᾣభ ,ẍẉᾣమ  
As doxycycline treatment began concurrently with the first scan, controlling for the inter-
TP period in the GLM also controlled for the time from initial intervention (although 
not mouse age). 
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Figure 5.12 Longitudinal TBM results for UT vs. WT and UT vs. TR comparisons. 
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The same representative coronal, transverse and sagittal slices of the final TP2 GWR 
structural average, overlaid with FDR-corrected t-statistics for each comparison. In each 
column, the TBM results are red: UT locally shrinking over time compared with either 
WT (columns 1 and 2) or TR (cols 3, 4); blue: expanding. C1 and C2 were combined in 
each case. 
Very few, or no, voxels were significant between TP1-2, whether comparing UTs with 
WTs (a few bilateral reductions were detected in the cortex and forebrain) or TRs (none). 
The former comparison suggests that, rather than changes initially occurring in the 
entorhinal cortex or hippocampus, as would be consistent with human Braak staging 
(Braak & Braak, 1995), in this model of FTD-linked tauopathy, the earliest signs of 
degeneration occur in the cortex and forebrain. Although these are subtle effects, 
encouragingly, they are bilateral. 
Between TP2-3, changes are more obvious: there is significant bilateral shrinkage of the 
cortex, striatum and hippocampus, and symmetric enlargement of the lateral, third and 
fourth ventricles, in UTs compared with WTs. The axial slices reveal expansion of eCSF 
pools in the entorhinal cortex region. These results suggest the most severe effects of 
tauopathy, manifesting as neurodegeneration, occur after approximately 150 days (5 
months). 
As expected, the differences between UT and TRDOX brains are less dramatic, but 
bilateral, and consistent with doxycycline’s known ability to halt neurodegeneration in 
the model. The red regions of columns 3 and 4 show relative preservation of the TR 
group, compared with UTs, which shrink over time in comparison. The same regions are 
affected, but their extent is reduced, and the t-statistics, representing group separation, 
are lower. Doxycycline’s preservative effects are, however, not detected with significant 
voxels until after TP2, 1—2 months after treatment began (Table 6.1). 
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5.6 The TIV covariate 
In both the Tc1 study (§4.1) and this rTg4510 chapter, consideration of the TIV 
covariate proved important for statistical analysis. The “TIV” measurement here is based 
upon binarised brain masks, including ventricular CSF and meninges (see Fig 5.19), but 
excluding some external CSF. Although it only approximates TIV, it is here likely closer 
to TIV than BV (GM and WM only), as in most cases there appeared to be a greater 
proportion of CSF in the ventricles than external spaces. The measurement’s accuracy 
could be improved by using the probabilistic output of STEPS, rather than a sum of the 
binary parcellations, ensuring all eCSF was included. (A more accurate, tissue-based 
estimation of each animal’s BV, which required further development, is included in §6.) 
In healthy WT mice, the brain is tightly encased within the skull, and the ventricles are 
small. Especially in the UT rTg4510 group, however, BV decreases substantially with 
atrophy over time. As in human studies (Whitwell et al., 2001; Scahill et al., 2003; Barnes 
et al., 2010), I expected TIV to remain approximately constant8. This facilitates the 
simple comparison of cross-sectional and longitudinal measurements. 
For morphometry, some studies remove global volume change from consideration in 
statistics by omitting the scaling factor applied by the affine matrix during GWR (e.g. 
Xie et al., 2010). This is the technique employed by Freesurfer (Buckner et al., 2004). 
Using the Tc1 and WT data from §4.1, I investigated whether the determinant of the 
affine matrices from the final iteration of affine registration during GWR correlated with 
the TIV measurement from tissue segmentation (§3.6; Table 4.1). Fig 5.13 shows the 
result. Pearson’s ݎῼ = 0.85; the p-value on the slope was 1.33 × 10ିῼᾨ. 
 
                                                        
8: Barnes et al., (2010) reported a nonsignificant 0.1% TIV increase per annum in healthy human adults. 
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Figure 5.13 Comparing the TIV measurement with the GWR affine determinant. 
WT and Tc1 TIV measurements and affine determinants from §4.1. The affine 
determinant scales each brain to the group average, so linearly correlates with tissue-derived 
TIV. 
The linear relationship in Fig 5.13 appears strong. However, the spread of points away 
from an exact linear relationship indicates that subtle effects differentiate the two 
measurements. The GWR is applied to voxels within a dilated brain mask. The 
registration will optimise the overall transformation using the skull, brain tissue, and any 
extraneous material included. It is therefore partially driven by variable tissues. The affine 
determinant will hence be an imperfect representation of consistent TIV, and may be 
biased by disease-related atrophy (Ridgway et al., 2011). Malone et al. (2015) found that 
segmentation-based estimates of TIV (e.g. in SPM12) outperformed affine registration-
based methods. 
210 
 
Figure 5.14 TBM results in rTg4510 brains, comparing affine and TIV covariates. 
Three cross-sectional TBM comparisons (FDR corrected, ݍ = 0.05) overlaid on the same 
representative structural GWR average slices from C1 TP3: TR vs. WT; UT vs. TR and 
UT vs. WT. Within each, three versions of the statistics are shown: the first column 
omitting the affine from statistical tests (only NRR deformations tested); the second 
column including the affine; the third column, for each comparison, including the affine 
but also including the brains’ TIV as a covariate in the GLM. Red: ẍẉ < ẓẍ;ẏẍ <
ẍẉ;ẏẍ < ẓẍ locally; blue: ẍẉ > ẓẍ;ẏẍ > ẍẉ;ẏẍ > ẓẍ locally. 
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To investigate whether the two measurements had different effects on rTg4510 TBM 
results, I repeated the statistical tests of C1 TP3 from the multi-TP study (§5.5.1), with 
the affine determinate excluded from the ṳௗ௘௧  values (to remove the global scaling from 
affine GWR); included, and included but with a TIV covariate to remove any global 
volume difference between animals’ skulls. The results are shown in Fig 5.14. No 
additional smoothing was performed prior to statistics for these in vivo tests, as the 
combination of minor registration error, interpolation from resampling, and the larger 
voxel volume (compared with the ex vivo analysis) likely provided enough spatial 
smoothing. 
In the comparison between UT and WT brains, removing the affine determinant had 
very little effect on TBM results, whereas including a TIV covariate in the GLM removed 
almost all voxels from significance. This suggests a strong linear relationship between the 
local volume reductions detected in the cortex, hippocampus and forebrain, as well as 
ventricular expansion. The relationship between affine determinant and TIV may be 
weaker in this dataset than in Fig 5.13. The TIV measurement also accounts for almost 
all the observed differences in the TR vs. WT and UT vs. TR comparisons. In the former, 
there remain some scattered, preferential local shrinkage in the forebrain not accounted 
for by global differences. At these locations, tissue atrophy may be particularly 
pronounced. In the latter, there are very few significant voxels which survive FDR 
correction in any comparison (as §5.5.1). The subtle differences between this TRDOX-4M 
group and the UTs are accounted for by TIV, but not by the affine determinant. 
The strong correlation between all results and TIV justified my exclusion of the covariate 
when assessing cross-sectional results of the multi-TP study, above. Gross volume 
differences between groups, especially at this late TP, are visible by eye, particularly in 
the ventricles. However, these volume changes are not present globally throughout the 
brain: TBM remains useful to localise their concentration in the forebrain, hippocampus 
and cortex. The single-TP study (§5.4) included a TIV covariate, but many more 
statistically significant voxels survived FDR correction (Fig 5.6, c.f. column 3 of Fig 5.14). 
I attribute this improved sensitivity to the greater animal numbers of that study. 
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5.7 Comparing ex vivo morphometry to in vivo 
Following their TP3 scans, 25 C1 mice were culled and perfuse-fixed using the protocol 
optimised for high-contrast ex vivo scans described in §4.1.2. After 9 weeks’ fixation, the 
brains were secured in the 3-brain holder and MR scanned (acquisition parameters as per 
§4.1.2). 8 WTs, 10 UTs and 7 TRDOX-4M brains were included. This afforded the 
opportunity to directly compare the same brains with both in vivo and ex vivo techniques.  
The purpose was to determine whether the compromises inherent to in vivo µMRI – 
including lower resolution (hence, greater partial volume and reduced contrast), potential 
movement artefacts, and lack of contrast agents – hamper TBM to such an extent that it 
is not as useful for detecting morphological differences between groups as ex vivo TBM. 
Ex vivo imaging has its own drawbacks, including the possibility of perfusion artefacts 
(§4.1.14; Cahill et al., 2012), tissue dehydration and shrinkage (Zhang et al., 2010; Lerch 
et al., 2012) and possible damage (Ma et al., 2008; Sawiak et al., 2012). These may 
confound morphometric analysis. If equivalent sensitivity is achievable in vivo, a strong 
argument could be made for the exclusive use of in vivo µMRI, which allows other MR 
measurements, and consumes fewer scanner resources (including time), and, by enabling 
longitudinal studies, fewer mice. By comparing UT and WT, then TR and UT groups, 
I show the sensitivity of TBM to both large and small structural differences. 
The first analysis undertaken was a repeat of the ex vivo TBM processing steps from §3, 
applied to this rTg4510 cohort. My colleague Da Ma also performed a structural 
parcellation comparison. Prior to processing, in vivo and ex vivo data were scaled 
according to a gradient-specific calibration (O’Callaghan et al., 2014), to remove any 
global scaling effects of scanning each dataset with different coils. 
5.7.1 TBM results compared, in vivo and ex vivo 
For the ex vivo data, I applied the same complete set of image pre-processing steps for 
TBM as those described in §3 and §4, including multiple subject extraction and GWR. 
The GLM used for statistics was the same as that for in vivo C1 TP3. Results from that 
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data (§5.5) are repeated here alongside ex vivo results. To discern its effect upon statistical 
maps in both datasets, and isolate local deformations, I tested both the inclusion and 
omission of a TIV covariate, where TIV was measured from binarised brain masks, 
including ventricles, as discussed above. Smoothing of the log-transformed ṳௗ௘௧  values 
was performed prior to statistics using a kernel with the same FWHM, 0.16mm, in both 
cases. All voxel-wise statistical results were corrected using FDR, ݍ = 0.05. 
In a comparison of UT and WT groups (Fig 5.15), both in and ex vivo TBM revealed 
substantial, extensive regions of significance when TIV was not covariated out (hence, in 
A & C, I included global scaling). Volume differences in the cortex, caudate putamen, 
hippocampus and thalamus were bilaterally significant in both, indicating widespread 
contraction of these tissues in the UT group. A greater proportion of voxels appeared 
significantly reduced in the caudate and cortex, and the t-score was generally higher, in 
the ex vivo comparison, despite slightly reduced subject numbers – indicating that, thanks 
to the increased local contrast available ex vivo, registration was better able to deform 
structures, and thus separate the two groups’ ṳௗ௘௧  means. The in vivo voxels are limited 
by greater volume (150 40⁄ μⅎᾨ ≈ 52.7). More tissue types share a single sampled 
image region, increasing PV and homogeneity, and the available detail is thus lower. 
Central and bilateral ventricular expansion was far more robustly recovered in vivo. 
Although the ex vivo images did reveal some ventricular (and entorhinal eCSF) change, 
t-statistic values were greater in vivo. This is likely due to the variable levels of ventricular 
collapse instigated by the perfusion-fixation process. Poor registration in these areas may 
contribute (see §5.7.4). 
Using the TIV covariate (Fig 5.15 B & D), many of these regions disappear below the 
threshold of significance. Ex vivo, some small bilateral clusters of significant reductions 
survived FDR in the cortex (iii), and the hippocampus (v, vii). In vivo, more voxels 
retained significance, indicating local contractions (especially the cortex, hippocampus, 
and striatum) and expansion (the ventricles) in the UT group independent of the global 
volume difference. The process of tissue relaxation, dehydration and adjustment during 
fixation may have obscured true local volume differences – however, this would not 
explain the extensive significant regions seen without the TIV covariate. 
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Figure 5.15 In and ex vivo TBM, comparing UT rTg4510s with WTs. 
Results of in vivo (A, B) and ex vivo (C, D) morphometry (TBM two-tailed t-tests, after 
FDR correction ݍ = 0.05) overlaid on equivalent, representative coronal and transverse 
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slices of the final GWR structural average image, in each case. Without (A, C) and with 
(B, D) a TIV covariate in the GLM. Red: UT brains were relatively locally smaller than 
WTs; blue: larger. In vivo results from the same statistical tests on C1 TP3 as Fig 5.10. 
Instead, it is possible that the larger voxels in vivo allow small regions of volume change 
– homogeneous in intensity and thus poorly registering – to contribute collectively to 
larger structures with some elevated contrast, which do register well. These structures 
manifest the local changes which, ex vivo, are spread evenly across many voxels, and do 
not attain significance independently. This is similar to the improved power of 
parcellation-based volume measurements (§4.1.5). 
In Fig 5.16, I compare UT and TRDOX-4M groups. In this case, red regions represent 
relative preservation of the TR group in comparison with the UTs. Just as in Fig 5.10, 
few local structural differences were detected in the late-treated group compared with 
UTs in vivo. There were some small indications of relative contraction bilaterally in the 
UT hippocampus (A iv). When TIV was used to standardise results (B), as above, these 
disappeared. The reduced contrast in vivo, in combination with the lower animal number 
(TR N=7), likely diminished the power of this test. 
Ex vivo TBM encouragingly highlights more regions of significant difference, indicating 
bilateral conservation of the hippocampus, cortex, forebrain and olfactory bulbs in the 
TR animals. Again, this is likely due to the superior local contrast. Because the differences 
are subtler, the dispersion of significant voxels, and their t-scores, is reduced. Although 
expansion of the UT ventricles is highlighted by a small region of significance (C v), these 
suffered the same unpredictable collapse as described above. Thus, large significant 
changes are not discerned. As the in vivo brains’ ventricles are not significant either, this 
may also be because intervention began too late to interrupt the period of ventricular 
expansion. Conversely, the entorhinal cortex eCSF region is highlighted by robust regions 
of significant bilateral expansion in the UTs (C vi). Because it is not surrounded by tissue, 
external pressure, and hence collapse, is not an issue during perfusion-fixation. 
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Figure 5.16 In and ex vivo TBM, comparing TR rTg4510s with UTs. 
In vivo (A, B) and ex vivo (C, D) TBM results, as Fig 5.15 (two-tailed t-tests, with the same 
slices and FDR ݍ = 0.05). (A, C): without TIV covariate in the GLM; (B, D): with TIV. 
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Red: UTs locally significantly smaller than TRs; blue: larger. The most prominent changes 
in vivo and ex vivo are in the hippocampus. Ex vivo, substantial forebrain and cortical 
differences are also detected. 
More of these regions survive with the TIV covariate (D) in this comparison than UT vs. 
WT, or indeed the in vivo set. This is possibly because TIV explains a greater proportion 
of the differences between UT and WT brains than TR and UT brains: in the latter 
comparison, significant changes are concentrated in the regions highlighted, and not 
attributed to global volume differences. The brains’ initial volumes, at TP1, were indeed 
more similar to one another than to WTs. 
The parcellation results (not shown in figures) quantified a global shrinkage, across 
groups, from in vivo to ex vivo (excluding the ventricles, WT: 7.5%; TR: 9.3%; UT: 
9.6%, all significant within-group paired t-test results with ݌ < 0.01). While the overall 
correlation between equivalent structures, across groups, was strong (ݎῼ = 0.98), 
shrinkage was non-uniformly distributed between structures. The cortex was relatively 
preserved; however, the ventricles almost completely collapsed (85.7% volume decrease) 
– confirming visual observations. This was expected: previously published work has 
implicated tissue fixation with dehydration and subsequent global shrinkage. Zhang et al. 
(2010) observed 4.4—7.8% whole-brain volume reductions, and concluded that, despite 
dramatic shrinkage of the ventricles, the structure of the rest of the brain was preserved 
sufficiently for morphometry. Ma et al. (2008) measured a 10.6% decrease in C57Bl/6J 
WT brain volumes, and similarly observed ventricular collapse. 
5.7.2 Local structural differences between in vivo and ex vivo 
To measure, and visualise, the degree of local variability between ex vivo and in vivo 
images, I used a method similar to that employed by Ma et al. (2008)9. I registered each 
of the 25 ex vivo brains to their corresponding C1 TP3 in vivo counterpart, and calculated 
 
                                                        
9: Their Fig 8 (c & f) inspired this analysis, but is not exactly equivalent, as their registration was group-wise 
instead of the pair-wise registration here. 
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the mean positional distance (MPD) at each voxel (E3.15), after resampling the resulting 
deformation fields into the in vivo brains’ average space, from the GWR of C1 TP3. 
Fig 5.17 shows the mean distance moved by each voxel during registration, when aligning 
ex vivo images pair-wise to in situ, in vivo images, from all three cohorts (NRR only; rigid 
and affine transformations were excluded). It thus shows physical differences between the 
brains, as scanned. This could tell us whether the ex vivo preparation of mouse brains 
added significant structural deformations. Coarsely, the figure could be considered a map 
of the degree of reliability of morphometry from ex vivo structural scans, compared with 
the in vivo paradigm, which is more likely to reflect in situ biological reality. As might be 
expected, the greatest displacements (between 0.25 and 0.5mm) occur within the 
brainstem, which was in different positions during in vivo and ex vivo scans – and was 
subject to different FOV placements or the position of the cut, when the skulls were 
removed from the mice. 
 
Figure 5.17 Mean positional distance image showing the mean distances moved by 
voxels during pair-wise registration from ex vivo to in vivo data. 
Deformation maps showing the local distortions of ex vivo brains (the distance travelled, 
in mm) compared with in vivo counterparts. Voxel-wise deformations were calculated and 
resampled into the same average space for comparison. 
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The rostral aspect of the olfactory bulbs was also affected, although as the ex vivo scans 
were in skull, the displacements were not of the same degree as those seen by Ma et al. 
(2008). The ventricles do not show a great deal of variability between in and ex vivo. This 
may be because this group average, including WT, UT and TR groups, has such large 
variability that the vectors are averaged out. It may also be because the images are similar: 
as the registration was pair-wise, large deformations should not necessarily be expected 
between in and ex vivo brains of the same group. In the ex vivo scans, as in prior datasets, 
the ventricles usually partly or fully collapsed during perfusion and fixation (though not 
always; see Fig 5.19). Registration sometimes failed to capture this gross deformation (see 
§5.7.4). This could perhaps be corrected via the use of a more liberal bending energy 
penalty term in NRR – however, as the term is global, other regions of the brain, which 
do not require such freedom to register correctly, may then deform incorrectly. 
The remainder of the olfactory bulbs and the cerebellum also showed displacements of 
between 0 and 0.25mm (under 2 voxels in vivo). The rest of the brain, including the 
midbrain, hippocampus, thalamus and cortex, was relatively unaffected ex vivo; I attribute 
this preservation to keeping the brains in skull for scanning, to prevent damage. It is 
notable that the cortical surface shows very few signs of systematic perturbation, which 
bodes well for the validity of ex vivo morphometric results in this structure. 
Another possible cause of the apparent displacements seen in Fig 5.17 is the different 
sequences used for in vivo (FSE) and ex vivo (GE) acquisition. The latter may have 
induced some geometric distortion away from the bore isocentre, giving a similar pattern. 
However, the ex vivo brains were always positioned in the scanner so that their centres 
were aligned with the isocentre. According to O’Callaghan et al. (2014), gradient warp 
distortion was below 0.1mm within ±20mm of the isocentre; mouse skulls easily fit 
within this window. Additionally, the displacements seen caudally appear predominately 
in the brainstem (rather than equally in the cerebellum, directly above), so it is more 
likely that physical distortion caused the dominant appearance here. 
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5.7.3 Power analysis 
With enough subjects, any group difference between means can be declared “significant” 
(Cohen, 1994). TBM results themselves are often insufficient; what is important is a 
measure of the effect size; the magnitude of the physical difference between groups’ local 
volumes, and whether this magnitude is scientifically interesting (Coe, 2002). 
As described, the ex vivo and in vivo groups underwent separate GWR and TBM analysis. 
Each dataset may be treated as a preliminary study from which to estimate the number 
of mice ṻ (per group) required in a future ex or in vivo study to show meaningful 
differences between the WT and UT groups, with specified statistical power. I chose a 
conventional significance level of ߙ = 0.05, a false negative rate ߚ = 0.2, and initially 
assumed the WT group provided a reasonable estimation of local structural variability 
within the rTg4510 mouse population. To detect a 25% local volume difference between 
WT and UT groups measured in ṳௗ௘௧  values, at each voxel, the required number of 
animals in each arm of the study is (Florey, 1993): 
E5.2 ṻ௔௥௠ = ൫ẗఈ ῼ⁄ + ẗῺିఉ ῼ × 2 ×ẓẍ௦௧ௗ௘௩ῼ(0.25 × ẓẍ௠௘௔௡)ῼ  
where ẗఈ ῼ⁄ = 1.96 is the approximate number of standard deviations from the mean of 
a standard normal distribution of 1 − (ߙ 2⁄ ) = 0.975; likewise ẗῺିఉ = 0.84 for 1 −
ߚ = 0.8. ẓẍ௠௘௔௡  and ẓẍ௦௧ௗ௘௩ are the mean and SD of the WT ṳௗ௘௧  values, from 
GWR, at a particular voxel. These vary across the brain depending upon local WT 
variability. ṻ௔௥௠ is rounded up to the nearest integer. 
As the actual difference between mean UT and WT ṳௗ௘௧  values is known post-hoc, the 
effect sizes (Cohen’s ẛ), both in vivo and ex vivo, may be visualised and compared at each 
voxel. This helps to quantify which regions are most different, between groups, regardless 
of statistical significance: 
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E5.3 Cohen’s ẛ = ẏẍ௠௘௔௡ −ẓẍ௠௘௔௡ẓẍ௦௧ௗ௘௩  
I calculated ẛ using a pooled standard deviation, replacing ẓẍ௦௧ௗ௘௩ in E5.3 with 
ߪ௣௢௢௟௘ௗ : 
E5.4 σἥἡἡἤἒἔ = └ቀẓẍ௦௧ௗ௘௩ῼ × (ṻௐ் − 1) + ẏẍ௦௧ௗ௘௩ῼ × (ṻ௎் − 1)ቁṻௐ் + ṻ௎் − 2  
Because the ẓẍ௦௧ௗ௘௩ was usually smaller than the overall standard deviation, and 
therefore not representative of the whole cohort, I made the same substitution in E5.2. 
Fig 5.18 shows equivalent slices from the in vivo and ex vivo group-wise average images, 
overlaid with the ẛ and ṻ௔௥௠ required at each voxel to detect a 25% variation in ṳௗ௘௧  
from the WT mean. We might wish for greater power (e.g. 1 − ߚ = 0.99), or to detect 
a subtler effect (e.g. 0.01 × ẓẍ௠௘௔௡) – however, these estimates of ṻ give a realistic 
lower bound for a future study. 
In each case, in vivo and ex vivo exhibit similar patterns. The map of Cohen’s ẛ, in 
measuring group mean separation, is similar to the thresholded statistical maps of Fig 
5.15. The separation of groups in the hippocampus and cortex is clearly greater ex vivo. 
This may be facilitated by higher contrast enabling better alignment during registration, 
reducing local standard deviation. The greatest group separation, in vivo, is achieved in 
the hippocampus and striatum. 
The ṻ௔௥௠ required to detect a significant effect, with the specified ߙ and ߚ, is elevated 
around the ventricles and at the entorhinal cortex – likely both due to reduced WT 
volumes and increased variability around these structures. This may explain the greater 
numbers required in some regions of the in vivo group. That statistically significant results 
are still obtained in these regions, despite this study incorporating fewer animals, is due 
to the actual difference between groups being greater than 0.25 × ẓẍ௠௘௔௡. 
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Figure 5.18 Power analysis results in rTg4510 data: Cohen’s d and sample sizes. 
Equivalent sagittal, coronal and transverse slices on in vivo and ex vivo GWR average 
images, overlaid with the Cohen’s ẛ (left) and sample sizes ṻ (right) required to show a 
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significant effect, with ߙ = 0.05, ߚ = 0.2, and an effect size 25% of the local WT mean 
volume. For Cohen’s ẛ: red, UT group locally smaller than WTs; blue: larger. Solid lines, 
top left, indicate slice locations. 
From E5.2, the power of TBM to detect a local volumetric expansion or contraction is 
dependent upon the standard deviation of ṳௗ௘௧  values in the groups at each voxel, 
ẓẍ௦௧ௗ௘௩ (or σἥἡἡἤἒἔ). This variability is itself dependent upon the ability of the 
registration algorithm to successfully align equivalent voxels, which depends upon 
constraint parameters (bending energy and control point spacing) as well as on the 
inherent image contrast of the brain structures. Low contrast regions are more likely to 
register poorly: structures with relatively homogeneous intensities have less information 
to inform registration. Here, misalignments may arise. This may result in greater local 
ẓẍ௦௧ௗ௘௩ (or σἥἡἡἤἒἔ), and hence a higher local effect size (or ṻ௔௥௠) requirement in order 
to achieve the desired power. This appears to be the case in the midbrain and striatum of 
the in vivo group, where there is lower structural contrast than ex vivo, and registration 
consequently struggles to accurately align voxels. 
The formula E5.2 itself is well-known. However, voxel-wise implementations of this 
method in TBM studies are uncommon in the literature – even in humans. This may be 
because post-hoc tests are undesirable (although they may be interpreted to inform future 
studies); it may be an incidence of the frequently-noted observation (Cohen, 1994) that 
power analyses are uncommon; or it may be that their interpretation is not simple over 
millions of voxels. As the ẓẍ௦௧ௗ௘௩ and ẓẍ௠௘௔௡ vary between brain regions, the power 
of each test varies and different sample size estimates are prescribed, throughout the brain. 
To obtain a useful sample size for a study focussing on a specific brain region (e.g. the 
hippocampus or cortex, in the rTg4510s), it would be sensible to use that region to set 
the ṻ per study arm. Maheswaran et al. (2009a) reported that voxel-wise techniques 
required reduced sample sizes in several brain regions, compared with atlas-based 
techniques. Several other groups have reported the effect size of their TBM 
measurements, at specific voxels (as §4.1.8, e.g. Hua et al., 2008; Lerch et al., 2008; 
Badhwar et al., 2013). 
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5.7.4  Fundamentally differing morphologies 
Registration may fail between two images when one lacks features present in another: 
large ventricles in one brain image may incorrectly register to another whose ventricles 
have collapsed, leaving no visible CSF, for example. The presence and location of eCSF 
is especially variable in the rTg4510s. The large negative intensity gradients from eCSF 
to BG, or from cortical GM to BG, may be incorrectly deemed equivalent by the 
gradient-driven registration algorithm of NiftyReg, and eCSF and GM surfaces in 
different images may thus align. This problem afflicted the ex vivo images prior to 
registration parameter optimisation. During GWR, mid-grey intensities resulted where 
CSF and BG or brain tissue improperly overlap at the brain surface, producing artificial 
layers in the average image (later used as a registration target), which are not biologically 
meaningful or present in any one structural image (Fig 5.20). 
 
Figure 5.19 Selected anatomical features of the meninges and skull in an ex vivo 
rTg4510 brain (10 months of age), after severe atrophy due to tauopathy. 
From the outside, layers include: surface flesh (a very thin residual layer indicated in pink, 
after the flesh has been removed); skull (blue), which tightly encases the brain and produces 
minimal signal; meninges; brain. The meninges include, again from the outer layer: dura 
mater (relatively hard and thick); arachnoid mater (green: thin, attached to the dura, like 
a loose-fitting sack); pia mater (orange: tightly seals the brain surface). CSF is contained 
within the “subarachnoid” space, between the arachnoid and pia mater. CC: cisterna 
cerebellomedullaris (Drake & Lowrie, 2009; McGavern & Kang, 2011). 
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Figure 5.20 GWR averages of an ex vivo rTg4510 and WT littermate cohort (10 
months of age), after one iteration of... 
(a): …rigid-only registration; (b): NRR; (c): NRR, rTg4510 only; (d): NRR, WT only. 
While the cerebellum is sharply registered, the cortical surface between rTg4510 and WT 
images (a, b) did not correctly register: instead, mid-grey regions (average of GM and CSF, 
or GM and BG) form artificial layers in the average image. Within-group registrations (c, 
d) were more successful. In the WTs, as is typical for ex vivo images, the ventricles almost 
completely collapsed upon fixation. The rTg4510s’ large ventricles survive. 
The rTg4510 mice undergo severe brain atrophy when the tauopathy is allowed to 
progress without suppressive drugs (such as doxycycline). This atrophy occurs 
predominately in regions analogous to the human brain: the ventricles, entorhinal cortex, 
and eventually the whole cortex. Fig 5.19 shows the brain of a 10 month old rTg4510 
mouse with large accumulations of CSF both in the expanded ventricles, and externally, 
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where tissue has atrophied. Steps were taken during fixation, such as using a low flow 
rate, to avoid pressure build-up and hence ventricular collapse. Here, the ventricles and 
eCSF spaces have been preserved and are likely filled with a mixture of CSF and fixative. 
The eCSF in rTg4510s is thought to arise entirely from tauopathy, being consistently 
located within the untreated group and more severe (Fig 5.19) than that seen in the Tc1 
cohort (Fig 4.10), with perfusion-linked external fluid. This variability could cause severe 
inter-group registration artefacts (Fig 5.20). 
5.8 Discussion 
5.8.1 Cross-sectional and longitudinal TBM 
The rTg4510 dataset described in this chapter holds great promise for the monitoring of 
disease and drug intervention. Scanning WT and UT mice alongside treated groups is 
vital to provide controls exhibiting “normal healthy ageing” or natural disease 
progression. The effectiveness of therapeutics must be measured as divergence from this 
UT trajectory (see also §6). 
The single-TP TBM investigation of rTg4510 brains encouragingly repeated previously 
published findings (Xie et al., 2010; Yang et al., 2011) of localised volume reductions in 
rTg4510s, attributable to NFTs, compared with WT littermates. These volume 
differences were severe at the late time-point chosen, and spread throughout the 
forebrain, cortex, hippocampus and caudate putamen, supporting tau-driven 
neurodegeneration. 
The purpose of the multi-time-point study was to assess the sensitivity of structural MRI, 
analysed using TBM, to these neurodegenerative effects at earlier TPs, and to the ability 
of two therapeutic interventions, doxycycline and EpoD, to modulate this detected 
atrophy. Other MRI measures shared each mouse’s total 3 hours of scan time (per TP), 
including CBF and DTI. 
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None of the cross-sectional TBM analyses was able to detect a significant difference 
between EpoD-treated animals and UTs, despite the application of comparable doses to 
a previous study (Zhang et al., 2012), in which EpoD treatment led to reductions in tau 
pathology and improvement in hippocampal neuronal integrity, measured via histology. 
Corroborating this negative finding, DTI measures (mean diffusivity, MD and fractional 
anisotrophy, FA, in the high-NFT-burdened cortex) were also unable to distinguish a 
neuroprotective effect of EpoD, although both cortical CBF and its atlas parcellation-
derived volume were significantly different from UTs in the high-dose group at the final 
TP, perhaps indicating preservation (data not shown). 
TBM was, however, sensitive to the doxycycline treatment, and its ability to halt the 
progression of tauopathy-linked neurodegeneration was observed here, distinguishing 
UT, late, and early-treatment groups from WTs, as well as TR groups from UT. TBM 
therefore provided a sensitive downstream indicator of therapeutic effectiveness. In these 
mice, the measurement was not, however, reliably able to discern very early atrophy: cross 
sectional significant volume differences between groups at TP1 were limited. The 
detection of such early differences, in humans, will be vital for intervention to successfully 
interrupt cognitive decline (Weiner et al., 2013). 
Histology results (not shown) confirmed NFT deposition, with high densities in the 
cortex and hippocampus of UT animals, and comparatively low density in the thalamus. 
The TRDOX-3M (early) group had lower densities in these regions than the late-TR group, 
validating the correlation between NFTs and atrophy detected by TBM. The DTI 
measures, cortical FA and MD, were both able to distinguish TR groups from UT, and 
UT from WTs, but only at the final TP: structural MRI was a consistent, earlier surrogate 
marker of change. 
It is important to note that doxycycline halts atrophy progression, saving tissues from 
future degeneration – but it does not promote re-growth. As expected, the earlier 
intervention appeared to substantially benefit brain preservation. The gradual increase in 
the sensitivity of TBM, at successive time-points, to gross progressive morphometric 
brain changes across groups would likely be improved by greater animal numbers. 
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Although groups of rTg4510 mice may be distinguished by eye at late time-points, the 
changes within each group over time are subtler and less easily discerned. My longitudinal 
inter-TP analysis demonstrates the versatility of registration and ṳௗ௘௧-based techniques. 
It would be interesting, for drug studies, to observe WT changes over time, using a larger 
cohort and deformation magnitude maps, rather than thresholded statistics: only a few 
papers have reported longitudinal healthy ageing volumes of WT mouse brains (e.g. Lau 
et al., 2008; Maheswaran et al., 2009a; Zhang et al., 2010). 
Hua et al. (2013) measured the power of TBM to detect atrophy rates in a longitudinal 
human study of the ADNI MR dataset. They noted an approximately linear rate of brain 
atrophy over two years. In the longitudinal TBM measurements here, the TP2-3 pair 
showed a markedly greater degree of atrophy than TP1-2, controlling for the inter-TP 
period. This suggests that atrophy rates in rTg4510 mice are non-linear, and appear to 
accelerate in the time window studied here. A longer study would be necessary to ascertain 
the continued trajectory of this decline. It would be interesting, additionally to Fig 5.12, 
to replicate Hua et al. (2013)’s measurements of within-group longitudinal atrophy, 
which use ṳௗ௘௧  values to show voxel-wise cumulative volume change over time. 
A disadvantage of structural imaging for TBM is the relatively long (1.5-hour) acquisition 
time, which, while possible preclinically, could ideally be lowered to increase throughput. 
Reducing this may compromise resolution, SNR or CNR. Non-isotropic voxels could be 
used instead. However, an increase in slice thickness, maintaining in-plane resolution, 
would increase PV, and lower the performance of registration and TBM. This would 
likely have to be balanced with increased subject numbers to preserve statistical power. 
Nonetheless, it would be interesting to perform experiments in this direction. 
5.8.2 In vivo versus ex vivo 
Before undertaking a morphometric investigation of mouse brains – of which, thanks to 
large-scale phenotyping efforts and the need for accurate disease models and drug studies, 
there are an increasing number – it is important to consider whether in vivo or ex vivo 
imaging and analysis techniques would be superior, to detect differences between groups, 
or therapies’ disease-modifying effects. 
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The ex vivo protocol employed here was optimised, as far as possible, for image quality 
and contrast (Cleary et al., 2011b). Some distortion due to the perfusion and fixation 
process is inevitable. The ventricles collapse to an unpredictable degree, and the 
brainstem, which is physically severed, is moved. Had the brains been extracted from 
skulls, the olfactory bulbs would also have been free to move and the cortex highly 
susceptible to damage (Ma et al., 2008). Despite the fixation-linked tissue shrinkage, as 
Zhang et al. (2010) observed, morphometry was here still able to resolve subtle and 
important local physical differences between the TR, UT and WT groups. 
The spatial specificity of in vivo TBM is compromised by the necessity of larger voxels. 
Nonetheless, the voxel-wise statistical tests performed here were highly localised in 
comparison to atlas-based parcellation techniques, which are limited in resolution by the 
atlas labels. In comparing in vivo and ex vivo imaging, Zhang et al. (2010) noted that in 
vivo parcellation was unreliable owing to the reduced contrast. For parcellation and skull-
stripping, it is important to select an appropriate atlas (an in vivo atlas would register 
better with in vivo data). Even though in vivo TBM performed well, and highlighted 
similar structural differences between groups, it should be noted that the imaging 
protocol described (§5.2.3) only used half the available three hours for which, under 
project license authority, animals could be anaesthetised. Other MR measurements 
shared the time. A longer scan might improve resolution or SNR, which was nevertheless 
comparable to the multi-brain ex vivo acquisitions (§4.1.5, Table 5.2), perhaps due to the 
larger voxel size in vivo (improving signal, Kale et al., 2008) and dehydration effects 
inherent to ex vivo tissue fixation (decreasing proton density). A contrast agent, such as 
manganese (avoided here, as it could interact with the pharmacology of the therapeutics, 
or cause additional neuron loss), could also improve CNR in vivo. The comparison 
performed was not, therefore, between the best possible ex and in vivo images. Such a 
compromise is, however, realistic, and likely to be repeated in future preclinical imaging 
studies: one advantage of in vivo MR is the ability to collect other MR measures. 
For increased sensitivity in vivo, it may yet be practical to use a manganese contrast agent. 
Allemang-Grand et al. (2015) investigated the effects of repeated manganese exposure on 
the in vivo mouse brain, in a longitudinal study of early-onset AD, and found no effect 
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on neuroanatomy or survival rate. The same group reported a similar direction and 
location of volumetric changes detected in lower-contrast images without manganese. 
Given observed variability of WT mice, Lerch (2010) recommended using 10 mice per 
study arm, to detect at least 17% volume differences, in morphometry studies. Given Fig 
5.18 (showing numbers for 25% differences), this estimate appears reasonable, although 
it is important to note that WT variance is spatially-dependent, and more animals may 
be required if subtle differences are expected in regions of high variance, such as the 
ventricles. 
Lerch et al. (2012) recommend the use of more mice, rather than more time-points, in 
vivo, to detect subtle effects, as they found structural variation across populations was 
greater than between measurements. A similar conclusion could be made here; the single-
TP in vivo investigation, with more mice, yielded greater TBM sensitivity than the oldest 
TP of the mutli-TP study, despite comparable mouse ages. However, this must be 
balanced by ethical considerations for the number of mice employed, and the time and 
cost of scanning. 
For this purpose, power analyses are invaluable. Likely thanks to increased contrast and 
improved registration, ex vivo TBM requires fewer animals to detect subtle differences 
between groups. It was also better able to localise those small differences, thanks to greater 
resolution. This does not preclude the usefulness of non-invasive, in vivo MRI, however. 
In the final chapter, I develop and investigate another longitudinal measure of structural 
volume change: the Boundary Shift Integral.
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6 Longitudinal atrophy 
measurement using the 
Boundary Shift Integral in the 
mouse brain 
The previous chapter focussed on the application of the V/TBM pipeline to perform both 
cross-sectional and longitudinal analysis of in vivo data using group-wise morphometric 
techniques and voxel-wise statistical tests. This chapter introduces a new technique for 
longitudinal analysis of individual animals’ scans. The Boundary Shift Integral (BSI) is a 
sensitive, robust measure of tissue volume change in human MRI, and has become a 
popular method employed in clinical trials to assess neurodegenerative disease progression 
and, potentially, drug efficacy. The measurement uses voxel-wise intensity differences 
between aligned serial MRI scans to estimate the rate of volume change. This is 
constrained to structures’ boundaries – the cortical surface; ventricles’ edges – where 
atrophy is most discernible (Fig 6.1). Until now, it has never been applied outside of 
human studies – nor to T2-weighted (T2W) MR images. 
In this final experimental chapter, I describe and demonstrate the adaptation of the BSI 
to T2W mouse brain images, using the rTg4510 mouse model of tauopathy introduced 
and investigated earlier. After testing different parameters to optimise the measurement, 
I used the BSI to record atrophy in wild-type (WT) and untreated (UT) mice, and groups 
treated (TR) with different drugs. The BSI distinguished reduced atrophy rates, with high 
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sensitivity, in doxycycline-treated groups. Epothilone D (EpoD) had a much smaller, but 
discernible, beneficial protective effect against neurodegeneration, in the short term. 
 
Figure 6.1 Progressive atrophy in the human brain revealed with difference images. 
T1W brain MRI of healthy control (HC) and Alzheimer’s disease (AD) patients, with 
baseline and registered repeat scans some time later (usually six months – one year). 
Equivalent coronal slices shown. The difference image highlights the change in position of 
the ventricle boundaries, as well as around the cortical surface and at the hippocampus, in 
AD. Note in the AD patient, the intensity difference at the cortical surface is the same as 
that at the ventricle boundary: a dark rim. Adapted from a presentation by Professor Daniel 
Rueckert (2013). 
Ferran Prados developed the Generalised BSI (gBSI) implementation (Prados et al., 
2014), and code for symmetric registration and multi-time-point differential bias 
correction (MTPDBC), at CMIC. Kelvin Leung coded the k-means (KN-BSI, Leung et 
al., 2010b) and original double window BSI (DW-BSI) implementations. I show 
modifications here for T2W mouse MRI. 
6.1 Introduction 
The early signs of neurodegeneration may fall within the normal range of tissue loss seen 
in healthy ageing or natural volume difference between subjects. Errors in manual and 
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segmentation-based methods of volume measurement may be of the same order as these 
natural differences (Fox & Freeborough, 1997). Expert manual segmentation is the current 
“gold standard” technique, but has high inter-animal and intra-rater variability. Such 
errors are likely to be compounded in the mouse brain, where structures are much smaller 
and partial volume more significant. An accurate, objective, quantitative and repeatable 
measure of tissue change over time within a single subject is therefore likely to be 
advantageous for the early detection of pathology, and to quantify the efficacy of disease-
modifying drugs over short timescales, particularly in preclinical trials (Freeborough & 
Fox, 1997). 
Imaging biomarkers are increasingly used to detect, diagnose and stage neurodegenerative 
disease (Rudin, 2007, Gustaw-Rothenberg et al., 2010). The BSI, a sensitive, registration-
based measure of tissue volume change, has been shown to robustly quantify the rate of 
cerebral structure atrophy of in Alzheimer’s disease (AD, Freeborough & Fox, 1997; Leung 
et al., 2012), frontotemporal dementia (FTD, Chan et al., 2001), and Huntington’s 
disease (Hobbs et al., 2009; Tabrizi et al., 2013), in humans, by measuring the volume 
through which their boundaries shift in serial MRI. 
In AD, atrophy occurs diffusely and inhomogeneously throughout the brain; not 
exclusively at the cortical and ventricular boundaries highlighted in Figs 6.1, 6.2. As the 
gross tissue structure adjusts to this cell death, volume change manifests at these surfaces 
(Freeborough & Fox, 1997). This may be measured directly, using changes in voxel 
intensities. 
Atrophy is a macroscopic proximity marker of disease progression: it is dynamic at mild 
cognitive impairment (MCI) symptom onset (see Fig 2.13), and correlates well with 
cognitive test score decline and neuronal loss (Fox et al., 1999). Structural imaging 
biomarkers thus show potential as surrogate, objective measures of disease progression 
and drugs’ disease-modifying effects. The BSI has been used to reveal subtle atrophy rates 
distinguishing healthy ageing from MCI and AD over 6 month – 2 year periods 
(Freeborough & Fox, 1997; Schott et al., 2005; Leung et al., 2010a; Weiner et al., 2013; 
Gutman et al., 2014). It compares well with the accuracy of manual segmentation (Barnes 
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et al., 2008), and can be fully automated (Prados et al., 2014). However, the BSI has, as 
yet, never been applied outside of human studies, nor to my knowledge to T2W images. 
Animal models are important for understanding disease onset and progression, and an 
essential component of the drug development pipeline. Preclinical trials are used to assess 
therapeutic effectiveness in living systems. As discussed in §1, mice are apt models: they 
are fast to breed and develop, cheap to house, and share 99% of their genes with humans 
(Rosenthal & Brown, 2007). For ethical reasons, as well as to reduce costs, it is desirable 
to use as few animals as possible1. Just as in humans, imaging biomarkers must offer the 
power and repeatability to detect subtle effects over short periods (Gutman et al., 2014). 
As I showed using morphometry in §5, the rTg4510 mouse exhibits profound structural 
atrophy of the entorhinal cortex, hippocampus and forebrain, and ventricular expansion, 
after 3 months of age – reflecting the progressive neurodegeneration seen in tauopathies 
such as human Alzheimer’s disease (AD, §2.3) and other dementias – over short 
timescales (c. one month) (Fig 5.7, 6.2; Santacruz et al., 2005). These changes are 
interruptible via administration of doxycycline, a mutant-tau suppressor. 
Existing drugs for AD seek to slow the onset of symptoms; there are as yet no cures or 
disease-modifying treatments (Salomone et al., 2011). Early detection and intervention 
are vital to mitigate the effects of dementia, and accurate differential diagnosis, to 
distinguish diseases, is essential for treatments’ safe application (Götz & Ittner, 2008). 
Drug trials require clinically meaningful endpoints – measurable outcomes relevant to 
the disease and intervention – such as functional improvement, or survival. Atrophy is a 
surrogate biomarker which, being slowed or halted, may substitute (Hampel et al., 2010). 
The rTg4510 mouse is thus a good test-bed for the algorithmic development and 
measurement of the BSI in an animal model. If found to be a sensitive measure of the 
change in atrophy rate, the measurement could be applied in mouse trials of prospective 
therapies whose efficacy is unknown. Taking the brain BSI as an outcome measure, a 
change in atrophy rate is analogous to the drug’s disease-modifying effect. 
 
                                                        
1: See the NC3Rs’ “ARRIVE” guidelines: https://www.nc3rs.org.uk 
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Figure 6.2 Progressive atrophy clearly visible in T2W rTg4510 mouse brain images. 
Equivalent coronal, transverse and sagittal slices from representative WT and UT brains at 
each time-point of the late intervention doxycycline study (C1), after rigid registration. 
Compare with Fig 6.1 and Freeborough & Fox (1997) figure 1. (a) WT, showing relative 
brain preservation; (b) WT difference image ẍṿῺ − ẍṿᾨ; (c) UT; (d) UT difference image 
ẍṿῺ − ẍṿᾨ . Scale units in difference images are arbitrary. In (d) atrophy is represented by 
both positive and negative differences: a bright rim around the cortex, and dark ventricles. 
I describe below the algorithmic adaptations necessary for the BSI’s application to T2W 
mouse brain images, including a modified “double window” approach, and assess ideal 
parameters. I based this upon the generalised BSI (gBSI, Prados et al., 2014), an 
automated pipeline, and show the necessary pre-processing steps. I measured the BSI 
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using in vivo structural MRI at three time-points in 87 rTg4510 mice from §5: a baseline 
(TP1) and two serial follow-up scans (TP2, TP3), and compared values between untreated 
(UT) animals, wild-type (WT) littermates, and those treated with doxycycline, and 
Epothilone D (EpoD), a microtubule stabilising agent (all introduced in §5.2). 
In each group, I calculate the volume, percentage brain volume change (PBVC), and rate 
of atrophy between TPs. I evaluated my implementation via comparison with volume 
measurement from tissue segmentation; linear regression of atrophy rates; the transitive 
consistency over all TPs; and the ability of the BSI to distinguish groups and measure 
changes in atrophy rate – an assessment of the drugs’ effectiveness. I also calculate the 
sample sizes required in a future study for a drug to show a therapeutic effect. This is the 
first demonstration of the BSI’s viability in an animal study and the first objective 
longitudinal measure of atrophy in the rTg4510 model at short timescales (of around one 
month). 
6.2 Methodology 
6.2.1 Study design 
This investigation was based upon the in vivo longitudinal rTg4510 mouse brain data, 
whose acquisition and study design is described fully in §5.2. Briefly, I applied the BSI 
to six groups of animals, each imaged serially in vivo at three scan time-points 
{ẍṿῺ,ẍṿῼ,ẍṿᾨ}, detailed in Table 5.1 and Fig 5.2. Groups were distinguished by 
genotype – either rTg4510 or wild-type (WT) littermates – and treatment regime. In 
untreated rTg4510s (UT), tauopathy was allowed to progress unhindered. Treatment of 
rTg4510 animals with doxycycline began ‘early’ (approx. 3 months of age, TRDOX-3M) or 
‘late’ (4 months, TRDOX-4M), to elucidate the importance of intervention time. To 
distinguish the effects of the drug’s concentration, ‘low’ and ‘high’ doses of EpoD were 
administered (TREpoD-LO; TREpoD-HI), with the same treatment start time. 
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Up to three animals could practically be scanned per day. Consequently, inter-time-point 
periods differed between animals (Fig 5.2). I therefore report measurements of volume 
change standardised to 30 days (in humans, these are typically annualised). Mouse ages 
at each time-point are shown in Table 5.1; periods between baseline and follow-up scans 
are shown in Table 6.1. 
Table 6.1 Number of baseline and follow-up image pairs, and days between time-
points, for the BSI investigation. 
For each TP pair, the number (N) of complete image pairs included in this BSI 
investigation, and the mean and standard deviation (SD) scan interval, in days. For the 
number of animals scanned at each TP individually, see Table 5.1. 
I used the BSI to sensitively measure the rate of volume change between TP pairs 
{ẍṿῺିῼ,ẍṿῼିᾨ ,ẍṿῺିᾨ} under differing treatment regimes and at different stages of 
disease and treatment. For each TP pair, the earlier scan was denoted “baseline” and the 
later follow-up “repeat”. For the purpose of statistical tests, my null hypothesis H0 was 
the same atrophy measurement outcome for each group, although based upon earlier 
morphometry investigations in this model (§5; Wells et al., 2015; Holmes et al., 2016), I 
expected WTs to display stable brain volumes (BV), or gradual, age-related, linear BV 
reduction over the study course, whereas UT animals should display severe atrophy. 
Similarly, one might expect doxycycline and EpoD treatments to improve brain volume 
preservation, and that early treatment with doxycycline and the higher dose of EpoD 
would more dramatically slow the rate of atrophy compared with UTs. I used two-tailed 
t-tests for statistics, to be agnostic as to the direction of any disease-modifying effect. 
 TP1-2 TP2-3 TP1-3 
group N pairs 
mean 
interval  SD 
N 
pairs 
mean   
interval SD 
N 
pairs 
mean   
interval SD 
WT 19 41.8 17.95 19 57.30 7.95 19 99.11 11.71 
UT 30 57.2 27.64 30 68.90 18.31 30 126.07 42.71 
TRDOX-3M 9 56.4 2.35 10 51.00 0 9 107.44 2.35 
TRDOX-4M 6 27.8 6.11 7 71.86 6.28 6 101.00 7.13 
TREpoD-LO 10 90.8 0.42 9 91.56 1.42 9 182.33 1.32 
TREpoD-HI 10 90.7 0.95 8 91.75 0.46 8 182.75 0.46 
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To evaluate results (§6.4), I measured the transitive error, regression intercept and ability 
of the BSI to differentiate groups. I correlated brain BSI with the difference between 
automatically segmented volumes, and calculated sample sizes required to measure 10, 
25 and 50% reductions in the rate of atrophy. I compared volume loss in the UT, TR 
and WT groups and considered its rate as a percentage of total brain volume. 
Animals 
All mice (ṻ = 87; numbers in Tables 5.1 and 6.1) were female rTg4510 or WT 
littermates, licensed, bred, imported and housed as previously described (§5.2.1; 
SantaCruz et al., 2005; Wells et al., 2015; Holmes et al., 2016). Animals were 
distinguished between scans using ear notches. Genotypes were re-confirmed following 
the study with PCR (polymerase chain reaction) and histology. 
6.2.2 Data quality control, image selection and animal attrition 
Fewer animals are reported here than in §5; this is due to attrition. In total, 255 scans 
were performed for cohorts C1, C2, C3. To avoid bias from outliers and image artefacts, 
I quality controlled the data via visual inspection while blinded to the BSI results. 87 
animals were imaged with more than one time-point. 81 completed all three (Table 6.1). 
Drop-outs were due to premature animal death (N=4), poor image quality, assessed 
visually (N=8), or indeterminate genotyping (N=1). Poor image quality was due to large 
regions of unrecoverable signal loss at, or cropping of, the brainstem or cerebellum (due 
to FOV placement, or mouse motion during the scan, such as the head slipping out of 
the head holder); motion artefact; or severe noise arising from a loose cable. 
I considered performing quality checks on the data using three more criteria: (1) SNR; 
(2) transitive error (see later); (3) volume discrepancy. Visual inspection could fairly 
reliably predict (3), which I measured using tissue segmentations at each TP. For (1) and 
(2), I calculated the Z-score (௠௘௔௦௨௥௘௠௘௡௧ି௠௘௔௡
௦௧௔௡ௗ௔௥ௗ ௗ௘௩௜௔௧௜௢௡ ) to identify outliers, and chose an 
arbitrary cut-off. However, SNR (measured in the GM regions and BG) was reasonably 
consistent between images (Table 5.2) and a poor predictor of transitive error or signal 
drop-off. I did not use transitive error or volume discrepancy, as such post-hoc 
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measurements would artificially boost the power of the study, and images with consistent 
error or volume across all TPs (e.g. cerebellum cropped in all images) would not be 
excluded. 
6.2.3 Image processing pipeline 
I used the previously-described pipeline (§3, §5.3) to pre-process images, including image 
orientation; whole-brain masking based upon atlases (Ma et al., 2014); and non-
uniformity correction (NUC) with N4. Brain tissue (GM, WM) and CSF were 
segmented using iterative expectation maximisation, beginning with prior tissue 
probability maps (TPMs) based upon the NUS atlas (Bai et al., 2012). I integrated aspects 
of the gBSI pipeline (Prados et al., 2014), including symmetric registration of all TPs to 
a middle space, and multi-time-point differential bias correction. I also replaced k-means 
tissue classification with the TPM-based expectation maximisation, changed intensity 
window parameters, and adjusted how different intensities were handled between those 
windows. The necessary pre-processing steps are outlined in Fig 6.3. 
 
Figure 6.3 Overview of pre-processing steps prior to BSI calculation 
The segmented tissues were forward-propagated to the rigid GWR average space of all 
subjects and TPs. I then created a brainstem correction region, propagated this to each 
image, and used it to constrain segmentations. Segmented tissues were resampled into the 
intra-subject middle space, and used to construct the probabilistic XOR (pXOR) boundary 
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region (§6.2.4). “Intra-subject” here indicates between scans from the same animal. The 
GWR was used for brainstem correction only; images were resampled just once prior to 
BSI analysis, into the intra-subject middle space. 
Initial non-uniformity correction 
An accurate measurement of whole brain atrophy with the BSI requires the inclusion of 
all brain surfaces. Brain tissues must also occupy a similar intensity range, so the fixed 
intensity windows, calculated for each image pair, may be applied globally. Intensity non-
uniformity correction (NUC) is thus vital. A smoothly-varying bias field arose from the 
use of both a high field strength magnet, and surface receiver coils placed over the cortex, 
and manifested predominately as signal drop-off caudally and ventrally (in particular at 
the brainstem). As discussed previously (§5.3.1), an initial application of NUC to the 
whole image benefits orientation correction. I used N4ITK, which provides robust NUC 
in high field-strength images (Tustison et al., 2010). Parameters were: 200 iterations; 
FWHM=0.15; subsampling factor 2; 4 levels; convergence threshold 0.001; 256 
histogram bins. 
Probabilistic brain masks 
Brains were oriented to RAS space. Images from an external in vivo atlas database with 
accurate corresponding masks (UFL, Ma et al., 2008) were registered to each rTg4510 
brain, using NiftyReg, with symmetric, inverse-consistent 12-DOF affine (Modat et al. 
2014; 3 resolution levels and default parameters) followed by non-rigid registration 
(Modat et al. 2012; up to 150 iterations; bending energy penalty 0.01; control point 
spacing 5 voxels; 4 resolution levels; normalised mutual information used as the similarity 
measure). 
I then performed multi-atlas label fusion using STEPS, a method shown to result in 
greater accuracy than single-atlas-based mask propagation (Cardoso et al., 2013b; Ma et 
al., 2014; §2.2.3; §3.5.1). During this procedure, registered atlas images were ranked in 
order of local similarity to the data (kernel standard deviation ߪ = 3 voxels), and the ẕ =12 most similar atlas images’ masks were propagated to the data space, following the 
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registration-derived deformations. A voting scheme then determined a particular voxel’s 
inclusion in the mask. In cases where the UFL atlas failed to produce accurate whole-
brain masks – such as by omitting the low-signal brainstem or cerebellum, or including 
extraneous material – (especially above the cortex, assessed visually), I substituted the in 
vivo rTg4510 database created by Da Ma and used a bootstrapping procedure to generate 
masks (as §5.3.2). 
I binarised the resulting probabilistic masks, dilated them by 3 voxels, and used these to 
constrain a repeat NUC with N4. NUC with N3 is performed as part of the standard 
ADNI pipeline for human data2. Prados et al. (2014) showed that its re-application was 
beneficial in human brains. The example difference images in Fig 5.4 reveal additional 
improvement in brain intensity homogeneity in mice, particularly at the brainstem. 
The BSI requires accurate brain masks at each time-point, to initialise the intensity 
window selection and accurately identify surface regions of interest. The STEPS 
procedure provided probabilistic brain masks. In human images, this is sufficient. 
However, because the mouse brain is very tightly encased inside the skull, even at high 
resolutions, the separation between brain and external tissues (including the skull, 
meninges; fat on the skull surface; muscle tissue inferior to the brain and the olfactory 
epithelium) can be extremely small (less than one voxel – see Fig 2.1). Owing to their 
variability between groups, ventricle labels from the UFL brains were also sometimes 
inaccurate. Consequently, these masks required further improvement. 
Brain tissue, surface and ventricle classification 
In existing human BSI algorithms, brain masks are either dilated (the KN-BSI method) 
or are probabilistic (the gBSI method), and hence include some eCSF and vCSF, assumed 
to be dark. These low-signal voxels are included in subsequent k-means tissue 
classification. In human T1W images, the k-means scheme clusters CSF, GM and WM 
tissues. The mean intensity of each tissue underlying the resulting binary class masks is 
then used to standardise intensities between images (using linear regression) and calculate 
 
                                                        
2: The ADNI pre-processing pipeline is detailed at http://adni.loni.usc.edu/methods/mri-analysis/mri-pre-
processing (accessed November 2015). 
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intensity window limits (see below). This has been shown to reduce sample sizes required 
to detect a reduction in atrophy (Leung et al., 2010b) compared with the previous BSI 
implementation, which used only one value to normalise brain intensities (the mean 
intensity within the brain). 
I found that the 3-class k-means algorithm performed poorly in the mouse brain, which, 
at minimum, exhibits four classes in T2W images (see E6.5): {BG, WM, GM, CSF}, with 
variable total volumes. The high degree of PV in mouse brains is also unsuitable for binary 
classification. Additionally, the tight-fitting skull and external material could be 
misclassified as brain tissue, without improved masks. 
To mitigate these issues, I used TPMs propagated from the NUS atlas, as in §3.6, to 
classify vCSF, GM and WM in the in vivo rTg4510 images with some spatial 
initialisation. I again tested a range of NRR parameters (bending energy and control point 
spacing in NiftyReg). To choose the optimum combination (bending energy penalty 
0.001; control point spacing 4 voxels), I registered one NUS brain to all three TPs of a 
single UT rTg4510 and measured the resulting Pearson’s r within a dilated brain mask. 
Ventricles, surface and external tissues required refinement. To classify external tissues, I 
binarised brain masks, dilated by 3 voxels, and subtracted the original mask, creating a 
‘rim region’. This constrained an intensity-based, prior-free expectation-maximisation 
(EM) classification using NiftySeg, with four classes, for {BG, GM, WM, eCSF}. External 
material (particularly adjacent to the cortex and caudal to the cerebellum) usually had 
similar intensity to brain tissue, and hence was misclassified as “GM” or “WM”. To avoid 
classification of true brain tissue as external tissue, I weighted these classifications using a 
Euclidean distance transform up to three voxels from the brain surface, such that voxels 
adjacent to the existing binary brain mask were weighted 0.33; those two voxels from the 
brain were weighted 0.66; and voxels at least three voxels from the brain were weighted 
1.0. I then used these weighted tissue classifications as priors in a second iteration of EM. 
As the initial ventricular labels from the NUS atlas were generally over-generous, I 
binarised them and again used these masks to constrain a prior-free EM, with 3 classes, 
for {GM, WM, vCSF}. 
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Within the three-voxel-dilated masks, I used the results of the above EM schemes as 
TPMs (re-labelling external “GM” and “WM” as external material and combining eCSF 
and vCSF into a single class) to re-initialise EM using NiftySeg. I discarded the resulting 
external material and BG and combined the GM and WM segmentations to give a 
probabilistic brain mask (Fig 6.6), used for measuring whole brain volumes and atrophy 
rate. Upon visual inspection, the brain surface was considerably improved over the initial 
STEPS probabilistic masks, as were the ventricular regions. 
Mask brainstem consistency 
One of the greatest regions of variability in the brain masks was the brainstem, owing to 
the position of the mouse in the scanner, field-of-view selection, variable performance of 
the registration to atlas images, and signal drop-off (even accounting for NUC). This 
could potentially lead to substantial inconsistencies in the brain volume measurement 
(which is based upon binarised brain tissues), and hence mismeasurement of the atrophy 
rate (in terms of percentage brain volume change), as well as misrepresentations of the 
brain boundary in the brainstem region. In humans, a consistent cut-off point for BV 
segmentation is chosen; for example, in Whitwell et al. (2001) at “the lowest point of the 
cerebellum”. 
 
Figure 6.4 Binary brainstem region in average space. 
Average of all probabilistic masks in the groupwise average space, with a painted binary 
brainstem region overlaid in red (a) sagittal; (b) coronal views. 
To improve accuracy, I defined a protocol to consistently crop the brainstem masks 
inferiorly and caudally. I performed a group-wise rigid registration of all brains to a 
randomly-chosen target member of the group, using NiftyReg (6 DOF: rotation and 
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translation only). Using the resulting transformations, I resampled the probabilistic 
masks to the target space using linear interpolation, and calculated their average. To 
reduce variability, I thresholded the average at 0.2, and binarised the result. I then 
manually painted a binary mask around the structural average image’s brainstem using 
ITK-Snap (Yushkevich et al., 2006), ensuring the inferior brainstem surface was covered, 
from the cerebral peduncle to the cisterna magna (Fig 6.4). 
I back-propagated the binarised, thresholded average probabilistic mask and the 
brainstem region mask to the space of the original images (using nearest neighbour 
interpolation). Then, within each brainstem region mask, I multiplied the original 
probabilistic masks by the binarised, thresholded average mask. This had the effect of 
constraining the probabilistic masks and substantially reducing variability. 
Symmetric, inverse-consistent registration 
The BSI measurement requires initial alignment of the baseline and repeat images. If the 
repeat is registered and resampled to the baseline (or vice versa), the resulting 
interpolation of only one image of the pair introduces directional bias (Fox et al., 2011; 
Leung et al., 2012). Each animal’s brain images were thus aligned to a “middle space” 
using symmetric, inverse-consistent registration of all 3 TPs, such that the resampling 
interpolation in all images was of the same order (Fig 6.5). 
 
Figure 6.5 Illustration of symmetric registration to a middle space, for three TPs. 
Thin blue arrows represent inter-TP pair-wise 12-DOF symmetric affine registrations; 
black arrows represent equidistant resampling to the middle space (M), such that each TP 
image undergoes the same degree of interpolation. 
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I used NiftyReg with 12 DOF symmetric affine registration (Modat et al., 2014; three 
resolution levels; normalised cross-correlation used as the similarity measure) to align 
each possible TP pair combination. After symmetric registration, the resulting affine 
transformation was inverted, to give the exact inverse. Thus the affine ẍṿῼ → ẍṿῺ 
inverted gave ẍṿῺ → ẍṿῼ; ẍṿᾨ → ẍṿῺ gave ẍṿῺ → ẍṿᾨ; ẍṿᾨ → ẍṿῼ gave ẍṿῼ → ẍṿᾨ. 
The affine matrix ṡ௜ to resample each ẍṿ௜ into the middle space is given by the log 
Euclidean average (similar to E3.12, §3.3.2): the geometric mean of each pairwise affine 
transformation. For three TPs: 
E6.1 
ṡῺ = ⱡݔ݌ⅎቆↄⱷⱦⅎ(ṱ) + ↄⱷⱦⅎ(ẍṿῺ → ẍṿῼ) + ↄⱷⱦⅎ(ẍṿῺ → ẍṿᾨ)3 ቇ 
ṡῼ = ⱡݔ݌ⅎቆↄⱷⱦⅎ(ṱ) + ↄⱷⱦⅎ(ẍṿῼ → ẍṿῺ) + ↄⱷⱦⅎ(ẍṿῼ → ẍṿᾨ)3 ቇ 
ṡᾨ = ⱡݔ݌ⅎቆↄⱷⱦⅎ(ṱ) + ↄⱷⱦⅎ(ẍṿᾨ → ẍṿῼ) + ↄⱷⱦⅎ(ẍṿᾨ → ẍṿῺ)3 ቇ 
Where ṱ is the 4x4 identity matrix which represents the affine transformation of an image 
to itself: the final pair, ẍṿ௜ → ẍṿ௜. 
This technique has been shown to reduce bias in the BSI measurement (Leung et al., 
2012). I resampled structural images using cubic interpolation and corresponding 
probabilistic masks with trilinear interpolation. 
Differential bias correction 
In addition to the within-subject NUC already applied, after registration I also applied 
multi-time-point differential bias field correction (MTPDBC) between all three time-
points, for each animal. This procedure, consistent with the KN-BSI and gBSI pipelines, 
helps to reduce local intensity variability between alike tissues, and has been shown to 
improve atrophy measurements in human data (Lewis & Fox, 2004; Leung et al., 2012). 
Each image ݒ௜ (where ⱪ is one of the TPs) is log-transformed. The difference image for 
each possible pair is found. A median filter is then applied at each voxel, over a given 
kernel size, to remove remaining small-scale structures such as registration errors, true 
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atrophy, and noise. This is inverse log-transformed (E6.3). The results are multiplied 
(voxel-wise), and the Nth-root found, where N is the number of TPs, to give the geometric 
mean. As the bias is considered to be multiplicative, each image is divided by the result. 
For the three TPs here, the corrected images are therefore: 
E6.2 
ݒῺ
ᇱ = ݒῺ │ݎῺῺ × ݎῺῼ × ݎῺᾨయ⁄  
ݒῼ
ᇱ = ݒῼ │ݎῼῺ × ݎῼῼ × ݎῼᾨయ⁄  
ݒᾨ
ᇱ = ݒᾨ │ݎᾨῺ × ݎᾨῼ × ݎᾨᾨయ⁄  
Where the intensity inhomogeneity between a pair is for example: 
E6.3 rῺῼ = exp (ⅎⱡẛⱪẘⱶ ⱥⱪↄݐⱡݎ(log(ݒῺ) − log(ݒῼ)) 
For humans, the median filter kernel has default radius 5 voxels (around 5-6mm)3. Thus 
the travelling kernel ‘cube’ has sides of 11 voxels. Structures less than half of this side-
length are removed (Paranjape, 2009) and not considered part of the bias field. In these 
150µm3 resolution mouse brain images, this kernel (equivalent 0.75mm) was of a similar 
order of scale as, or smaller than, fine anatomical variation between brains, including 
structures such as the corpus callosum and ventricles, and I found (via visual inspection) 
that it was thus too small. If a late-TP image had large ventricles, surrounding tissues in 
earlier TPs were artificially brightened. I therefore chose a broader kernel radius (10 
voxels). This allowed removal of structural artefacts up to 10 voxels in size from the 
difference image. If atrophy, or misregistration, were expected to translate equivalent 
tissue boundaries greater than 10 voxels, a larger radius should be chosen. 
6.2.4 Probabilistic XOR boundary shift region 
The boundary shift region confines the calculation of intensity differences between 
images to a ROI. This spatial window, adapted to each TP pair individually, is vital to 
 
                                                        
3: In Lewis & Fox (2004), resolution was approx. 1 × 1 × 1.5ⅎⅎ; in Leung et al. (2012) it was 1.25 ×1.25 × 1.2ⅎⅎ. 
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exclude highly variable external tissues (revealed in the difference images of Fig 6.1 and 
6.2) and include variable tissue interfaces, such as the ventricles. 
For binary masks A and B at two TPs, ṡ ∪ ṣ is the union, the set of voxels which are in 
A, or B, or both. ṡ ∩ ṣ is the intersection, the set containing all those elements that A 
and B have in common. ṡ ẕṽẉ ṣ (ṡ⊕ ṣ) is an exclusive OR, true when either A or B, 
but not both, are true. In earlier BSI implementations, the boundary region was identified 
using a binary XOR: the dilated union minus the eroded intersection of A and B. 
 
Figure 6.6 Probabilistic masks, and pXOR region. 
Equivalent sagittal, coronal and transverse slices of a UT brain, showing probabilistic brain 
segmentations at TP1 (a) and TP2 (b), and the resulting pXOR region (c). The lateral, third 
and fourth ventricle boundaries are all included. 
In gBSI, a probabilistic XOR (pXOR) region, generated using the STEPS masks, is used 
instead (Fig 6.6c). This beneficially weights the BSI calculation to the tissue boundaries: 
the inclusion of non-brain tissues and noise during binary erode/dilate operations may 
reduce sensitivity (Ledig et al., 2012; Prados et al., 2014). This is especially relevant in the 
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mouse brain, wherein external tissues (dura; skull) are extremely close-fitting, compared 
with the human cranium. 
The pXOR region is calculated from two probabilistic brain masks, resampled into the 
middle space, as follows: 
E6.4 ݌ẕṽẉ(ṡ,ṣ) = (ṡ × ṣԋ) + (ṡ̅ × ṣ) − ൫(ṡ × ṣԋ) × (ṡ̅ × ṣ)  
where ṡ̅ is the complement of ṡ. It is greater when the segmentations disagree. Each 
voxel ݒ (at 3D coordinate ݔ,ݕ, ݖ) in this region is then weighted by ߢ, the mean of all 
non-zero voxels in the pXOR region, such that: 
E6.5 ẉ௣௑ைோ = ൝݌ẕṽẉ(ݒ)ߢ       ⱪⱥ ݌ẕṽẉ(ݒ) < ߢ1                  ⱷݐℎⱡݎݓⱪݏⱡ  
As ߢ < 1, this has the effect of broadening the ROI (Prados et al., 2014). An example of 
the resulting region (RpXOR) for a pair of TPs in a UT mouse is shown in Fig 6.6c. 
6.2.5 Double-window approach for T2W mouse brains 
 
Figure 6.7 Comparing T1W human and T2W mouse brain images 
Human T1W MRI (a, coronal view) has one possible profile through either the ventricle 
or external cortical boundary region (Fig 6.4a), from CSF (low intensity) → GM/WM 
(higher). The mouse brain (b, transverse view) typically has little external CSF, as the skull 
more tightly encases the brain. In T2W MRI, this dark “background” region produces a 
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similar profile (green line; lower part of Fig 6.4b). The CSF (high intensity) → GM/WM 
(lower) boundary produces a different profile (pink line; upper part of Fig 6.4b). In late-
stage rTg4510 mice, eCSF pools in the cisternae, above the cortex, and in the entorhinal 
region, so an equivalently aligned voxel may also transition between TPs from BG → CSF 
directly. 
The BSI has so far been applied to, and designed exclusively for, T1W images, where 
CSF, air, skull, or background (BG) signal appear dark (low intensity), whereas GM and 
WM tissues have higher intensities. Tissue/CSF and tissue/BG interfaces thus share 
similar intensity gradients. The rTg4510 cohort was acquired with a T2W FSE sequence, 
in whose images {BG, skull, air} all appear dark, but CSF has higher intensity than tissue 
(Fig 6.7). The intensity scales are: 
E6.6 
ẍῺ: {ṥẋṫ,ṣṭ, ݏⱴݑↄↄ,ẘⱪݎ} < ṭṹ < ẓṹ 
ẍῼ: {ṣṭ, ݏⱴݑↄↄ,ẘⱪݎ} < ẓṹ < ṭṹ < ṥẋṫ 
In most BSI implementations, only one intensity window is required to capture 
brain/non-brain boundaries (Fig 6.8a). Hobbs et al. (2009) showed how a double-window 
(DW) approach may be used to capture atrophy of the caudate putamen. Leung et al. 
(2010a) extended this to the hippocampus. Both are predominately GM structures 
bounded by CSF and WM. 
I adapted the DW technique for the whole brain in T2W images (Fig 6.8b). I combined 
GM and WM tissue classes (see Brain tissue, surface and ventricle classification in §6.2.3 
above) to give a single ‘brain’ class. The DW approach accommodates the BG-brain and 
brain-CSF intensity gradients, both of which may display the effects of atrophy in 
rTg4510s. Figs 5.7, 6.2, 6.7 show cortical atrophy to both BG and eCSF (especially in 
the entorhinal region) and ventricular atrophy to vCSF. 
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Figure 6.8 Idealised 1D boundary intensity profiles of (a) T1W single window BSI and 
(b) T2W double window BSI. 
Sigmoidal representations of intensities along profiles drawn through brain boundaries in 
T1W and T2W images (as in Fig 6.7), at baseline and repeat time-points, in intensity-
normalised scan pairs. The single window is appropriate for whole-brain BSI in T1. In T2, 
the double window BSI is necessary to capture the two boundary regions, BG → brain and 
brain → CSF. The black arrows indicate the direction of atrophy, on both fronts. The 
shaded areas A and B can provide estimates of the boundary shifts ∆ݓᾡ, ∆ݓᾥ . These are 
modulated by both the actual intensity change and the probabilistic XOR region (see 
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§6.2.7). Predominant tissue classes for each intensity range are shown at left. Note the 
brain consists of both GM and WM, so to accommodate intra-brain tissue intensity 
changes, the region between windows [ṱῼ, ṱᾨ] should not be too narrow. Compare with Fig 
2 of Freeborough & Fox (1997), for the single-window T1W case, and Fig 2 of Hobbs et al. 
(2009) for the double-window T1W case in the human caudate. 
6.2.6 Intensity standardisation and window selection 
The intensities of each TP pair were standardised so that the boundary profiles of the 
baseline and repeat image pass through the same universally-applicable intensity window. 
In Fig 6.8, standardisation should result in the tissue means of each TP occupying 
approximately equal intensities. 
I binarised the probabilistic tissue classifications (at 0.5) and found the mean and 
standard deviation (SD) of each class within these masks, as well as the mean intensity 
within the intersection region of the two binarised brain masks. I then used the 
coefficients of a linear regression of these intensities between TP pairs to normalise 
images’ intensities (as per Leung et al., 2010b; Prados et al., 2014). Both images were then 
divided by the baseline CSF mean, to constrain the intensity range of most tissues 
between [0 1], which helps for visualisation. 
The DW BSI aims to capture tissue intensity changes between two windows (Fig 6.8b). 
To increase sensitivity, these windows should be as wide as possible. However, to increase 
specificity to intensity changes between relevant tissue types, intensity changes between 
the same or alike tissues (e.g. within the brain, between GM and WM) should be ignored. 
Thus in this figure, the range [I3 I4] should be sufficiently broad. To achieve this, the SD 
of each tissue class was employed. This adaptive window selection method improves 
robustness over fixed intensity window limits (Leung et al., 2010b). Fig 6.9 illustrates 
some image pairs’ histograms and SDs, after intensity standardisation. 
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Figure 6.9 Intensity windows overlaid upon baseline and repeat image histograms. 
Example baseline (blue) and repeat (red-orange) histograms within a dilated mask, for four 
subjects’ TP pairs. Dashed lines indicate intensity means of baseline image tissues, from 
left: BG; brain; CSF. Shaded regions cover respective standard deviations of each class, 
from left in (a), yellow-green: 1 BG SD above the BG mean; green: 1 SD ±brain mean; 
yellow-orange: 1 SD below the CSF mean. Solid lines (and x-axis labels) indicate the lower 
and upper window boundaries: I1, I2, I3, I4. (a) exhibits similar, overlapping histograms 
with aligned brain intensity peaks and a narrow CSF SD. However, in (a), the upper 
window is wide, decreasing sensitivity to small changes within the window. 
As Fig 6.9 shows, this technique had some limitations for these mouse brain images. 
Owing to variable intensity ranges, the linear regression was not always successful at 
aligning alike classes’ means. The SD of tissue classes, especially CSF, was also highly 
variable. This may be due to poor initial classification performance, over-generous 
probabilistic masks, or the inclusion of (low intensity) blood vessels misclassified as CSF. 
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I chose the following window limits, with reference to Fig 6.8: 
E6.7 
ṱῺ = ṣṭ௠௘௔௡ + 2 × ṣṭௌᾧ 
ṱῼ = ẙݎẘⱪⱶ௠௘௔௡ − 2 × ẙݎẘⱪⱶௌᾧ 
ṱᾨ = ẙݎẘⱪⱶ௠௘௔௡ + 1 × ẙݎẘⱪⱶௌᾧ 
ṱᾬ = ṥẋṫ௠௘௔௡ − 0.1 × ṥẋṫௌᾧ 
To prevent negative window widths, if ṱῺ > ṱῼ, I automatically set ṱῺ = ṱῼ − 1 ×
ẙݎẘⱪⱶௌᾧ. Similarly, if ṱᾬ < ṱᾨ , ṱᾬ = ṱᾨ + 1 × ẙݎẘⱪⱶௌᾧ. 
The coefficients in E6.7 were chosen following parameter tests about the DW BSI 
defaults, respectively {1, 1, 0.5, 0.5}. In mouse brains, these gave an over-wide lower 
window and, due to the large ṥẋṫௌᾧ, a narrow upper window. As the tissues have 
different SDs, it is advantageous to vary each factor independently (the prior code used a 
single coefficient for each window). The ṣṭௌᾧ was multiplied by a factor of 2 in I1 to 
narrow the window, thereby increasing sensitivity to small changes (see later). The mean 
brain intensity was weighted in favour of GM (as there are more GM voxels than WM) 
– therefore, to allow some variation in WM intensity, the ẙݎẘⱪⱶௌᾧ in I2 was multiplied 
by 2, whereas in I3 it was multiplied by 1. In I4, the factor 0.1 controlled the variability 
and breadth of the ṥẋṫௌᾧ (Fig 6.9), sometimes at the expense of increasing the window 
width (Fig 6.9a). 
6.2.7 Boundary Shift Integral calculation 
For each animal, TP pairs were {TP1, TP2; TP2, TP3; TP1, TP3}. For each “baseline” and 
registered “repeat” scan pair (ṡ,ṣ), the BSI was calculated between two intensity 
windows {[I1 I2], [I3, I4]} chosen (above) to incorporate the brain boundary. For the single 
window, T1W case (Freeborough & Fox, 1997; Prados et al., 2014): 
E6.8 ṣẋṱ = ṧ × Ѷ Rἥᾃᾱᾀ(ݒ) × ẚↄⱪ݌(ṱᾡ , ṱ௠௔௫ , ṱ௠௜௡) − ẚↄⱪ݌(ṱᾥ , ṱ௠௔௫ , ṱ௠௜௡)ṱ௠௔௫ − ṱ௠௜௡௩௢௫௘௟௦ ∈ ɦ  
where ṧ is a voxel’s volume; Rἥᾃᾱᾀ(ݒ) is the weighting factor given by the pXOR region 
at the current voxel; ṱᾡ and ṱᾥ  refer to individual voxel intensities; ṱ௠௔௫  and ṱ௠௜௡  are the 
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upper and lower window limits; ɦ is the voxel space occupied by both registered scans, 
and clip is a function to include only intensities within the window, such that: 
ẚↄⱪ݌(ẘ, ṱ௠௔௫ , ṱ௠௜௡) = ൝  ṱ௠௔௫  ẘ  ṱ௠௜௡          ⱪⱥ     ẘ > ṱ௠௔௫ṱ௠௜௡ ≤ ẘ ≤ ṱ௠௔௫ẘ < ṱ௠௜௡  
The effect of E6.8 is to render intensity differences between voxels at baseline and repeat 
as a proportion of window width, before weighting by the pXOR. As tissue intensities 
are greater than BG or CSF in T1, the BSI is given as the positive volume loss (atrophy). 
For a particular voxel shared between (ṡ,ṣ), the existing DW implementation calculated 
the BSI from E6.8 using only one of the two intensity windows, {[I1 I2], [I3, I4]}: 
ⱪⱶ E6.8, ൜   ṱ௠௜௡ = ṱᾨ , ṱ௠௔௫ = ṱᾬ   ṱ௠௜௡ = ṱῺ , ṱ௠௔௫ = ṱῼ                      ⱪⱥ ṱᾡ > ṱῼ ẘⱶẛ ṱᾥ > ṱῼⱷݐℎⱡݎݓⱪݏⱡ  
Additionally, ⱪⱥ ṱᾡ > ṱῼ ẘⱶẛ ṱᾥ > ṱῼ, the result was multiplied by -1, so atrophy 
involving the upper window was still given by a positive value. However, this does not 
accurately accommodate all possible T2W image scenarios, as shown below. 
For the T2W, DW case I adjusted this to consider both windows for each voxel. This 
allows for inter-window PV and direct BG/CSF transitions: 
E6.9 
ṣẋṱ (ⅎↄ) = ṧ × Ѷ Rἥᾃᾱᾀ(ݒ)
௩௢௫௘௟௦ ∈ ɦ× ቆẚↄⱪ݌(ṱᾡ , ṱῼ , ṱῺ) − ẚↄⱪ݌(ṱᾥ, ṱῼ, ṱῺ)
ṱῼ − ṱῺ
−
ẚↄⱪ݌(ṱᾡ, ṱᾬ , ṱᾨ) − ẚↄⱪ݌(ṱᾥ , ṱᾬ , ṱᾨ)
ṱᾬ − ṱᾨ
ቇ 
Here, D = (150μm)ᾨ = 3.375 × 10ିᾮml. The first clipping term is as per E6.8 and 
applies to the lower window, handling brain/BG boundaries. The second handles 
brain/CSF boundaries, but is subtracted (as CSF intensities are greater than brain tissues’) 
so that a positive value still represents volume loss. To give some explicit examples of 
possible inter-TP voxel intensity transitions using E6.9: 
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1. If IA is CSF and IB is BG, ṱᾡ > ṱᾬ > ṱῺ > ṱᾥ , thus the first clipping term is +1, the second 
is +1 and the net BSI is ṧ × ẉ௣௑ைோ(ݒ) × (1 − 1) = 0. 
2. If IA is brain and IB is CSF, ṱ୆ > Iᾬ > ṱᾨ > ṱᾡ > ṱῼ, thus the first clipping term is 0, the 
second is -1 and the net BSI is ṧ × ẉ௣௑ைோ(ݒ) × 1. 
3. If IA is PV brain/CSF and IB is CSF, ṱᾥ > Iᾬ > ṱ୅ > ṱᾨ. Here, the first clipping term is 
determined by the distance of IA from the window limits, and the second is 0. For 
example, if ṱᾨ = 0.8, ṱᾬ = 1.0, ṱᾡ = 0.95, ṣẋṱ = ṧ × ẉ௣௑ைோ(ݒ) × Ώ.ΏᾪΏ.ῼ . 
4. If IA is PV brain/BG and IB is PV brain/CSF, Iᾬ > ṱᾥ > ṱᾨ > ṱῼ > ṱ୅ > ṱῺ. Each 
clipping term is determined by the relative position of IA and IB from respective window 
limits. For example, if ṱῺ = 0.1, ṱῼ = 0.3, ṱᾨ = 0.8, ṱᾬ = 1.0, ṱᾡ = 0.2, ṱᾥ = 0.85, 
ṣẋṱ = ṧ × ẉ௣௑ைோ × ൬ቀ− Ώ.ῺΏ.ῼቁ − ቀ− Ώ.ΏᾪΏ.ῼ ቁ . The BSI is negative, representing growth. 
In examples (1) and (2), the intensities IA, IB transition entire window widths; in (3) and 
(4) the windows are only partially crossed. For the same image pair, narrower windows 
increase the chance of whole-window transitions. This increased sensitivity is balanced 
by the corresponding increased chance of intra-class intensity changes which do not cross 
either window. 
To illustrate the improvement offered by E6.9, consider examples (1) and (4). In the 
earlier DW implementation, only the lower window would be considered in each case. 
In (1), the clipping term would be +1 and the BSI is incorrectly positive (atrophy). In 
(4), the clipping term becomes (− 1 2⁄ ): the tissue increase is overestimated. 
To increase robustness, because the linear regression is asymmetric (Leung et al., 2010b), 
I calculated the “forward” and “backward” BSI for each TP pair (i.e. baseline and repeat 
images swapped; linear regression and window limits re-calculated), and took the mean. 
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6.3 Results 
Fig 6.10 illustrates the primary regions of atrophy in the two extreme cases, WT and UT 
rTg4510 groups, by showing the voxel-wise average brain BSI results for each TP pair 
(achieved using GWRs of each group and resampling BSI results into the final average 
space). The ventricles, entorhinal cortex and cortical surface are all well-delineated by 
tissue volume loss in the UT group, and these clearly differentiate the UTs from WTs. 
The WT group displays some scattered regions of growth and minor atrophy, but this 
appears stable across TPs. This is likely due to the sensitivity of the intensity windows 
chosen (§6.2.6); however, image artefacts and imprecise registration may also contribute. 
Apparent expansion of the cerebellum is particularly noticeable in the UT group. To 
investigate this unexpected feature, my colleague Da Ma used the multi-atlas parcellation 
protocol described earlier to measure WT and UT cerebellums in C1 and C2 (Table 6.2). 
The group means were not significantly different at any TP, but overall mean cerebellar 
volumes increased in both cases (also non-significantly, ݌ > 0.05). Despite this, the 
mean BSI image highlights much greater regions of apparent expansion in the UT group. 
This was detected by cross-sectional TBM (Fig 5.10). Fig 6.15 shows that overall UT 
brain volumes decreased over time, whereas WT volumes remained relatively stable. 
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Figure 6.10 WT and UT brain BSI result visualisations 
Voxel-wise average brain BSI results overlaid on TP1 and TP2 structural averages, after 
GWR of the respective WT and UT images. WT (columns 1—3) and UT (columns 4—
6) groups, with TP pairs indicated. Three equivalent coronal, transverse and sagittal views 
of each. The scale is mean BSI (voxel proportion), hence atrophy (volume loss) is positive. 
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Table 6.2 WT and UT cerebellar volumes for C1, C2. 
Mean and standard deviation (SD) cerebellar volumes (mm3), from automatic parcellation 
with STEPS, and inter-TP % volume changes of the means (not standardised for age or to 
inter-TP period). Volumes were not significantly different (p>0.1 at all TPs). 
I used the BSI to assess rates of whole brain volume change in the WT, treated 
(doxycycline and EpoD) and UT rTg4510 groups. The BSI measurements provide the 
absolute volume loss (in ml) over time (standardised, here, to 30 days, as the inter-TP 
periods varied), while the percentage brain volume change (PBVC) allows direct 
comparison between animals with different initial BVs. 
Tables 6.3, 6.4, 6.5 show the mean and SD measures of BSI, segmentation and PBVC, 
for each TP pair, as well as overall means. The PBVC was calculated, for a TP pair TPi-j: 
E6.10 ṿṣẑṥ௜ି௝  (%) = −100 × ṣẋṱ௜ି௝ẍṿΏ ݒⱷↄݑⅎⱡ 
where ẍṿΏ ݒⱷↄݑⅎⱡ is the segmentation-derived brain volume (probabilistic mask 
thresholded at 50%) at the earliest available TP. The segmentation volume change is the 
difference between thresholded, segmented volumes between each TP. 
The standardised BSI measurements illustrated in Fig 6.11 suggest the rate is different 
between TPs. To elucidate whether this was a factor of mouse age, I performed a linear 
regression between the standardised BSI (ml/30d) and age at the mid-TP point, for TP1-
2 and TP2-3. Only the UT and TREPOD-LO groups had slopes significantly different from 
zero (p<0.05), suggesting atrophy accelerated slightly4 with mouse age during the period 
studied, in rTg4510s, but not when treated with doxycycline or the high dose of EpoD. 
 
                                                        
4: For both: ݕ(ⅎↄ 30ẛ⁄ ) ≈ 7 × 10ିᾪݔ − 5.6 × 10ିᾨ, where x is in days. Approximately 0.69 voxels/day, 
per day of age, -1659 voxels/day (intercept). 
  % change in mean 
 TP1 SD TP2 SD TP3  SD TP1-2  TP2-3 TP1-3 
WT 93.32 5.81 93.11 5.75 96.06 4.04 -0.24 3.18 2.93 
UT 91.33 4.83 92.26 4.52 93.92 3.77 1.03 1.79 2.84 
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Both the WT and TRDOX-4M groups exhibited greater rates of volume loss between the 
earlier TPs – however, these groups had by far the greatest SDs in all measures. This may 
be an artefact of measurement error, or the very short TP1-2 period for some mice in C1 
(minimum 10 days, Fig 5.2). Discounting error, the TP1-3 measurement should be the 
average of the other two; this was true in most cases. 
The variance of all measures was relatively large, compared to respective means, despite 
my exclusion of 8 poor-quality images. Evaluation (§6.4) showed that, overall, BSI 
measurements were reasonable across groups and TPs. The measurements’ means (TP1-2, 
TP2-3, TP1-3) provide an estimate of overall BSI and PBVC (Fig 6.13). These values are 
broadly as expected for each group (see §6.2.1). The differences in segmented volumes – 
from the same masks used to generate the pXOR region – are shown for comparison (Fig 
6.12, values in Table 6.4). These follow a similar pattern to the BSI, but the recovered 
volumes are larger – notably, the WT group between TP1-2, which may suggest the 
segmentation was more prone to measurement bias. This is explored further in §6.4.1. 
As brains had different initial volumes (Fig 6.15), the PBVC provides a useful comparison 
of proportional volume loss between groups. Early treatment with doxycycline resulted 
in the lowest rate of proportional volume loss, followed by late doxycycline treatment, 
the low dose of EpoD, and the high dose of EpoD (although the actual rate of volume 
loss was slightly greater in the TREpoD-HI group). 
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Figure 6.11 Mean absolute brain volume loss (ml), from the BSI, per 30 days. 
BSI measurements from each TP pair (from left for each group: TP1-2, TP2-3, TP1-3). Values 
are shown in Table 6.3. Horizontal lines represent overall mean (all TPs). In this plot and 
for Figs 6.12, 6.13, SDs are shown in accompanying tables, as they were comparatively 
large. 
Table 6.3 Standardised BSI results (ml/30 days). 
Mean and standard deviation BSI measurements (ml), all standardised to 30d. The overall 
mean for each group includes all three TP pairs. Values greater than ±2 SD removed in 
this table and in Tables 6.4, 6.5. 
group TP1-2 mean SD 
TP2-3 
mean SD 
TP1-3 
mean SD 
overall 
mean SD 
WT 0.0031 0.0106 0.0014 0.0064 0.0017 0.0025 0.0020 0.0070 
UT 0.0033 0.0058 0.0092 0.0036 0.0065 0.0023 0.0063 0.0047 
TRDOX-3M 0.0030 0.0061 0.0045 0.0021 0.0028 0.0037 0.0034 0.0040 
TRDOX-4M 0.0065 0.0106 0.0017 0.0050 0.0038 0.0054 0.0039 0.0070 
TREpoD-LO 0.0020 0.0029 0.0092 0.0016 0.0043 0.0012 0.0049 0.0036 
TREpoD-HI 0.0040 0.0032 0.0067 0.0034 0.0055 0.0030 0.0053 0.0032 
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Figure 6.12 Mean segmentation volume change measurements. 
Mean measurements from all groups and TP pairs (TP1-2, TP2-3, TP1-3), standardised to 
30d. Horizontal lines represent mean of all TPs. Values in Table 6.4. 
Table 6.4 Standardised segmentation-based volume change (ml/30 days). 
Mean and standard deviation segmentation volume differences between TPs, (ml) all 
standardised to 30d. The overall mean for each group includes all three TP pairs. The 
means and standard deviations are greater than those from the BSI in almost all cases 
(exceptions underlined). 
group TP1-2 mean SD 
TP2-3 
mean SD 
TP1-3 
mean SD 
overall 
mean SD 
WT 0.0071 0.0131 0.0022 0.0099 0.0036 0.0032 0.0042 0.0095 
UT 0.0066 0.0078 0.0135 0.0051 0.0102 0.0038 0.0101 0.0063 
TRDOX-3M 0.0071 0.0048 0.0049 0.0091 0.0055 0.0053 0.0058 0.0063 
TRDOX-4M 0.0124 0.0114 0.0024 0.0059 0.0066 0.0042 0.0069 0.0082 
TREpoD-LO 0.0022 0.0039 0.0136 0.0027 0.0067 0.0016 0.0071 0.0055 
TREpoD-HI 0.0064 0.0037 0.0099 0.0040 0.0078 0.0034 0.0079 0.0038 
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Figure 6.13 Overall standardised PBVC per group, per 30 days. 
Mean PBVC (relative to earliest available BV) calculated from the BSI, for all three TP 
pairs: TP1-2, TP2-3, TP1-3 and overall mean (horizontal lines), standardised to 30d. Values 
in Table 6.5. 
Table 6.5 Percentage brain volume change (PBVC) per group, per 30d. 
Mean and standard deviation PBVC, standardised to 30d and relative to TP1 volume 
(E6.10). Overall mean includes all three TP pairs. Excludes values where the corresponding 
BSI (Table 6.3) was >±2 SD. 
To assess effectiveness of doxycycline and EpoD, I calculated each TR group’s effect size 
from BSI measurements, between each TP pair, by finding the difference in means from 
the UTs (ẏẍ௠௘௔௡ − ẍẉ௠௘௔௡ , Fig 6.14). I did not standardise this (e.g. with Cohen’s d, 
group TP1-2 mean SD 
TP2-3 
mean SD 
TP1-3 
mean SD 
overall 
mean SD 
WT -0.52 1.75 -0.20 1.10 -0.28 0.42 -0.33 1.17 
UT -0.64 1.12 -1.77 0.68 -1.26 0.45 -1.22 0.91 
TRDOX-3M -0.54 1.12 -0.84 0.40 -0.52 0.68 -0.63 0.75 
TRDOX-4M -1.19 1.98 -0.30 0.97 -0.70 1.02 -0.71 1.32 
TREpoD-LO -0.40 0.57 -1.85 0.30 -0.88 0.24 -0.99 0.72 
TREpoD-HI -0.77 0.63 -1.29 0.67 -1.06 0.60 -1.02 0.64 
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E5.3), as the units of difference (millilitres per 30 days) are inherently meaningful. Only 
the early treatment with doxycycline produced an effect significantly different from the 
UT animals. 
 
Figure 6.14 Effect sizes (difference of means from UT) for each treatment group. 
The difference in each TR group’s inter-TP mean from the corresponding UT mean 
atrophy rate (ml/30d), using BSI. From left, TP1-2, TP2-3, TP1-3. Horizontal lines represent 
overall mean difference (all TPs). The y-axis corresponds to the tissue volume “preserved”, 
ml per 30 days, by the treatment. Values are negative when the group exhibits a greater 
atrophy rate than UTs. The error bars represent ±1 SD of the difference between overall 
means. Only the TRDOX-3M group was significantly different, overall (*, p<0.05, Table 6.6). 
Outliers (±2 SDs) excluded from Tables 6.3, 6.4, 6.5 were included in this calculation. 
6.4 Evaluation 
A quandary for clinical atrophy assessment is the lack of “ground truth” tissue loss, which 
must always be indirectly measured (until death). In mice, this can be serially, 
histologically investigated ex vivo (with neuron counts in proxy animals at different time-
points), but in this longitudinal study, the true rate of atrophy was unknown. Fox et al. 
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(2011) discussed some “bronze standard” assessments to evaluate whether measurements 
are consistent and reasonable, including comparison with known disease biology and 
other measures; transitivity; and symmetry. Leung et al. (2012) included bias assessment 
via linear regression. 
 Transitivity: given three TPs, the atrophy ẍṿῺିῼ + ẍṿῼିᾨ should equal ẍṿῺିᾨ. 
 Symmetry: the atrophy ẍṿῺିῼ should equal the absolute of the reverse, ẍṿῼିῺ. 
 Linear regression: atrophy should approach zero as the period between TPs decreases; the 
regression intercept should be zero if there is no measurement bias. 
6.4.1 Comparison with segmentation 
Fig 6.15 illustrates the progression of each group’s brain volume, with time, using the 
binarised tissue class masks. WT and UT groups are clearly differentiated, but there is 
overlap between each of the treated groups. To compare the sensitivity of the BSI with 
the differences in segmented volumes, I performed a t-test between WT and UT atrophy 
rates (ml/30d), which should be different (Smith et al., 2007). Freeborough & Fox (1997) 
showed the BSI better-able to separate human AD and healthy control groups than 
segmentation. To identify any significant disease-modifying effect on atrophy rates, I 
performed t-tests between the UT and each TR group, with both BSI and segmentation 
(Table 6.6). 
I also compared the difference in overall atrophy rates between BSI and segmentation 
measures. In the WT, TRDOX and TREpoD-LO groups, atrophy rates did not differ 
significantly (p>0.05). In the UT and TREpoD-HI groups, the segmentation value was 
significantly greater (respectively, p<0.001; p<0.05). 
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Table 6.6 BSI and segmentation’s ability to separate WT and UT groups 
Two-tailed t-test (unequal variances) t scores comparing 30d-standardised BSI and 
segmentation-based atrophy rates between WT and UT animals, and between UT and 
each treatment group, over each TP pair, and overall. Significant p-values bold (<0.05). 
Original values in Tables 6.3, 6.4. 
Segmentation was slightly better-able than BSI to separate WT and UT groups, except 
between TP2-3, where BSI was superior. This may be thanks to the increased late atrophy 
rate in UTs (Fig 6.11). Neither method separated groups between TP1-2, except BSI for 
UT and TREPOD-LO. Segmentation performed slightly better overall, except distinguishing 
UT from TRDOX-3M. Both measures reveal a disease-modifying effect in TRDOX groups 
between TP2-3, and overall in TRDOX-3M. The EpoD treatment’s preservative effect was 
smaller (Fig 6.14) and only detected as significant via segmentation. 
  TP1-2 p TP2-3 p TP1-3 p 
all TP 
pairs p 
WT vs. 
UT 
BSI 0.68 0.507 -4.53 1.0x10-4 -5.49 5.1x10-6 -2.32 0.023 
seg. 0.84 0.414 -3.96 4.5x10-4 -6.08 4.1x10-7 -2.36 0.021 
UT vs. 
TRDOX-3M 
BSI 0.14 0.894 3.76 0.002 3.14 0.010 3.42 0.001 
seg. -0.21 0.838 2.75 0.018 2.69 0.021 3.15 0.003 
UT vs. 
TRDOX-4M 
BSI -0.72 0.499 3.68 0.005 1.41 0.211 1.55 0.135 
seg. -1.18 0.280 4.05 0.002 2.16 0.067 1.57 0.129 
UT vs. 
TREPOD-LO 
BSI 0.89 0.380 0.69 0.499 2.24 0.039 1.73 0.089 
seg. 2.22 0.033 0.12 0.908 2.83 0.010 2.21 0.031 
UT vs. 
TREPOD-HI 
BSI -0.48 0.634 1.77 0.096 1.22 0.249 1.49 0.142 
seg. 0.09 0.928 1.54 0.138 1.99 0.068 2.04 0.045 
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Figure 6.15 Segmented volumes vs. mouse age. 
Brain tissue masks’ volumes, for each group, at each scan TP. (a): WT, UT; (b): TRDOX-
3M, TRDOX-4M; (c): TREpoD-LO, TREpoD-HI. The linear regression fits between TP1-2 and TP2-3 
(solid lines) and their 95% confidence intervals (dashed lines) are shown. 
Fig 6.16 shows the correlation between brain BSI and the difference between semi-
automatically segmented brain volumes (the probabilistic brain segmentation 
thresholded at 50% and binarised). In the first plot a, the relationship was ݕ = 0.67ݔ −5.3 × 10ିᾬ, ݎῼ = 0.83. Freeborough & Fox (1997) showed (in their equivalent figure 4 
including human AD and healthy controls) a gradient of ݕ = 0.899ݔ + 4.014. 
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Figure 6.16 BSI vs. segmentation-measured volume differences (in ml). 
Illustrating two approaches with original probabilistic brain masks (a) and smoothed by 
one voxel (b). The proportion of segmented difference recovered by BSI is greater in the 
latter, at the expense of consistency. 
To test whether the comparative under-representation of mouse BV loss measured by 
BSI was due to a conservative pXOR region, I smoothed the probabilistic masks 
(Gaussian kernel with FWHM 1 voxel) – thus broadening the high-probability region of 
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the pXOR. In the second plot Fig 6.16b, ݕ = 0.76ݔ − 2 × 10ିᾨ, ݎῼ = 0.56. More 
external materials (dura, skull, non-brain tissues) were included, increasing the variability 
– notably in the WTs. The BSI recovered a still greater proportion of segmented 
differences using a binarised XOR region (not shown) – however, this foregoes the 
advantages of the pXOR, and decreased the ݎῼ measure further. For this work, I used the 
unsmoothed pXOR (Fig 6.16a). An alternative could be to increase the ߢ parameter in 
E6.5, which would narrow the high-probability peak in the pXOR and decrease the 
influence of variable nearby tissues. 
6.4.2 Transitivity 
I evaluated the consistency of BSI measurements using the transitive error (TE) for each 
animal, defined as: 
E6.11 ẍṩ (ⅎↄ) = ṣẋṱῺିῼ + ṣẋṱῼିᾨ − ṣẋṱῺିᾨ 
If there is no inherent measurement bias, TE should be zero. To compare TE between 
animals, I calculated the transitive error rate, defined as this error divided by the mean of 
absolute BSI measurements for the total period studied: 
E6.12 ẍṩ௥௔௧௘  (%) = ẘẙݏ ቆ100 × ẍṩⅎⱡẘⱶ൫ẘẙݏ(ṣẋṱῺିῼ + ṣẋṱῼିᾨ),ẘẙݏ(ṣẋṱῺିᾨ) ቇ 
This was more sensitive in the WTs, as the denominator tended to be smaller. Fig 6.17 
shows the linear relationship between TP1-2 + TP2-3 and TP1-3. Table 6.7 shows the mean 
TE (in ml) for each group, and Fig 6.18 illustrates the rate.  
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Figure 6.17 Scatter plot illustrating BSI transitive error. 
The technique achieved a high transitive consistency with low error. ṣẋṱῺିᾨ was generally 
slightly greater than ṣẋṱῺିῼ + ṣẋṱῼିᾨ: ݕ = 1.03ݔ − 1.1 × 10ିᾨ; ݎῼ = 0.975. Using the 
smoothed brain masks (§6.4.1), ݕ = 0.99ݔ − 1.3 × 10ିᾨ; ݎῼ = 0.911 (not shown). 
Equivalent to Fox & Freeborough (1997), figure 7, in human brains. 
Table 6.7 Mean transitive error measurements, for each group. 
The mean and standard deviation TE (ml), with confidence interval and p-value for the t-
test comparing TP1-2+TP2-3 with TP1-3. The difference never approached significance, and 
there was no appreciable group bias toward greater TE. 
group N mean TE (ml) SD CI (95%) p 
WT 16 0.000407 0.001603 [-0.0066, 0.0074] 0.911264 
UT 26 0.000956 0.003592 [-0.0058, 0.0077] 0.782980 
TRDOX-3M 8 6.82x10-05 0.001548 [-0.0133, 0.0135] 0.992545 
TRDOX-4M 6 0.001078 0.003400 [-0.0162, 0.0184] 0.911695 
TREpoD-LO 9 0.000642 0.001302 [-0.0110, 0.0123] 0.918278 
TREpoD-HI 8 -0.001380 0.002209 [-0.0179, 0.0151] 0.878062 
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Figure 6.18 Transitive error rate, per group. 
The mean transitive error standardised between groups using E6.12. Error bars: ±1 SD. 
6.4.3 Linear regression 
To provide an estimate of systematic bias in the BSI and segmentation measurements, I 
performed a linear regression of all independent measurements (TP1-2, TP2-3, TP1-3) with 
the number of days between scans. If there is no bias, the y-intercept should be zero in 
Fig 6.19 and Tables 6.8, 6.9. 
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Figure 6.19 Linear regression of BSI measurements with scan interval between TPs. 
Illustrating a test for bias in the BSI. If there is no bias, the y-intercept should not be 
significantly different from zero. The black dotted line is the same in (a,b,c) and represents 
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the linear fit for all data. Split into three plots for clarity, (a): WT, UT; (b): TRDOX-3M, 
TRDOX-4M; (c): TREpoD-LO, TREpoD-HI. As per Leung et al. (2012) Fig 4. The slope reveals any 
linear relationship between time and BSI. TP1-2, TP2-3 and TP1-3 are all plotted here, as 
each is independently measured. See Table 6.8 for values. 
Table 6.8 Linear regression of BSI (ml) with scan interval (days), for each group. 
Slope and intercept values corresponding to Fig 6.19. The confidence interval and p-value 
are shown for the intercept term. No group’s p-value approached (arbitrary) significance 
p<0.05, separately or combined. As per Leung et al. (2012) table 5. 
Table 6.9 Linear regression of segmentation difference (ml) with scan interval (days). 
For comparison with Table 6.8 (plots not shown). CI and p-values again shown for 
intercept term. The slope and r2 values are greater in every case. The intercept term is also 
greater, and its p-value lower, in the majority of cases (and overall), indicating greater bias 
in the segmentation measurements. 
The results of linear regression with segmentation-based measures of volume change 
(Table 6.9) indicate that BSI had a smaller measurement bias than segmentation in the 
group slope r2 intercept CI (95%) p 
WT 3.0x10-5 0.006 2.53x10-3 [-0.006     0.011] 0.534 
UT 2.1x10-4 0.438 1.51x10-3 [-0.004     0.007] 0.552 
TRDOX-3M 9.4x10-5 0.054 4.90x10-4 [-0.012     0.013] 0.937 
TRDOX-4M 1.4x10-4 0.101 -1.29x10-3 [-0.017     0.014] 0.864 
TREpoD-LO 1.6x10-4 0.236 4.17x10-4 [-0.015     0.016] 0.955 
TREpoD-HI 1.9x10-4 0.293 -1.87x10-3 [-0.018     0.014] 0.813 
all 1.9x10-4 0.307 -2.51x10-3 [-0.006     0.001] 0.174 
group slope r2 intercept CI (95%) p 
WT 4.8x10-5 0.008 5.17x10-3 [-0.006     0.016] 0.347 
UT 3.1x10-4 0.495 3.27x10-3 [-0.003     0.010] 0.323 
TRDOX-3M 2.1x10-4 0.118 -2.10x10-3 [-0.021     0.016] 0.817 
TRDOX-4M 1.8x10-4 0.141 1.35x10-3 [-0.015     0.018] 0.865 
TREpoD-LO 2.5x10-4 0.266 -1.32x10-3 [-0.023     0.020] 0.902 
TREpoD-HI 2.6x10-4 0.355 7.42x10-4 [-0.018     0.019] 0.935 
all 2.8x10-4 0.342 -1.93x10-3 [-0.007     0.003] 0.425 
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WT, UT and doxycycline-treated groups, although when all groups were considered 
together – assuming methodological bias is equal across groups (Holland et al., 2012) – 
segmentation performed better. This may be because of the greater scan interval available 
for the EpoD measurements, reducing the importance of measurement bias. To better-
estimate true volume change, the overall linear regression intercept could be subtracted 
from all measurements (Hua et al., 2013 – however, I did not do this). 
6.4.4 Power calculation 
A good quantification of a measurement’s sensitivity and effectiveness, compared with 
other measures, is an estimate of the minimum sample sizes required for a hypothetical 
future study to detect a “significant” effect, i.e., a meaningful reduction in the rate of 
atrophy, under different treatment regimes. This is also import for ethical reasons, to 
reduce the number of mice used as far as possible (for the 3Rs); as well as to reduce costs 
and increase efficiency. I used the group atrophy rates and measurement standard 
deviations recorded above to compare the BSI with segmentation-derived volume 
differences. 
When considering a reduction in atrophy rate, a more realistic alternative than reducing 
the rate to 0% is a restoration to WT levels (healthy ageing; Fox et al., 2011). This likely 
requires additional sensitivity, hence more animals. I therefore calculated reductions in 
the atrophy rate as proportions of the difference between UT and WT rates between each 
TP pair (Fox et al., 2000; Schott et al., 2010; Leung et al., 2010b; Prados et al., 2014). To 
calculate sample sizes, I used E6.13 (as E5.2): 
E6.13 ṻ௔௥௠ = ൫ẗఈ ῼ⁄ + ẗῺିఉ ῼ × 2 × ẓẍ௦௧ௗ௘௩ῼΔߤῼ  
Here, ẗఈ ῼ⁄ = 1.96 for two-tailed, 5% significance, and ẗῺିఉ = {0.84, 1.28} for 80% 
and 90% power, respectively. Δߤ is 10%, 25% or 50% of the difference between mean 
30-day WT and UT atrophy rates for each TP pair. Results are shown in Table 6.10. 
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In keeping with Fox et al. (2000), I calculated increased sample sizes to account for subject 
attrition (× 110%) and insufficient quality in either image of the scan pair (× 110%). 
Table 6.10 Sample sizes for a significant effect, using BSI or segmentation 
The number of animals, N, per arm, to detect 10% or 25% changes in the rate of atrophy 
at 80 and 90% power. The maximum possible effect (100%) was taken as a reduction to 
WT levels rather than to no atrophy, which would produce lower sample size estimates. 
The increase represents 121% of the value calculated from all TP pairs. All calculated values 
rounded up to the nearest integer. Note the very large N for TP1-2: error in some 
measurements was likely exaggerated when scaling a short inter-TP period to 30 days. 
As can be seen from Table 6.10, the ṻ௔௥௠ for the first TP pair is extremely unrealistic, 
due to both high WT variability and the very small difference between early WT and UT 
rates. Note from Fig 5.2 and Table 6.1 that the TP1-2 periods were short in C1; this likely 
increased the importance of measurement error when standardising to 30-day rates. The 
sample sizes were lowest over the longest inter-TP period (TP1-3). 
Between TP2-3 and TP1-3, the BSI required lower ṻ௔௥௠ than segmentation to detect a 
significant effect (ߙ = 0.05). To detect a 25% reduction in atrophy, these BSI sample 
sizes were respectively 11.5% and 45.5% lower. When TP1-2 was included (‘all TP pairs’), 
the sample size increased. This is likely peculiar to this study and it may be beneficial to 
 power effect TP1-2 TP2-3 TP1-3 
all TP 
pairs 
all, with 
increase 
BSI 
80% 
50% 62922 16 3 14 17 
25% 251687 61 12 54 66 
10% 1573040 378 71 332 402 
90% 
50% 72810 18 4 16 20 
25% 291238 70 14 62 76 
10% 1820232 437 82 384 465 
seg. 
80% 
50% 15377 18 6 6 8 
25% 61506 69 22 21 26 
10% 384407 430 132 130 158 
90% 
50% 17793 20 7 7 9 
25% 71171 80 25 25 31 
10% 444814 498 153 151 183 
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remove more WT scan pairs from this measurement before calculating the mean and 
standard deviation atrophy. 
6.5 Discussion 
I have for the first time demonstrated the use of the Boundary Shift Integral, a sensitive, 
quantitative and objective measure of longitudinal tissue volume change – which meets 
or exceeds the accuracy of manual segmentation in humans – in a mouse model of disease. 
To better classify mouse brain tissues, I substituted the k-means algorithm of KN-BSI for 
a prior-based expectation maximisation method. I adapted a double window approach to 
accommodate T2W images, which are commonly employed in the preclinical paradigm. 
I used this to capture brain boundary shifts from GM/WM to CSF (in the ventricles, or 
at various intracranial locations such as the cisternae and entorhinal cortex) and 
background (including skull, meninges and other low-signal external material). My new 
DW approach more accurately accounts for direct BG—CSF and BG/brain—brain/CSF 
PV transitions. 
The rTg4510 mouse model of tauopathy exhibits gross whole-brain atrophy after 
approximately 3 months of age. I measured the BSI at three time-points in the brains of 
untreated (UT) rTg4510s, WT littermate controls, and rTg4510s treated with 
doxycycline (a known tau suppressor in this model) or Epothilone D (EpoD, an 
experimental microtubule stabiliser), to demonstrate the usefulness of the BSI both as a 
measure of progressive volume change and as a preclinical outcome measure for the 
effectiveness of disease-modifying drug treatments. 
I monitored PBVC with respect to a baseline BV at the earliest time-point. While WT 
brains were relatively preserved, exhibiting around 0.33% volume reduction between the 
TPs observed (comparable to the annual rate in humans), as expected, the UT group 
exhibited the greatest tissue loss of all groups between most TPs (Figs 6.11, 12, 13 – the 
TREPOD-HI group had a higher rate between TP1-2). This is in line with UT brain weight 
loss previously observed up to 16 months (Ramsden et al., 2005): atrophy continues 
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throughout the animal’s life when left untreated. The rate was most severe, at 1.77% BV 
loss per 30 days, between TP2-3, and steadily increased (age had a small, significant effect 
on the rate of UT atrophy), although a longer study would be required to thoroughly 
investigate this trajectory and its linearity. Taking a combination of all BSI 
measurements, all treatments preserved tissue relative to UT progression (Fig 6.14; Table 
6.6), but only the early doxycycline treatment had a statistically significant effect on the 
rate of atrophy. 
The BSI returns a whole-brain summary measure, combining the actual atrophy volume 
with growth, which should balance misregistration. The apparent cerebellar expansion in 
UTs highlighted by Fig 6.10 may thus have masked some atrophy, which was restricted 
to the forebrain. Such an artefact – growth caudally, balanced by atrophy rostrally – is 
consistent with a rigid registration misalignment. This may partially account for the 
observed pattern. However, visual inspection of both BSI and registration results reveals 
a more complex picture. Unlike the human brain, wherein structural changes are 
relatively subtle over the course of years, the rTg4510 brain undergoes severe 
morphometric changes – both locally, to internal structures (ventricles; hippocampus), 
and to the global shape. The forebrain, including ventricles, and the entorhinal cortex 
region all registered well between TPs; the misalignment of the caudal cerebellar surface 
appears to result from a shape change to this structure not accounted for by affine 
registration. Cerebellar expansion could be compensatory to the deleterious forebrain 
degeneration, but was also observed in WTs (Table 6.2). 
6.5.1 Brain volumes in human and healthy mouse ageing 
Healthy human adults exhibit slight progressive deviation of BV below TIV (Scahill et 
al., 2003, found that the atrophy rate was constant, but accelerated after age 70); AD 
symptoms manifest as a greater deviation. In human AD, the PBVC has been estimated 
using the BSI at around 1.3—2.4%; the ventricles grow by around 5.4—13.8%, and the 
hippocampus atrophies by around 4.6%, all per year. In normal healthy ageing, the brain 
atrophies by around 0.2—0.5%; the ventricles grow by 1.7—4.1%; and the 
hippocampus shrinks by 0.3—1.1% per year (Preboske et al., 2006; Barnes et al., 2008; 
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Leung et al., 2010a; Prados et al., 2014). Human studies must space scans over long 
periods to assess these subtle volume changes. Additionally, large numbers of subjects are 
often needed in study arms, in order to confidently show a drug’s disease-modifying 
effect: with the latest gBSI pipeline, ṻ௔௥௠ ≈ 180 subjects for whole brain BSI, 
controlling for normal ageing (as here)5. Both these factors contribute to clinical drug 
trials’ high costs. In the rTg4510 model, I was able to accurately assess whole-brain 
atrophy, with good sensitivity, over short (1-3 month) timescales. As mice breed, mature 
and age quickly, this could be highly advantageous in potential drug therapy treatment 
trials. 
As mentioned earlier (§5.8.1), relatively few imaging studies have investigated mice 
serially in vivo. Delatour et al. (2006), Lau et al. (2008), and Maheswaran et al. (2009b) 
all measured longitudinal BV increases in APP/PS1 mice. The latter group noted that 
TIV unexpectedly also increased, up to 14 months of age in adulthood, allowing both 
the ventricles and brain to expand, but that “there appears to be no literature on 
neurocranial change in the mature normal mouse”. This should be investigated. Lau et 
al. (2008) and Maheswaran et al. (2009b) also measured parallel WT BV increases. 
As brain growth patterns differ with mouse strain, comparison with age-matched controls 
– WT and UT animals here – is vital to monitor the natural process of ageing, and hence 
evaluate the effects of disease and treatments. WT volumes in this study mirrored the 
slow volume loss of healthy human adults, and UT rTg4510s the atrophy of AD. 
6.5.2 Treatments and power 
To elucidate the sensitivity of the BSI to different treatments, and their effectiveness at 
reducing disease progression, I calculated changes in atrophy rates in rTg4510s under 
treatment with doxycycline (from either an early, 3-month or late, 4-month initial TP) 
and Epothilone D, a microtubule stabiliser. 
 
                                                        
5: 25% effect, 80% power, ߙ = 0.05. Without controlling for normal aging, ṻ௔௥௠: 66 (1.5T) – 82 (3T). 
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The BSI revealed a disease-modifying effect – a reduction in the rate of atrophy from UT 
levels – in both doxycycline and EpoD-treated groups (Fig 6.14). This was only 
significant in the early TRDOX-3M group, however. Segmentation was able to show a 
significant, but smaller, beneficial effect of EpoD treatment at both high and low doses. 
However, the effect size of EpoD was much lower. It could be that a longer treatment 
regime, or higher doses, are necessary before substantial slowing of the atrophy rate 
occurs. 
Compared with segmented whole-brain volume differences, the BSI underestimated 
atrophy. However, BSI SD was almost always lower (Table 6.4), and in all but the TREpoD 
groups, its measurement bias was lower (Tables 6.8, 6.9). Between time-points after 50 
days of age, and at equivalent power, the BSI also required fewer animals than 
segmentation to detect a significant disease-modifying effect (a change in the rate of 
atrophy, Table 6.10). This bodes well for its usefulness at short timescales, which is apt 
for pre-clinical trials. (Between TP1-2, both the BSI and segmentation had high SD: the 
shorter inter-TP period may have magnified errors.) Segmentation was better able to 
separate TR groups from UT, but the BSI performed better in separating UT from WT 
(Table 6.6). As noted in §6.4.4, selectively removing some image pairs with high TP1-2 
variance could have produced more achievable sample size estimates for this period. 
However, Hua et al. (2013), in a TBM study, noted how selective data exclusion 
introduced an implicit bias and “undue optimism” into sample size estimates. It is not 
considered good statistical practice to remove data post-hoc, and this would not be done 
in a clinical trial, so here I did not remove the problematic image pairs. 
Mouse attrition was around 5.4%6. This is a likely corollary of practical investigations; 
for this reason, sample numbers are usually inflated above the minimum necessary to 
detect a significant effect. For example, Fox et al. (2000) assumed both a 10% patient 
dropout rate and that 10% of scan pairs would be unusable. 
 
                                                        
6: From 261 possible scans (87 mice, 3 TPs), 4 were lost to premature death (4.6% of animals); 2 were lost 
to indeterminate genotyping; 8 (3.1% of the remaining 255 scans) were discarded for image quality reasons. 
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Given the relatively small treatment group sample sizes (Table 6.1), some of the 
measurements from this study (retrospectively) were underpowered to detect the desired 
effect sizes, at the given significance. However, even with the increases to account for 
image problems and animal loss, the numbers are reasonable for a future study to detect 
25—50% reductions in atrophy across all three TPs, at 80—90% power (Table 6.10). 
As Lerch et al. (2012) noted, increased animal numbers in longitudinal studies are 
beneficial for statistical power. Here, the inter-TP period also played an important role 
in separating measurement bias and variance from the true effect of interest. Whereas 
random errors, such as image noise and inhomogeneity, have a stable magnitude, atrophy 
accumulates over time, thus SNR increases (Hua et al., 2013). Required sample sizes 
could be decreased by increasing the separation of TPs, thereby increasing the intervening 
volume losses. Although it is better to detect a drug’s disease modifying effect quickly, 
with limited animal numbers and allowing for attrition, this should be balanced with 
sufficient inter-TP time, to ensure a study’s robustness. Around two months appears 
reasonable in this case. A caveat is that the rTg4510 model exhibits severe atrophy, which 
manifests early in life and is visible by eye. Future work in a model of subtler changes 
may require greater numbers or longer inter-TP periods. 
6.5.3 BSI of substructures 
In humans, the hippocampus is a prime target for the BSI measurement, owing to its 
early, preferential sensitivity to neurodegeneration in AD (Braak & Braak, 1991; Leung 
et al., 2010a). It is predominantly surrounded by CSF, providing good contrast: Barnes 
et al., 2004 and 2008 used the single-window BSI. As some WM also bounds the 
structure, Leung et al. (2010a) applied a DW technique. I have shown hippocampal 
shrinkage via TBM in rTg4510s (§5). The mouse hippocampus is comparatively large, 
and bounded by WM of the corpus callosum and fornix, ventricular CSF, and GM of 
the thalamus and midbrain (Fig 2.1). A DW approach would almost certainly be required 
– but especially at these GM boundaries, it may be very difficult to evoke sufficient 
contrast to accurately measure mouse hippocampal BSI, even with highly accurate 
parcellation. A contrast agent may aide the differentiation of hippocampal tissues; this 
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would require prior investigation. In this study, scan parameters were optimised for high 
GM/WM contrast, to aide inter-subject group registration. A contrast agent was not 
administered, because manganese has neurotoxic effects, which would have been difficult 
to disentangle from the longitudinal effects of tauopathy (Lerch et al., 2012). 
Similar impediments might be expected in the mouse caudate putamen (striatum) – a 
simple symmetric structure in the mouse bounded by the cortex (GM); corpus callosum 
and fornix (WM); and ventricles. TBM detected severe, early volumetric reductions here, 
in rTg4510s (e.g. Fig 5.8). Hobbs et al. (2009) nevertheless successfully measured caudate 
BSI in humans, using the DW approach. 
Freeborough & Fox (1997) found that human ventricular BSI recovered around 97% of 
segmentation-based volume difference (whole brain BSI: 90%). This performance is 
attributable to the structures’ high contrast. As discussed earlier (§3.6, §5.3.2), ventricular 
registration with the available multi-subject mouse atlases (UFL; NUS) can be 
problematic: ventricle shape and volume between subjects and groups was highly variable 
(§5.7.4). The ventricles were here removed from brain masks via expectation-
maximisation-based segmentation. They could also be removed via thresholding, which 
would require prior intensity standardisation. Once segmented, ventricular BSI may be 
calculated. This would only require a single intensity window in T2W images, as both 
brain tissue and BG have lower intensities. It may be more sensitive than whole-brain 
BSI, as the ventricles appear to grow dramatically in UT brains at all surfaces. However, 
brain-ventricle contrast was here lower than brain-BG (§6.2.6), and the fourth ventricle 
was especially variable, even in WTs (Fig 6.10). It would be interesting to include eCSF 
in this measurement. In humans, modelling eCSF explicitly can be impractical as its 
segmentation in T1W images is easily confused with skull and BG (Smith et al., 2002; 
Malone et al., 2015). 
6.5.4 Limitations and potential future improvements 
Several features of mouse brains make the BSI’s application non-trivial. The thin, close-
fitting skull may allow brain and external tissues to share PV voxels, complicating tissue 
classification, surface detection, and likely compounding measurement errors. The 
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pXOR region, inherited here from the gBSI pipeline, is thus well-suited to the mouse 
brain. Finer resolution may further improve results; however, the increased time 
requirements may be unrealistic for high-throughput or multi-parametric studies 
(§5.8.2). 
The many gyri and sulci of the folded human cortex provide a large surface area, 
proportional to BV, over which to detect atrophy and calculate the BSI. The smooth, 
lissencephalous mouse cortex has a significantly lower surface area compared with BV, 
which is also several orders of magnitude smaller (compare the available boundary regions 
of Figs 2.16, 6.6c). This magnifies the significance of small measurement and parcellation 
(or tissue classification) errors. 
To lend confidence to outcome measures of experimental therapies, the repeatability of 
structural imaging analysis is vital. This is especially important because human treatment 
dosages can be selected from preclinical trials (Reagan-Shaw et al., 2008; Jucker, 2010). 
All scans for this study were performed on the same scanner. In large-scale investigations, 
robustness must extend between centres and scanner manufacturers. Previous BSI-driven 
studies have reported standardised analysis parameters (Prados et al., 2014). One of the 
BSI’s chief advantages and reasons for its popularity is its repeatability at different sites. 
Future work should target refinement of the adaptive parameters selected here, such as 
the intensity window limits. In particular, the upper window’s dependence upon the 
highly variable CSF intensity SDs (§6.2.6) could be limited – for example by 
standardising tissue intensities and using a fixed window, as in earliest BSI 
implementations. Narrowing the window would increase sensitivity – the BSI may 
recover a greater proportion of the atrophy measured by segmentation – but decrease 
specificity to subtle intensity changes. 
Common imaging artefacts, such as noise, motion and differing contrast severely affect 
BSI measurements (Freeborough & Fox, 1997; Preboske et al., 2006). I excluded 8 images 
with severe, subjective quality problems (including motion artefact and noise). However, 
I did not exclude images with smaller or localised problems. A more conservative 
approach, such as by ranking images with different raters and excluding subsets of 
consistently low-ranked images, may have reduced measurement variability, particularly 
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that unexpectedly observed between TP1-2 in WTs, although would likely require a boost 
in animal numbers. Both signal drop-off and the animals’ head position contributed to 
variability and error around the base of the brainstem. I constrained the brain mask to 
account for this, resulting in fewer detected intensity changes in this region (Fig 6.10). 
Susceptibility artefacts also caused some variability (Fig 6.20). 
 
Figure 6.20 Susceptibility artefact from the aural cavity causes false BSI results in two 
registered TP images of a WT brain. 
Cross-hairs indicate equivalent positions in the images, and slice locations. There is 
significant local intensity loss, compared with (a), in (b). BSI results (c) show artificial 
atrophy (left, from a—b) and growth (right, from b to the next TP). This region, near the 
mouse ear canals, contains both air and bone (Goodburn et al., 2015). A similar feature is 
noticeable in the group mean images (Fig 6.10), suggesting this was a common artefact. 
It is disappointing that the variance of measures was so high, early in the study (Figs 6.11, 
6.12; Tables 6.3, 6.4) – in particular, the WT group. It is likely that subtle early separation 
of WT and UT atrophy rates was missed. 
In addition to the evaluation methods employed here, as a further test of robustness, in a 
future study it would be informative to perform “back-to-back” scans of the same animal, 
in the same scanner, at one TP. (The total scan time would need to remain under three 
hours per session.) The BSI could then be calculated between TPs from each scan to 
assess the scan-rescan reproducibility (same-day error): no atrophy would be expected 
between the scan-rescan pair, so any difference in the longitudinal measurement should 
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be due to noise, scanner artefacts, movement or animal physiology (Smith et al., 2007; 
Leung et al., 2012). This would have the benefit of providing a “back-up” scan, in case 
there were problems with one acquisition. Lewis & Fox (2004) suggested that a very small 
amount of true atrophy may have been obscured by differential bias correction. Although 
I made parameter adjustments to account for this, the kernel size could be optimised 
further using back-to-back scans. 
A potential extension of this work would be to compare the BSI measurements with 
Jacobian integration, using the longitudinal TBM technique described in §5.5.2 to 
generate ṳௗ௘௧  maps, and integrating the volume changes within brain masks. Boyes et al. 
(2006) performed this comparison in humans using the original implementation of the 
BSI technique (binary XOR region; asymmetric registration), and found that the BSI 
non-significantly underestimated atrophy. 
SIENA7, an alternative technique also only requiring affine registration, has to my 
knowledge not been applied to mice, but this could also be attempted. Smith et al. (2007) 
showed high correlation between SIENA and BSI results. The method relies upon skull 
delineation (for registering brains), EM-based tissue classification for accurately 
identifying brain surfaces, and a normal vector projected from each point of the brain 
surface, along which intensities are recorded to a given distance. The gradient intensity 
change along this vector is found at each point, and the surface shift between TPs 
estimated from the distance required to move vectors for maximum correspondence. 
6.6 Conclusions 
I used the Boundary Shift Integral – an objective and accurate measure of atrophy used 
to detect structural changes associated with neurodegenerative disease – in a mouse model 
of tauopathy, and showed early brain tissue losses at short timescales (around one month). 
The measure showed the ability of doxycycline to limit atrophy in rTg4510 mice, and 
 
                                                        
7: Structural Image Evaluation, using Normalisation, of Atrophy (part of FSL). 
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differentiated early and late interventions. Epothilone D, a microtubule-stabilising trial 
drug, did not appear from the BSI to have a significant beneficial effect on brain 
preservation at the doses tested, although segmentations of the whole brain did detect a 
comparatively small effect. 
This study indicates the viability of BSI in the mouse brain. Unlike TBM, which relies 
upon non-rigid registration to align voxels and which is hence best-suited to subtle 
changes, the BSI can be readily deployed to measure gross longitudinal volume 
differences. Because it does not involve non-rigid registration, the calculation itself is 
faster. The technique shows promise as a sensitive measure of brain atrophy in mouse 
disease models – it may be used as an outcome measure in future preclinical drug trials, 
and to detect early signs of neurodegeneration. The rTg4510 model is well-suited to this 
paradigm. 
While the BSI has been well-optimised in the human brain, the mouse brain posed some 
challenges, including an increased proportion of PV; a narrower separation of brain and 
extraneous material; and the reduced surface area offered by the cortex. Despite these 
difficulties, the BSI showed a comparable ability to segmentation to separate groups in 
terms of atrophy rate, good consistency (with low transitive error) and lower bias than 
segmentation. The T2W double window technique could also be applied to T2W human 
brain images, and the pipeline could be applied to other preclinical animal images, such 
as rat brains. 
The BSI provides a sensitive, quantified measure for assessing early structural changes in 
mouse brains. It is a promising technique for future longitudinal tests of preclinical 
therapeutic efficacy in slowing neurodegenerative disease.
285 
7 General discussion, conclusions 
and future work 
This thesis followed the development of software pipelines for phenotyping mouse brains 
and assessing pathology using voxel-wise techniques; their application to several datasets, 
and the advance from the ideal case for image quality, ex vivo, to in vivo scans – enabling 
longitudinal analyses, including the Boundary Shift Integral, which are useful for 
monitoring disease progression and for drug studies. The main contributions are: 
 The development of a complete, fully automated software pipeline for phenotyping 
mouse brains with Voxel- and Tensor-Based Morphometry, integrating open-source 
tools (NiftyReg; NiftySeg) and best-practice clinical analysis techniques (multi-atlas based 
parcellation and subject-specific tissue segmentation; symmetric registration). With 
appropriate atlases (e.g. Johnson et al., 2010; Cleary et al., 2011a; Calabrese et al., 2013), 
it would be simple to extend this to other animals’ brains, or embryos, for high-
throughput studies. 
 The application of this pipeline to several datasets and models, both ex vivo and in vivo, 
and investigation of the results, including the first morphometric analysis of a mouse 
model of Down syndrome, as well as a DS model cross-bred with an APP model, and 
the first longitudinal morphometric investigation of a tauopathy mouse model. The 
comprehensive whole-brain results (§4, §5), including novel morphological findings, 
demonstrate the utility of these techniques for the unbiased structural characterisation of 
brains. 
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 An assessment of cross-sectional and longitudinal TBM, in the same dataset, for detecting 
atrophy, and of ex vivo and in vivo morphometry for sensitively distinguishing groups. 
 The adaptation and application of the Boundary Shift Integral for the first time to non-
human animal brains, and also its first application to T2W MRI. I showed its sensitive 
measurement of atrophy over short time periods of 1—2 months and the assessment of 
a novel drug for reducing atrophy. This technique, too, could be simply translated to 
other preclinical subjects or T2W scans, with an appropriate atlas for prior tissue 
segmentation. 
Although widely used with clinical data, software customised for high-throughput 
preclinical analysis with these techniques was hitherto unavailable. Labour-intensive pre-
processing was required. Consequently, few mouse models have been analysed with the 
powerful morphometric techniques common to clinical studies. Longitudinal in vivo 
studies are also uncommon, but confer several advantages for monitoring disease 
progression, including the reduction of inter-individual variability and the number of 
animals employed. Furthermore, the use of up-to-date, bias-reducing techniques, such as 
symmetric registration and multi-atlas tissue segmentation and parcellation, should be 
considered especially important in preclinical studies, whose sensitivity and repeatability 
are vital for drug trials. However, they have been slower to catch on, and their use is not 
yet standardised (McConville et al. 2005). 
Limitations 
In this thesis, I focussed on voxel-wise statistical tests of local structural volume or 
intensity difference between groups. Statistical parametric maps are valuable for 
exploratory, unbiased or naïve investigations. However, interpretation is still required; a 
disadvantage of null hypothesis testing is the p-value’s disconnection from values of 
scientific interest. For this reason, I calculated effect sizes and in the BSI investigation the 
sample sizes required to detect a suitable effect, which should be more useful for 
therapeutic trials (Cohen, 1994). Additionally, statistical tests can only reject H0, rather 
than prove an alternative hypothesis or give an explanatory cause for a difference. 
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Artefacts not due to volume change or tissue density may arise systematically, for example 
if one group is more likely to move during the scan. 
Significance thresholding is quite arbitrary. Some factors may lend credence to a 
significant result: bilaterally significant voxels some distance apart likely did not interact 
during registration and are fully independent. Certain results may also be expected, for 
example based upon previous studies. Finally, images can be visually inspected for regions 
of misregistration. An extension of this could involve the integration of nonparametric 
permutation tests, such as with FSL’s Randomise, which allows integration of a GLM. 
These are more robust to data which are not normally distributed (Ashburner & Friston, 
2000; Nichols & Holmes, 2001), and are increasingly employed in morphometric 
investigations (e.g. Chen et al., 2005; Sawiak et al., 2013). 
Like atrophy, which is quantified via the BSI, V/TBM changes are downstream effects of 
a presumed upstream cause (such as genetic difference, or disease). As Davatzikos (2004) 
noted, and unlike atrophy, these may have many underlying causes and expressions, 
which are only partially detected using morphometric techniques and not fully explained. 
With V/TBM, the effect size is only of the concentration or volume difference; with BSI, 
it is more easily interpretable, and can be directly related to drug treatment. A 
disadvantage of using atrophy as a disease marker is that many neurochemical processes 
are upstream in pathology: although treatments preventing atrophy may be beneficial, 
they may not address the underlying causes. 
In §5.7.3 and §6.4.4 I discussed statistical power. Studies which hope to detect a subtle 
effect without enough subjects are a waste of resources. Power calculations should be 
made before all morphometric studies, considering the expected effect size, and numbers 
increased as per Fox et al. (2000): +10% to allow for longitudinal attrition and +10% 
for image quality issues. These unexpected deleterious outcomes will inevitably occur, no 
matter how careful and rigorous the study. 
Voxel-wise morphometry can complement parcellation-based segmentation, allowing the 
detection and quantification of small changes within atlas-defined structures. As Zhang 
et al. (2010) noted, subtle changes which are diffuse throughout a particular structure 
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may be better-detected by parcellation techniques, by combining the contribution of all 
voxels, as individual voxel-wise tests may lack the power to reach significance. Indeed, 
the finding of Van Eede et al. (2013) that with TBM only 38% of true positive voxels 
were detected from a 20% volume change is disconcerting. The authors found that a 
“matched filter” – Jacobian integration over the structure – was more sensitive. With a 
prior theorised region of difference, one might limit scans to a few ROIs. However, this 
limits the usefulness of morphometry; whole-brain, unbiased coverage allows the 
discovery of unexpected changes. 
7.1 Can in vivo replace ex vivo? 
This thesis followed a progression from ex vivo to in vivo imaging. There remain some 
advantages to the former: at high field strengths, long (overnight) multi-subject scans can 
improve throughput, reduce operator workload and, with optimised fixation, scanning 
protocols and contrast agents (Cleary et al., 2011b), allow fine structural detail at high 
contrast, improving sensitivity to subtle effects. For high-throughput image processing, 
these necessitate automated techniques such as multi-subject extraction and orientation 
(§3.2; §3.3). Steps were employed to reliably fix brains without artefacts, such as by using 
a low flow rate during perfusion (§4.1.14). Unfortunately, ventricular collapse is 
common, and occurs to an unpredictable degree. External CSF spaces, such as the 
entorhinal region, do not appear as susceptible, perhaps due to the lack of surrounding 
tissues causing compression. Tissues also take a long time to fix (around 9 weeks); 
however, von Bohlen und Halbach et al. (2014) recently showed high-resolution ex vivo 
scans, with good contrast, without fixative, which substantially reduced the necessary 
preparation time and also precluded tissue shrinkage. Ex vivo scans are also currently 
essential for assessing structural development in embryos (Nieman et al., 2011). 
In vivo opens a wide range of analysis possibilities, and the paradigm additionally allows 
many other quantitative physiological MR measurements to be made in parallel with 
structural imaging, such as ASL, DTI, and functional response. These measures may be 
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more powerful than individual biomarkers, when combined (Kohannim et al., 2010; 
Teipel et al., 2013; Wells et al., 2015). UK regulations stipulate a maximum time a live 
animal may be anaesthetised to ensure recovery post-scan (the project license for §5 
allowed 3 hours, Wolfensohn & Lloyd, 2007), and hence image resolution, SNR and CNR 
are compromised. Additionally, scans risk physiological or motion artefacts. These issues 
may be overcome using custom equipment. Baltes et al. (2009) and Biedermann et al. 
(2012) reported in vivo SNR improvements of × 2.4 − 3.5 by using cryogenically cooled 
surface coils, allowing high-resolution isotropic voxels (60µm3 in the former, in under 
one hour) suitable for VBM, visualisation of the Purkinje cell layer, and angiography. 
The structural data acquired for §5 and §6 was complemented by other MR techniques 
(including ASL and DTI: see Wells et al., 2015; Holmes et al., 2016). The structural scan 
time was necessarily shortened to include these methods; thus, the in vivo/ex vivo 
comparison did not represent a like-for-like comparison of the best “possible” scenarios. 
However, this is a realistic reflection of “real-world” usage, and the volumetric results 
from structural data nevertheless provided the earliest marker of tauopathy. 
7.2 Future work 
I hope that the tools developed and described for this thesis may be of use to future 
investigators. The morphometry pipeline uses Python 2.7 and widely-available, free 
libraries, including: NumPy, SciPy, NiBabel and Pandas1, alongside the open-source, 
cross-platform tools developed at CMIC (NiftyReg, NiftySeg and NiftyView for 
visualisation). It was developed for ease-of-use, requiring only command-line input. For 
example, to orient brains, this is simply: 
run mm_orient.py -i [input directory] -o [output directory] 
 
                                                        
1: Respectively: http://www.numpy.org; http://scipy.org; http://nipy.org/nibabel; http://pandas.pydata.org. 
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where input directory contains NIfTI images. The majority runs in both Windows and 
Linux environments. It should be straightforward to perform future phenotyping studies 
using this pipeline, without prior image processing knowledge. Ashburner & Friston 
(2005) noted that unifying segmentation, registration and bias field correction into a 
single framework can improve results, but it also increases complexity and reduces the 
ability to customise parameters easily. This is still necessary for the preclinical paradigm, 
where fewer atlases are available, acquired images can be more variable, and techniques 
remain non-standardised. It is an advantage to be able to use pipeline steps modularly, 
for example performing non-uniformity correction before and after masking, and to 
better-elucidate the source of errors. 
The task of identifying phenotypes for each of the 20—25,000 mouse genes is too great 
for one centre to perform alone. Standardisation and validation of mouse phenotyping 
screens is recognised as an important step for collaboratively building a complete picture 
of mammalian gene function (de Angelis et al., 2015). MR image analysis techniques for 
phenotyping should also be standardised, with methodological transparency and the open 
release of data for validation and duplication between groups, as is increasingly performed 
in the clinical paradigm (e.g. ADNI; Cash et al., 2015). 
The BSI could be extended to the mouse ventricles and external CSF spaces. These have 
been shown in humans to be highly sensitive to disease (Schott et al., 2005), could be 
earlier predictors than whole brain volume, and are less likely to be diluted by 
corresponding regions of apparent “growth”, as was observed in the cerebellum in 
rTg4510 mice (Fig 6.10). Owing to variability of shape and size, their segmentation in 
mice is difficult. The hippocampus is another obvious target, but would likely require 
administration of a contrast agent to achieve sufficient delineation of its boundaries in 
vivo. It should also be possible to translate the T2W BSI technique I developed directly 
back to clinical, human data. 
Another approach to the assessment of the BSI could be to artificially simulate atrophy, 
giving a known “ground truth”, which is lacking from clinical data and would be helpful 
for comparing techniques. Atrophy simulations are still being developed (e.g. Camara et 
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al., 2008), and may however introduce their own biases, such as the types of deformations 
employed (Fox et al., 2011). 
7.2.1 Further phenotyping investigations 
Future µMRI phenotyping studies should ideally use in vivo subjects; multi-time-point 
TBM and the BSI are powerful and sensitive measures of both volume difference between 
groups, and change over time, in the mouse brain, even without contrast agent. However, 
at the end of a study, ex vivo MRI may be warranted. The optimised perfusion and 
acquisition protocols described by Cleary et al. (2011b) should be combined with a low 
fixative flow rate during perfusion, to prevent artefacts such as the hyperintense rim 
discussed in §4.1.14. The SNR and CNR achieved in multi-subject scans (which enable 
increased throughput) were lower than single-subject, but sufficient for morphometry. 
High resolution, isotropic voxels should ideally be used, but the lower-resolution in vivo 
protocols (100µm voxels) were sufficient to detect early morphometric changes in 
rTg4510 mice. As MR field strengths continue to increase, higher resolutions may be 
possible. However, given the success of morphometry in vivo, phenotyping may be 
possible using much smaller, cheaper, lower field strength scanners, such as the Bruker 
“benchtop” 1T. This would increase the accessibility of structural investigations. 
For the development of the pipeline in §3, I focused upon robustness to different µMR 
mouse imaging paradigms: brain (in and ex vivo) and embryo; single and multi-subject 
scans. Thanks to the wealth and variety of data made available through collaboration with 
CABI, pitfalls arising from variations in image quality and brain shape were encountered 
and overcome: for example, touching subjects in multi-subject scans (§3.2) and subtle, 
systematic changes which may have influenced morphometry, such as the “hyperintense 
rim” perfusion artefact (§4.1.14). 
The pipeline has been successfully applied to other ex vivo mouse brain datasets, including 
(but not limited to) a study investigating the effects of sciatic nerve injury on mouse 
brain morphology, an ex vivo single time-point analysis of another FTD mouse model, 
and a morphological investigation of young transgenic knockout mice modelling 
Adenosine deaminase (ADA) deficiency, a serious immunodeficiency in humans. I also 
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optimised the pipeline for high-throughput mouse embryo data (as briefly alluded to, 
using a model of spina bifida) and rat brains, investigating the neuroprotective effect of 
nicotinamide in a model of Parkinson’s disease. 
The early pipeline steps cover necessary pre-processing for atlas-based parcellation, for 
volume measurement, regional investigation (Ma et al., 2014), or localisation of fMRI 
responses. Steps may be repeated automatically, using their initial outputs, on data 
corresponding to the structural images. For example, phase contrast images and MR 
angiographs can be automatically oriented, skull-stripped and aligned into the final GWR 
average space using the orientation matrices, masks, and deformations generated from 
structural data. This allows comparison in the average space. It may also be interesting to 
complement voxel-wise morphometric tests with shape analysis of larger structures: Badea 
et al. (2007b) examined the distance maps at structures’ surfaces to compare a mutant 
mouse with WTs. Costafreda et al. (2011) used deformations from the human 
hippocampal surface to predict AD onset in MCI patients. The unexpected cerebellum 
change in untreated rTg4510 brains (§6) hints at global shape changes over the whole 
brain. These could be captured by shape analysis. 
Behavioural studies could be undertaken to follow-up the morphometry findings of 
localised reductions in the Tc1 cerebellum. They could also be used to corroborate a 
negative result, such as a finding of no structural differences with morphometry or atlas 
parcellation in the abovementioned nerve injury dataset. However, behavioural or 
cognitive differences may be further downstream from pathology than structural changes 
in the brain. 
It is valuable to follow-up µMRI investigations with histology, to confirm unexpected 
volumetric findings and investigate the cytoarchitectural changes (cell size; number; 
density; type) underlying V/TBM results. µMRI does not reach cellular resolution (Bock 
et al., 2006). Histology was performed in rTg4510 brains (Wells et al., 2015; Holmes et 
al., 2016): TBM findings of local volume loss correlated with elevated 
immunohistochemically stained neurons containing hyperphosphorylated tau, as well as 
visibly-reduced tissue volumes. Histology was attempted for the Tc1 dataset (§4.1); 
however, unfortunately, the tissues had deteriorated from prolonged fixation, rendering 
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histology impossible. Promisingly, Keifer et al. (2015) recently showed increases in 
dendritic spine density in the auditory cortex, after fear conditioning, correlated with 
VBM findings of increased GM voxel intensity. Other imaging methods to investigate 
microstructure, such as high-resolution episcopic microscopy, may enable computational 
techniques on more detailed 3D images (Norris et al., 2013). 
This thesis was limited to structural MRI. Morphological phenotypes may be examined 
using many other imaging modalities. For example, Verma et al. (2005) and Zhang et al. 
(2005) used DTI to measure mouse brain morphological development and phenotypes. 
Wong et al. (2014) recently showed an atlas-based morphometry pipeline in µCT images 
of embryos, including a technique for the assessment of gross structural differences not 
resolveable via registration. Aligned images were instead subtracted to find regions of 
large intensity difference, and hence morphological variation. This is similar in concept 
to precursors of the BSI (Fox et al., 1996), but was quantified in terms of significant 
differences in intensity. The authors suggested µCT was more appropriate than MRI; 
excellent contrast and detail was possible; radiation exposure is not an issue ex vivo, and 
the modality is cheaper and faster. 
There is also scope to improve understanding of inter-WT mouse brain variability (which 
would aide sample size calculations) and volume changes in adulthood, especially given 
the number of in-bred strains (Beck et al., 2000) and that different WT backgrounds are 
often used as controls in experimental studies. In following APP models of AD, Lau et 
al. (2008) and Maheswaran et al. (2009b) both unexpectedly showed BV increase in WT 
brains throughout adulthood (a finding not repeated in §5 or §6). Skull volume could be 
monitored longitudinally using µCT for a variety of different strains. This highlights the 
importance of using WT controls in longitudinal therapeutic investigations. Given the 
overall TIV finding in Tc1s, controlling for global volume is extremely important in 
TBM to highlight local differences. 
Machine learning methods, such as support vector machines, could be employed to 
investigate phenotypes and stage disease. Davatzikos (2004) advocated the use of support 
vector machines over whole images, to separate groups, rather than voxel-wise tests on 
specific features, (volume; intensity). Advantageously for phenotyping, these might not 
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require images be segmented, parcellated, or registered to perform comparisons, thus 
negating the issues of atlas applicability or error, or quality loss and artefacts from 
interpolation. Machine learning techniques may also combine multiple biomarkers to 
increase statistical power (Kohannim et al., 2010; Teipel et al., 2013). 
7.2.2 Mouse brain atlasing 
Much of the work conducted for this thesis was dependent upon the availability of 
applicable mouse brain atlases. There are very few multi-subject mouse atlases presently 
publicly available. Ma et al. (2014) produced a summary. The UFL and NUS atlas 
databases have several drawbacks: the former contains just 10 brains, compared with 
hundreds, for humans. Although its ex vivo images are high resolution (47µm isotropic 
voxels), they were skull-stripped prior to scanning (with consequent damage), so 
registration with in-skull images (preferred for phenotyping) is sometimes problematic. 
Additionally, tissue contrast is low and only 20 structures are delineated. The NUS atlas 
has more (39), but fewer brains (5), and images are lower resolution (100µm isotropic), 
in vivo and skull-stripped. GM/WM contrast is also low. That, for example, the thin, 
dark Purkinje cell layer is not delineated in the NUS atlas led to its misclassification as 
WM in Fig 3.15. This was consistent across all Tc1 cohort scans and was not therefore 
thought to affect VBM results. 
Several other public mouse brain atlases exist or are in development, but effort is focussed 
on the construction of single-subject, probabilistic or average atlases rather than multi-
subject databases (Dorr et al., 2008; Johnson et al., 2010; Ullmann et al., 2012), rendering 
the advantages of multi-atlas approaches impossible. Sawiak et al. (2012) released a 
database of 399 WT and transgenic mouse brain scans online, with GM, WM tissue 
classes from SPMMouse. The segmentations have problems, such as a WM rim (§2.2.5), 
and some of the brains are damaged from skull stripping. 
Given the quantity of high-quality structural MRI data acquired by my collaborators 
during this study, an opportunity exists for the development of a large, high-resolution 
mouse brain atlas database which could be used for multi-atlas approaches, cover a wide 
range of ages and strains and fit a diverse array of morphologies. The utility of such 
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databases has been demonstrated in humans (Leung et al., 2011). Accurate brain masks 
(for skull-stripping) and TPMs (for tissue segmentation) would be extremely useful for 
other studies, and could be generated semi-automatically. A method for doing so might 
follow these steps: 
1. Gather prospective wild-type in or ex vivo mouse brain images, and associated metadata 
(genetic background; age; sex; scan parameters, etc.) 
2. Filter for quality (exclude damaged brains and images with substantial artefacts) 
3. Orient to standard (RAS) space (§3.3) 
4. Create brain masks using the UFL atlas, with STEPS (§3.5) 
5. Correct intensity inhomogeneities and standardise the intensity scale across images (§3.4, 
§3.7) 
6. Create probabilistic TPMs using the NUS atlas (§3.6), including GM, WM, ventricular 
and external CSF, background and non-brain tissue classes. 
Steps 4 and 6 could employ a “bootstrapping” strategy (§5.3.2): 
a. Rank or classify results by quality, and select the ṻ best 
b. Manually correct these ṻ if necessary 
c. Include these with the external atlas database, or replace the external atlas entirely 
d. Repeat masking or tissue classification on the remaining brains using the augmented atlas 
e. Repeat a—d until all brains are masked or segmented to a high quality. 
A more ambitious extension might be the parcellation of anatomical structures. Manually 
delineating a large number would be time-consuming and laborious, and require 
meticulous expert assessment. This could be performed with increasing granularity (larger 
structures first), but would not be necessary for the atlas to be useful. Other groups 
(above) have released high-resolution, detailed parcellations using documented protocols. 
It would be sensible to extend these, using semi-automated techniques, to create large 
databases. Manual correction would be important, so as not to propagate errors. 
The benefits of propagating atlas labels to experimental data are not limited to structural 
investigations: functional MRI experiments rely upon judgment of the locations of the 
signal: for this, anatomical reference images could be registered to a sufficiently detailed 
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atlas. Other investigations requiring ROI measurements (e.g. calculation of T1 or T2; or 
of FA from DTI) may also benefit from automatic parcellation, which is more repeatable 
than manual delineation. 
This large database of wild-type scans could also be used in future to reduce the number 
of WT animals it is necessary to scan to compare with a transgenic mouse or disease 
model of interest. However, this may be impractical; a large number of variables must be 
recorded and kept constant for proper comparison, including background strain; age; sex; 
feeding and light/dark regime (Zeiss et al., 2012). 
7.2.3 The future of animal studies 
Common ancestors likely underlie homologous genetic sequences shared between mice 
and humans. However, diverging evolution of genes’ function between species, and the 
relative heterogeneity of the human genome, mean mouse models must address specific 
research questions to avoid the confounding effects of interacting genes and environment 
(Crum et al., 2003; Zeiss et al., 2012). The failure of Aβ immunisation in human AD 
patients (after successfully restoring function in mice) threw the validity of mouse models 
into question (Giacobini & Gold, 2013). Tau may be a better therapeutic target. It is also 
clearly important to report apparent negative findings – such as the EpoD results reported 
in §5 and §6 – so studies are not needlessly repeated and a balanced picture can be formed 
of where mouse models are appropriate (Jucker, 2010). EpoD did show some effect in 
§6, and there is likely an ideal time to begin treatment (Kipps et al., 2005). Longitudinal 
MRI, with the pipelines and computational techniques developed here, could be used to 
further investigate when this is. 
As discussed in §1.2, in many cases mice are excellent models for helping to understand 
disease processes and potential interventions. However, the eventual aim should be to 
reduce the use of animals in research as far as possible. Computational simulations of 
neuronal interactions and the entire brain, such as the OpenWorm project2, may 
eventually realise this goal. To this end, more immediately, data should be shared; 
 
                                                        
2: http://www.openworm.org 
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techniques standardised for reproducibility; and highly sensitive, high-powered analysis 
techniques such as morphometry and the BSI should be used where appropriate. I have 
shown comparable performance of these techniques ex vivo and in vivo. In vivo scans offer 
comparable sensitivity and permit longitudinal studies, other acquisition parameters, and 
a reduction of mice used overall. 
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Wee, sleekit, cowran, tim'rous beastie, 
O, what a panic's in thy breastie! 
Thou need na start awa sae hasty, 
Wi' bickering brattle! 
I wad be laith to rin an' chase thee, 
Wi' murd'ring pattle! 
I'm truly sorry Man's dominion 
Has broken Nature's social union, 
An' justifies that ill opinion, 
Which makes thee startle, 
At me, thy poor, earth-born companion, 
An' fellow-mortal! 
I doubt na, whyles, but thou may thieve; 
What then? poor beastie, thou maun live! 
A daimen-icker in a thrave 'S a sma' request: 
I'll get a blessin wi' the lave, 
An' never miss't! 
(…) 
Robert Burns, 1785 
 
